Patent Publication Number: US-2021171598-A1

Title: Peptide hormone with one or more o-glycans

Description:
FIELD OF THE INVENTION 
     The present invention relates to a peptide hormone with one or more O-glycans attached at specific amino acid residues. The present invention also relates to formulations, in particular pharmaceutical formulations comprising these peptide hormones. 
     BACKGROUND OF THE INVENTION 
     Peptide hormones, including neuropeptides and other biologically active peptides (here designated peptide hormones) are synthesized as precursor proteins that travel through the secretory pathway where they undergo limited proteolytic processing for activation (by e.g. proprotein convertases (PCs), carboxypeptidases, Corin) 1 , C-terminal α-amidation 2  and a number of other PTMs like tyrosine sulfation 3 , N-terminal acetylation 4  and serine phosphorylation 5 , during their biosynthesis and packaging into secretory vesicles, ready for secretion. Under appropriate physiological conditions, the mature peptide hormones are released from the cell, where they exert a multitude of functions regulating complex physiological processes. For this and other reasons, analogues of peptide hormones are emerging as major drug targets in neurological and metabolic disorders where they are tested as agonists or antagonists for their cognate receptors. 
     Once secreted most peptide hormones are prone to specific proteolytic degradation and have short half-lifes 6-8 , making them very difficult to isolate and characterize with respect to naturally occurring variants and PTMs. Recently, however, mass spectrometry based studies have identified peptide hormone PTMs like C-terminal amidation, N-terminal acetylation and serine phosphorylation. 
     Mucin-type (GalNAc-type) O-glycosylation (hereafter simply O-glycosylation) is an abundant PTM found on many proteins trafficking the secretory pathway, but the presence of O-glycans on peptide hormones have only been found in a few high-throughout mass spectrometry driven studies listed in large supplementary files 9-12 . Just recently, glycosylation was described on insulin and calcitonin in more directed studies analysing pancreatic beta-cells and small cell lung cancer cell line, respectively 13,14 . O-glycosylation of proteins is a non-template driven PTM initiated in the Golgi where up to 20 polypeptide GalNAc-transferase (GalNAc-T) isoenzymes initiate the transfer of α-GalNAc to the hydroxyl group of Ser and Thr (and possibly Tyr) residues 15 . The large number of 20 GalNAc-T isoenzymes have different albeit partly overlapping substrate specificities and the enzymes are differentially expressed in cells and tissues, which leaves this type of protein glycosylation the only one with high degree of differential and potentially dynamic regulation in eukaryotic cells compared to other PTMs. 
     Our understanding of the biosynthesis and genetic regulation of O-glycosylation is incomplete, partly because there are seemingly no simple primary peptide sequence motifs that guide us to the functions of GalNAc-T isoenzymes and their contributions to O-glycosylation, and partly because of overlap in functions as well as interdependent sequential functions among the many isoenzymes. The first congenital deficiencies in GALNT genes demonstrate that despite this, individual GalNAc-Ts serve highly specific regulatory roles of important body functions including phosphate homeostasis and lipoprotein metabolism. These fundamental functions are directed by non-redundant site-specific O-glycosylation 11,16-18 . 
     Here, the present inventors used a novel strategy for exploring potential O-glycosylation of peptide hormones in mammalian neuronal and endocrine tissues as well as cerebrospinal fluid and plasma using sensitive mass spectrometry, and surprisingly identified wide occurrence of O-glycans on peptide hormones. The present inventors identified these O-glycans in the receptor ligand binding domains of mammalian native mature peptide hormones, and demonstrate that these O-glycans serve to modulate receptor signalling and peptide hormone stability.
     U.S. Pat. No. 8,183,340 B2 relates to GLP-1 pegylated compounds   EP 1105409 B1 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components   WO 2006082517 A1 relates to Pyy agonists and uses thereof   WO 2015071355 A1 relates to selective pyy compounds and uses thereof   WO 2015177572 A1 relates to Peptide yy (pyy) analogues   WO 2006077035 A1 relates to Peptides with neuropeptide-2 receptor (y2r) agonist activity   

     OBJECT OF THE INVENTION 
     An object of the present invention relates to a peptide hormone comprising one or more O-linked glycans at specific sites. The modified, that means the O-linked glycan bearing peptide hormone has different and/or improved stability and/or pharmacokinetic properties. 
     It is an object of embodiments of the invention to provide methods for preparing peptide hormones, wherein one or more O-linked glycan are placed at predetermined sites. Yet another object of embodiments of the invention is to provide formulations, in particular pharmaceutical formulations, which comprise said peptide hormones. 
     SUMMARY OF THE INVENTION 
     Peptide hormones including neuropeptides and certain prohormones (here peptide hormones) encompass a large class of biologically active small peptides that have crucial biological functions. Peptide hormones are produced in a long preproform and undergo limited proteolytic cleavage to produce the final active peptides. Peptide hormones function as signaling molecules by binding to specific receptors and mediate intracellular signaling and stimuli. Peptide hormones can be classified into approximately 46 families where members undergo differential processing and give rise to approximately 279 known active peptide hormones. This invention relates to the identification of O-glycans in specific positions on proforms and mature active peptide hormones, and more specifically the presence of O-glycans in receptor-binding regions of peptide hormones that is demonstrated to modify the activity of such peptide hormones. The invention discloses multiple examples of such peptide hormones with O-glycans attached that have increased stability and lower bioactivity in receptor signaling and thus represent improved peptide hormone designs with altered drug effects. 
     This invention relates primarily to the Neuropeptide Y family (NPY, PPY and PYY), the Glucagon/Secretin family (GIP, Glucagon, GLP-1, GLP-2, PACAP, Secretin, Somatoliberin, PHM-27/PHV-42 and VIP), and the Natriuretic peptide family (ANP, BNP and CNP). Members of the neuropeptide Y family are well-known regulators of appetite and energy balance, and members of the Secretin family regulate glucose homeostasis (Glucagon, GLP-1, GLP-2, GIP), smooth muscle cell relaxation (VIP, PACAP), secretion of pancreatic juice (Secretin) and growth hormone release (Somatoliberin). Natriuretic peptides regulate the blood pressure through cardiorenal homeostasis. 
     It has been found by the present inventor(s) that 92 peptide hormones are O-glycosylated and it has been demonstrated for selected examples that the O-glycosylated proteoforms comprise a minor fraction of the total pool of the given peptide hormone in vivo. 
     As illustrative examples of this invention, the present inventors demonstrate that peptide hormones ANP, VIP, Secretin, GLP-1, Glucagon, NPY, PPY, PYY and Galanin with O-glycans in specific amino acid positions in the receptor-binding region require more than 28 fold higher concentrations in appropriate receptor stimulation assays to induce signaling compared to peptides without O-glycans. Furthermore, the present inventors demonstrate that the stability of peptide hormones ANP, VIP, Secretin, GLP-1, Glucagon, NPY, PYY and Galanin with O-glycans in specific amino acid positions is greater than the peptides without O-glycans in vitro using IDE/NEP/DPP-IV proteases as well as ex vivo using plasma and in vivo using rodent animal models. 
     Throughout the description, the term “peptide hormone species” is frequently used to refer to specific types of peptide hormones. For example, a peptide hormone with a given amino acid sequence may comprise more than one amino acid residue that serves as a site for O-linked glycan attachment. A peptide hormone with two such amino acid residues can have three different O-linked glycan patterns, because either one of the two or both amino acid residue may carry an O-linked glycan. As used herein, each pattern corresponds to one peptide hormone species. 
     It is generally challenging to use peptide hormones as therapeutic drugs due to their extremely short circulatory half-life and in some cases extreme potency. 
     So, in a first aspect the present invention relates to peptide hormones (or “peptide hormone species”) with different O-glycans attached at specific amino acids and the use of these to increase stability and circulatory half-life of drugs as well as to modulate the potency and receptor selectivity of peptide hormone drugs. These peptide hormones may have wide applications for the treatment of many common human diseases including hypertension, heart disease, metabolic syndromes and psychological disorders. In embodiments of the first aspect, the present invention relates to formulations, particularly pharmaceutical formulations, which comprise a peptide hormone, i.e. at least one molecule of a “peptide hormone species”, exhibiting a specific, determined glycosylation pattern of one or more O-linked glycan at a predetermined specific site of said peptide hormone, wherein specific, determined glycosylation pattern means that each molecule of said peptide hormone in said formulation, particularly in said pharmaceutical formulation, displays structural homogeneity with respect to the site of the glycan attachment and/or with respect to the glycan attachment. In further embodiments of the first aspect, the present invention relates also to mixtures of peptide hormones (“peptide hormone species”) as described above that are present in the formulations, particularly the pharmaceutical formulations according to the invention. A formulation mixture, particularly the pharmaceutical formulation mixture, comprises at least two or more, e.g., three, four, five, six, seven, eight, nine, ten, or even more peptide hormones (“peptide hormone species”) exhibiting each a specific, determined glycosylation pattern of one or more O-linked glycan at a predetermined specific site of said peptide hormone, wherein specific, determined glycosylation pattern means that each molecule of said peptide hormones in said formulation, particularly in said pharmaceutical formulation, displays structural homogeneity with respect to the site of the glycan attachment and/or with respect to the glycan attachment. 
     In a second aspect the present invention relates to an isolated peptide hormone, such as recombinant, such as a peptide hormone comprising one or more O-linked glycan at a predetermined specific site, such as in the receptor-binding region. In embodiments of the second aspect, the invention relates to the above mentioned formulations, particularly pharmaceutical formulations, and to mixtures of peptide hormones (“peptide hormone species”) as described above that are present in the formulations, particularly the pharmaceutical formulations according to the invention. 
     In a third aspect the present invention relates to a host cell comprising one or more glycosyltransferase genes that have been inactivated such that
         a) Homogenous Tn (GalNAc) glycosylation is obtained (COSMC/C1GALT1);   b) Homogenous T (Gal/GalNAc) glycosylation is obtained (ST6GALNAC1-6/ST3GAL1/GCNT3/GCNT4/B3GNT6);   c) Homogenous ST or STn glycosylation is obtained (GCNT3/GCNT4/B3GNT6).       

     It is to be understood that specific, determined and/or homogenous Tn (GalNAc) glycosylation may be obtained by inactivation and/or downregulation of one or more genes selected from COSMC and C1GALT1; that homogenous T (Gal/GalNAc) glycosylation may be obtained by inactivation and/or downregulation of one or more genes selected from GCNT3, GCNT4, B3GNT6, and that homogenous ST or STn glycosylation may be obtained by inactivation and/or downregulation of one or more genes selected from ST6GALNAC1-6, ST3GAL1, GCNT3, GCNT4, B3GNT6. 
     In some embodiments, the host cell further comprising a gene encoding an exogenous peptide hormone, such as a peptide hormone according to the invention. 
     This combinatorial deconstruction of O-glycosylation pathways in cell lines is obtained using precise genetic engineering with Zinc Finger Nucleases or CRISPR/Cas9 to target specific glycosyl transferases in the mammalian O-glycan biosynthetic pathway ( FIG. 1 ). 
     In a further aspect the present invention relates to a method for producing an isolated peptide hormone comprising one or more O-linked glycan(s) at a predetermined specific site(s), such as in the receptor-binding region, the method comprising; a) inactivation and/or downregulation of one or more glycosyltransferases, and/or endogenous activation or knock in of one or more glycosyltransferases, or any combination hereof in a host cell, and b) expression of said peptide hormone in said host cell. In some embodiments, one or more genes selected from COSMC, C1GALT1, GCNT3, GCNT4, B3GNT6, ST6GALNAC1-6, ST3GAL1 has been inactivated and/or downregulated. 
     In a further aspect the present invention relates to a method for the production of an isolated peptide hormone, such as a neuropeptide comprising one or more O-linked glycan at a predetermined specific site, such as in the receptor-binding region, said method comprising a) providing a non-O-glycosylated peptide hormone; and b) treating said non-O-glycosylated synthetic peptide hormone with one or more recombinant purified glycosyl transferase, such as a GalNAc-transferase, such as GalNAc-T1, T2, T3, T4, T5, T6, T7, T10, T11, T12, T13, T14, and/or T16, and/or a Galactosyl-transferases (C1GalT1) and/or a sialyl-transferases, such as ST6GalNAc1 and/or ST3Gall under conditions to add one or more specific O-linked glycan to said peptide hormone. In some embodiments, the non-O-glycosylated peptide hormone is provided as a chemically produced peptide hormone produced using solid phase peptide synthesis Fmoc SPPS. In some embodiments, the non-O-glycosylated peptide hormone is provided as a recombinantly produced peptide hormone, such as produced in a production cell line. 
     In a further aspect the present invention relates to a method for the production of an isolated peptide hormone, such as a neuropeptide comprising one or more O-linked glycan at a predetermined specific site, such as in the receptor-binding region, said method comprising the building of said peptide hormone using solid phase peptide synthesis Fmoc SPPS including the use of glycosylated amino acids building blocks at said predetermined specific site(s). 
     In a further aspect of the present invention, formulations comprising at least one of the herein disclosed peptide hormones (“peptide hormone species”) are provided. As known to a person skilled in the art, formulation is a mixture comprising an active principle (in the present case at least one of the herein disclosed peptide hormones/“peptide hormone species”) and excipients at specific, defined amounts. A formulation is different from a mere solution of an active principle in a solvent, i.e. without any further excipient. Further, a pharmaceutical formulation usually comprises the active principle, for example at least one of the herein described peptide hormones/“peptide hormone species” in admixture with pharmaceutical excipients, which are known to a person of skill in the art (reference can be made to the European Pharmacopoeia, which may be considered as a representation of the common knowledge of the person of skill in the art). Therefore, in specific aspects of embodiments relating to formulations of the herein disclosed peptide hormones, the formulations of pharmaceutical formulations. Also, encompassed by this disclosure are formulations, particularly pharmaceutical formulations, which comprise a mixture of at least two of the herein disclosed peptide hormones (“peptide hormone species”) in specific, defined (i.e. predetermined) quantities. 
     In a further aspect the present invention relates to a method for the production of formulations, particularly pharmaceutical compostions, comprising at least one of the herein disclosed peptide hormones (“peptide hormone species”), or mixtures thereof. 
    
    
     
       LEGENDS TO THE FIGURES 
         FIG. 1  illustrates the biosynthetic pathways of Mucin-type O-glycosylation. The glycosylation process is initiated by the transfer of UDP-GalNAc to acceptor Ser/Thr/Tyr amino acid residues in the protein or peptide backbone by GalNAc-transferases (20 different isoforms). The O-glycan structure can be further elongated to up to 8 different core structures by a number of glycosyl-transferases. Only 4 core structures are illustrated here. 
         FIG. 2  illustrates the enrichment process and identification of glycosylated peptide hormones. A) Schematic workflow for analysis of O-glycosylated peptide hormones. The proteins of plasma, neuroendocrine cells (STC-1, N2a) and neuronal as well as endocrine tissues (Brain, Pancreas, Ileum, Heart, Prostate, Cerebellum) were extracted using up to three different extraction procedures pr. sample. Subsequently, The proteins were reduced, alkylated, digested with either trypsin, Glu-C or chymotrypsin followed by de-sialylation using neuraminidase. Glycopeptides were subjected to LWAC using either PNA, Jacalin or VVA lectins. Subsequently, fractionation using either isoelectric focusing or high pH-fractionation was performed before separation and sequencing of the glycopeptides on LC-MS/MS. The resulting O-glycoproteome was matched against the NeuroPeP database, and further realignment of the preproprotein glycopeptides was done against the homologous human proproteins annotated in the same database. B) Overlap of glycosylated peptide hormones or C) Proproteins identified and matched to the human preproproteins with previously published O-glycoproteins or O-glycopeptide hormones. D) The number of identified O-glycosylated peptide hormones in each sample analysed. 
         FIG. 3  illustrates the prevalence of O-glycosylation in peptide hormone families. Peptide hormones from NeuroPep database (279 peptide hormones) distributed across their respective gene families (46 peptide hormone families). Glycosylated peptide hormones identified in this study that have not previously been reported (red), glycosylated peptide hormones identified in this study and previously published (orange), peptide hormones not identified in this study but previously published (green), peptide hormones not identified in this study but predicted to be glycosylated by NetOGlyc 4.0 (yellow), peptide hormones not identified in this study and not predicted by NetOGlyc (grey). 
         FIG. 4  illustrates selected peptide hormone families and their identified O-glycosylation sites. Multiple sequence alignment analysis of the A) Secretin/Glucagon, B) Calcitonin, C) Insulin-like growth factor, D) Galanin, E) Neuropeptide Y family and F) Natriuretic peptides family with the identified, predicted and conserved O-glycosylation sites shown. Only the mature peptides are shown. Yellow boxes indicate identified glycosylation sites in this study, grey boxes indicate predicted glycosylation sites by NetOGlyc 4.0, and white boxes indicate conserved glycosylated residues. The sequence conservation of the mature peptides is shown below each peptide family. Dark grey: completely conserved sites; medium and light grey: less conserved sites; white: non-conserved sites. The peptide sequence shown in the alignments are A) secretin, B) calcitonin, C) insulin, D) galanin E) NPY and F) ANP. 
         FIG. 5  illustrates receptor activating capability of non-glycosylated and glycosylated peptide hormones. Secondary messenger accumulation assay for naked and Tn/T/ST-glycosylated peptide agonists for A) VPAC1, B) VPAC2, C) SCTR, D) GLP1R, E) GCGR, F &amp; G) NPY1R, H-J) NPY2R, K&amp;L) NPY4R, M&amp;N) NPY5R. For VPAC1&amp;2, GLP1R, GCGR and SCTR accumulation of cAMP was measured upon stimulation with increasing concentrations of the ligand whereas for NPY1R, NPY2R, NPY4R and NPY5R accumulation of IP-1 was measured upon stimulation with ligand after co-transfection with Gqo5. O) naked and ANP-19 and ANP-25 glycosylated variants receptor binding and activation measured as % cGMP generated. 
         FIG. 6  illustrates neprilysin (A) and insulin-degrading enzyme (B) proteolytic degradation of ANP and glycosylated proteoforms (monoglycosylated ANP-Ser19/Tn, ANP-Ser 25/Tn and double glycosylated ANP-Ser19+25/Tn in an time course from t=0 to t=24 hr monitored by MALDI-TOF analysis. Masses corresponding to intact peptide or glycopeptide are labelled “uncleaved” in green and indicated by arrows. 
         FIG. 7  illustrates Neprilysin, DPP-IV and IDE degradation pattern of non-glycosylated and glycosylated peptide hormones monitored by MALDI-TOF analysis. Peptides were incubated at 37 degrees in the presence of recombinant peptidase or 20% plasma. Aliquots were taken at 0, 15, 30, 60, 120 min for peptidase studies and 0 h, 1 h, 3 h, 6 h and 24 h for plasma studies and monitored by MALDI-TOF mass spectrometry. A) An illustrative example of peptidase digest with Neprilysin (NEP) on secretin and its glycoforms. The m/z of the degraded forms correlate with the N-terminal fragments shown in the sequence of secretin in panel B. B) Summary of cleavage sites and protection state of the glycans. a: DPPIV cleavage site, b: NEP cleavage site, c: plasma cleavage site. Nomenclature for protection: −: no protection, +: Partial protection, non-digested peak is present at least one timepoint after full degradation of the naked peptide has been observed. ++: full protection, no degradation products are observed within the timeframe of full degradation of the non-glycosylated peptide. In the example in panel A, partial protection is observed at the Tn form and the T form and full protection from the ST-form. *no protection in the N-terminus at the DPIV cleavage site, however, full protection was observed at C-terminal cleavage site already at the incorporation of Tn. C) summary of neprilysin, DPP-IV and plasma degradation assays. Nomenclature for protection: −: no protection, P: Partial protection, F: full protection, NT: Not tested, NC: No degradation of non-glycosylated peptide within timeframe. *Only the C-terminal inactivating cleavage of PYY is fully protected by glycans. The two N-terminal amino acids are removed and partial protected by only the ST-glycoform. 
         FIG. 8  illustrates a table summary of secondary messenger accumulation assay for naked and Tn/T/ST-glycosylated peptide for members of the glucagon- (VIP, GLP-1, Glucagon) and NPY (NPY, PYY)-families. For glucagon family members, cAMP accumulation was measured. For NPY family members, IP1-accumulation was measured. EC50-values are defined as concentration of peptide hormone needed to elicit 50% maximal response (Maximal achievable accumulation of either cAMP or IP1). The confidence interval is calculated from log-transformed data of at least 3 experiments. 
         FIG. 9  illustrates how natural o-glycans on ANP attenuate the acute renal and cardiovascular actions in vivo. A) schematic overview of the acute study protocol. B) Graph of changes in mean arterial pressure (MAP) overtime during the 60 minutes infusion period with ANP, ST-ANP19 and ST-ANP25 and after the 30 minutes clearance period. C) Urine flow (UV) was calculated as urine volume clearance per min. Values are plotted in a bar-graph displaying volume (uL) urine produced per minute in the 60-minutes infusion period and after the 30 minutes clearance period D) Urinary sodium excretion (UNaV) was calculated as urine sodium clearance per minute and values for ANP, ST-ANP19 and ST-ANP25 are plotted in a scatter-plot. E) Plasma ANP was measured after 90 minutes using a radioimmuneassay and values in pg/mL was plotted for ANP, ST-ANP19 and ST-ANP25. F) Urine ANP was measured after 90 minutes using a radioimmuneassay and values in pg/mL was plotted for ANP, ST-ANP19 and ST-ANP25. 
     
    
    
     DETAILED DISCLOSURE OF THE INVENTION 
     O-glycosylation is emerging as an important regulator of protein stability and function. In this study, for the first time, the present inventors identify protein O-glycosylation as a common post translational modification of peptide hormones, present a detailed comprehensive map of O-glycosylation sites and suggest a biological function of site-specific O-linked glycosylation on peptide hormones. 
     Peptide hormones are produced by cells of the endocrine, neuronal or neuroendocrine tissues and are secreted in response to stimulus to bind to their cognate receptors and regulate complex physiological processes like appetite, blood pressure and anxiety. During biosynthesis peptide hormones undergo a range of PTMs. Besides a common complex proprotein convertase activation 19 , peptide hormones can undergo C-terminal amidation, N-terminal acetylation, tyrosine sulfation and serine phosphorylation 20  that may change the biochemical properties of the peptides. Furthermore, peptide hormones circulate in minute amounts and are inherently prone to proteolytic degradation. Thus, as a result of their instable nature, low abundance and complex post translational modifications peptide hormones have been difficult to isolate and characterize. 
     Now with the advantage of sensitive mass spectrometry the present inventors explore the occurrence of O-glycans on peptide hormones and show that approximately one third of all classified (NeuroPeP) peptide hormones are O-glycosylated ( FIG. 2B  and table 6), report the specific sites and demonstrate that the majority of sites resides within important structural or functional regions of the mature peptide hormones ( FIG. 4  and table 6). Tables 6A to 6D disclose specific embodiments of the present invention, and table 6E discloses all of the herein disclosed peptide hormones with the respective sequence identity numbers (SEQ ID NOs). 
     GalNAc O-glycosylation is an exceptional PTM in that there are 20 differentially expressed isoforms with partly overlapping specificities conducting the addition of the initial GalNAc residue to the protein backbone Ser/Thr/Tyr residues. This leaves ample room for regulating the addition of site-specific O-glycosylation and the findings presented here may have revealed a novel regulatory level in peptide hormone biosynthesis and function. 
     It is becoming increasingly clear that site-specific O-glycosylation fine-tune the biological function of proteins 21-32 . Previously the present inventors have demonstrated that O-glycosylation protects proproteins from PC processing 24,33,34 , that O-glycans increase the stability of GPCR N-termini 32  and modulates ectodomain shedding 26  and most recently the present inventors have shown that loss of site-specific O-glycosylation impair ligand binding and uptake of the LDLR related receptor family 35,36 . 
     Here the present inventors demonstrate that O-glycosylation of VIP, Secretin, NPY, PYY and PPY in specific well conserved amino acid positions lowers receptor affinity and signalling, reducing EC50 more than 28-fold where the size of the glycan correlates with signal reduction ( FIG. 5 ). Between the selected examples presented here, a similar effect was seen with ANP/NPRA, Secretin/SCTR, Glucagon/GCGR, GLP1/GLP1R, VIP/VPAC1, VIP/VPAC2, NPY/NPY1R, NPY/NPY2R, NPY/NPY4R, NPY/NPY5R, PYY/NPY1R, PYY/NPY2R, PYY/NPY4R and PYY/NPY5R. 
     Our data indicates that the presence of glycan structures somehow alters the interaction between peptide hormone ligand and cognate receptor. Well in line with these data, especially well-studied in the Neuropeptide Y family, it has been demonstrated that other bulky chemical modifications of amino acids in the receptor binding domain alter receptor sub-class selectivity of the ligand 37 . Such a sub-class receptor selectivity was observed for Thr32-Tn modified NPY that retained activity at the NPY2R and NPY5R receptors with a 118-fold and 37-fold decrease in potency ( FIGS. 5H &amp;J), respectively, whereas activity at the NPY1R and NPY4R receptors was almost abolished in the assayed range ( FIGS. 5F &amp;L). Thus glycosylation of NPY changes NPY&#39;s receptor sub-class selectivity from NPY2R&gt;NPY1R&gt;NPY5R&gt;NPY4R to NPY2R&gt;NPY5R&gt;&gt;NPY1R&gt;NPY4R ( FIG. 8 ). Thr32PYY-Tn showed same retained activity at NPY2R and NPY5R with 61-fold and 37-fold reduction in potency, respectively ( FIGS. 5I &amp;K), but minimal activity at the NPY1R and NPY4R in the assayed range ( FIGS. 5G &amp;K). Thus glycosylation of PYY changes NPY&#39;s receptor-subtype selectivity from NPY1R&gt;NPY2R&gt;NPY5R&gt;NPY4R to NPY2R&gt;NPY5R&gt;&gt;NPY1R&gt;NPY4R ( FIG. 8 ). 
     Peptide hormones are inherently unstable and circulate only in minute amounts. Here, it is demonstrated that site-specific O-glycosylation on Secretin, VIP, Galanin, PYY, GLP-1 and ANP protects the peptide hormones from proteolytic degradation in vivo using a rat model, ex vivo using plasma degradation assays and in vitro using recombinant proteases ( FIG. 6  &amp;  FIG. 7 ). Most prominent is the stability of the naturally occurring sialylated structures where e.g. Thr-32 ST-PYY remained partially in its biologically active form even after prolonged incubation time with plasma and Ser-23 ST-Galanin remained partially intact after overnight incubation with neprilysin. Even though the sialylated structures of VIP and PYY were also protected from DPP-IV degradation, the Tn-glycosylated structures were in some cases somewhat faster degraded compared to non-glycosylated, perhaps related to the unphysiological nature of the Tn structure that is primarily observed in cancer cells. 
     The Neuropeptide Y family members are ubiquitously expressed in the body and act as neurotransmitters to regulate a vast array of physiological processes via binding and signalling through the Gi coupled NPY receptors (YR1, YR2, YR4 or YR5). 
     The main function of GLP-1 is to increase insulin secretion, i.e. to act as an “incretin”, but it also inhibits gastrointestinal motility and function as a physiological regulator of appetite. Recently it was demonstrated that GLP-1, Oxyntomodullin and PYY in combination injected subcutaneously using a pump device into obese volunteers reduced their mean caloric intake with 32% 38 . 
     ANP is classically released from secretory granules from the atria in a regulated fashion which makes it able to rapidly regulate hemodynamics in response to increased pressure. Glycosylated ANP was protected from degradation in vitro by IDE and NEP which suggest that glycosylated ANP may have increased half-life. The combined effects of glycosylated ANP, i.e decreased potency and increased stability, could render a positive effect in the treatment of acute decompensated heart failure and hypertension, where ANP and BNP are already introduced as infusion therapy 39-41 . 
     Thus, there is a need to identify selective peptide hormone receptor agonists or antagonists with good biostability to pursue as potential therapeutic candidates for treating e.g. cardiovascular diseases, anxiety, depression, obesity, epilepsy, alcoholism. 
     Peptide based design of therapeutics is attractive in many ways since biological active peptides have the potential to regulate specific functions of GPCRs and ion-channels and in general in vivo based drug design is favourable due to lower toxicity and immunogenicity and higher selectivity and predictable in vivo behaviour. However, probing the function and efficacy of what was thought of as “naturally occurring” unmodified peptides have demonstrated low biostability and circulation time and therefore low efficacy 42,43  and a number of strategies have been taken to chemically alter the biochemical properties of peptide hormones or synthetic analogues and improve these parameters 44 . It is generally found that large N-glycans on proteins may enhance circulatory half-life, although mainly by increase of the size and hydrodynamic size of proteins. However, introduction of O-glycans into smaller peptides have also been used to enhance circulatory half-life especially when combined with the GlycoPegylation strategy 45 . In one relevant example an O-glycosylation sequon was introduced in the C-terminus of the GLP-1 receptor antagonist Exendin (9-39) increasing functional half-life 46 . Other studies have explored the chemical synthesis of peptide hormones with glycans 46-52 , e.g. O-linked galactose on vasopressin, PYY and VIP, glucose on Leu-enkephalin and PYY, N-linked GlcNAc on GLP-1 and N-terminal chemical glycation of GIP, GLP-1(7-36) and Insulin. Interestingly all studies, except one describing O-linked galactose on Vasopressin, find, very much in line with what the present inventors show here for the naturally occurring O-GalNAc glycans, that the chemically modified glycosylated analogues are less or equally potent in in vitro receptor activation assays, yet these other studies demonstrate higher stability and potency in vivo. 
     Naturally occurring O-glycans positioned within the receptor-interaction region of peptide hormones have not been demonstrated previously, and we hypothesize that such naturally occurring glycans selectively affect function and biostability as our preliminary studies suggest. 
     The inventors of the present invention also identified O-glycosylation on the pro-part of peptide hormones. Here, sequestered from the bioactive part, the sugars might regulate PC processing and activation and furthermore coincidentally mask antibody binding epitopes 9,24,53-56 . One such well-studied example is proBNP which is synthesized in the ventricles of the failing heart and undergo limited proteolysis by PCs releasing the C-terminal peptide hormone BNP that regulate natriuresis and blood pressure. ProBNP is O-glycosylated in the N-terminal proprotein (NT-proBNP) close to the PC processing site and amino acid substitution experiments have validated that Thr71 protects proBNP from processing by Corin or Furin 53 . The present inventors identified O-glycans on proBNP, POMC, Kininogen-1, Chromogranin A (Table 6). NT-proBNP is an important biomarker for heart failure and commercial immunoassays are being used in the clinic to quantify NT-proBNP in heart related diseases. However some variability among the assays have been noted and caution raised against O-glycans potentially masking antibody binding epitopes 57 . As POMC 58 , Kininogen-1 59  and chromogranin A 60  are also used as biomarkers it is particular important to note the degree of glycosylation identified in this study. 
     In summary the present inventors show that O-glycans in conserved residues in various peptide hormone families, are far more abundant than previously recognized, and that glycans change peptide hormone induced receptor activity and furthermore alter recognition by proteolytic enzymes that otherwise inactivate the peptide hormones. 
     EXAMPLES 
     The purpose of the following examples are given as an illustration of various embodiments of the invention and are thus not meant to limit the present invention in any way. Along with the present examples the methods described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses which are encompassed within the spirit of the invention as defined by the scope of the claims will occur to those skilled in the art. 
     Biological samples were prepared as follows: 
     Tissue Extraction: Porcine brain, cerebellum, ileum and a pool of human prostate gland tissue 61  was isolated according to standard protocols. Proteins were extracted by crushing the frozen tissue using a CryoPrep tissue extractor (Covaris, Woburn, Mass.), boiled in water for 20 minutes, and homogenized with an Ultra-Turrax (IKA, Staufen, Germany). For ileum tissue, instead of boiling in water, the tissue was homogenized and rotated at 4° C. for 4 hours in 0.18 M HCl/70% ethanol. After 30 minutes centrifugation at 13,000 g, the supernatants were collected and pooled, and protein concentration was determined by BCA assay (Pierce). Prostate gland samples were further processed as crude water extract, acetone precipitated extract and acetone precipitated extract after acidification. Brain and cerebellum extracts were either crude extracts or acetone precipitated extracts after acidification. For precipitation of insoluble proteins samples in water or adjusted to 0.5 M CH3COOH were added icecold acetone (67%), incubated for 1 h at −20° C., and centrifuged at 16.000 g for 30 min. Subsequently the supernatant was lyophilized and reconstituted in water. 
     Plasma extraction: Plasma for O-glycoproteomic analyses was collected and pooled from two healthy volunteers into EDTA-treated tubes (K2E K2EDTA Vacuette) followed by centrifugation at 5,000×g for 10 min and stored at −20° C. until use. 
     Both crude and low molecular weight fraction (LMWF) enriched plasma was subjected to the O-glycoproteome strategy. For LMWF enrichment a volume of plasma containing approximately 60 mg of protein (measured by BCA assay (Pierce)) was precipitated by adding two parts of 96% ethanol followed by incubation at RT for 30 min. Supernatant and pellet was separated by centrifugation at 10.000×g for 10 minutes, and the supernatant was lyophilized and resuspended in 0.05% rapigest. 50 mM sodium acetate buffer and desialylated with 0.1 U/mL neuraminidase ( Clostridium perfringens  neuramidase type VI, Sigma). The LMWF-enriched sample was further enriched for O-glycopeptides by capture on a short (300 ml contained in 1 ml syringe) PNA agarose column. Glycoproteins were eluted by heating the lectin (2×90° C., 10 min) with 0.05% RapiGest (as previous described 11 ). The LMWF-enriched plasma sample was 0.2 μm filtered prior to the glycoprotein enrichment. In parallel, 5 mg of total protein (as determined by BCA assay (Pierce)) from non-LMWF-enriched biofluid samples was desialylated by the same procedure as described above, before enzymatic degradation omitting the glycoprotein enrichment. 
     Cell protein extraction: Conditioned media cleared from dead cells and debris obtained from 2×T175 flasks cultured for 48-72 h were dialyzed, neuraminidase treated and enriched for glycoprotein as done for the the LMWF-enriched plasma. Total cell lysates (TCL) were obtained by washing a monolayer of cells in icecold PBS, scrabing off the cells and adding 2 ml 0.05% RapiGest to solubilize the cell pellet. The resulting homogenate was sonicated and cleared by centrifugation. 
     Mass Spectrometry Workflow 
     Enzyme digestion and desialylation: The extracted samples from the various neuronal and endocrine sources were adjusted to 50 mM ammonium bicarbonate, heated for 10 min at 80° C., followed by reduction with 5 mM dithiothreitol (DTT) (60° C., 30 min) and alkylation with 10 mM iodoacetamide (30 min, room temperature, kept dark). Subsequently, the samples were incubated with trypsin, Glu-C or chymotrypsin (Roche) (37° C., overnight, 1 μg enzyme pr 100 μg protein). The following day, the enzyme reaction was quenched and RapiGest, if present in the sample, was precipitated by acidifying with trifluoroacetic acid (TFA). The solution was cleared by centrifugation (10,000×g, 10 min.) and peptides were purified on C18 Sep-Pak columns (Waters), and dried down using SpeedVac. If not already desialylated, the dried peptides were resuspended in 1 mL 50 mM Sodium acetate (pH 5.5) containing 0.1 U/mL Neuraminidase followed by incubation at 37° C. for 1 h, purified by Sep-Pak and dried down. 
     LWAC O-glycopeptide enrichment: Dried samples were reconstituted in 2 mL PNA/Jacalin/VVA buffer (PNA-binding buffer 10 mM HEPES (pH 7.4), 150 mM NaCl, 0.1 mM CaCl 2 , and 0.01 mM MnCl 2 ; Jacalin-binding buffer 175 mM Tris (pH 7.5); VVA-binding buffer 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM CaCl 2 /MgCl 2 /MnCl 2 /ZnCl 2 , and 1 M urea), 0.45 μm filtered and injected onto a pre-equilibrated 2.6-m long column packed with lectin-bound (PNA, Jacalin or VVA, Vector Laboratories) agarose beads at a constant flow-rate of 0.1 mL/min. For VVA the column was first washed for 3×CV in 0.4 M glucose and then eluted with 2 CV 0.2 M GalNAc and 1×CV 0.4 M GalNAc. For PNA and Jacalin LWAC, the column was washed 2×CV in lectin-binding buffer, and then eluted with 2×1 column volume 0.5 M galactose and 1×1 column volume 1 M galactose, respectively. The elution fractions were concentrated and glycopeptides were purified using Stage tips and submitted for nLCMS/MS analysis. 
     nLC/MS/MS Analysis: Liquid chromatography-tandem mass spectrometry was performed on a system composed of an EASY-nLC 1000 (Thermo Fisher Scientific) interfaced via a nanoSpray Flex ion source to an LTQ-Orbitrap Velos pro hybrid spectrometer or Orbitrap Fusion Tribrid (Thermo Fisher Scientific), equipped for both higher energy collisional dissociation (HCD) and electron transfer dissociation (ETD) modes, enabling peptide sequence analysis without and with retention of glycan site-specific fragments, respectively. The nLC was operated in a one-column set up with an analytical column (20 cm length, 75 μm inner diameter) packed with C18 reverse phase material (1.9-μm particle size, ReproSil-Pur, Dr. Maisch). Each sample dissolved in 0.1% formic acid was injected onto the column and eluted in a gradient from 2 to 30% B in 105 min, from 30% to 100% B in 5 min and 100% B for 10 min at 200 nl min-1 (solvent A, 100% H 2 O; solvent B, 100% acetonitrile; both containing 0.1% (v/v) formic acid). A data-dependent mass spectral acquisition routine, HCD triggering of subsequent ETD scan, was used for all runs. Briefly, a precursor MS1 scan (m/z 350-1,700) of intact peptides was acquired in the Orbitrap at a resolution setting of 30,000 (Velos Pro) or 120,000 (Fusion), followed by Orbitrap HCD-MS2 (m/z of 100-2,000) of the five most abundant multiply charged precursors in the MS1 spectrum; this event was followed up by an ETD-MS2 fragmentation for the same precursor ion. In cases where preliminary screening of fractions for glycopeptide enrichment was carried out prior to IEF, the ETD-MS2 step was omitted, and HCD-MS2 (m/z 100-2,000) of the five most abundant multiply charged precursors was acquired (“top five method”). These HCD-MS2 spectra were simply screened for the appearance of the HexNAc fragment at m/z 204.086. 
     Data analysis: The raw data were processed using Proteome Discoverer 1.4 software (Thermo Fisher Scientific) and searched against the human, porcine, mouse or rat-specific Uniprot database downloaded on January 2013. The Sequest HT search node was used for HCD and ETD data. In all cases the precursor mass tolerance was set to 15 p.p.m. and fragment ion mass tolerance to 20 millimass units (mmu). Carbamidomethylation on cysteine residues was used as a fixed modification. Methionine oxidation, C-terminal amidation (plasma and pancreas), and HexNAc or HexHexNAc attachment to serine, threonine or tyrosine were used as variable modifications. As an additional preprocessing procedure, all HCD data showing the presence of fragment ions at m/z 204.08 were extracted into a single .mgf file, and the exact mass of 1×, 2×, 3× and 4× HexNAc or HexHexNAc units was subtracted from the corresponding precursor ion mass, generating four distinct files. These preprocessed data files were submitted to a Sequest HT node under the same conditions mentioned above, except considering a HexNAc or HexHexNAc attachment. All spectra were searched against a decoy database using a target false discovery rate of 1%; unassigned spectra were submitted to a second Sequest HT node using the same parameters as above with the exception of performing the search using semi-specific trypsin cleavage. The final list was filtered to include only peptide hormones. 
     Multiple sequence alignment: All alignments were performed in ClustalW using the peptide sequences of  H. sapiens, M. musculus , and  R. Norvegicus.    
     In some aspects of the present application, mammalian host cells are modified to inactivate or downregulate certain glycosyltransferase genes. Details for for modifying or adding all subtypes of O-GalNAc linked mucin-type O-glycans are described in WO 2017/194699, which reference is hereby incorporated by reference. 
     In brief the present invention may incorporate the use of mammalian host cells with individual and combinatorial knock out of one or more of the GALNT1-T20 glycogenes (listed in Table 1 below). Determining changes in interactions with a plurality of mammalian cells with knock out of GALNT1 and/or GALNT2 and/or GALNT3 and/or GALNT4 and/or GALNT5 and/or GALNT6 and/or GALNT7 and/or GALNT9 and/or GALNT10 and/or GALNT11 and/or GALNT12 and/or GALNT13 and/or GALNT14 and/or GALNT16 and/or GALNT18 and/or GALNT19 is used to identify if said interaction occurs through subsets of O-GalNAc glycoproteins controlled by one or more of the 20 GALNTs, respectively, such that loss or reduction in measured interactions with mammalian cells with knock out of one or more of the named gene(s) confer that the O-glycoprotein(s) responsible for the interaction requires glycosylation by the corresponding GALNT(s). 
     
       
         
           
               
               
             
               
                 TABLE 1 
               
               
                   
               
             
            
               
                 O-Gly (Ser/Thr/Tyr) 
                 GALNT1-T20 (O-GalNAc) 
               
               
                   
               
            
           
         
       
     
     O-Glycan Branching 
     The present invention may incorporate the use of mammalian host cells with individual and combinatorial knock out of C1GalT1, GCNT1, GCNT2, GCNT3, GCNT4, GCNT6, GCNT7, B3GNT6 or B3GNT2 glycogenes (listed in Table 2 below) suitable for determining O-linked branching in Core2, Core3 and Core4 structures ( FIG. 1 ), involved in observed interactions. Determining changes in interactions with a plurality of mammalian cells with knock out of GCNT1 and/or GCNT2 and/or GCNT3 and/or GCNT4 and/or GCNT6 and/or GCNT7 and/or B3GNT6 and/or B3GNT6 is used to identify if said interaction occurs through O-linked branched structures by one or a plurality of the branching enzymes, such that loss or reduction in measured interactions with mammalian cells with knock out of one or more of the named gene(s) confer that the O-linked branched structure is responsible for the interaction as indicated. 
     
       
         
           
               
               
             
               
                 TABLE 2 
               
               
                   
               
             
            
               
                 O-Gly 
                 C1GALT1, B3GNT6 (O-GalNAc) 
               
               
                   
                 GCNT1/T2/T3/T4/T6/T7 (O-GalNAc) 
               
               
                   
                 B3GALNT1/T2 (O-Gly) 
               
               
                   
                 B3GNT2/T3/T4/T7/T8/T9 (O-Gly) 
               
               
                   
                 B4GALT1/T2/T3/T4 (O-Gly) 
               
               
                   
                 B4GALNT3/T4 (O-Gly) 
               
               
                   
               
            
           
         
       
     
     The present invention may incorporate the use of mammalian host cells with individual and combinatorial knock out of genes involved in N and O-glycan and glycolipid capping (sialylation); ST3GAL1/2/3/4/5/6 (α2,3NeuAc capping/sialylation) and/or ST6GAL1/2 (α2,6NeuAc capping/sialylation) and/or ST8SIA1/2/3/4/5/6 (capping by poly-sialylation) and/or ST6GALNAC1/2/3/4/5/6 (α2,6NeuAc capping/sialylation) (glycogenes listed in table 3 below) suitable for determining the capped (sialylated or fucosylated) glycan structure involved in observed interactions. Determining changes in interactions with a plurality of mammalian cells with knock out of ST3GAL1/2/3/4/5/6 and/or ST6GAL1/2 and/or ST8SIA1/2/3/4/5/6 and/or ST6GALNAC1/2/3/4/5/6 is used to identify if said interaction occurs through the type of capping indicated in parenthesis, such that loss or reduction in measured interactions with mammalian cells with knock out of one or more of the named groups of genes confer that the type of capping is responsible for the interaction as indicated. 
     
       
         
           
               
               
             
               
                 TABLE 3 
               
               
                   
               
             
            
               
                 N-Gly,  
                 FUT1/2/3/4/5/6/7/8/9/10/11 
               
               
                 O-Gly, 
                 ST3GAL1/2/3/4/5/6 
               
               
                 Glycolipids 
                 ST6GAL1/2 
               
               
                   
                 ST6GALNAC1/2/3/4/5/6 
               
               
                   
                 ST8SIA1/2/3/4/5/6 
               
               
                   
                 B3GAT1/T2 
               
               
                   
                 ABO 
               
               
                   
                 A4GNT 
               
               
                   
               
            
           
         
       
     
     Engineering GTfs in Cells 
     Only little information exists as to the effects of knock out of glycosyltransferase genes in mammalian cell lines. For human cell lines only a few spontaneous mutants of glycosyltransferase genes have been identified. For example the colon cancer cell line LSC derived from LS174T has a mutation in the COSMC chaperone that leads to misfolded and non-functional Core1 synthase C1GalT 62 . The COSMC gene is also mutated in the human lymphoblastoid Jurkat cell line 62,63 . 
     Knock Out of Glycosylation Genes in Cell Lines 
     The limited information of effects of knock out of glycosyltransferase genes in cell lines is partly due to past difficulties with making knock outs in cell lines before the recent advent of precise gene editing technologies 64 . Thus, until recently essentially only one glycosyltransferase gene, FUT8, had been knocked out in a directed approach using two rounds of homologous recombination including massive clone screening efforts. The conventional gene disruption by homologous recombination is typically a very laborious process as evidenced by this knock out of Fut8 in CHO, as over 100,000 clonal cell lines were screened to identify a few growing Fut8−/− clones 65  (U.S. Pat. No. 7,214,775). With the advent of the Zinc finger nuclease (ZFN) gene targeting strategy it became less laborious to disrupt genes, which was first demonstrated by knock out of the Fut8 gene in a CHO cell line, where additional two other genes unrelated to glycosylation were also effectively targeted 66 . More recently, TALENs and the CRISPR/Cas9 editing strategies have emerged, and the latter editing strategy was used to knock out the Fut8 gene 67 . 
     It is thus clear that targeted genetic engineering is now a tool the skilled person may use but editing of the glycosylation genes in mammalian cells and animals are prone to substantial uncertainty, and thus identifying the optimal engineering targets for display of a given glycan structure will require extensive experimental efforts. Therefore a random type approach involving testing of a multiplicity of different glycogene and glycoform variations may be beneficial. 
     Overexpression of Glycosylation Genes in Cell Lines 
     It is noteworthy that transient or stable overexpression of a glycosyltransferase gene in a cell most often result in only partial changes in the glycosylation pathways in which the encoded enzyme is involved. A number of studies have attempted to overexpress e.g. the core2 C2GnT1 enzyme in CHO to produce core2 branched O-glycans, the ST6GAL1 sialyltransferase to produce α2,6linked sialic acid capping on N-glycoproteins 68 , and the ST6GALNAC1 sialyltransferase to produce α2,6linked sialic acid on O-glycoproteins forming the cancer-associated glycan STn 69 . However, in all these studies heterogeneous and often unstable glycosylation characteristics in transfected cell lines have been obtained. This is presumably partly due to competing endogenous glycosyltransferase activities whether acting with the same substrates or diverging pathway substrates. Other factors may also explain the heterogeneous glycosylation characteristics. 
     Definitions 
     Before disclosing the subject-matter in greater detail, definitions of terms/expressions used herein are provided. 
     Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. 
     Each of the patents, applications and articles cited herein, and each document cited or referenced therein, including during the prosecution of any of the patents and/or applications cited herein (“patent cited documents”), and any manufacturer&#39;s instructions or catalogues for any products cited herein or mentioned in any of the references and in any of the patent cited documents, are hereby incorporated herein by reference. Documents incorporated by reference into this text or any teachings therein may be used in the practice of this invention. 
     Documents incorporated by reference into this text are not admitted to be prior art. As used herein, the words “may” and “may be” are to be interpreted in an open-ended, non-restrictive manner. At minimum, “may” and “may be” are to be interpreted as definitively including structure or acts recited. 
     The articles “a” and “an” are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. 
     Throughout this specification, unless the context requires otherwise, the words “comprise”, “comprises” and “comprising” will be understood to imply the inclusion of a stated step or element or group of steps or elements but not the exclusion of any other step or element or group of steps or elements. 
     By “therapeutically effective amount or dose” or “sufficient amount or dose” herein is meant a dose that produces effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques. 
     The terms “pharmaceutically effective”, “therapeutically effective”, “pharmaceutically active”, or “therapeutically active” means that a synthetic compound of the invention so described is determined to have activity that affects a medical parameter or disease state. 
     “Patient” as that term is used herein, refers to the recipient of the treatment. In a specific embodiment, the patient is a mammal, such as a human, canine, murine, feline, bovine, ovine, swine or caprine. In a particular embodiment, the patient is a human. 
     As used herein, the terms “function” or “functional activity” refer to a biological, e.g., enzymatic function. 
     By “isolated” is meant material that is substantially or essentially free or purified from components that normally accompany it in its native state. For example, the compound according to the invention may be modified subsequent to isolation from their natural or laboratory-produced environment, or they may be used in isolated form in vitro, or as components of devices, compositions, etc. 
     By “obtained from” is meant that a sample such as, for example, a polypeptide (peptide hormone) is isolated from, or derived from, a particular source of the host or cells cultured in vitro. For example, the extract can be obtained from a tissue or a biological fluid sample isolated directly from the host. Therefore, the compounds of the present invention may be recombinantly produced or obtained from biological sources and be purified before further use in vitro and/or in vivo. 
     By “pharmaceutically acceptable carrier” is meant a solid or liquid filler, stabilizer, diluent or encapsulating substance that can be safely used in administration routes when applied to an animal, e.g. a mammal, including humans. 
     “Therapeutic treatment”, and “treatment”, refers any type of therapy. 
     The terms “peptide hormone”, “polypeptide,” “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply also to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer. 
     The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid. Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. 
     As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” or “derivative” where the alteration results in the substitution of an amino acid, e.g., with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. According to the present invention, modified variants of the peptide hormones of the invention functionally retain their specific hormone activity when analyzed in a suitable model to determine said activity. 
     As used herein the term “peptide hormone” refers to any protein or peptide with hormonal activity, i.e. a peptide with signaling activity through the binding on its cognate receptor or to the class of peptide hormones involved in neuronal signaling, such as involved in a wide range of brain functions, including analgesia, reward, food intake, metabolism, reproduction, social behaviors, learning and memory. A peptide hormone may also be referred to as a neuropeptide. 
     The term “O-linked glycan” as used herein refers to the O-linked glycosylation with the addition of N-acetyl-galactosamine (GalNAc) to serine or threonine residues in the peptide hormones of the invention followed by other carbohydrates (such as galactose and sialic acid). 
     The phrase “at a predetermined specific site, such as in the receptor-binding region” as used herein refers to the addition or selection of peptides with an O-linked glycan at a site specifically selected. 
     The phrase “a truncated version or a variant as compared to the corresponding wild-type peptide hormone found in nature” is intended to refer to a peptide hormone which has been modified by either truncation or amino acid substitutions as compared with the same peptide hormone found in nature, such as found in vivo in the human body. Typically, the peptide hormone may be genetically engineered and/or chemically synthesized to include 1, 2, 3, 4, 5, 6, or 7 amino acids of the native peptide sequence being substituted with any other amino acid, such as conservative substitutions. Alternatively or in addition to this, 1, 2, 3, 4, 5, 6, or 7 amino acids may have been removed or added to the native peptide sequence. Accordingly, in some embodiments, the peptides hormone according to the present invention comprises 1, 2, 3, 4, 5, 6, or 7 substitutions, additions or deletions relative to the native wild-type peptide hormone. The amino acids used in the amino acid sequences according to the invention may be in both L- and/or D-form. It is to be understood that both L- and D-forms may be used for different amino acids within the same peptide sequence. In some embodiments the amino acids within the peptide sequence are in L-form, such as natural amino acids. 
     The term “improved stability” as used herein refers to peptides of the invention, which when tested e.g. in an in vitro assays as described in 70  exhibit improved stability as compared to the same peptide without this one or more O-linked glycan at a predetermined specific site, such as in the receptor-binding region. 
     The term “receptor sub-type selectivity switch” as used herein refers to peptides of the invention being receptor sub-type specific. 
     The term “O-linked glycan” or “O-glycosylation” refers to the attachment of a sugar molecule to an oxygen atom in an amino acid residue in a protein. 
     Specific Embodiments of the Invention 
     1. A formulation comprising at least one molecule of a peptide hormone species exhibiting a specific glycosylation pattern of one or more O-linked glycan(s) at a predetermined specific site of said peptide hormone species, wherein specific, defined glycosylation pattern means that the each molecule of said peptide hormone in said pharmaceutical formulation displays structural homogeneity with respect to the site of glycan attachment and/or with respect to the glycan attachment. 
     2. A formulation comprising at least one molecule of a peptide hormone species according to embodiment 1, wherein said peptide hormone species is selected from the group of sequences comprising SEQ ID NOs: 1, 2, 3, 5, 6, 7, 14, 15, 16, 21, 22, 23, 24, 25, 36, 37, 38, 39, 40, 41, 42, 43, 45, 46, 47, 48, 49, 51, 52, 54, 55, 56, 57, 72, 73, 74, 76, 79, 8, 81, 83, 84, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 106, 107, 108, 109, 113, 116, 117, 118, 119, 120, 130, 131, 135, 136, 143, 144, 147, 163, 164, 167, 168, 170, 184, 185, 186, 188, 189, 190, 191, 192, 204, 215, 217, 219, 222, 227, 229, 230, 231, 233, 234, 236, 252, 260, 262, 267, 272, and/or 279. 
     3. A formulation comprising at least one molecule of a peptide hormone species according to embodiment 1 or 2, wherein said peptide hormone species is selected from the group of sequences comprising SEQ ID NOs: 6, 7, 21, 22, 23, 24, 72, 74, 92, 95, 97, 99, 106, 107, 108, 116, 117, 118, 147, 163, 167, 185, 186, and/or 188. 
     4. A formulation comprising at least one molecule of a peptide hormone species according to any one of embodiments 1 to 3, wherein said peptide hormone species is selected from the group of sequences comprising SEQ ID NOs: 72, 95, 97, 106, 108, 147, 185, and/or 188. 
     5. A formulation comprising at least one molecule of a peptide hormone species according to any one of embodiments 1 to 4, wherein said peptide hormone species is SEQ ID NO: 147. 
     6. A formulation comprising at least one molecule of a peptide hormone species according to any one of embodiments 1 to 5, wherein said predetermined specific site of said peptide hormone is within the receptor-binding region. 
     7. A formulation comprising at least one molecule of a peptide hormone species according to any one of embodiments 1 to 6, wherein said peptide hormone exhibiting an specific glycosylation pattern of one or more O-linked glycan(s) at a predetermined specific site of said peptide hormone is obtainable by recombinant production using a host cell in which one or more glycosyltransferase gene(s) is/are inactivated or downregulated by inactivation and/or downregulation of one or more gene(s) selected from COSMC and C1GALT1; and/or by inactivation and/or downregulation of one or more gene(s) selected from GCNT3, GCNT4, B3GNT6, and/or by inactivation and/or downregulation and/or upregulation/activation of one or more gene(s) selected from ST6GALNAC1-6, ST3GAL1, GCNT3, GCNT4, and/or B3GNT6. 
     8. A formulation comprising comprising at least one molecule of a peptide hormone species according to any of embodiments 1 to 7, wherein said peptide hormone species exhibits a specific glycosylation pattern of one or more O-linked glycan(s) at a predetermined specific site of said peptide hormone and, wherein the one or more O-glycan structures include a glycan structure selected from a Core1, core2, core3, or core4 structure with optional elongation and sialic acid capping, wherein optionally the first monosaccharide attached in the synthesis of O-linked glycans is N-acetyl-galactosamine and wherein a core1 structure may be obtained by the addition of galactose, and wherein a core2 structure may be obtained by the addition of N-acetyl-glucosamine to the N-acetyl-galactosamine of the core1 structure and wherein the core3 structures may be obtained by the addition of a single N-acetyl-glucosamine to the first monosaccharide N-acetyl-galactosamin and core4 structures may be obtained by the addition of a second N-acetyl-glucosamine to the core3 structure. 
     9. A formulation comprising at least one molecule of a peptide hormone species according to any of embodiments 1 to 8, wherein the one or more O-glycan structures include a Tn (GalNAc) structure. 
     10. A formulation comprising at least one molecule of a peptide hormone species according to any of embodiments 1 to 9, wherein the one or more O-glycan structures include Tn (GalNAc) structure with one sialic acid capping (alpha2-6). 
     11. A formulation comprising at least one molecule of a peptide hormone species according to any of embodiments 1 to 10, wherein the one or more O-glycan structures include the core1 structures with one sialic acid capping (alpha2-6). 
     12. A formulation comprising at least one molecule of a peptide hormone species according to any of embodiments 1 to 11, wherein the one or more O-glycan structures include the core1 structures with one sialic acid capping (alpha 2-3) 
     13. A formulation comprising at least one molecule of a peptide hormone species according to any of embodiments 1 to 12, wherein the one or more O-glycan structures include the Core1 structures with two sialic acids capping (alpha 2-3 and alpha 2-6). 
     14. A formulation according to any one of embodiments 1 to 13, wherein said formulation is a pharmaceutical formulation. 
     15. A formulation comprising at least one molecule of a peptide hormone species as defined in any of the preceding embodiments 1 to 14, wherein said peptide hormone species comprises one or more O-linked glycan at a site indicated in and one of Tables 6A to 6E, particularly, wherein the site is a site in a human peptide hormone, more particularly, wherein the site is a conserved site in a human peptide hormone. 
     16. A formulation comprising at least one molecule of a peptide hormone species as defined in embodiment 15, wherein said peptide hormone species comprises one or more O-linked glycan at a site indicated in Table 6A or 6B, particularly, wherein the site is a site in a human peptide hormone, more particularly, wherein the site is a conserved site in a human peptide hormone. 
     17. A formulation comprising at least one molecule of a peptide hormone species as defined in embodiments 15 or 16, wherein said peptide hormone species comprises one or more O-linked glycan at a site of a peptide hormone indicated in Table 6B, particularly, wherein the site is a site in a human peptide hormone, more particularly, wherein the site is a conserved site in a human peptide hormone. 
     18. A formulation comprising at least one molecule of a peptide hormone species as defined in any one of embodiments 15 to 17, wherein said peptide hormone species comprises one or more O-linked glycan at a site of a peptide hormone indicated in Table 6C, particularly, wherein the site is a site in a human peptide hormone, more particularly, wherein the site is a conserved site in a human peptide hormone. 
     19. A formulation comprising at least one molecule of a peptide hormone species as defined in any one of embodiments 15 to 17, wherein said peptide hormone species comprises one or more O-linked glycan at a site of a peptide hormone indicated in Table 6C, particularly, wherein the site is a site in a human peptide hormone, more particularly, wherein the site is a conserved site in a human peptide hormone. 
     20. A formulation comprising at least one molecule of a peptide hormone species as defined in any one of embodiments 15 to 17, wherein said peptide hormone species comprises one or more O-linked glycan at a site of a peptide hormone indicated in Table 6D, particularly, wherein the site is a site in a human peptide hormone, more particularly, wherein the site is a conserved site in a human peptide hormone. 
     21. A modified peptide hormone comprising one or more O-linked glycan at a predetermined specific site selected from the group comprising the peptide hormones indicated in 6A, particularly, wherein the site is a site in a human peptide hormone, more particularly, wherein the site is a conserved site in a human peptide hormone, and wherein said peptide hormone is selected from the group comprising SEQ ID Nos: 1, 2, 3, 5, 6, 7, 14, 15, 16, 21, 22, 23, 24, 25, 36, 37, 38, 39, 40, 41, 42, 43, 45, 46, 47, 48, 49, 51, 52, 54, 55, 56, 57, 72, 73, 74, 76, 79, 8, 81, 83, 84, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 106, 107, 108, 109, 113, 116, 117, 118, 119, 120, 130, 131, 135, 136, 143, 144, 147, 163, 164, 167, 168, 170, 184, 185, 186, 188, 189, 190, 191, 192, 204, 215, 217, 219, 222, 227, 229, 230, 231, 233, 234, 236, 252, 260, 262, 267, 272, and/or 279. 
     22. The modified peptide hormone according to embodiment 21 comprising one or more O-linked glycan at a predetermined specific site selected from the group comprising the peptide hormones indicated in 6B, particularly, wherein the site is a site in a human peptide hormone, more particularly, wherein the site is a conserved site in a human peptide hormone, and wherein said peptide hormone is selected from the group comprising SEQ ID Nos: 6, 7, 21, 22, 23, 24, 72, 74, 92, 95, 97, 99, 106, 107, 108, 116, 117, 118, 147, 163, 167, 185, 186, and/or 188. 
     23. The modified peptide hormone according to embodiments 21 or 22 comprising one or more O-linked glycan at a predetermined specific site selected from the group comprising the peptide hormones indicated in 6C, particularly, wherein the site is a site in a human peptide hormone, more particularly, wherein the site is a conserved site in a human peptide hormone, and wherein said peptide hormone is selected from the group comprising SEQ ID Nos: 72, 95, 97, 106, 108, 147, 185, and/or 188. 
     24. The modified peptide hormone according to any one of embodiments 20 to 23 comprising one or more O-linked glycan at a predetermined specific site selected from the group comprising the peptide hormones indicated in 6D, particularly, wherein the site is a site in a human peptide hormone, more particularly, wherein the site is a conserved site in a human peptide hormone, and wherein said peptide hormone is depicted in SEQ ID NO: 147. 
     25. The modified peptide hormone according to any one of embodiments 20 to 24, wherein the one or more O-glycan structures include a glycan structure selected from a Core1, core2, core3, or core4 structure with sialic acid capping, wherein the one or more O-glycan structures include a glycan structure selected from a core1, core2, core3, or core4 structure with optional elongation and sialic acid capping, wherein optionally the first monosaccharide attached in the synthesis of O-linked glycans is N-acetyl-galactosamine and wherein a core1 structure may be obtained by the addition of galactose, and wherein a core2 structure may be obtained by the addition of N-acetyl-glucosamine to the N-acetyl-galactosamine of the core1 structure and wherein the core3 structures may be obtained by the addition of a single N-acetyl-glucosamine to the first monosaccharide N-acetyl-galactosamin and core4 structures may be obtained by the addition of a second N-acetyl-glucosamine to the core3 structure. 
     26. The modified peptide hormone according to any of embodiments 21 to 25, wherein the one or more O-glycan structures include a Tn (GalNAc) structure. 
     27. The modified peptide hormone according to any of embodiments 21 to 26, wherein the one or more O-glycan structures include Tn (GalNAc) structure with one sialic acid capping (alpha2-6). 
     28. The modified peptide hormone according to any of embodiments 21 to 27, wherein the one or more O-glycan structures include the core1 structures with one sialic acid capping (alpha2-6). 
     29. The modified peptide hormone according to any of embodiments 21 to 28, wherein the one or more O-glycan structures include the core1 structures with one sialic acid capping (alpha 2-3) 
     30. The modified peptide hormone according to any of embodiments 21 to 29, wherein the one or more O-glycan structures include the core1 structures with two sialic acids capping (alpha 2-3 and alpha 2-6). 
     The present invention relates also to an isolated peptide hormone, such as recombinant, such as a neuropeptide comprising one or more O-linked glycan at a predetermined specific site, such as in the receptor-binding region. 
     In some embodiments according to the present invention, the one or more O-glycan structures include a glycan structure selected from a core1, core2, core3, or core4 structure with sialic acid capping, such as a structure as illustrated in  FIG. 1 . 
     In some embodiments according to the present invention, the one or more O-glycan structures include a Tn (GalNAc) structure. 
     In some embodiments according to the present invention, the one or more O-glycan structures include Tn (GalNAc) structure with one sialic acid capping (alpha2-6). 
     In some embodiments according to the present invention, the one or more O-glycan structures include the core1 structures with one sialic acid capping (alpha2-6). 
     In some embodiments according to the present invention, the one or more O-glycan structures include the core1 structures with one sialic acid capping (alpha 2-3) 
     In some embodiments according to the present invention, the one or more O-glycan structures include the core1 structures with two sialic acids capping (alpha 2-3 and alpha 2-6). 
     In some embodiments according to the present invention, the peptide hormone has improved, such as increased stability and/or circulatory half-life and/or other pharmacokinetic properties, such as improved stability in in vitro assays, plasma and/or bodyfluids. 
     In some embodiments according to the present invention, the peptide hormone has lower bioactivity in receptor signalling, such as decreased receptor stimulation in in vitro cell assays and/or in man. 
     In some embodiments according to the present invention, the peptide hormone exhibits improved receptor stimulation in in vitro cell assays and/or in animal models and/or in man. 
     In some embodiments according to the present invention, the peptide hormone exhibits altered blood-brain barrier uptake in animals or in man, such as increased blood-brain barrier uptake in animals or in man, or decreased blood-brain barrier uptake in animals or in human. 
     In some embodiments according to the present invention, the peptide hormone exhibits receptor sub-type selectivity switch. 
     In some embodiments according to the present invention, the peptide hormone is specific to one or more tissue in human, such as specific to tissue of the nervous system. 
     In some embodiments according to the present invention, the peptide hormone is selected from any one of tables 4, 5, or 6, such as selected from the list consisting of a peptide of the Neuropeptide Y family, such as NPY, PPY and PYY; a peptide of the Glucagon/Secretin family, such as GIP, Glucagon, GLP-1, GLP-2, PACAP, Secretin, PHM-27/PHV-42, Somatoliberin and VIP; a peptide of the Natriuretic peptide family, such as ANP, BNP and CNP, a peptide of the calcitonin family, such as calcitonin, and a peptide of the insulin family such as amylin. 
     In some embodiments according to the present invention, the peptide hormone is not found in nature. Accordingly, in some embodiments the peptide hormone according to the invention is not a wild-type hormone found in any species in nature. The peptide hormone according to the invention may be a peptide hormone that is a variant of a wild-type peptide hormone. Such peptide hormone variant may be a peptide that differ from the wild-type version by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid differences, such as amino acid substitutions, additions or deletions. A peptide variant according to the invention may have more than 80%, such as more than 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity with a corresponding wild-type peptide hormone found in nature. 
     In some embodiments according to the present invention, the peptide hormone is a truncated version or a variant as compared to the corresponding wild-type peptide hormone found in nature. 
     In some embodiments according to the present invention, the peptide hormone is selected from any one of table 6 comprising one or more O-linked glycan at a site as indicated in table 6, such as at a bold underlined position and/or an italic underlined position. 
     In some embodiments according to the present invention, the peptide hormone is selected from any one of table 6 comprising at least, not more than, or the exact number of O-linked glycan sites as indicated in table 6. 
     In some embodiments according to the present invention, the peptide hormone is selected from any one of table 5. 
     Subject matter of the present invention is also a (pharmaceutical or diagnostic) composition or formulation comprising a compound as defined in any of the preceding embodiments. 
     Subject matter of the present invention is also a (pharmaceutical or diagnostic) composition or formulation comprising a synthetic compound as defined in any of the preceding embodiments, wherein said (pharmaceutical or diagnostic) composition or formulation is suitable for administration to a patient in need thereof. 
     Subject matter of the present invention is also a peptide hormone or a pharmaceutical composition or formulation according to any of the above embodiments, wherein said composition or formulation is suitable for the localized or systemic administration, wherein the localized administration is preferably selected from the group of topical administration, including transdermal, ophthalmic, nasal, otologic, enteral, pulmonal and urogenital administration or local or systemic injection, including subcutaneous, intra-articular, intravenous, intracardiac, intramuscular, intraosseous or intraperitoneal administration. 
     Subject matter of the present invention is also a device according to the previous embodiment, wherein the device is suitable as a delivery system for immediate and/or sustained release of a peptide hormone as defined in anyone of the preceding embodiments, e.g., they may be used as drug (peptide hormone) delivery system or controlled drug (peptide hormone) release systems. 
     Subject-matter of the invention is also a device comprising a pharmaceutical composition or a pharmaceutical formulation as defined in any of the foregoing embodiments. A device may take any form that is suitable to deliver the synthetic compounds or any one of the compositions or formulations of the present invention. It may comprise biological and/or synthetic materials and may take form of a patch, a stent, an implantable device, hydrogel, etc. 
     Subject-matter of the invention is also a device as defined in any of the foregoing embodiments, wherein the device is a delivery system for immediate and/or sustained release of the peptide hormone as defined in any of the foregoing embodiments. 
     Subject-matter of the invention is also a method of treatment of an individual in need thereof and/or the amelioration of and/or the prevention of deterioration of a disease in an individual in need thereof, by administration to said individual of a therapeutically efficient amount of any of the peptide hormones according to the present invention and/or pharmaceutical compositions as defined above. 
     The administration of the compounds (peptide hormones) according to this invention and pharmaceutical compositions according to the invention may be performed in any of the generally accepted modes of administration available in the art. Illustrative examples of suitable modes of administration include intravenous, oral, nasal, inhalable, parenteral, topical, transdermal and rectal delivery. Parenteral and intravenous delivery forms are preferred. In aspects of the invention injectable formulations comprising a therapeutically effective amount of the compounds (peptide hormones) of the invention are provided, including salts, esters, isomers, solvates, hydrates and polymorphs thereof, at least one vehicle comprising water, aqueous solvents, organic solvents, hydro-alcoholic solvents, oily substances, or mixtures thereof, and optionally one or more pharmaceutically acceptable excipients. Standard knowledge regarding these pharmaceutical ingredients and pharmaceutical formulations/compositions may be found, inter alia, in the ‘Handbook of Pharmaceutical Excipients’; Edited by Raymond C Rowe, Paul J Sheskey, Walter G Cook and Marian E Fenton; May 2012 and/or in Remington: The Science and Practice of Pharmacy, 19th edition. The pharmaceutical compositions/formulations may be formulated in the form of a dosage form fororal, intravenous, nasal, inhalable, parenteral, topical, transdermal and rectal and may thus comprise further pharmaceutically acceptable excipients, such as buffers, solvents, preservatives, disintegrants, stabilizers, carriers, diluents, fillers, binders, lubricants, glidants, colorants, pigments, taste masking agents, sweeteners, flavorants, plasticizers, and any acceptable auxiliary substances such as absorption enhancers, penetration enhancers, surfactants, co-surfactants, and specialized oils. 
     The proper excipient(s) is (are) selected based in part on the dosage form, the intended mode of administration, the intended release rate, and manufacturing reliability. Examples of common types of excipients include also various polymers, waxes, calcium phosphates, sugars, etc. 
     Polymers include cellulose and cellulose derivatives such as HPMC, hydroxypropyl cellulose, hydroxyethyl cellulose, microcrystalline cellulose, carboxymethylcellulose, sodium carboxymethylcellulose, calcium carboxymethylcellulose, and ethylcellulose; polyvinylpyrrolidones; polyethylenoxides; polyalkylene glycols such as polyethylene glycol and polypropylene glycol; and polyacrylic acids including their copolymers and crosslinked polymers thereof, e.g., Eudragit® (Rohm), polycarbophil, and chitosan polymers. Waxes include white beeswax, microcrystalline wax, carnauba wax, hydrogenated castor oil, glyceryl behenate, glycerylpalmitol stearate, and saturated polyglycolyzed glycerate. Calcium phosphates include dibasic calcium phosphate, anhydrous dibasic calcium phosphate, and tribasic calcium phosphate. Sugars include simple sugars, such as lactose, maltose, mannitol, fructose, sorbitol, saccharose, xylitol, isomaltose, and glucose, as well as complex sugars (polysaccharides), such as maltodextrin, amylodextrin, starches, and modified starches. 
     The pharmaceutical compositions/formulations of the present invention may be formulated into various types of dosage forms, for instance as solutions or suspensions, or as tablets, capsules, granules, pellets or sachets for oral administration. 
     The pharmaceutical composition of the present invention can be manufactured according to standard methods known in the art. Granulates according to the invention can be obtained by dry compaction or wet granulation. These granulates can subsequently be mixed with e.g. suitable disintegrating agents, glidants and lubricants and the mixture can be compressed into tablets or filled into sachets or capsules of suitable size. Tablets can also be obtained by direct compression of a suitable powder mixture, i.e. without any preceding granulation of the excipients. Suitable powder or granulate mixtures according to the invention are also obtainable by spray drying, lyophilization, melt extrusion, pellet layering, coating of the active pharmaceutical ingredient or any other suitable method. The so obtained powders or granulates can be mixed with one or more suitable ingredients and the resulting mixtures can be delivered in sterile primary packaging devices for reconstitution before parenteral administration Injectable compositions of the present invention may contain a buffer (for example, sodium dihydrogen phosphate, disodium hydrogen phosphate and the like), an isotonizing agent (for example, glucose, sodium chloride and the like), a stabilizer (for example, sodium hydrogen sulfite and the like), a soothing agent (for example, glucose, benzyl alcohol, mepivacaine hydrochloride, xylocaine hydrochloride, procaine hydrochloride, carbocaine hydrochloride and the like), a preservative (for example, p-oxybenzoic acid ester such as methyl p-oxybenzoate and the like, thimerosal, chlorobutanol, benzyl alcohol and the like) and the like, if necessary. In addition, the injectable composition of the present invention may contain vitamins and the like. Further, injectable compositions of the present invention may contain an aqueous solvent, if necessary. Examples of the aqueous solvent include purified water for injection, physiological saline solution, and glucose solution. In injectable compositions of the present invention, the pharmaceutical compound (peptide hormone) may be solid. As used herein, the “solid” comprises crystals and amorphous substances which have conventional meanings. The form of the solid component is not particularly limited, but powder is preferred in view of dissolution rate. 
     Pharmaceutical Formulations 
     Still another aspect of the present invention relates to the use of the peptide hormones according to the present invention, e.g. as shown in Tables 6A-E) as an active ingredient, together with at least one pharmaceutically acceptable carrier, excipient and/or diluents for the manufacture of a pharmaceutical composition for the treatment and/or prophylaxis of appropriate disorders or diseases. 
     Administration forms include, for example, pills, tablets, film tablets, coated tablets, capsules, liposomal formulations, micro- and nano-formulations, powders and deposits. Furthermore, the present invention also includes pharmaceutical preparations for parenteral application, including dermal, intradermal, intragastral, intracutan, intravasal, intravenous, intramuscular, intraperitoneal, intranasal, intravaginal, intrabuccal, percutan, rectal, subcutaneous, sublingual, topical, or transdermal application, which preparations in addition to typical vehicles and/or diluents contain the compounds according to the present invention. 
     The compounds of the invention can also be administered in form of its pharmaceutically active salts. Suitable pharmaceutically active salts comprise acid addition salts and alkali or earth alkali salts. For instance, sodium, potassium, lithium, magnesium or calcium salts can be obtained. 
     The pharmaceutical compositions/formulations according to the present invention will typically be administered together with suitable carrier materials selected with respect to the intended form of administration, i.e. for oral administration in the form of tablets, capsules (either solid filled, semi-solid filled or liquid filled), powders for constitution, aerosol preparations consistent with conventional pharmaceutical practices. Other suitable formulations are hydrogels, elixirs, dispersible granules, syrups, suspensions, creams, lotions, solutions, emulsions, suspensions, dispersions, and the like. Suitable dosage forms for sustained release include tablets having layers of varying disintegration rates or controlled release polymeric matrices delivered with the active components. The pharmaceutical compositions may be comprised of 0.01 to 95% by weight of the peptide hormones of the invention. 
     As pharmaceutically acceptable carrier, excipient and/or diluents can be used HSA, lactose, sucrose, cellulose, mannitol. 
     Suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethyl-cellulose, polyethylene glycol and waxes. Among the lubricants that may be mentioned for use in these dosage forms, boric acid, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include starch, methylcellulose, guar gum and the like. Sweetening and flavoring agents and preservatives may also be included where appropriate. Some of the terms noted above, namely disintegrants, diluents, lubricants, binders and the like, are discussed in more detail below. Additionally, the compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components or active ingredients to optimize the therapeutic effects. Suitable dosage forms for sustained release include controlled release polymeric matrices or hydrogels embedding the active components. Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier such as inert compressed gas, e.g. nitrogen. 
     For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides such as cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein by stirring or similar mixing. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify. 
     Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for parenteral administration. Such liquid forms include solutions, suspensions and emulsions. 
     The compounds of the present invention may also be deliverable transdermally. The transdermal compositions may take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose. 
     The transdermal formulation of the compounds of the invention is understood to increase the bioavailability of said compound into the circulating blood. One problem in the administration of peptidic drugs in general is the loss of bioactivity due to the formation of insolubles in aqueous environments or due to degradation. Therefore, stabilization of compounds for maintaining their fluidity and maintaining their biological activity upon administration to the patients in need thereof needs to be achieved. Prior efforts to provide active agents for medication include incorporating the medication in a polymeric matrix whereby the active ingredient is released into the systemic circulation. Known sustained-release delivery means of active agents are disclosed, for example, in U.S. Pat. Nos. 4,235,988, 4,188,373, 4,100,271, US447471, U.S. Pat. Nos. 4,474,752, 4,474,753, or U.S. Pat. No. 4,478,822 relating to polymeric pharmaceutical vehicles for delivery of pharmaceutically active chemical materials to mucous membranes. The pharmaceutical carriers are aqueous solutions of certain polyoxyethylene-polyoxypropylene condensates. These polymeric pharmaceutical vehicles are described as providing for increased drug absorption by the mucous membrane and prolonged drug action by a factor of two or more. The substituents are block copolymers of polyoxypropylene and polyoxyethylene used for stabilization of drugs such as insulin. 
     Aqueous solutions of polyoxyethylene-polyoxypropylene block copolymers (poloxamers) are useful as stabilizers for the compounds. Aside from serving as a stabilizer for the compound, poloxamers provide excellent vehicles for the delivery of the compound, and they are physiologically acceptable. Poloxamers, also known by the trade name Pluronics (e.g. Pluronic F127, Pluronic P85, Pluronic F68) have surfactant properties that make them useful in industrial applications. Among other things, they can be used to increase the water solubility of hydrophobic, oily substances or otherwise increase the miscibility of two substances with different hydrophobicities. For this reason, these polymers are commonly used in industrial applications, cosmetics, and pharmaceuticals. They have also been used as model systems for drug delivery applications. In situ gelation of pharmaceutical compositions based on poloxamer that are biologically triggered are known in the art (e.g. U.S. Pat. No. 5,256,396), describing compositions containing poloxamer 407 and water at specified concentrations. 
     Gels refer to the active ingredients dispersed or solubilized in a hydrophilic semi-solid matrix. Powders for constitution refer to powder blends containing the active ingredients and suitable diluents which can be suspended in water and may contain optionally buffer salts, lactose, amino acids, excipients, sugars and isotonisation reagents. 
     Recently, increasingly improved and potent protein-based and peptide-based drugs have been developed by the biotech industry. However, the prophylactic and/or therapeutic use of many other protein- or peptide-based compounds has been hampered because of their susceptibility to proteolytic breakdown, rapid plasma clearance, peculiar dose-response curves, immunogenicity, bioincompatibility, and/or the tendency of peptides and proteins to undergo aggregation, adsorption, and/or denaturation. These characteristics often render traditional methods of drug delivery ineffective or sub-optimal when applied to protein or peptide based drugs. Therefore, an immense amount of interest has been increasingly placed on controlled and/or sustained release drug delivery systems to maintain the therapeutic efficacy or diagnostic value of these important classes of biologically active agents. One of the primary goals of sustained delivery systems is to maintain the levels of an active agent within an effective range and ideally at a constant level. One approach for sustained delivery of an active agent is by microencapsulation, in which the active agent is enclosed within a polymeric matrix. The importance of biocompatible and/or biodegradable polymers as carriers for parenteral drug delivery systems is now well established. Biocompatible, biodegradable, and relatively inert substances such as poly(lactide) (PLA) or poly(lactide-co-glycolide) (PLG) structures such as microparticles or films containing the active agent to be administered are commonly employed sustained delivery devices (for review, see M. Chasin, Biodegradable polymers for controlled drug delivery. In: J.O. Hollinger Editor, Biomedical Applications of Synthetic Biodegradable Polymers CRC, Boca Raton, Fla. (1995), pp. 1-15; T. Hayashi, Biodegradable polymers for biomedical uses. Prog. Polym. Sci. 19 4 (1994), pp. 663-700; and Harjit Tamber, Pal Johansen, Hans P. Merkle and Bruno Gander, Formulation aspects of biodegradable polymeric microspheres for antigen delivery Advanced Drug Delivery Reviews, Volume 57, Issue 3, 10 Jan. 2005, Pages 357-376). A relatively steady release of one or more active agents incorporated within such polymers is possible because of the degradation profile of these polymers in an aqueous environment. By encapsulating active agents in a polymer matrix in various forms such as microparticles and/or films the active agent is released at a relatively slow rate over a prolonged time. Achieving sustained drug release in such a manner may afford less frequent administration, thereby increasing patient compliance and reducing discomfort; protection of the therapeutic compound within the body; potentially optimized prophylactic or therapeutic responses and prolonged efficacy; and avoidance of peak-related side-effects by maintaining more-constant blood levels of the active agent. Furthermore, these compositions can oftentimes be administered by injection, allowing for localized delivery and high local concentrations of the active agents. 
     With regard to highly active biologies, such as growth factors, local in the form of a bolus injection results in rapid diffusion from the region of interest and can cause severe side effects and limit efficacy. The oldest way is to use biophysical retention by changing the biophysical properties in form of viscosity, porosity, hydrophobicity or charge of the material to attain a purposeful delivery. This strategy often substantially modifies the properties of the tissue and conditions for cells, requiring more appropriate, biocompatible release mechanisms. 
     Methods of Treatment 
     Treatment methods of the invention comprise the step of administering to a subject a therapeutically effective amount of at least one peptide hormone according to the invention or a pharmaceutical composition/formulation of the invention. The administration may be effected by any route, e.g., dermally, parenterally, topically, etc. 
     As indicated previously “therapeutically effective amount” of a at least one peptide hormone according to the invention preferably refers to the amount necessary to achieve the therapeutic outcome. 
     The choice of the optimal dosage regime and duration of medication, particularly the optimal dose and manner of administration of the active compounds necessary in each case can be determined by a person skilled in the art on the basis of his/her expert knowledge. 
     Subject matter of the present invention is also any of the above the above at least one peptide hormone in method of manufacturing a medicament for the treatment of an appropriate condition or diseases. 
     EXAMPLES 
     Example 1 
     Development of a Sensitive O-Glycoproteomics Work Flow Enriching for Peptide Hormones 
     The present inventors originally developed the so-called SimpleCell O-glycoproteomics strategy 18,71 , and provided a vast expansion of the knowledge of the human O-glycoproteome. While more than 3,000 O-glycosites were identified in almost 1,000 human proteins 28,71 . In order to specifically explore potential O-glycans on peptide hormones the present inventors developed a novel proteomics based strategy selective for smaller peptides. The overall strategy for exploring O-glycosylation of peptide hormones is presented in  FIG. 2A . The present inventors chose to use the strategy on cells and organs known to produce and secrete high levels of diverse peptide hormones. For tissues the present inventors selected the whole-brain and cerebellum from both rat and pig as neuronal sources, porcine pancreas, ileum and heart as endocrine sources. For human samples, prostate cancer was chosen as well as plasma since both endocrine and neuroendocrine tissues secrete peptide hormones into the blood stream. For cell lines, the present inventors chose the mouse neuroblastoma cell line N2A and the mouse enteroendocrine STC1 cell line that is a natural source of gut hormones. 
     Peptide hormones are typically short peptides of 30-50 amino acids, and to achieve optimal peptide hormone coverage in the mass spectrometry analysis, the present inventors used different pre-extraction methods for the tissue- and plasma samples (precipitation with organic solvents or acidic water extraction) to ensure enrichment of shorter peptides. For the cell lines, the present inventors furthermore used different proteolytic enzymes (trypsin, Glu-C and/or chymotrypsin) for protein digestion to facilitate better coverage of proteins in the LWAC-LC/MS workflow ( FIG. 1N ). 
     When studying protein O-glycosylation in complex mixtures enrichment of glycopeptides is essential for glycan detection due to suppression of glycopeptide ionization by the presence of large amounts of unglycosylated peptides 72 . In the case of N2A cells expressing truncated O-glycans due to a spontaneous mutation in the COSMC gene 73 , the Tn (GalNAc) binding VVA ( vicia villosa  lectin) was used as previously described. Normal cells generally produce elongated O-glycans of core 1 or in some cases cores 2-4 structures with capping sialic acids ( FIG. 1 ), and the majority of O-glycoproteins found in plasma carry the sialylated Core 1 structures (Core 1) 12,74 . The present inventors therefore hypothesized that secreted and circulating peptide hormones would carry similar O-glycan structures if they were O-glycosylated, and based on this the present inventors designed an enrichment strategy that depended on initial neuraminidase treatment of plasma, tissue extracts and cell pellets to remove capping sialic acids followed by protease digestion and LWAC enrichment using the lectins PNA (peanut agglutinin) and/or Jacalin that recognize and bind Core 1 O-glycans as previously described 11,12 . Following lectin enrichment, glycopeptides were fragmented and sequenced using HCD and ETD LC-MS/MS ( FIG. 2A ). 
     Example 2 
     Identification of O-Glycans on Peptide Hormones 
     In total the present inventors identified 2,327 O-glycoproteins (199 from human, 898 from pig, 509 from rat and 721 from mouse) with approximately 5,000 unambiguously assigned sites and another approximately 8,000 ambiguously assigned modification specific O-glycopeptides where site information was not obtained due to poor quality spectra or lack of ETD data from 10 different tissues and multiple species ( FIG. 2A ). 
     In order to extract information on glycosylated peptide hormones across several species (see  FIG. 2A  right panel for schematic summary), the sequenced glycopeptide fragments were aligned to the 104 human proproteins annotated in the most comprehensive available database of both neuropeptides and peptide hormones (NeuroPeP) 75 . This analysis resulted in 6347 glycopeptide fragments from 135 orthologous proproteins. 
     To further explore the total number of O-glycosylated peptide hormones across the mammalian species analysed, the present inventors realigned the resulting peptide fragments to the corresponding human homolog resulting in 62 preproproteins ( FIG. 2B ). Subsequently, mapping the identified sites onto the mature peptide hormones demonstrated that 92 out of the 279 annotated mature human peptide hormones carried O-glycans at one of more sites (Table 6 and  FIG. 2B ). A minor fraction of these proteins and glycosites were reported previously, and the data thus confirmed the presence of known O-glycans on 17 preproproteins and 33 mature peptide hormones with the vast majority belonging to the well-described chromogranin and SAAS families 9-14,54-56,76-79 . The majority of the identified O-glycoproteins were novel and included 45 preproproteins and 59 mature peptide hormones ( FIG. 2B ). Among these were well-characterized peptide hormones including GLP-1, insulin, cholecystokinin, PYY, galanin and secretin, which unexpectedly were found to carry O-glycans. 
     On average, our strategy resulted in the identification of 10-20 glycosylated peptide hormones per analyzed sample, with the exception of the plasma and brain samples that resulted in identification of 5 and 39 glycosylated peptide hormones, respectively ( FIG. 2D ).  FIG. 3  presents a summary of glycosylated peptide hormones in the respective peptide hormone families. Out of 46 peptide hormone families (279 members) the present inventors found O-glycans in 29 families (92 members). 
     Example 3 
     O-Glycans Identified in Conserved Receptor Binding Domains of Peptide Hormone Families 
     PTMs are known to change the biochemical properties and diversify protein function. In particular O-glycosylation in close proximity to limited proteolytic cleavage sites has been demonstrated to e.g. co-regulate limited proteolytic processing. Therefore, the present inventors first explored if the identified sites were in close proximity (+/−3 a.a.) to physiological relevant cleavage sites in peptide hormones. However, mapping the identified sites relative to peptide hormone length revealed that this was not the case. 
     The major characterized structural or functional features of peptide hormones, besides limited proteolytic processing, are their ability to be recognized by and bind highly selective receptors. The present inventors therefore explored the positions of glycosites relative to characterized structural and/or functional receptor binding regions, and surprisingly, in six different peptide hormone families the majority of identified or predicted sites were indeed located in known receptor binding regions ( FIG. 4A-F ). Furthermore, evolutionary analysis by alignment of individual peptide hormones for each family revealed that clear conservation of the O-glycosites, both between members within families as well as through evolution of the individual peptide hormones ( FIG. 4A-F ), strongly suggesting that these O-glycosites have functionally and/or structurally importance. 
     The following details findings in each of the hormone families. Glycosylated residues are numbered according to the length of the mature processed bioactive peptide hormones: 
     Example 4 
     O-Glycans Identified in Conserved Receptor Binding Domains of the Secretin/Glucagon Family 
     The members of the Secretin/Glucagon family function in water homeostasis and regulation of feeding behavior and have remarkable sequence homology. Here the present inventors identified O-glycans on Secretin, Vasoactive Intestinal Peptide (VIP), Peptide Histidine Methionine/valine (PHM-27/PHV-42), Glucagon and Glucagon-like peptide 1(GLP-1), positioned in the N-terminal part of the peptide hormones, which has been shown to be important for receptor binding and activation 80  ( FIG. 4A ). While the present inventors did not identify glycans in all members of this family, the identified O-glycosite is fully conserved in Glucagon-like peptide 2 (GLP-2), Pituitary Adenylate Cyclase-activating Peptide (PACAP) and Somatoliberin, as well as partially in Gastric inhibitory peptide (GIP), where the predicted site is shifted 1 amino acid in the C-terminal direction. Furthermore, aligning all the members of the Secretin/Glucagon family demonstrated a highly conserved sequence motif Phe-Thr-Ser/Asp as a common denominator for glycosylation where both Thr and Ser are possible acceptor sites for glycosylation ( FIG. 4A ). 
     Example 5 
     O-Glycans Identified in Conserved Receptor Binding Domains of the Calcitonin Family 
     Members of the Calcitonin control a number of processes, including calcium/phosphate balance (Calcitonin), insulin dependent glucose metabolism (Amylin/IAPP) and vasodilation (Adrenomedullin and Intermedin) 81 . The present inventors identified O-glycans on all members of the Calcitonin family with the exception of Intermedin ( FIG. 4B ). Similar to the Secretin/Glucagon family, the present inventors identified a possible common sequence motif in the small conserved disulfide loop C(x)xxxTC for glycosylation of members of the Calcitonin family, where two cysteines are spaced by 4-5 amino acids including the Thr acceptor. This conserved Thr residue (Thr5 in Calcitonin) the present inventors found glycosylated in Amylin located in the disulfide ring structure, which is essential for receptor binding 82 . Moreover, in a study with artificial O-glycans it was shown that O-glycans may alter the alpha-helical structure of the Calcitonin peptide 83 . 
     Example 6 
     O-Glycans Identified in Conserved Receptor Binding Domains of the Insulin-Like Growth Factor Family 
     In the IGF/Insulin subfamily of the Insulin gene superfamily, the present inventors identified an O-glycan on Insulin in the B-chain at Thr27 in a semi-conserved residue found as a serine in Insulin Growth Factor II (IGFII) and a threonine shifted a few positions C-terminally in Insulin Growth Factor I (IGFI) ( FIG. 4C ). This is surprising as Insulin is one of the most well-studied polypeptides, and the glycan identified in the sequence  47 GFFYTPKA 54  (HexHexNAc) was consistently found in 2 different species tested. 
     Example 7 
     O-Glycans Identified in Conserved Receptor Binding Domains of the Galanin Family 
     Galanin and Galanin-like peptide have multiple functions stimulating smooth muscle cell contraction and growth hormone and insulin release. On Galanin itself the present inventors identified an O-glycan on Thr3, which is an essential residue for receptor activation 84  and conserved in both members. In addition to this the present inventors found an O-glycan on Ser11, which is only present in Galanin and not the other family member Galanin-like peptide ( FIG. 4D ). 
     Example 8 
     O-Glycans Identified in Conserved Receptor Binding Domains of the Neuropeptide Y Family 
     The Neuropeptide Y family members, Neuropeptide Y (NPY), Peptide YY (PYY) and Pancreatic Polypeptide (PPY) share structural features and they all adopt a specific three-dimensional structure called the PP-fold. The peptides are involved in appetite regulation and anxious behavior, and the present inventors found all three members to carry O-glycans at the same conserved C-terminal Thr32 residue ( FIG. 4E ). The present inventors identified an additional N-terminal glycosylation site on NPY (Ser3) that was not conserved in the other members of the family. The C-terminal region of the NPY family members is essential for receptor binding, receptor selectivity and activation but also the mid-region and N-terminal has been shown to be important for receptor interaction 85 . 
     Example 9 
     O-Glycans Identified in Conserved Receptor Binding Domains of the Natriuretic Peptides Family 
     The present inventors identified O-glycans on all three precursors (pro Atrial Natriuretic peptide (ANP), pro B-type Natriuretic Peptide (BNP), pro C-type Natriuretic Peptide (CNP)) as previously described for proBNP 79 . However, the present inventors also identified O-glycans at Ser19 and Ser25 in the C-terminal cyclic receptor-binding region of mature ANP where Ser19 is highly conserved in all three members ( FIG. 4F ). 
     O-glycans on peptide hormones modulate receptor activation. 
     Considering the high degree of conservation and structural position of the identified O-glycans the present inventors next decided to explore the potential functional impact of site-specific O-glycosylation on mature peptide hormones. The present inventors selected Glucagon, GLP-1, Secretin, VIP, ANP, NPY, PYY and PPY as examples of peptide hormones where the present inventors identified O-glycosylation sites in known receptor activating regions for analysis in in vitro receptor binding assays. First, the present inventors used recombinant GalNAc-transferases for chemoenzymatic synthesis or chemically synthesized (SynPeptides, China) glycopeptide variants with Tn (GalNAcα1-O-Ser/Thr), elongated to T (Galβ1-3GalNAcα1-O-Ser/Thr) and sialylated ST (NeuAcα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures using recombinant purified glycosyl transferases. Secretin, Glucagon. GLP-1 and VIP were enzymatically GalNAc-glycosylated by GalNAc-T1 corresponding to position Thr7 (MS validated) in the mature peptide sequences and peptides from the NPY family were chemically synthesized with GalNAc at position Thr32. ANP was chemically synthesized with an O-glycan at position 19 and/or 25. Next HEK293 or COS-7 cells transiently expressing selected relevant cognate receptors were incubated with increasing concentrations of peptide or glycopeptide. Ligand/agonist efficacy and potency was measured by receptor activation as an increase in secondary messenger cAMP. 
     Cell Culture and Transfection: HEK293 and COS7-cells were cultured in DMEM containing 10% FBS in a humidified atmosphere at 37° C. with 5% C02 (Sigma-Aldritch, Germany). For experiments, cells were seeded onto 6- or 10-cm plates and cultured for 1-3 days to 60-80% confluency. Cells were transfected with 1-2.5 pg of receptor constructs for 24-48 h using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer&#39;s instructions, or alternatively, using linear 25-kDa polyethyleneimine (Polysciences). Both reagents were used at 1:3 DNA to reagent ratio. 
     cAMP and cGMP Accumulation Measured by HTRF®: Intracellular cAMP/cGMP levels were measured using a homogeneous time-resolved fluorescence (HTRF®) cAMP/cGMP Gs dynamic assay kit (CisBio Bioassays). Forty-eight hours post-transfection cells were detached and seeded into white 384-well microplates with 1,000 cells/well in 5 μl of stimulation buffer (DMEM, 1 mM 3-isobutyl-1-methylxanthine (IBMX), 0.2% BSA). For their stimulation, μl/well of the stimulation buffer containing appropriate doses of either naked peptide hormone or glycosylated variants were added. Then, cells were incubated for 30 min at 37° C. followed by lysis by addition of 5 μl/well of each of the supplied conjugate-lysis buffer containing d2-labeled cAMP/cGMP and Europium cryptate-labeled anti-cAMP/cGMP antibody, both reconstituted according to the manufacturer&#39;s instructions. Plates were incubated for 1 h in the dark at room temperature and time-resolved fluorescence signals were excited at 340 nm and measured at 620 and 665 nm, respectively using the EnSpire Multilabel Reader (PerkinElmer Life and Analytical Sciences). The cAMP/cGMP generated was interpolated from a cAMP standard curve generated in parallel for each experiment. 
     IP-1 Accumulation Measured by HTRF®: Intracellular IP-1 levels were measured, similarly to cAMP, using a homogeneous time-resolved fluorescence (HTRF®) IP-1 Gq assay kit (CisBio Bioassays). This assay is dependent on co-transfection of the receptor with a chimeric G-protein to obtain sufficient signal of the Gq pathway. In this assay NPY2R was used together with Gqo5. Forty-eight hours post-transfection cells were detached and seeded into white 384-well microplates with 10,000 cells/well in 7 μl of supplied stimulation buffer supplemented with 0.1% BSA. For stimulation, 7 μl/well of the supplemented stimulation buffer containing appropriate doses of either naked peptide hormone or glycosylated variants were added. Then, cells were incubated for 2 h at 37° C. followed by lysis by addition of 3 μl/well of each of the supplied conjugate-lysis buffer containing d2-labeled IP-1 and Europium cryptate-labeled anti-IP-1 antibody, both reconstituted according to the manufacturer&#39;s instructions. Plates were incubated for 1 h in the dark at room temperature and time-resolved fluorescence signals were excited at 340 nm and measured at 620 and 665 nm, respectively using the EnSpire Multilabel Reader (PerkinElmer Life and Analytical Sciences). The IP-1 generated was interpolated from a IP-1 standard curve generated in parallel for each experiment. 
     Example 10 
     O-Glycans on VIP Modulate Receptor Activation. 
     The two VIP/PACAP receptors (VPAC1 and VPAC2) show comparable affinities for VIP 52,86 , thus the present inventors selected VPAC1 for analysis of VIP binding and activation. In this assay VIP exhibited a potency of 0.2 nM and 0.4 for VPAC1 &amp; 2 respectively, which is in good agreement with previous studies. VIP with one O-glycan (GalNAc/Tn) at residue 7 (VIP-Thr7/Tn) showed a 581-fold decrease in potency to 102 nM for VPAC1 ( FIG. 5A ) and a 681-fold decrease to 242 nM for VPAC2 ( FIG. 5B ). Elongation of the O-glycan on VIP to T and ST structures changed the potency to 44 nM and 74 nM, respectively for VPAC1 and 130 and 244 nM respectively for VPAC2 ( FIG. 8 ). 
     Example 11 
     O-Glycans on Secretin Modulate Receptor Activation. 
     Secretin binds and signals exclusively through the secretin receptor (SCTR), and in our assay secretin had a potency of 0.1 nM for SCTR, comparable to values found in previous studies, whereas secretin with a single O-glycan (GalNAc/Tn) at residue 7 (Secretin-Thr7-Tn) decreased the potency 2200-fold to 205 nM. Elongation of the glycan on secretin to T and ST structures further reduced potency 1-7 fold for each elongation step to 292 nM and 1932 nM, respectively ( FIG. 5C ). 
     Example 12 
     O-Glycans on GLP-1 Modulates Receptor Activation. 
     GLP-1 binds and signals exclusively through the GLP-1 receptor (GLP-1R), and in our assay GLP-1 showed a potency of 0.04 nM for GLP-1R, comparable to values found in previous studies. Elongation of the glycan at position 7 on GLP-1 to T, ST and diST (GLP1-Thr7/Tn/T/diST) further reduced potency approximately 20-40 fold fold for each elongation step to 253 nM, 266 nM, and 461 nM, respectively ( FIG. 5D  and  FIG. 8 ). 
     Example 13 
     O-Glycans on Glucagon Modulates Receptor Activation. 
     As with GLP-1 and the GLP-1R, Glucagon binds and signals exclusively through the glucagon receptor (GCGR). The non-glycosylated glucagon showed a potency of 1.29 nM in line with previous literature. Upon introducing a Tn-glycoform at Thr7 (Glucagon-Thr7/Tn), the potency is decreased almost a 100-fold to 126 nM. This potency is reduced 5 times further when elongating to T (667.9 nM). However, the introduction of sialic acid (ST) did not significantly influence the potency further compared to the non-sialylated T-structure (615.7 nM). Importantly, removal of the glycan from the T-glycosylated glucagon restored the potency to the non-glycosylated levels eliciting an EC50 of 1,235 nM ( FIG. 5E  and  FIG. 8 ). 
     Example 14 
     O-Glycans on NPY, PYY and PPY Modulate Receptor Activation. 
     The NPY family peptide hormones activate members of the NPY receptor family (Y1, Y2, Y4, and Y5), where mature NPY (1-36) and PYY (1-36) preferentially binds Y1, Y2 and Y5, and PPY preferentially binds Y4. The Y1 receptor seem to have strict requirements for the N-terminal part of the peptides as N-terminal truncation gradually decreases affinity for NPY. In contrast the Y2 receptor is more sensitive to alterations in the C-terminus of NPY and PYY and single amino acid substitutions in the C-terminus can lower affinity for the Y2 receptor 87 . 
     The present inventors developed a receptor assay for the binding study of the NPY family to the four known receptors. As expected according to reference values in the literature PYY, NPY, had respective potencies (EC50-values) of 0.47 nM and 2.16 nM at NPY1R, 0.34 nM and 4.11 nM at receptor NPY2R, 11.35 nM and 199.9 nM at receptor NPY4R, and 12.04 and 15.03 nM at receptor NPY5R ( FIGS. 5F-M  and  FIG. 8 ). Introduction of a Tn-glycan on position Thr32 in NPY (NPY-Thr32/Tn) inferred a 118-fold and 37-fold decrease in potency at receptor NPY2R and NPY5R, respectively ( FIGS. 5H &amp;J) whereas receptor potencies at NPY4R and NPY5R was decreased to a level beyond the assayed range. Even though the receptor activation at these receptors did not did not reach Emax within the assayed range, activity was still observable which indicates potencies in terms of EC50-values that are above 1 pM. NPY-Thr32/T and NPY-Thr32-ST exhibited minimal activation and did not reach Emax within the assayed range at all receptors, thus indicating potencies in terms of EC50-values above 1 pM ( FIGS. 5  F &amp; H &amp; J &amp; L). As with NPY, Introduction of a Tn-glycan on position Thr32 in PYY inferred a 61-fold (249.2 nM) and 37-fold (556.7 nM) decrease in potency at receptors NPY2R and NPY5R, respectively ( FIGS. 5I  &amp; K) whereas receptor activation at NPY4R and NPY5R was only retained to a minimal degree indicating potencies at levels above 1 μM. PYY-Thr32/T and PYY-Thr32/ST exhibited minimal activation and did not reach Emax in the assayed range at all receptors, thus indicating potencies in terms of EC50-values above 1 pM ( FIGS. 5  G &amp; I &amp; K &amp; M). Data is summarized in  FIG. 8 . A receptor preference shift was thus observed for both PYY and NPY when incorporating Tn at position 32, where the glycosylated peptide hormones activates the receptor in the following order NPY2R&gt;NPY5R&gt;&gt;NPY1R&gt;NPY4R upon increasing levels of agonist, whereas their non-glycosylated counterparts activates the receptors in a different order, namely: NPY2R&gt;NPY1R&gt;NPY5R&gt;NPY4R for NPY and NPY1R&gt;NPY2R&gt;NPY5R&gt;NPY4R for PYY. 
     Example 15 
     O-Glycans on ANP Modulate Receptor Activation. 
     ANP exerts its physiological effects mainly via the NPR-A receptor but binds also to NPR-C. NPR-C, however, is mainly regarded a clearance receptor thus the present inventors selected NPR-A for ANP binding and activation. 
     In this assay ANP exhibited a potency of 0.9 nM for NPR-A, which is in good agreement with previous studies 88 . ANP with one O-glycan (GalNAc/Tn) at residue 19 or 25 showed a 63- and 139-fold decrease in potency to 57 and 125 nM, respectively, whereas simultaneous O-glycans at residue 19 and 25 completely dismiss receptor activation. Elongation of the O-glycan on ANP residue 19 to T, ST and diST further reduced the potency 3- to 50-fold to 160 nM and 296 nM and 2699 nM, respectively. Elongation of the O-glycan on ANP residue 25 to T, ST and diST further reduced the potency 2- to 3-fold to 265 nM and 717 nM and 460 nM respectively ( FIGS. 5N and 5O ). O-glycans on ANP residue 19 resulted in approximately 20% reduction in efficacy and O-glycans on ANP residue 25 resulted in approximately 20% increase in efficacy. 
     In summary, all peptide hormones with O-glycans attached at one or more specific sites elicited a right-shifted full, partial agonist or superagonist response positively correlated to glycan size. 
     Example 16 
     O-Glycans Modulate Peptide Hormone Stability In Vitro 
     Many peptide hormones are destined for endocrine circulation where they are rapidly degraded with half-lives reaching only a few minutes 6-8 . The present inventors have previously demonstrated that O-glycans in close proximity to proteolytic processing sites can modulate the rate of processing 33 . To study if O-glycosylation of peptide hormones altered the inherent proteolytic instability of this class of biomolecules, the present inventors subjected selected glycopeptide hormones to ex vivo degradation assays using human plasma and in vitro degradation using neprilysin (NEP), insulin degrading enzyme (IDE) and dipeptidyl peptidase IV (DPP-IV) enzymes known to degrade peptide hormones and other bioactive peptides in vivo including ANP, GLP-1, PYY, VIP, Secretin and Galanin 89,90  ( FIGS. 6 and 7 ). The degradation pattern was monitored by MALDI-TOF analysis in a time-course assay with timepoints from 15 minutes to up to 24 hrs. 
     Degradation Assay: 
     For enzymatic degradation assays using either NEP or DPP-IV (R&amp;D systems, UK), an enzyme titration was carried out to ensure full degradation within one hour of reaction time. 15 pM of non-glycosylated peptide substrate and either 50 mM Tris, pH 9, 0.05% Brij for NEP or 50 mM Tris, pH 8 for DPP-IV was treated with varying enzyme amounts in a total volume of 10 μL incubated at 37° C. The degradation assay of the three glycoforms (Tn, T and ST) was performed under same reaction-parameters along with the non-glycosylated peptide (four separate reactions). The following amounts of enzyme were used for NEP reactions: 150 pg/pL enzyme for VIP, Galanin, secretin and their glycoforms, 20 ng/pL for PYY and its glycoforms. 4 and 10 ng/pL DPIV was used for the degradation of VIP+glycoforms and PYY+glycoforms respectively. For ex vivo plasma degradation assays, plasma was diluted to a final concentration of 20% plasma, 50 mM Tris (pH 7.7) and degradation of 15 pM (glyco-) peptide substrate was investigated. Degradation was carried out at 37° C. and several aliquots were taken between 0 minutes and 24 hours and degradation was monitored by MALDI-TOF-MS. 
     MALDI-TOF-MS was performed on a Bruker Autoflex instrument (Bruker Daltonik GmbH, Bremen, Germany) by mixing the quenched aliquots with a saturated solution of α-Cyano-4-hydroxycinnamic acid in ACN/H 2 O/TFA (70:30:0.1) at a ratio 1:1 on a target steel plate and mass-spectra were acquired in linear mode. 
     Example 17 
     O-Glycans on ANP Modulate Stability In Vitro 
     For the degradation assays with (glyco-)ANP, the amount of recombinant enzyme used was optimized to fully digest the naked peptide of interest within one hour of incubation at 37° C. In vitro cleavage activity was assayed by adding 2.5 ng Neprilysin (R&amp;D Systems) or 125 ng Insulin-degrading enzyme (IDE, R&amp;D Systems) to 813 pmol peptide or glycopeptide substrate in a total volume of 25 μL. Reactions were performed in 50 mM Tris, 0.05% Brij-35, pH 9 (Neprilysin), or 50 mM Tris, 20 mM NaCl, pH 7.5 (IDE) and incubated at 37° C. Product development was evaluated after 15 min, 30 min, 60 min, and 24 hours by MALDI-TOF and reverse-phase HPLC (C18). Neprilysin degraded ANP completely within 15 min, whereas and ANP-S25/Tn were degraded slower with residual full length ANP-S19/Tn detectable even after 60 min and residual ANP-S25/Tn detectable after 15 min. Residual ANP-S19/Tn, -S25/Tn was detectable after 30 min. After 1 hour, non-modified ANP was completely degraded whereas major degradation products of ANP-S19/Tn and ANP-S19/Tn, -S25/Tn remained detectable even after 24 hours incubation ( FIG. 6A ). In a similar time-course with insulin-degrading enzyme, ANP was completely degraded within 15 min, whereas ANP-S19/Tn and ANP-S25/Tn remained partly as full length glycopeptides after 30-60 minutes. Interestingly, ANP-S19/Tn, -S25/Tn was degraded within 15 minutes ( FIG. 6B ). 
     Example 18 
     O-Glycans on Secretin Modulate Stability In Vitro 
     In a similar manner, NEP completely degraded Secretin 1-27 to 1-22 within 60 minutes. Also here, glycosylation had a protective effect such that Thr34-Tn remained intact after 60 min and Thr34-T after 120 minutes. Again, sialylated Secretin Thr34-ST appeared resistant to NEP degradation even after 24 hrs ( FIGS. 7A and 7C ). 
     Example 19 
     O-Glycans on Galanin Modulate Stability In Vitro 
     Nonglycosylated Galanin 1-27 was degraded by NEP within 60 minutes whereas the Ser23-Tn and -T extended glycoforms were degraded after 120 min. The sialylated Galanin-Ser55/ST variant remained intact even after 24 hrs in solution suggesting that sialylation of Galanin is necessary for complete protection from NEP degradation, at least in vitro ( FIGS. 7B and 7C ). 
     Example 20 
     O-Glycans on VIP Increase Stability In Vitro 
     NEP cleaves VIP sequentially at Asp3/Ala4 then Phe6/Thr7, Lys21/Tyr22 and ultimately at Ala18/Val19 in vitro ( FIG. 7  for a summary). Non-glycosylated VIP peptide was completely degraded after 15 minutes with NEP treatment whereas Thr7-Tn glycosylated VIP remained partially intact after 15 minutes, Thr7-T glycosylated VIP remained partially intact after 30 minutes and VIP-Thr7/ST remained completely intact after 60 minutes ( FIGS. 7B and 7C ). 
     Example 21 
     O-Glycans on VIP Increase Stability In Vitro 
     DPP-IV also degrades VIP both in vivo and in vitro initially cleaving off two N-terminal amino acids Ser2/Asp3, then cleaves at Ala4/Val5 and lastly C-terminally at Tyr22/Leu23. Where the non-glycosylated VIP, Thr7-Tn and Thr7-T glycosylated VIP were degraded equally fast within 60 minutes, the sialylated VIP-Thr7/ST remained fully intact after 30 minutes and partially intact after 60 minutes ( FIGS. 7B and 7C ). 
     Example 22 
     O-Glycans on PYY Increase Stability In Vitro 
     NEP cleaves PYY at 4 positions at Tyr20/Tyr21, Ser23/Leu24, His26/Tyr27 and Leu30/Val31 in a sequence the present inventors were not able to decide. However whereas non-glycosylated PYY was degraded after 15 minutes all three PYY-Thr32/Tn/T/ST glycosylated peptides remained intact up to 120 minutes ( FIGS. 7B and 7C ). 
     Example 23 
     O-Glycans on PYY Increase Stability In Vitro 
     DPP-IV cleaves PYY both in vivo and in vitro N-terminally at Pro2/Ile3. Subjecting the non-glycosylated and Thr32 glycopeptide variants to in vitro DPPIV degradation revealed that where Tn- and T-glycosylation had no effect on DPP-IV activity Thr32/ST weakly protected the peptide from N-terminal degradation ( FIGS. 7B and 7C ). 
     Example 24 
     O-Glycans on PYY Increase Stability Ex Vivo 
     PYY is quickly removed from circulation due to the action of a number of proteases. To approximate in vivo conditions the present inventors chose to analyse PYY degradation using human plasma ex vivo. In plasma PYY is degraded both N-terminally at Pro2/Ile3 and Pro5/Glu6 and C-terminally at Gln34/Arg35 and where O-glycans at residue Thr32 (Thr32/Tn/T/ST) had no effect on the N-terminal degradation, as seen for the in vitro DPP-IV degradation, the present inventors observed full protection from the C-terminal degradation up to 24 hours of the PYY-Thr32/Tn/T/ST glycosylated PYY peptides whereas the non-glycosylated peptide was C-terminally degraded only after 1 hour ( FIGS. 7B and 7C ). 
     Example 25 
     O-Glycans on GLP-1 7-36  Increase Stability In Vitro and Predicts Increased Stability in Vivo 
     DPP-IV is one of the primary enzymes degrading GLP-1 7-36  (from hereon GLP-1) in the circulation in vivo 91 . DPP-IV removes the two N-terminal amino acids by cleaving between Ala2/Ser3 both in vitro and in vivo thus inactivating GLP-1, and mutating this DPP-IV cleavage site greatly enhances GLP-1 half-life in vivo 92 . Due to this link, DPP-IV inhibitors have successfully been used therapeutically to enhance the effects of endogenous GLP-1 91 . To test the effect of glycosylation in close proximity to the DPP-IV cleavage site we incubated GLP-1 with and without glycans with DPP-IV in vitro. Where the non-glycosylated GLP-1 was fully degraded after 30 minutes incubation with equimolar amounts of monoglycosylated GLP-1-Thr5/Tn and GLP-1-Thr7/Tn and equimolar amounts of GLP-1-Thr5/T or GLP-1-Thr7/T were protected against degradation until 120 minutes incubation. Equimolar amounts of the sialylated monoglycosylated GLP-1-Thr5/ST or GLP-1-Thr7/ST remained fully intact until the 120 minute-timepoint and small amounts of intact silaylated GLP-1 was detectable even after 24 h of incubation. The large body of literature on DPP-IV resistant GLP-1 analogs 91-93  taken together with the presented data on Tn, T or ST glycosylated GLP-1, predict that the GLP-1 decorated with either GalNAc (Tn), Gal-GalNAc (T) or Sialyl-GalGalNAc on positions Thr5 or Thr7 has an extended half-life in vivo. Results are summarized in  FIG. 7C . 
     NEP also play a role in the degradation of GLP-1 in the circulation, and it has been suggested that NEP is responsible for up to 50% of the degradation of GLP-1 93 . In our in vitro assay, NEP cleaves GLP-1 initially at Trp25/Leu26 followed by a second cleavage at Glu21/Phe22 consistent with NEP cleavage sites on GLP-1 reported earlier 94  ( FIG. 7C  for a summary). Non-glycosylated GLP-1 peptide was completely degraded after 60-minutes whereas a equimolar amounts monoglycosylated GLP- 1 -Thr5/Tn and GLP- 1 -Thr7/Tn remained partially intact after 60 minutes when treated with same amount of NEP. When elongating the glycan structure, equimolar amounts of GLP-1-Thr5/T or GLP-1-Thr7/T remained partially intact after 60 minutes. Equimolar amounts of GLP-1-Thr5/ST or GLP1-Thr7/ST remained completely intact after 60 minutes incubation indicating that either glycosite provide protection of the peptide hormone from NEP-mediated degradation. Small amounts of sialylated GLP-1 was still detectable after 20 h of incubation. Results are summarized in  FIG. 7C . 
     Example 26 
     O-Glycans on PYY and VIP are Present in Low Stoichiometry in Porcine Intestinal Extracts 
     Where the shotgun glycoproteomics strategy is designed to sequence and identify individual O-glycosylation sites it does not allow us to determine site occupancy in a given protein, i.e what is the proportion of glycosylated protein in the total pool of that protein in a given system (e.g. blood, lymph fluid, cell lysate, tissue etc.). To answer this question the present inventors developed a technique to quantify endogenous glycopeptides using either sensitive LC-MS or radioimmunaassay (RIA). Using extracted proteins from pig ileum the present inventors separated proteins from glycoproteins using Jacalin-LWAC and quantified non-glycosylated and glycosylated PYY using either a sensistive PYY-RIA 95  or in the case of VIP, sensitive LC-MS by comparing to isotope labelled standards in the form of in vitro synthesized (glyco-)VIP. In order to prepare the extract for mass spectrometry, the extracted proteins as well as the standards were digested with trypsin prior to Jacalin-LWAC in the case of LC-MS analysis of site occupancy on VIP. 
     The present inventors identified approximately 1% glycosylated PYY-Thr32/T and VIP-Thr7-T in porcine ileum tissue ethanol extracts confirming that (sialylated)-T-PYY and -VIP exist in the porcine intestine presumably at a concentration approximately two orders of magnitude below the non-glycosylated. 
     Example 27 
     O-Glycans on ANP Confer Retained and Prolonged Differential Agonist Effect In Vivo 
     To evaluate the function of O-glycans on ANP in vivo we investigated the cGMP generating, renal and blood pressure actions of equimolar dose (600 pmol/kg/min) ANP-Ser19/ST or ANP-Ser25/ST [n=4/group] in male Sprague Dawley rats (250-350 grams; Charles River Laboratories, Wilmington, Mass.). The protocol is outlined in  FIG. 9A . 
     Anesthesia in rats was induced with 133 mg/kg i.p. inactin (Sigma, St Louis, Mo.) and rats were maintained on a heating pad for 1 hour until completely anesthetized. Rats were then subjected to vessel and bladder cannulation for peptide infusion, BP measurement, blood sampling and urine collection. A polyethylene (PE)-5G tube catheter was placed into the jugular vein for inulin, peptide intravenous infusion. The carotid artery was cannulated with a PE-50 tube catheter for BP measurement (Sonometrics, London, Ontario, Canada) and blood sampling. The bladder was accessed and cannulated with a PE-50 tube catheter for passive urine collection. After completion of the above procedural set up, a 45 min equilibration period was performed that included continuous IV inulin and saline infusion. After the 45 min equilibration period, baseline (Time==Q min) parameters were recorded and one blood sampling (0.7 ml) was performed. The inulin and saline infusion was replaced by a continuous intravenously (i.v.) infusion of equimolar ANP-Ser19/ST or ANP-Ser25/ST for 60 min. The infusion rate was weight adjusted and equals weight*0.7/6000 ml/min. After 60 min infusion (Time=60 min), another blood sampling (0.7 ml) was conducted. A post-infusion clearance (Time=90 min) was performed for 30 min. At the end of the study, blood was collected to determine plasma ANP and cGMP levels and to calculate glomerular filtration rate (GFR). Urine was collected at the end of the infusion (Time=60 min) and the study (Time=90 min). Urinary sodium was measured with pHOx Ultra (Nova Biomedical, Waltham, Mass.). Urine flow (UV) and urinary sodium excretion (UNaV) were calculated as urine volume or sodium clearance per min, Inulin concentrations were measured with enthrone method and inulin clearance was used for GFR quantification. Urinary cGMP and ANP excretion rate was calculated based on raw values obtained in the urine and UV. 
     In Vivo Cardiovascular and Renal Actions 
     Infusion with ANP, ANP-Ser19/ST and ANP-Ser25/ST resulted in decrease in mean arterial pressure (MAP) and increase in plasma cGMP over the 60 minutes infusion period ( FIG. 9B ). In the following 30 minutes clearance period, in rats infused with ANP, the MAP rebounded whereas the glycosylated ANP (ANP-Ser19/ST or ANP-Ser25/ST) variants produced a sustained or further reduced in MAP. 
     Infusion with ANP resulted in an 4-5 fold increase in urine volume (UV) measured after 60 minutes ( FIG. 9C ) and a 5-10 fold increase in urinary sodium excretion (UNaV) ( FIG. 9D ) after 90 minutes. After a clearance period of 30 minutes the UV was normalized. In striking contrast infusion with ANP-Ser19/ST and ANP-Ser25/ST did not result in increased diuresis nor natriuresis and remained constant at 11-18 uL/min. ( FIG. 9D ). 
     Example 28 
     O-Glycans on ANP Increase Stability In Vivo 
     The sustained cardiovascular effect seen with ANP-Ser19/ST and ANP-Ser25/ST suggested that the glycosylated peptides circulate longer compared to the non-glycosylated ANP. Measuring plasma ANP after 90 minutes demonstrated that the non-glycosylated ANP circulated at low concentrations (mean, 148 ng/mL) whereas ANP-Ser19/ST and ANP-Ser25/ST was still present at 17-33 fold higher concentrations ( FIG. 9E ). Further supporting an increased stability the present inventors could measure both ANP-Ser19/ST and ANP-Ser25/ST at concentrations 41-74 fold higher than ANP in the urine after 90 minutes ( FIG. 9F ). 
     Comparison of Identified Glycosylated Peptide Hormones to Published Glycosylated Peptide Hormones 
     A number of pro-peptide hormones have been reported to be O-glycosylated on the pro-part (non-matured) (pro-brain natriuretic peptide (proBNP), POMC, proglucagon and kininogen). Very recently, two reports describing mature insulin, somatostatin and amylin as well as calcitonin O-glycosylation were released 13,83 . Apart from these, only adiponectin has been described as being O-glycosylated before in mammalian studies. 
     Definition of Peptide Hormones/Neuropeptides/Regulatory Peptides 
     Peptide hormones, regulatory peptides or neuropeptides are bioactive peptides that are approximately 3-100 amino acids long. They are involved in cell-cell signaling where they can bind and activate highly specific peptide hormone receptors upon binding. 
     
       
         
           
               
             
               
                 TABLE 4 
               
             
            
               
                   
               
               
                 (Human peptide hormones the SEQ ID Nos. of which are disclosed in Tables 6A to 6E infra) 
               
            
           
           
               
               
               
               
               
            
               
                 ID 
                 Sequence 
                 Length 
                 Family 
                 Name 
               
               
                   
               
            
           
           
               
               
               
               
               
            
               
                 NP00002 
                 SVPHFSDEDKDPE 
                 13 
                 7B2 
                 C-terminal peptide (By 
               
               
                   
                   
                   
                   
                 similarity) 
               
               
                   
               
               
                 NP00012 
                 YSPRTPDRVSEADIQRLLHGVMEQLGIARPRVEYPAHQAMNLVGPQSIEGGAHEGL 
                 186 
                 7B2 
                 Neuroendocrine protein 7B2 
               
               
                   
                 QHLGPFGNIPNIVAELTGDNIPKDFSEDQGYPDPPNPCPVGKTADDGCLENTPDTAE 
                   
                   
                   
               
               
                   
                 FSREFQLHQHLFDPEHDYPGLGKWNKKLLYEKMKGGERRKRRSVNPYLQGQRLD 
                   
                   
                   
               
               
                   
                 NVVAKKSVPHFSDEDKDPE 
                   
                   
                   
               
               
                   
               
               
                 NP00013 
                 YSPRTPDRVSEADIQRLLHGVMEQLGIARPRVEYPAHQAMNLVGPQSIEGGAHEGL 
                 150 
                 7B2 
                 N-terminal peptide (By 
               
               
                   
                 QHLGPFGNIPNIVAELTGDNIPKDFSEDQGYPDPPNPCPVGKTADDGCLENTPDTAE 
                   
                   
                 similarity) 
               
               
                   
                 FSREFQLHQHLFDPEHDYPGLGKWNKKLLYEKMKGGE 
                   
                   
                   
               
               
                   
               
               
                 NP00026 
                 MALQADFDRAAEDVRKLKARPDDGELKELYGLYKQAIVGDINIACPGMLDLKGK 
                 88 
                 ACBP 
                 Acyl-CoA-binding domain- 
               
               
                   
                 AKWEAWNLKKGLSTEDATSAYISKAKELIEKYGI 
                   
                   
                 containing protein 7 
               
               
                   
               
               
                 NP00034 
                 SQAEFEKAAEEVRHLKTKPSDEEMLFIYGHYKQATVGDINTERPGMLDFTGKAKW 
                 86 
                 ACBP 
                 Acyl-CoA-binding protein 
               
               
                   
                 DAWNELKGTSKEDAMKAYINKVEELKKKYGI 
                   
                   
                   
               
               
                   
               
               
                 NP00042 
                 TQAQLLRVGCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY 
                 47 
                 Adrenomedullin 
                 Adrenomedullin-2 (By 
               
               
                   
                   
                   
                   
                 similarity) 
               
               
                   
               
               
                 NP00043 
                 VGCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY 
                 40 
                 Adrenomedullin 
                 Intermedin-short (Potential) 
               
               
                   
               
               
                 NP00044 
                 YRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKDKDNVAPRSKISPQGY 
                 52 
                 Adrenomedullin 
                 Adrenomedullin 
               
               
                   
               
               
                 NP00045 
                 ARLDVASEFRKKWNKWALSR 
                 20 
                 Adrenomedullin 
                 Proadrenomedullin N-20 
               
               
                   
                   
                   
                   
                 terminal peptide 
               
               
                   
               
               
                 NP00601 
                 QRPRLSHKGPMPF 
                 13 
                 Apelin 
                 Apelin-13 (By similarity) 
               
               
                   
               
               
                 NP00602 
                 NGPGPWQGGRRKFRRQRPRLSHKGPMPF 
                 28 
                 Apelin 
                 Apelin-28 (By similarity) 
               
               
                   
               
               
                 NP00603 
                 GSRNGPGPWQGGRRKFRRQRPRLSHKGPMPF 
                 31 
                 Apelin 
                 Apelin-31 (By similarity) 
               
               
                   
               
               
                 NP00604 
                 LVQPRGSRNGPGPWQGGRRKFRRQRPRLSHKGPMPF 
                 36 
                 Apelin 
                 Apelin-36 (By similarity) 
               
               
                   
               
               
                 NP00790 
                 VPLPAGGGTVLTKMYPRGNHWAVGHLM 
                 27 
                 Bombesin/neuromedin- 
                 Gastrin-releasing peptide 
               
               
                   
                   
                   
                 B/ranatensin 
                   
               
               
                   
               
               
                 NP00791 
                 GNHWAVGHLM 
                 10 
                 Bombesin/neuromedin- 
                 Neuromedin-C 
               
               
                   
                   
                   
                 B/ranatensin 
                   
               
               
                   
               
               
                 NP00792 
                 GNLWATGHFM 
                 10 
                 Bombesin/neuromedin- 
                 Neuromedin-B 
               
               
                   
                   
                   
                 B/ranatensin 
                   
               
               
                   
               
               
                 NP00793 
                 APLSWDLPEPRSRASKIRVHSRGNLWATGHFM 
                 32 
                 Bombesin/neuromedin- 
                 Neuromedin-B-32 
               
               
                   
                   
                   
                 B/ranatensin 
                   
               
               
                   
               
               
                 NP00811 
                 RPPGFSPFR 
                 9 
                 Bradykinin 
                 Bradykinin 
               
               
                   
               
               
                 NP00812 
                 KRPPGFSPFR 
                 10 
                 Bradykinin 
                 Lysyl-bradykinin 
               
               
                   
               
               
                 NP00813 
                 ISLMKRPPGFSPFR 
                 14 
                 Bradykinin 
                 T-kinin 
               
               
                   
               
               
                 NP00846 
                 CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP 
                 32 
                 Calcitonin 
                 Calcitonin 
               
               
                   
               
               
                 NP00847 
                 DMSSDLERDHRPHVSMPQNAN 
                 21 
                 Calcitonin 
                 Katacalcin 
               
               
                   
               
               
                 NP00848 
                 ACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF 
                 37 
                 Calcitonin 
                 Calcitonin gene-related 
               
               
                   
                   
                   
                   
                 peptide 1 
               
               
                   
               
               
                 NP00849 
                 ACNTATCVTHRLAGLLSRSGGMVKSNFVPTNVGSKAF 
                 37 
                 Calcitonin 
                 Calcitonin gene-related 
               
               
                   
                   
                   
                   
                 peptide 2 
               
               
                   
               
               
                 NP00850 
                 KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 
                 37 
                 Calcitonin 
                 Islet amyloid polypeptide 
               
               
                   
               
               
                 NP00869 
                 QEDAELQPRALDIYSAVDDASHEKELIEALQEVLKKLKS 
                 39 
                 CART 
                 CART(1-39) 
               
               
                   
               
               
                 NP00870 
                 VPIYEKKYGQVPMCDAGEQCAVRKGARIGKLCDCPRGTSCNSFLLKCL 
                 48 
                 CART 
                 CART(42-89) 
               
               
                   
               
               
                 NP00881 
                 QEDAELQPRALDIYSAVDDASHEKELIEALQEVLKKLKSKRVPIYEKKYGQVPMCD 
                 89 
                 CART 
                 Cocaine- and amphetamine- 
               
               
                   
                 AGEQCAVRKGARIGKLCDCPRGTSCNSFLLKCL 
                   
                   
                 regulated 
               
               
                   
               
               
                 NP00904 
                 QNDTEPIVLEGKCLVVCDSNPATDSKGSSSSPLGISVRAANSKVAFSAVRSTNHEPS 
                 174 
                 Cerebellins 
                 Cerebellin-4 
               
               
                   
                 EMSNKTRIIYFDQILVNVGNFFTLESVFVAPRKGIYSFSFHVIKVYQSQTIQVNLMLN 
                   
                   
                   
               
               
                   
                 GKPVISAFAGDKDVTREAATNGVLLYLDKEDKVYLKLEKGNLVGGWQYSTFSGFL 
                   
                   
                   
               
               
                   
                 VFPL 
                   
                   
                   
               
               
                   
               
               
                 NP00909 
                 GSAKVAFSAIRSTNH 
                 15 
                 Cerebellins 
                 [des-Ser1]-cerebellin 
               
               
                   
               
               
                 NP00910 
                 SGSAKVAFSAIRSTNH 
                 16 
                 Cerebellins 
                 Cerebellin 
               
               
                   
               
               
                 NP00911 
                 QNETEPIVLEGKCLVVCDSNPTSDPTGTALGISVRSGSAKVAFSAIRSTNHEPSEMSN 
                 172 
                 Cerebellins 
                 Cerebellin-1 
               
               
                   
                 RTMIIYFDQVLVNIGNNFDSERSTFIAPRKGIYSFNFHVVKVYNRQTIQVSLMLNGW 
                   
                   
                   
               
               
                   
                 PVISAFAGDQDVTREAASNGVLIQMEKGDRAYLKLERGNLMGGWKYSTFSGFLVF 
                   
                   
                   
               
               
                   
                 PL 
                   
                   
                   
               
               
                   
               
               
                 NP00912 
                 QNDTEPIVLEGKCLVVCDSSPSADGAVTSSLGISVRSGSAKVAFSATRSTNHEPSEM 
                 173 
                 Cerebellins 
                 Cerebellin-2 
               
               
                   
                 SNRTMTIYFDQVLVNIGNHFDLASSIFVAPRKGIYSFSFHVVKVYNRQTIQVSLMQN 
                   
                   
                   
               
               
                   
                 GYPVISAFAGDQDVTREAASNGVLLLMEREDKVHLKLERGNLMGGWKYSTFSGF 
                   
                   
                   
               
               
                   
                 LVFPL 
                   
                   
                   
               
               
                   
               
               
                 NP00913 
                 QEGSEPVLLEGECLVVCEPGRAAAGGPGGAALGEAPPGRVAFAAVRSHHHEPAGE 
                 173 
                 Cerebellins 
                 Cerebellin-3 
               
               
                   
                 TGNGTSGAIYFDQVLVNEGGGFDRASGSFVAPVRGVYSFRFHVVKVYNRQTVQVS 
                   
                   
                   
               
               
                   
                 LMLNTWPVISAFANDPDVTREAATSSVLLPLDPGDRVSLRLRRGNLLGGWKYSSFS 
                   
                   
                   
               
               
                   
                 GFLIFPL 
                   
                   
                   
               
               
                   
               
               
                 NP00983 
                 AYGFRGPGPQL 
                 11 
                 Chromogranin/ 
                 AL-11 
               
               
                   
                   
                   
                 secretogranin 
                   
               
               
                   
               
               
                 NP00984 
                 LPVNSPMNKGDTEVMKCIVEVISDTLSKPSPMPVSQECFETLRGDERILSILRHQNLL 
                 439 
                 Chromogranin/ 
                 Chromogranin-A 
               
               
                   
                 KELQDLALQGAKERAHQQKKHSGFEDELSEVLENQSSQAELKEAVEEPSSKDVME 
                   
                 secretogranin 
                   
               
               
                   
                 KREDSKEAEKSGEATDGARPQALPEPMQESKAEGNNQAPGEEEEEEEEATNTHPPA 
                   
                   
                   
               
               
                   
                 SLPSQKYPGPQAEGDSEGLSQGLVDREKGLSAEPGWQAKREEEEEEEEEAEAGEEA 
                   
                   
                   
               
               
                   
                 VPEEEGPTVVLNPHPSLGYKEIRKGESRSEALAVDGAGKPGAEEAQDPEGKGEQEH 
                   
                   
                   
               
               
                   
                 SQQKEEEEEMAVVPQGLFRGGKSGELEQEEERLSKEWEDSKRWSKMDQLAKELT 
                   
                   
                   
               
               
                   
                 AEKRLEGQEEEEDNRDSSMKLSFRARAYGFRGPGPQLRRGWRPSSREDSLEAGLPL 
                   
                   
                   
               
               
                   
                 QVRGYPEEKKEEEGSANRRPEDQELESLSAIEAELEKVAHQLQALRRG 
                   
                   
                   
               
               
                   
               
               
                 NP00985 
                 EDSKEAEKSGEATDGARPQALPEPMQESKAEGNNQAPGEEEEEEEEATNTHPPASL 
                 92 
                 Chromogranin/ 
                 EA-92 
               
               
                   
                 PSQKYPGPQAEGDSEGLSQGLVDREKGLSAEPGWQA 
                   
                 secretogranin 
                   
               
               
                   
               
               
                 NP00986 
                 EEEGSANRRPEDQELESLSAIEAELEKVAHQLQALRR 
                 37 
                 Chromogranin/ 
                 ER-37 
               
               
                   
                   
                   
                 secretogranin 
                   
               
               
                   
               
               
                 NP00987 
                 EEEEEEEEEAEAGEEAVPEEEGPTVVLNPHPSL 
                 33 
                 Chromogranin/ 
                 ES-43 
               
               
                   
                   
                   
                 secretogranin 
                   
               
               
                   
               
               
                 NP00988 
                 GYPEEKKEEEGSANRRPEDQELESLSAIEAELEKVAHQLQALRR 
                 44 
                 Chromogranin/ 
                 GR-44 
               
               
                   
                   
                   
                 secretogranin 
                   
               
               
                   
               
               
                 NP00989 
                 GWRPSSREDSLEAGLPLQV 
                 19 
                 Chromogranin/ 
                 GV-19 
               
               
                   
                   
                   
                 secretogranin 
                   
               
               
                   
               
               
                 NP00990 
                 LEGQEEEEDNRDSSMKLSF 
                 19 
                 Chromogranin/ 
                 LF-19 
               
               
                   
                   
                   
                 secretogranin 
                   
               
               
                   
               
               
                 NP00991 
                 SEALAVDGAGKPGAEEAQDPEGKGEQEHSQQKEEEEEMAVVPQGLFRG 
                 48 
                 Chromogranin/ 
                 Pancreastatin 
               
               
                   
                   
                   
                 secretogranin 
                   
               
               
                   
               
               
                 NP00992 
                 SGELEQEEERLSKEWEDS 
                 18 
                 Chromogranin/ 
                 SS-18 
               
               
                   
                   
                   
                 secretogranin 
                   
               
               
                   
               
               
                 NP00993 
                 LPVNSPMNKGDTEVMKCIVEVISDTLSKPSPMPVSQECFETLRGDERILSILRHQNLL 
                 76 
                 Chromogranin/ 
                 Vasostatin-1 
               
               
                   
                 KELQDLALQGAKERAHQQ 
                   
                 secretogranin 
                   
               
               
                   
               
               
                 NP00994 
                 LPVNSPMNKGDTEVMKCIVEVISDTLSKPSPMPVSQECFETLRGDERILSILRHQNLL 
                 113 
                 Chromogranin/ 
                 Vasostatin-2 
               
               
                   
                 KELQDLALQGAKERAHQQKKHSGFEDELSEVLENQSSQAELKEAVEEPSSKDVME 
                   
                 secretogranin 
                   
               
               
                   
               
               
                 NP00995 
                 WSKMDQLA 
                 8 
                 Chromogranin/ 
                 WA-8 
               
               
                   
                   
                   
                 secretogranin 
                   
               
               
                   
               
               
                 NP00996 
                 WSKMDQLAKELTAE 
                 14 
                 Chromogranin/ 
                 WE-14 
               
               
                   
                   
                   
                 secretogranin 
                   
               
               
                   
               
               
                 NP00997 
                 SAEFPDFYDSEEPVSTHQEAENEKDRADQTVLTEDEKKELENLAAMDLELQKIAEK 
                 57 
                 Chromogranin/ 
                 CCB peptide 
               
               
                   
                 F 
                   
                 secretogranin 
                   
               
               
                   
               
               
                 NP00998 
                 FLGEGHHRVQENQMDKARRHPQGAWKELDRNYLNYGEEGAPGKWQQQGDLQD 
                 74 
                 Chromogranin/ 
                 GAWK peptide 
               
               
                   
                 TKENREEARFQDKQYSSHHTAE 
                   
                 secretogranin 
                   
               
               
                   
               
               
                 NP00999 
                 MPVDNRNHNEGMVTRCIIEVLSNALSKSSAPPITPECRQVLKTSRKDVKDKETTEN 
                 657 
                 Chromogranin/ 
                 Secretogranin-1 
               
               
                   
                 ENTKFEVRLLRDPADASEAHESSSRGEAGAPGEEDIQGPTKADTEKWAEGGGHSRE 
                   
                 secretogranin 
                   
               
               
                   
                 RADEPQWSLYPSDSQVSEEVKTRHSEKSQREDEEEEEGENYQKGERGEDSSEEKHL 
                   
                   
                   
               
               
                   
                 EEPGETQNAFLNERKQASAIKKEELVARSETHAAGHSQEKTHSREKSSQESGEETG 
                   
                   
                   
               
               
                   
                 SQENHPQESKGQPRSQEESEEGEEDATSEVDKRRTRPRHHHGRSRPDRSSQGGSLPS 
                   
                   
                   
               
               
                   
                 EEKGHPQEESEESNVSMASLGEKRDHHSTHYRASEEEPEYGEEIKGYPGVQAPEDL 
                   
                   
                   
               
               
                   
                 EWERYRGRGSEEYRAPRPQSEESWDEEDKRNYPSLELDKMAHGYGEESEEERGLE 
                   
                   
                   
               
               
                   
                 PGKGRHHRGRGGEPRAYFMSDTREEKRFLGEGHHRVQENQMDKARRHPQGAWK 
                   
                   
                   
               
               
                   
                 ELDRNYLNYGEEGAPGKWQQQGDLQDTKENREEARFQDKQYSSHHTAEKRKRLG 
                   
                   
                   
               
               
                   
                 ELFNPYYDPLQWKSSHFERRDNMNDNFLEGEEENELTLNEKNFFPEYNYDWWEK 
                   
                   
                   
               
               
                   
                 KPFSEDVNWGYEKRNLARVPKLDLKRQYDRVAQLDQLLHYRKKSAEFPDFYDSE 
                   
                   
                   
               
               
                   
                 EPVSTHQEAENEKDRADQTVLTEDEKKELENLAAMDLELQKIAEKFSQRG 
                   
                   
                   
               
               
                   
               
               
                 NP01000 
                 QRNQLLQKEPDLRLENVQKFPSPEMIRALEYIENLRQQAHKEESSPDYNPYQGVSV 
                 587 
                 Chromogranin/ 
                 Secretogranin-2 
               
               
                   
                 PLQQKENGDESHLPERDSLSEEDWMRIILEALRQAENEPQSAPKENKPYALNSEKN 
                   
                 secretogranin 
                   
               
               
                   
                 FPMDMSDDYETQQWPERKLKHMQFPPMYEENSRDNPFKRTNEIVEEQYTPQSLAT 
                   
                   
                   
               
               
                   
                 LESVFQELGKLTGPNNQKRERMDEEQKLYTDDEDDIYKANNIAYEDVVGGEDWN 
                   
                   
                   
               
               
                   
                 PVEEKIESQTQEEVRDSKENIEKNEQINDEMKRSGQLGIQEEDLRKESKDQLSDDVS 
                   
                   
                   
               
               
                   
                 KVIAYLKRLVNAAGSGRLQNGQNGERATRLFEKPLDSQSIYQLIEISRNLQIPPEDLI 
                   
                   
                   
               
               
                   
                 EMLKTGEKPNGSVEPERELDLPVDLDDISEADLDHPDLFQNRMLSKSGYPKTPGRA 
                   
                   
                   
               
               
                   
                 GTEALPDGLSVEDILNLLGMESAANQKTSYFPNPYNQEKVLPRLPYGAGRSRSNQL 
                   
                   
                   
               
               
                   
                 PKAAWIPHVENRQMAYENLNDKDQELGEYLARMLVKYPEIINSNQVKRVPGQGSS 
                   
                   
                   
               
               
                   
                 EDDLQEEEQIEQAIKEHLNQGSSQETDKLAPVSKRFPVGPPKNDDTPNRQYWDEDL 
                   
                   
                   
               
               
                   
                 LMKVLEYLNQEKAEKGREHIAKRAMENM 
                   
                   
                   
               
               
                   
               
               
                 NP01001 
                 TNEIVEEQYTPQSLATLESVFQELGKLTGPNNQ 
                 33 
                 Chromogranin/ 
                 Secretoneurin 
               
               
                   
                   
                   
                 secretogranin 
                   
               
               
                   
               
               
                 NP01002 
                 FPKPGGSQDKSLHNRELSAERPLNEQIAEAEEDKIKKTYPPENKPGQSNYSFVDNLN 
                 449 
                 Chromogranin/ 
                 Secretogranin-3 
               
               
                   
                 LLKAITEKEKIEKERQSIRSSPLDNKLNVEDVDSTKNRKLIDDYDSTKSGLDHKFQD 
                   
                 secretogranin 
                   
               
               
                   
                 DPDGLHQLDGTPLTAEDIVHKIAARIYEENDRAVFDKIVSKLLNLGLITESQAHTLE 
                   
                   
                   
               
               
                   
                 DEVAEVLQKLISKEANNYEEDPNKPTSWTENQAGKIPEKVTPMAAIQDGLAKGEN 
                   
                   
                   
               
               
                   
                 DETVSNTLTLTNGLERRTKTYSEDNFEELQYFPNFYALLKSIDSEKEAKEKETLITIM 
                   
                   
                   
               
               
                   
                 KTLIDFVKMMVKYGTISPEEGVSYLENLDEMIALQTKNKLEKNATDNISKLFPAPSE 
                   
                   
                   
               
               
                   
                 KSHEETDSTKEEAAKMEKEYGSLKDSTKDDNSNPGGKTDEPKGKTEAYLEAIRKNI 
                   
                   
                   
               
               
                   
                 EWLKKHDKKGNKEDYDLSKMRDFINKQADAYVEKGILDKEEAEAIKRIYSSL 
                   
                   
                   
               
               
                   
               
               
                 NP01097 
                 QESQSEEIDCNDKDLFKAVDAALKKYNSQNQSNNQFVLYRITEATKTVGSDTFYSF 
                 626 
                 Cystatin 
                 Kininogen-1 
               
               
                   
                 KYEIKEGDCPVQSGKTWQDCEYKDAAKAATGECTATVGKRSSTKFSVATQTCQIT 
                   
                   
                   
               
               
                   
                 PAEGPVVTAQYDCLGCVHPISTQSPDLEPILRHGIQYFNNNTQHSSLFMLNEVKRAQ 
                   
                   
                   
               
               
                   
                 RQVVAGLNFRITYSIVQTNCSKENFLFLTPDCKSLWNGDTGECTDNAYIDIQLRIAS 
                   
                   
                   
               
               
                   
                 FSQNCDIYPGKDFVQPPTKICVGCPRDIPTNSPELEETLTHTITKLNAENNATFYFKID 
                   
                   
                   
               
               
                   
                 NVKKARVQVVAGKKYFIDFVARETTCSKESNEELTESCETKKLGQSLDCNAEVYV 
                   
                   
                   
               
               
                   
                 VPWEKKIYPTVNCQPLGMISLMKRPPGFSPFRSSRIGEIKEETTVSPPHTSMAPAQDE 
                   
                   
                   
               
               
                   
                 ERDSGKEQGHTRRHDWGHEKQRKHNLGHGHKHERDQGHGHQRGHGLGHGHEQ 
                   
                   
                   
               
               
                   
                 QHGLGHGHKFKLDDDLEHQGGHVLDHGHKHKHGHGHGKHKNKGKKNGKHNG 
                   
                   
                   
               
               
                   
                 WKTEHLASSSEDSTTPSAQTQEKTEGPTPIPSLAKPGVTVTFSDFQDSDLIATMMPPI 
                   
                   
                   
               
               
                   
                 SPAPIQSDDDWIPDIQIDPNGLSFNPISDFPDTTSPKCPGRPWKSVSEINPTTQMKESY 
                   
                   
                   
               
               
                   
                 YFDLTDGLS 
                   
                   
                   
               
               
                   
               
               
                 NP01098 
                 QESQSEEIDCNDKDLFKAVDAALKKYNSQNQSNNQFVLYRITEATKTVGSDTFYSF 
                 362 
                 Cystatin 
                 Kininogen-1 heavy chain 
               
               
                   
                 KYEIKEGDCPVQSGKTWQDCEYKDAAKAATGECTATVGKRSSTKFSVATQTCQIT 
                   
                   
                   
               
               
                   
                 PAEGPVVTAQYDCLGCVHPISTQSPDLEPILRHGIQYFNNNTQHSSLFMLNEVKRAQ 
                   
                   
                   
               
               
                   
                 RQVVAGLNFRITYSIVQTNCSKENFLFLTPDCKSLWNGDTGECTDNAYIDIQLRIAS 
                   
                   
                   
               
               
                   
                 FSQNCDIYPGKDFVQPPTKICVGCPRDIPTNSPELEETLTHTITKLNAENNATFYFKID 
                   
                   
                   
               
               
                   
                 NVKKARVQVVAGKKYFIDFVARETTCSKESNEELTESCETKKLGQSLDCNAEVYV 
                   
                   
                   
               
               
                   
                 VPWEKKIYPTVNCQPLGMISLMK 
                   
                   
                   
               
               
                   
               
               
                 NP01099 
                 SSRIGEIKEETTVSPPHTSMAPAQDEERDSGKEQGHTRRHDWGHEKQRKHNLGHG 
                 255 
                 Cystatin 
                 Kininogen-1 light chain 
               
               
                   
                 HKHERDQGHGHQRGHGLGHGHEQQHGLGHGHKFKLDDDLEHQGGHVLDHGHK 
                   
                   
                   
               
               
                   
                 HKHGHGHGKHKNKGKKNGKHNGWKTEHLASSSEDSTTPSAQTQEKTEGPTPIPSL 
                   
                   
                   
               
               
                   
                 AKPGVTVTFSDFQDSDLIATMMPPISPAPIQSDDDWIPDIQIDPNGLSFNPISDFPDTT 
                   
                   
                   
               
               
                   
                 SPKCPGRPWKSVSEINPTTQMKESYYFDLTDGLS 
                   
                   
                   
               
               
                   
               
               
                 NP01100 
                 WGHE 
                 4 
                 Cystatin 
                 Low molecular weight 
               
               
                   
                   
                   
                   
                 growth-promoting factor 
               
               
                   
               
               
                 NP01125 
                 CSCSSLMDKECVYFCHLDIIWVNTPEHVVPYGLGSPRS 
                 38 
                 Endothelin/sarafotoxin 
                 Big endothelin-1 
               
               
                   
               
               
                 NP01126 
                 CSCSSLMDKECVYFCHLDIIW 
                 21 
                 Endothelin/sarafotoxin 
                 Endothelin-1 
               
               
                   
               
               
                 NP01127 
                 CSCSSWLDKECVYFCHLDIIW 
                 21 
                 Endothelin/sarafotoxin 
                 Endothelin-2 
               
               
                   
               
               
                 NP01128 
                 CTCFTYKDKECVYYCHLDIIW 
                 21 
                 Endothelin/sarafotoxin 
                 Endothelin-3 
               
               
                   
               
               
                 NP01760 
                 AGEGLNSQFWSLAAPQRF 
                 18 
                 FMRFamide related 
                 Neuropeptide AF 
               
               
                   
                   
                   
                 peptide 
                   
               
               
                   
               
               
                 NP01761 
                 FLFQPQRF 
                 8 
                 FMRFamide related 
                 Neuropeptide FF 
               
               
                   
                   
                   
                 peptide 
                   
               
               
                   
               
               
                 NP01762 
                 SQAFLFQPQRF 
                 11 
                 FMRFamide related 
                 Neuropeptide SF 
               
               
                   
                   
                   
                 peptide 
                   
               
               
                   
               
               
                 NP01763 
                 SLNFEELKDWGPKNVIKMSTPAVNKMPHSFANLPLRF 
                 37 
                 FMRFamide related 
                 Neuropeptide NPSF 
               
               
                   
                   
                   
                 peptide 
                 (Potential) 
               
               
                   
               
               
                 NP01764 
                 VPNLPQRF 
                 8 
                 FMRFamide related 
                 Neuropeptide NPVF 
               
               
                   
                   
                   
                 peptide 
                   
               
               
                   
               
               
                 NP01765 
                 MPHSFANLPLRF 
                 12 
                 FMRFamide related 
                 Neuropeptide RFRP-1 
               
               
                   
                   
                   
                 peptide 
                   
               
               
                   
               
               
                 NP01766 
                 SAGATANLPLRS 
                 12 
                 FMRFamide related 
                 Neuropeptide RFRP-2 
               
               
                   
                   
                   
                 peptide 
                 (Potential) 
               
               
                   
               
               
                 NP02007 
                 TPDINPAWYASRGIRPVGRF 
                 20 
                 FMRFamide related 
                 Prolactin-releasing peptide 
               
               
                   
                   
                   
                 peptide 
                 PrRP20 
               
               
                   
               
               
                 NP02008 
                 SRTHRHSMEIRTPDINPAWYASRGIRPVGRF 
                 31 
                 FMRFamide related 
                 Prolactin-releasing peptide 
               
               
                   
                   
                   
                 peptide 
                 PrRP31 
               
               
                   
               
               
                 NP02025 
                 GWTLNSAGYLLGPHAVGNHRSFSDKNGLTS 
                 30 
                 Galanin 
                 Galanin 
               
               
                   
               
               
                 NP02026 
                 ELRPEDDMKPGSFDRSIPENNIMRTIIEFLSFLHLKEAGALDRLLDLPAAASSEDIERS 
                 59 
                 Galanin 
                 Galanin message-associated 
               
               
                   
                   
                   
                 peptide 
                   
               
               
                   
               
               
                 NP02040 
                 APAHRGRGGWTLNSAGYLLGPVLHLPQMGDQDGKRETALEILDLWKAIDGLPYS 
                 60 
                 Galanin 
                 Galanin-like peptide 
               
               
                   
                 HPPQPS 
                   
                   
                   
               
               
                   
               
               
                 NP02242 
                 QPVPPADPAGSGLQRAEEAPRRQLRVSQRTDGESRAHLGALLARYIQQARKAPSGR 
                 95 
                 Gastrin/cholecystokinin 
                 Cholecystokinin 
               
               
                   
                 MSIVKNLQNLDPSHRISDRDYMGWMDFGRRSAEEYEYPS 
                   
                   
                   
               
               
                   
               
               
                 NP02243 
                 ISDRDYMGWMDF 
                 12 
                 Gastrin/cholecystokinin 
                 Cholecystokinin-12 
               
               
                   
               
               
                 NP02244 
                 LDPSHRISDRDYMGWMDF 
                 18 
                 Gastrin/cholecystokinin 
                 Cholecystokinin-18 (By 
               
               
                   
                   
                   
                   
                 similarity) 
               
               
                   
               
               
                 NP02245 
                 IVKNLQNLDPSHRISDRDYMGWMDF 
                 25 
                 Gastrin/cholecystokinin 
                 Cholecystokinin-25 (By 
               
               
                   
                   
                   
                   
                 similarity) 
               
               
                   
               
               
                 NP02246 
                 KAPSGRMSIVKNLQNLDPSHRISDRDYMGWMDF 
                 33 
                 Gastrin/cholecystokinin 
                 Cholecystokinin-33 
               
               
                   
               
               
                 NP02247 
                 YIQQARKAPSGRMSIVKNLQNLDPSHRISDRDYMGWMDF 
                 39 
                 Gastrin/cholecystokinin 
                 Cholecystokinin-39 
               
               
                   
               
               
                 NP02248 
                 GWMDF 
                 5 
                 Gastrin/cholecystokinin 
                 Cholecystokinin-5 (By 
               
               
                   
                   
                   
                   
                 similarity) 
               
               
                   
               
               
                 NP02249 
                 VSQRTDGESRAHLGALLARYIQQARKAPSGRMSIVKNLQNLDPSHRISDRDYMGW 
                 58 
                 Gastrin/cholecystokinin 
                 Cholecystokinin-58 
               
               
                   
                 MDF 
                   
                   
                   
               
               
                   
               
               
                 NP02250 
                 VSQRTDGESRAHLGALLARYIQQARKAPSGRMSIVKNLQNLDPSHRISD 
                 49 
                 Gastrin/cholecystokinin 
                 Cholecystokinin-58 
               
               
                   
                   
                   
                   
                 desnonopeptide (By 
               
               
                   
                   
                   
                   
                 similarity) 
               
               
                   
               
               
                 NP02251 
                 YMGWMDF 
                 7 
                 Gastrin/cholecystokinin 
                 Cholecystokinin-7 (By 
               
               
                   
                   
                   
                   
                 similarity) 
               
               
                   
               
               
                 NP02252 
                 DYMGWMDF 
                 8 
                 Gastrin/cholecystokinin 
                 Cholecystokinin-8 
               
               
                   
               
               
                 NP02253 
                 QLGPQGPPHLVADPSKKQGPWLEEEEEAYGWMDF 
                 34 
                 Gastrin/cholecystokinin 
                 Big gastrin 
               
               
                   
               
               
                 NP02254 
                 QGPWLEEEEEAYGWMDF 
                 17 
                 Gastrin/cholecystokinin 
                 Gastrin 
               
               
                   
               
               
                 NP02255 
                 WLEEEEEAYGWMDF 
                 14 
                 Gastrin/cholecystokinin 
                 Gastrin-14 
               
               
                   
               
               
                 NP02256 
                 DLELPWLEQQGPASHHRRQLGPQGPPHLVADPSKKQGPWLEEEEEAYGWMDF 
                 52 
                 Gastrin/cholecystokinin 
                 Gastrin-52 
               
               
                   
               
               
                 NP02257 
                 YGWMDF 
                 6 
                 Gastrin/cholecystokinin 
                 Gastrin-6 
               
               
                   
               
               
                 NP02258 
                 SWKPRSQQPDAPLGTGANRDLELPWLEQQGPASHHRRQLGPQGPPHLVADPSKKQ 
                 71 
                 Gastrin/cholecystokinin 
                 Gastrin-71 
               
               
                   
                 GPWLEEEEEAYGWMDF 
                   
                   
                   
               
               
                   
               
               
                 NP02464 
                 YAEGTFI   S   DYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ 
                 42 
                 Glucagon 
                 Gastric inhibitory polypeptide 
               
               
                   
               
               
                 NP02465 
                 RSLQDTEEKSRSFSASQADPLSDPDQMNEDKRHSQGTFTSDYSKYLDSRRAQDFVQ 
                 69 
                 Glucagon 
                 Glicentin (By similarity) 
               
               
                   
                 WLMNTKRNRNNIA 
                   
                   
                   
               
               
                   
               
               
                 NP02466 
                 RSLQDTEEKSRSFSASQADPLSDPDQMNED 
                 30 
                 Glucagon 
                 Glicentin-related polypeptide 
               
               
                   
                   
                   
                   
                 (By similarity) 
               
               
                   
               
               
                 NP02467 
                 HSQGTF   T   SDYSKYLDSRRAQDFVQWLMNT 
                 29 
                 Glucagon 
                 Glucagon 
               
               
                   
               
               
                 NP02468 
                 HDEFERHAEGTF   TS   DVSSYLEGQAAKEFIAWLVKGRG 
                 37 
                 Glucagon 
                 Glucagon-like peptide 1 
               
               
                   
               
               
                 NP02469 
                 HAEGTF   TS   DVSSYLEGQAAKEFIAWLVKGR 
                 30 
                 Glucagon 
                 Glucagon-like peptide 1(7-36) 
               
               
                   
               
               
                 NP02470 
                 HAEGTF   TS   DVSSYLEGQAAKEFIAWLVKGRG 
                 31 
                 Glucagon 
                 Glucagon-like peptide 1(7-37) 
               
               
                   
               
               
                 NP02471 
                 HADGSF   S   DEMNTILDNLAARDFINWLIQTKITD 
                 33 
                 Glucagon 
                 Glucagon-like peptide 2 (By 
               
               
                   
                   
                   
                   
                 similarity) 
               
               
                   
               
               
                 NP02472 
                 HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA 
                 37 
                 Glucagon 
                 Oxyntomodulin (By 
               
               
                   
                   
                   
                   
                 similarity) 
               
               
                   
               
               
                 NP02473 
                 DVAHGILNEAYRKVLDQLSAGKHLQSLVARGVGGSLGGGAGDDAEPLS 
                 48 
                 Glucagon 
                 PACAP-related peptide 
               
               
                   
               
               
                 NP02474 
                 HSDGIFTDSYSRYRKQMAVKKYLAAVL 
                 27 
                 Glucagon 
                 Pituitary adenylate cyclase- 
               
               
                   
                   
                   
                   
                 activating polypeptide 27 
               
               
                   
               
               
                 NP02475 
                 HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK 
                 38 
                 Glucagon 
                 Pituitary adenylate cyclase- 
               
               
                   
                   
                   
                   
                 activating polypeptide 38 
               
               
                   
               
               
                 NP02476 
                 HSDGTF   T   SEL   S   RLREGARLQRLLQGLV 
                 27 
                 Glucagon 
                 Secretin 
               
               
                   
               
               
                 NP02477 
                 YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL 
                 44 
                 Glucagon 
                 Somatoliberin 
               
               
                   
               
               
                 NP02478 
                 HADGVFTSDFSKLLGQLSAKKYLESLM 
                 27 
                 Glucagon 
                 Intestinal peptide PHM-27 
               
               
                   
               
               
                 NP02479 
                 HADGVFTSDFSKLLGQLSAKKYLESLMGKRVSSNISEDPVPV 
                 42 
                 Glucagon 
                 Intestinal peptide PHV-42 
               
               
                   
               
               
                 NP02480 
                 HSDAVF   T   DNYTRLRKQMAVKKYLNSILN 
                 28 
                 Glucagon 
                 Vasoactive intestinal peptide 
               
               
                   
               
               
                 NP02572 
                 DAENLIDSFQEIVKEVGQLAETQRFECTTHQPRSPLRDLKGALESLIEEETGQKKI 
                 56 
                 GnRH 
                 GnRH-associated peptide 1 
               
               
                   
               
               
                 NP02573 
                 QHWSYGLRPG 
                 10 
                 GnRH 
                 Gonadoliberin-1 
               
               
                   
               
               
                 NP02574 
                 QHWSYGLRPGGKRDAENLIDSFQEIVKEVGQLAETQRFECTTHQPRSPLRDLKGAL 
                 69 
                 GnRH 
                 Progonadoliberin-1 
               
               
                   
                 ESLIEEETGQKKI 
                   
                   
                   
               
               
                   
               
               
                 NP02575 
                 ALSSAQDPQNALRPPGRALDTAAGSPVQTAHGLPSDALAPLDDSMPWEGRTTAQ 
                 84 
                 GnRH 
                 GnRH-associated peptide 2 
               
               
                   
                 WSLHRKRHLARTLLTAAREPRPAPPSSNKV 
                   
                   
                   
               
               
                   
               
               
                 NP02576 
                 QHWSHGWYPG 
                 10 
                 GnRH 
                 Gonadoliberin-2 
               
               
                   
               
               
                 NP02577 
                 QHWSHGWYPGGKRALSSAQDPQNALRPPGRALDTAAGSPVQTAHGLPSDALAPL 
                 97 
                 GnRH 
                 Progonadoliberin-2 
               
               
                   
                 DDSMPWEGRTTAQWSLHRKRHLARTLLTAAREPRPAPPSSNKV 
                   
                   
                   
               
               
                   
               
               
                 NP02765 
                 GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRR 
                 70 
                 Insulin 
                 Insulin-like growth factor I 
               
               
                   
                 LEMYCAPLKPAKSA 
                   
                   
                   
               
               
                   
               
               
                 NP02766 
                 AYRPSETLCGGELVDTLQFVCGDRGFYFSRPASRVSRRSRGIVEECCFRSCDLALLE 
                 67 
                 Insulin 
                 Insulin-like growth factor II 
               
               
                   
                 TYCATPAKSE 
                   
                   
                   
               
               
                   
               
               
                 NP02767 
                 YRPSETLCGGELVDTLQFVCGDRGFYFSRPASRVSRRSRGIVEECCFRSCDLALLET 
                 66 
                 Insulin 
                 Insulin-like growth factor II 
               
               
                   
                 YCATPAKSE 
                   
                   
                 Ala-25 Del 
               
               
                   
               
               
                 NP02768 
                 DVSTPPTVLPDNFPRYPVGKFFQYDTWKQSTQRL 
                 34 
                 Insulin 
                 Preptin 
               
               
                   
               
               
                 NP02769 
                 GIVEQCCTSICSLYQLENYCN 
                 21 
                 Insulin 
                 Insulin A chain 
               
               
                   
               
               
                 NP02770 
                 FVNQHLCGSHLVEALYLVCGERGFFYTPKT 
                 30 
                 Insulin 
                 Insulin B chain 
               
               
                   
               
               
                 NP02771 
                 PYVALFEKCCLIGCTKRSLAKYC 
                 23 
                 Insulin 
                 Relaxin A chain (By 
               
               
                   
                   
                   
                   
                 similarity) 
               
               
                   
               
               
                 NP02772 
                 VAAKWKDDVIKLCGRELVRAQIAICGMSTWS 
                 31 
                 Insulin 
                 Relaxin B chain (By 
               
               
                   
                   
                   
                   
                 similarity) 
               
               
                   
               
               
                 NP02773 
                 QLYSALANKCCHVGCTKRSLARFC 
                 24 
                 Insulin 
                 Relaxin A chain 
               
               
                   
               
               
                 NP02774 
                 DSWMEEVIKLCGRELVRAQIAICGMSTWS 
                 29 
                 Insulin 
                 Relaxin B chain 
               
               
                   
               
               
                 NP02775 
                 DVLAGLSSSCCKWGCSKSEISSLC 
                 24 
                 Insulin 
                 Relaxin-3 A chain (By 
               
               
                   
                   
                   
                   
                 similarity) 
               
               
                   
               
               
                 NP02776 
                 RAAPYGVRLCGREFIRAVIFTCGGSRW 
                 27 
                 Insulin 
                 Relaxin-3 B chain (By 
               
               
                   
                   
                   
                   
                 similarity) 
               
               
                   
               
               
                 NP02840 
                 YNWNSFGLRF 
                 10 
                 KISS1 
                 Kisspeptin-10 
               
               
                   
               
               
                 NP02841 
                 LPNYNWNSFGLRF 
                 13 
                 KISS1 
                 Kisspeptin-13 
               
               
                   
               
               
                 NP02842 
                 DLPNYNWNSFGLRF 
                 14 
                 KISS1 
                 Kisspeptin-14 
               
               
                   
               
               
                 NP02843 
                 EPLEKVASVGNSRPTGQQLESLGLLAPGEQSLPCTERKPAATARLSRRGTSLSPPPES 
                 119 
                 KISS1 
                 Metastasis-suppressor KiSS-1 
               
               
                   
                 SGSPQQPGLSAPHSRQIPAPQGAVLVQREKDLPNYNWNSFGLRFGKREAAPGNHG 
                   
                   
                   
               
               
                   
                 RSAGRG 
                   
                   
                   
               
               
                   
               
               
                 NP02844 
                 GTSLSPPPESSGSPQQPGLSAPHSRQIPAPQGAVLVQREKDLPNYNWNSFGLRF 
                 54 
                 KISS1 
                 Metastin 
               
               
                   
               
               
                 NP02870 
                 VPIQKVQDDTKTLIKTIVTRINDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTL 
                 146 
                 Leptin 
                 Leptin 
               
               
                   
                 AVYQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHLPWASGLETLDSLGGVLE 
                   
                   
                   
               
               
                   
                 ASGYSTEVVALSRLQGSLQDMLWQLDLSPGC 
                   
                   
                   
               
               
                   
               
               
                 NP02908 
                 DFDMLRCMLGRVYRPCWQV 
                 19 
                 Melanin-concentrating 
                 Melanin-concentrating 
               
               
                   
                   
                   
                 hormone 
                 hormone 
               
               
                   
               
               
                 NP02909 
                 EIGDEENSAKFPI 
                 13 
                 Melanin-concentrating 
                 Neuropeptide-glutamic acid- 
               
               
                   
                   
                   
                 hormone 
                 isoleucine 
               
               
                   
               
               
                 NP02910 
                 GSVAFPAENGVQNTESTQE 
                 19 
                 Melanin-concentrating 
                 Neuropeptide-glycine- 
               
               
                   
                   
                   
                 hormone 
                 glutamic acid(Potential) 
               
               
                   
               
               
                 NP02937 
                 ILLSASKSIRNLDDDMVFNTFRLGKGFQKEDTAEKSVIAPSLEQYKNDESSFMNEEE 
                 144 
                 Melanin-concentrating 
                 Pro-MCH 
               
               
                   
                 NKVSKNTGSKHNFLNHGLPLNLAIKPYLALKGSVAFPAENGVQNTESTQEKREIGD 
                   
                 hormone 
                   
               
               
                   
                 EENSAKFPIGRRDFDMLRCMLGRVYRPCWQV 
                   
                   
                   
               
               
                   
               
               
                 NP03000 
                 GSSFLSPEHQRVQQRKESKKPPAKLQP 
                 27 
                 Motilin 
                 Ghrelins-27 
               
               
                   
               
               
                 NP03001 
                 GSSFLSPEHQRVQQRKESKKPPAKLQPR 
                 28 
                 Motilin 
                 Ghrelins-28 
               
               
                   
               
               
                 NP03002 
                 FNAPFDVGIKLSGVQYQQHSQAL 
                 23 
                 Motilin 
                 Obestatin 
               
               
                   
               
               
                 NP03003 
                 FVPIFTYGELQRMQEKERNKGQ 
                 22 
                 Motilin 
                 Motilin 
               
               
                   
               
               
                 NP03004 
                 SLSVWQRSGEEGPVDPAEPIREEENEMIKLTAPLEIGMRMNSRQLEKYPATLEGLLS 
                 66 
                 Motilin 
                 Motilin-associated peptide 
               
               
                   
                 EMLPQHAAK 
                   
                   
                   
               
               
                   
               
               
                 NP03027 
                 FVPIFTYGELQRMQEKERNKGQKKSLSVWQRSGEEGPVDPAEPIREEENEMIKLTA 
                 90 
                 Motilin 
                 Promotilin 
               
               
                   
                 PLEIGMRMNSRQLEKYPATLEGLLSEMLPQHAAK 
                   
                   
                   
               
               
                   
               
               
                 NP03617 
                 ETTTQGPGVLLPLPKGACTGWMAGIPGHPGHNGAPGRDGRDGTPGEKGEKGDPGL 
                 226 
                 NA 
                 Adiponectin 
               
               
                   
                 IGPKGDIGETGVPGAEGPRGFPGIQGRKGEPGEGAYVYRSAFSVGLETYVTIPNMPI 
                   
                   
                   
               
               
                   
                 RFTKIFYNQQNHYDGSTGKFHCNIPGLYYFAYHITVYMKDVKVSLFKKDKAMLFT 
                   
                   
                   
               
               
                   
                 YDQYQENNVDQASGSVLLHLEVGDQVWLQVYGEGERNGLYADNDNDSTFTGFLL 
                   
                   
                   
               
               
                   
                 YHDTN 
                   
                   
                   
               
               
                   
               
               
                 NP03618 
                 MIEVVCNDRLGKKVRVKCNTDDTIGDLKKLIAAQTGTRWNKIVLKKWYTIFKDHV 
                 73 
                 NA 
                 Ubiquitin-like protein 5 
               
               
                   
                 SLGDYEIHDGMNLELYYQ 
                   
                   
                   
               
               
                   
               
               
                 NP03619 
                 AQMGLAPMEGIRRPDQALLPELPGLGLRAPLKKTTAEQAEEDLLQEAQALAEVLD 
                 112 
                 NA 
                 Agouti-related protein 
               
               
                   
                 LQDREPRSSRRCVRLHESCLGQQVPCCDPCATCYCRFFNAFCYCRKLGTAMNPCSR 
                   
                   
                   
               
               
                   
                 T 
                   
                   
                   
               
               
                   
               
               
                 NP03624 
                 MNPAAEAEFNILLATDSYKVTHYKQYPPNTSKVYSYFECREKKTENSKLRKVKYE 
                 491 
                 NAPRTase 
                 Nicotinamide 
               
               
                   
                 ETVFYGLQYILNKYLKGKVVTKEKIQEAKDVYKEHFQDDVFNEKGWNYILEKYD 
                   
                   
                 phosphoribosyltransferase 
               
               
                   
                 GHLPIEIKAVPEGFVIPRGNVLFTVENTDPECYWLTNWIETILVQSWYPITVATNSRE 
                   
                   
                   
               
               
                   
                 QKKILAKYLLETSGNLDGLEYKLHDFGYRGVSSQETAGIGASAHLVNFKGTDTVA 
                   
                   
                   
               
               
                   
                 GLALIKKYYGTKDPVPGYSVPAAEHSTITAWGKDHEKDAFEHIVTQFSSVPVSVVS 
                   
                   
                   
               
               
                   
                 DSYDIYNACEKIWGEDLRHLIVSRSTQAPLIIRPDSGNPLDTVLKVLEILGKKFPVTE 
                   
                   
                   
               
               
                   
                 NSKGYKLLPPYLRVIQGDGVDINTLQEIVEGMKQKMWSIENIAFGSGGGLLQKLTR 
                   
                   
                   
               
               
                   
                 DLLNCSFKCSYVVTNGLGINVFKDPVADPNKRSKKGRLSLHRTPAGNFVTLEEGKG 
                   
                   
                   
               
               
                   
                 DLEEYGQDLLHTVFKNGKVTKSYSFDEIRKNAQLNIELEAAHH 
                   
                   
                   
               
               
                   
               
               
                 NP03673 
                 SLRRSSCFGGRMDRIGAQSGLGCNSFRY 
                 28 
                 Natriuretic peptide 
                 Atrial natriuretic factor 
               
               
                   
               
               
                 NP03674 
                 NPMYNAVSNADLMDFKNLLDHLEEKMPLED 
                 30 
                 Natriuretic peptide 
                 Cardiodilatin-related peptide 
               
               
                   
               
               
                 NP03675 
                 SPKMVQGSGCFGRKMDRISSSSGLGCKV 
                 28 
                 Natriuretic peptide 
                 BNP(1-28) 
               
               
                   
               
               
                 NP03676 
                 SPKMVQGSGCFGRKMDRISSSSGLGCKVL 
                 29 
                 Natriuretic peptide 
                 BNP(1-29) 
               
               
                   
               
               
                 NP03677 
                 SPKMVQGSGCFGRKMDRISSSSGLGCKVLR 
                 30 
                 Natriuretic peptide 
                 BNP(1-30) 
               
               
                   
               
               
                 NP03678 
                 PKMVQGSGCFGRKMDRISSSSGLGCKVLRR 
                 30 
                 Natriuretic peptide 
                 BNP(2-31) 
               
               
                   
               
               
                 NP03679 
                 KMVQGSGCFGRKMDRISSSSGLGCKVL 
                 27 
                 Natriuretic peptide 
                 BNP(3-29) 
               
               
                   
               
               
                 NP03680 
                 KMVQGSGCFGRKMDRISSSSGLGCKVLR 
                 28 
                 Natriuretic peptide 
                 BNP(3-30) 
               
               
                   
               
               
                 NP03681 
                 KMVQGSGCFGRKMDRISSSSGLGCKVLRRH 
                 30 
                 Natriuretic peptide 
                 BNP(3-32) 
               
               
                   
               
               
                 NP03682 
                 MVQGSGCFGRKMDRISSSSGLGCK 
                 24 
                 Natriuretic peptide 
                 BNP(4-27) 
               
               
                   
               
               
                 NP03683 
                 MVQGSGCFGRKMDRISSSSGLGCKVL 
                 26 
                 Natriuretic peptide 
                 BNP(4-29) 
               
               
                   
               
               
                 NP03684 
                 MVQGSGCFGRKMDRISSSSGLGCKVLR 
                 27 
                 Natriuretic peptide 
                 BNP(4-30) 
               
               
                   
               
               
                 NP03685 
                 MVQGSGCFGRKMDRISSSSGLGCKVLRR 
                 28 
                 Natriuretic peptide 
                 BNP(4-31) 
               
               
                   
               
               
                 NP03686 
                 MVQGSGCFGRKMDRISSSSGLGCKVLRRH 
                 29 
                 Natriuretic peptide 
                 BNP(4-32) 
               
               
                   
               
               
                 NP03687 
                 VQGSGCFGRKMDRISSSSGLGCKVL 
                 25 
                 Natriuretic peptide 
                 BNP(5-29) 
               
               
                   
               
               
                 NP03688 
                 VQGSGCFGRKMDRISSSSGLGCKVLRR 
                 27 
                 Natriuretic peptide 
                 BNP(5-31) 
               
               
                   
               
               
                 NP03689 
                 VQGSGCFGRKMDRISSSSGLGCKVLRRH 
                 28 
                 Natriuretic peptide 
                 BNP(5-32) 
               
               
                   
               
               
                 NP03690 
                 SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH 
                 32 
                 Natriuretic peptide 
                 Brain natriuretic peptide 32 
               
               
                   
               
               
                 NP03691 
                 HPLGSPGSASDLETSGLQEQRNHLQGKLSELQVEQTSLEPLQESPRPTGVWKSREV 
                 108 
                 Natriuretic peptide 
                 Natriuretic peptides B 
               
               
                   
                 ATEGIRGHRKMVLYTLRAPRSPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH 
                   
                   
                   
               
               
                   
               
               
                 NP03692 
                 GLSKGCFGLKLDRIGSMSGLGC 
                 22 
                 Natriuretic peptide 
                 CNP-22 
               
               
                   
               
               
                 NP03693 
                 YKGANKKGLSKGCFGLKLDRIGSMSGLGC 
                 29 
                 Natriuretic peptide 
                 CNP-29 
               
               
                   
               
               
                 NP03694 
                 DLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC 
                 53 
                 Natriuretic peptide 
                 CNP-53 
               
               
                   
               
               
                 NP03714 
                 ANLTNGGKSELLKSGSSKSTLKHIWTESSKDLSISRLLSQTFRGKENDTDLDLRYDT 
                 250 
                 Neurexophilin 
                 Neurexophilin-1 
               
               
                   
                 PEPYSEQDLWDWLRNSTDLQEPRPRAKRRPIVKTGKFKKMFGWGDFHSNIKTVKL 
                   
                   
                   
               
               
                   
                 NLLITGKIVDHGNGTFSVYFRHNSTGQGNVSVSLVPPTKIVEFDLAQQTVIDAKDSK 
                   
                   
                   
               
               
                   
                 SFNCRIEYEKVDKATKNTLCNYDPSKTCYQEQTQSHVSWLCSKPFKVICIYISFYST 
                   
                   
                   
               
               
                   
                 DYKLVQKVCPDYNYHSDTPYFPSG 
                   
                   
                   
               
               
                   
               
               
                 NP03715 
                 KEVVHATEGLDWEDKDAPGTLVGNVVHSRIISPLRLFVKQSPVPKPGPMAYADSM 
                 242 
                 Neurexophilin 
                 Neurexophilin-2 
               
               
                   
                 ENFWDWLANITEIQEPLARTKRRPIVKTGKFKKMFGWGDFHSNIKTVKLNLLITGKI 
                   
                   
                   
               
               
                   
                 VDHGNGTFSVYFRHNSTGLGNVSVSLVPPSKVVEFEVSPQSTLETKESKSFNCRIEY 
                   
                   
                   
               
               
                   
                 EKTDRAKKTALCNFDPSKICYQEQTQSHVSWLCSKPFKVICIYIAFYSVDYKLVQK 
                   
                   
                   
               
               
                   
                 VCPDYNYHSETPYLSSG 
                   
                   
                   
               
               
                   
               
               
                 NP03716 
                 QDDGPPGSEDPERDDHEGQPRPRVPRKRGHISPKSRPMANSTLLGLLAPPGEAWGI 
                 230 
                 Neurexophilin 
                 Neurexophilin-3 
               
               
                   
                 LGQPPNRPNHSPPPSAKVKKIFGWGDFYSNIKTVALNLLVTGKIVDHGNGTFSVHF 
                   
                   
                   
               
               
                   
                 QHNATGQGNISISLVPPSKAVEFHQEQQIFIEAKASKIFNCRMEWEKVERGRRTSLC 
                   
                   
                   
               
               
                   
                 THDPAKICSRDHAQSSATWSCSQPFKVVCVYIAFYSTDYRLVQKVCPDYNYHSDTP 
                   
                   
                   
               
               
                   
                 YYPSG 
                   
                   
                   
               
               
                   
               
               
                 NP03717 
                 QIPESGRPQYLGLRPAAAGAGAPGQQLPEPRSSDGLGVGRAWSWAWPTNHTGAL 
                 285 
                 Neurexophilin 
                 Neurexophilin-4 
               
               
                   
                 ARAGAAGALPAQRTKRKPSIKAARAKKIFGWGDFYFRVHTLKFSLLVTGKIVDHV 
                   
                   
                   
               
               
                   
                 NGTFSVYFRHNSSSLGNLSVSIVPPSKRVEFGGVWLPGPVPHPLQSTLALEGVLPGL 
                   
                   
                   
               
               
                   
                 GPPLGMAAAAAGPGLGGSLGGALAGPLGGALGVPGAKESRAFNCHVEYEKTNRA 
                   
                   
                   
               
               
                   
                 RKHRPCLYDPSQVCFTEHTQSQAAWLCAKPFKVICIFVSFLSFDYKLVQKVCPDYN 
                   
                   
                   
               
               
                   
                 FQSEHPYFG 
                   
                   
                   
               
               
                   
               
               
                 NP03732 
                 ILQRGSGTAAVDFTKKDHTATWGRPFFLFRPRN 
                 33 
                 Neuromedins 
                 Neuromedin-S 
               
               
                   
               
               
                 NP03733 
                 FRVDEEFQSPFASQSRGYFLFRPRN 
                 25 
                 Neuromedins 
                 Neuromedin-U-25 
               
               
                   
               
               
                 NP03744 
                 WYKPAAGHSSYSVGRAAGLLSGLR 
                 24 
                 Neuropeptide B/W 
                 Neuropeptide B-23 
               
               
                   
               
               
                 NP03745 
                 WYKPAAGHSSYSVGRAAGLLSGLRRSPYA 
                 29 
                 Neuropeptide B/W 
                 Neuropeptide B-29 
               
               
                   
               
               
                 NP03746 
                 WYKHVASPRYHTVGRAAGLLMGL 
                 23 
                 Neuropeptide B/W 
                 Neuropeptide W-23 
               
               
                   
               
               
                 NP03747 
                 WYKHVASPRYHTVGRAAGLLMGLRRSPYLW 
                 30 
                 Neuropeptide B/W 
                 Neuropeptide W-30 
               
               
                   
               
               
                 NP03755 
                 SFRNGVGTGMKKTSFQRAKS 
                 20 
                 Neuropeptide S 
                 Neuropeptide S 
               
               
                   
               
               
                 NP03782 
                 SDSEEEMKALEADFLTNMHTSKISKAHVPSWKMTLLNVCSLVNNLNSPAEETGEV 
                 125 
                 Neurotensin 
                 Large neuromedin N 
               
               
                   
                 HEEELVARRKLPTALDGFSLEAMLTIYQLHKICHSRAFQHWELIQEDILDTGNDKN 
                   
                   
                   
               
               
                   
                 GKEEVIKRKIPYIL 
                   
                   
                   
               
               
                   
               
               
                 NP03783 
                 IPYIL 
                 5 
                 Neurotensin 
                 Neuromedin N 
               
               
                   
               
               
                 NP03784 
                 QLYENKPRRPYIL 
                 13 
                 Neurotensin 
                 Neurotensin 
               
               
                   
               
               
                 NP03785 
                 DSYYY 
                 5 
                 Neurotensin 
                 Tail peptide (Potential) 
               
               
                   
               
               
                 NP03886 
                 SSPETLISDLLMRESTENVPRTRLEDPAMW 
                 30 
                 NPY 
                 C-flanking peptide of NPY 
               
               
                   
               
               
                 NP03887 
                 YPSKPDNPGEDAPAEDMARYYSALRHYINLI   T   RQRY 
                 36 
                 NPY 
                 Neuropeptide Y 
               
               
                   
               
               
                 NP03957 
                 APLEPVYPGDNATPEQMAQYAADLRRYINML   T   RPRY 
                 36 
                 NPY 
                 Pancreatic hormone 
               
               
                   
               
               
                 NP03958 
                 HKEDTLAFSEWGSPHAAVPR 
                 20 
                 NPY 
                 Pancreatic icosapeptide 
               
               
                   
               
               
                 NP03959 
                 YPIKPEAPREDASPEELNRYYASLRHYLNLV   T   RQRY 
                 36 
                 NPY 
                 Peptide YY 
               
               
                   
               
               
                 NP03960 
                 IKPEAPREDASPEELNRYYASLRHYLNLV   T   RQRY 
                 34 
                 NPY 
                 Peptide YY(3-36) 
               
               
                   
               
               
                 NP04021 
                 VPLERGAPNKEETPATESPDTGLYYHRYLQEVIDVLETDGHFREKLQAANAEDIKS 
                 435 
                 Nucleobindin 
                 Nucleobindin-1 
               
               
                   
                 GKLSRELDFVSHHVRTKLDELKRQEVSRLRMLLKAKMDAEQDPNVQVDHLNLLK 
                   
                   
                   
               
               
                   
                 QFEHLDPQNQHTFEARDLELLIQTATRDLAQYDAAHHEEFKRYEMLKEHERRRYL 
                   
                   
                   
               
               
                   
                 ESLGEEQRKEAERKLEEQQRRHREHPKVNVPGSQAQLKEVWEELDGLDPNRFNPK 
                   
                   
                   
               
               
                   
                 TFFILHDINSDGVLDEQELEALFTKELEKVYDPKNEEDDMREMEEERLRMREHVM 
                   
                   
                   
               
               
                   
                 KNVDTNQDRLVTLEEFLASTQRKEFGDTGEGWETVEMHPAYTEEELRRFEEELAA 
                   
                   
                   
               
               
                   
                 REAELNAKAQRLSQETEALGRSQGRLEAQKRELQQAVLHMEQRKQQQQQQQGH 
                   
                   
                   
               
               
                   
                 KAPAAHPEGQLKFHPDTDDVPVPAPAGDQKEVDTSEKKLLERLPEVEVPQHL 
                   
                   
                   
               
               
                   
               
               
                 NP04025 
                 VPIDIDKTKVQNIHPVESAKIEPPDTGLYYDEYLKQVIDVLETDKHFREKLQKADIE 
                 82 
                 Nucleobindin 
                 Nesfatin-1 
               
               
                   
                 EIKSGRLSKELDLVSHHVRTKLDEL 
                   
                   
                   
               
               
                   
               
               
                 NP04026 
                 VPIDIDKTKVQNIHPVESAKIEPPDTGLYYDEYLKQVIDVLETDKHFREKLQKADIE 
                 396 
                 Nucleobindin 
                 Nucleobindin-2 
               
               
                   
                 EIKSGRLSKELDLVSHHVRTKLDELKRQEVGRLRMLIKAKLDSLQDIGMDHQALLK 
                   
                   
                   
               
               
                   
                 QFDHLNHLNPDKFESTDLDMLIKAATSDLEHYDKTRHEEFKKYEMMKEHERREYL 
                   
                   
                   
               
               
                   
                 KTLNEEKRKEEESKFEEMKKKHENHPKVNHPGSKDQLKEVWEETDGLDPNDFDP 
                   
                   
                   
               
               
                   
                 KTFFKLHDVNSDGFLDEQELEALFTKELEKVYDPKNEEDDMVEMEEERLRMREHV 
                   
                   
                   
               
               
                   
                 MSEVDTNKDRLVTLEEFLKATEKKEFLEPDSWETLDQQQFFTEEELKEYENIIALQE 
                   
                   
                   
               
               
                   
                 NELKKKADELQKQKEELQRQHDQLEAQKLEYHQVIQQMEQKKLQQGIPPSGPAGE 
                   
                   
                   
               
               
                   
                 LKFEPHI 
                   
                   
                   
               
               
                   
               
               
                 NP04038 
                 YAFDVVG 
                 7 
                 Opioid 
                 Deltorphin I 
               
               
                   
               
               
                 NP04039 
                 ELTGQRLRQGDGPNAGADDGPGAQADLEHSLLVAAEKKD 
                 57 
                 Opioid 
                 Gamma-Lipotropin 
               
               
                   
                 EGPYRMEHFRWGSPPKD 
                   
                   
                   
               
               
                   
               
               
                 NP04040 
                 YVMGHFRWDRFG 
                 12 
                 Opioid 
                 □pmelanocyte-stimulating 
               
               
                   
                   
                   
                   
                 hormone 
               
               
                   
               
               
                 NP04123 
                 YGGFLRKYPK 
                 10 
                 Opioid 
                 Alpha-neoendorphin 
               
               
                   
               
               
                 NP04124 
                 YGGFLRKYP 
                 9 
                 Opioid 
                 Beta-neoendorphin 
               
               
                   
               
               
                 NP04125 
                 YGGFLRRIRPKLKWDNQKRYGGFLRRQFKVVT 
                 32 
                 Opioid 
                 Big dynorphin 
               
               
                   
               
               
                 NP04126 
                 YGGFLRRIRPKLK 
                 13 
                 Opioid 
                 Dynorphin A(1-13) (By 
               
               
                   
                   
                   
                   
                 similarity) 
               
               
                   
               
               
                 NP04127 
                 YGGFLRRIRPKLKWDNQ 
                 17 
                 Opioid 
                 Dynorphin A(1-17) 
               
               
                   
               
               
                 NP04128 
                 YGGFLRRI 
                 8 
                 Opioid 
                 Dynorphin A(1-8) (By 
               
               
                   
                   
                   
                   
                 similarity) 
               
               
                   
               
               
                 NP04129 
                 YGGFL 
                 5 
                 Opioid 
                 Leu-enkephalin 
               
               
                   
               
               
                 NP04130 
                 YGGFLRRQFKVVTRSQEDPNAYSGELFDA 
                 29 
                 Opioid 
                 Leumorphin 
               
               
                   
               
               
                 NP04131 
                 YGGFLRRQFKVVT 
                 13 
                 Opioid 
                 Rimorphin 
               
               
                   
               
               
                 NP04132 
                 YGGFM 
                 5 
                 Opioid 
                 Met-enkephalin 
               
               
                   
               
               
                 NP04133 
                 YGGFMRGL 
                 8 
                 Opioid 
                 Met-enkephalin-Arg-Gly-Leu 
               
               
                   
               
               
                 NP04134 
                 YGGFMRF 
                 7 
                 Opioid 
                 Met-enkephalin-Arg-Phe 
               
               
                   
               
               
                 NP04135 
                 MDELYPMEPEEEANGSEILA 
                 20 
                 Opioid 
                 PENK(114-133) (By 
               
               
                   
                   
                   
                   
                 similarity) 
               
               
                   
               
               
                 NP04136 
                 DAEEDDSLANSSDLLKELLETGDNRERSHHQDGSDNEEEVS 
                 41 
                 Opioid 
                 PENK(143-183) (By 
               
               
                   
                   
                   
                   
                 similarity) 
               
               
                   
               
               
                 NP04137 
                 FAEALPSDEEGESYSKEVPEME 
                 22 
                 Opioid 
                 PENK(237-258) (By 
               
               
                   
                   
                   
                   
                 similarity) 
               
               
                   
               
               
                 NP04138 
                 ECSQDCATCSYRLVRPADINFLACVMECEGKLPSLKIWETCKELLQLSKPELPQDG 
                 73 
                 Opioid 
                 Synenkephalin 
               
               
                   
                 TSTLRENSKPEESHLLA 
                   
                   
                   
               
               
                   
               
               
                 NP04139 
                 MPRVRSLFQEQEEPEPGMEEAGEMEQKQLQ 
                 30 
                 Opioid 
                 Neuropeptide 1 (Probable) 
               
               
                   
               
               
                 NP04140 
                 FSEFMRQYLVLSMQSSQ 
                 17 
                 Opioid 
                 Neuropeptide 2 (Probable) 
               
               
                   
               
               
                 NP04141 
                 FGGFTGARKSARKLANQ 
                 17 
                 Opioid 
                 Nociceptin 
               
               
                   
               
               
                 NP04400 
                 QPLPDCCRQKTCSCRLYELLHGAGNHAAGILTL 
                 33 
                 Orexin 
                 Orexin-A 
               
               
                   
               
               
                 NP04401 
                 RSGPPGLQGRLQRLLQASGNHAAGILTM 
                 28 
                 Orexin 
                 Orexin-B 
               
               
                   
               
               
                 NP04409 
                 SLALADDAAFRERARLLAALERRHWLNSYMHKLLVLDAP 
                 39 
                 Parathyroid hormone 
                 Tuberoinfundibular peptide of 
               
               
                   
                   
                   
                   
                 39residues 
               
               
                   
               
               
                 NP04423 
                 TRSAWLDSGVTGSGLEGDHLSDTSTTSLELDSR 
                 33 
                 Parathyroid hormone 
                 Osteostatin 
               
               
                   
               
               
                 NP04424 
                 AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTAEIRATSEVSPNSKPSPNTKNHPVR 
                 141 
                 Parathyroid hormone 
                 Parathyroid hormone-related 
               
               
                   
                 FGSDDEGRYLTQETNKVETYKEQPLKTPGKKKKGKPGKRKEQEKKKRRTRSAWL 
                   
                   
                 protein 
               
               
                   
                 DSGVTGSGLEGDHLSDTSTTSLELDSRRH 
                   
                   
                   
               
               
                   
               
               
                 NP04425 
                 AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTAEI 
                 36 
                 Parathyroid hormone 
                 PTHrP[1-36] 
               
               
                   
               
               
                 NP04426 
                 ATSEVSPNSKPSPNTKNHPVRFGSDDEGRYLTQETNKVETYKEQPLKTPGKKKKGK 
                 57 
                 Parathyroid hormone 
                 PTHrP[38-94] 
               
               
                   
                 P 
                   
                   
                   
               
               
                   
               
               
                 NP04892 
                 YGGFMTSEKSQTPLVTLFKNAIIKNAYKKGE 
                 31 
                 POMC 
                 Beta-endorphin 
               
               
                   
               
               
                 NP04893 
                 SYSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEF 
                 39 
                 POMC 
                 Corticotropin 
               
               
                   
               
               
                 NP04894 
                 PVKVYPNGAEDESAEAFPLEF 
                 21 
                 POMC 
                 Corticotropin-like 
               
               
                   
                   
                   
                   
                 intermediary peptide 
               
               
                   
               
               
                 NP04895 
                 ELTGQRLREGDGPDGPADDGAGAQADLEHSLLVAAEKKDEGPYRMEHFRWGSPP 
                 89 
                 POMC 
                 Lipotropin beta 
               
               
                   
                 KDKRYGGFMTSEKSQTPLVTLFKNAIIKNAYKKGE 
                   
                   
                   
               
               
                   
               
               
                 NP04896 
                 ELTGQRLREGDGPDGPADDGAGAQADLEHSLLVAAEKKDEGPYRMEHFRWGSPP 
                 56 
                 POMC 
                 Lipotropin gamma 
               
               
                   
                 KD 
                   
                   
                   
               
               
                   
               
               
                 NP04897 
                 SYSMEHFRWGKPV 
                 13 
                 POMC 
                 Melanotropin alpha 
               
               
                   
               
               
                 NP04898 
                 DEGPYRMEHFRWGSPPKD 
                 18 
                 POMC 
                 Melanotropin beta 
               
               
                   
               
               
                 NP04899 
                 YVMGHFRWDRF 
                 11 
                 POMC 
                 Melanotropin gamma 
               
               
                   
               
               
                 NP04900 
                 WCLESSQCQDLTTESNLLECIRACKPDLSAETPMFPGNGDEQPLTENPRKYVMGHF 
                 76 
                 POMC 
                 NPP 
               
               
                   
                 RWDRFGRRNSSSSGSSGAGQ 
                   
                   
                   
               
               
                   
               
               
                 NP04901 
                 EDVSAGEDCGPLPEGGPEPRSDGAKPGPRE 
                 30 
                 POMC 
                 Potential peptide 
               
               
                   
               
               
                 NP04921 
                 ARPVKEPRGLSAASPPLAETGAPRRFRRSVPRGEAAGAVQELARALAHLLEAERQE 
                 227 
                 ProSAAS 
                 ProSAAS 
               
               
                   
                 RARAEAQEAEDQQARVLAQLLRVWGAPRNSDPALGLDDDPDAPAAQLARALLRA 
                   
                   
                   
               
               
                   
                 RLDPAALAAQLVPAPVPAAALRPRPPVYDDGPAGPDAEEAGDETPDVDPELLRYL 
                   
                   
                   
               
               
                   
                 LGRILAGSADSEGVAAPRRLRRAADHDVGSELPPEGVLGALLRVKRLETPAPQVPA 
                   
                   
                   
               
               
                   
                 RRLLPP 
                   
                   
                   
               
               
                   
               
               
                 NP04922 
                 LETPAPQVPARRLLPP 
                 16 
                 ProSAAS 
                 Big LEN (By similarity) 
               
               
                   
               
               
                 NP04923 
                 AADHDVGSELPPEGVLGALLRVKRLETPAPQVPARRLLPP 
                 40 
                 ProSAAS 
                 Big PEN-LEN (By similarity) 
               
               
                   
               
               
                 NP04924 
                 ARPVKEPRGLSAASPPLAETGAPRRF 
                 26 
                 ProSAAS 
                 Big SAAS (By similarity) 
               
               
                   
               
               
                 NP04925 
                 ARPVKEP 
                 7 
                 ProSAAS 
                 KEP (By similarity) 
               
               
                   
               
               
                 NP04926 
                 LETPAPQVPA 
                 10 
                 ProSAAS 
                 Little LEN (By similarity) 
               
               
                   
               
               
                 NP04927 
                 GLSAASPPLAETGAPRRF 
                 18 
                 ProSAAS 
                 Little SAAS (By similarity) 
               
               
                   
               
               
                 NP04928 
                 AADHDVGSELPPEGVLGALLRV 
                 22 
                 ProSAAS 
                 PEN (By similarity) 
               
               
                   
               
               
                 NP05218 
                 KTLCSMEEAINERIQEVAGSLIFRAISSIGLECQSVTSRGDLATCPRGFAVTGCTCGS 
                 90 
                 Resistin/FIZZ 
                 Resistin 
               
               
                   
                 ACGSWDVRAETTCHCQCAGMDWTGARCCRVQP 
                   
                   
                   
               
               
                   
               
               
                 NP05219 
                 QCSLDSVMDKKIKDVLNSLEYSPSPISKKLSCASVKSQGRPSSCPAGMAVTGCACG 
                 88 
                 Resistin/FIZZ 
                 Resistin-like beta 
               
               
                   
                 YGCGSWDVQLETTCHCQCSVVDWTTARCCHLT 
                   
                   
                   
               
               
                   
               
               
                 NP05222 
                 QDEGSEATGFLPAAGEKTSGPLGNLAEELNGYSRKKGGFSFRF 
                 43 
                 RFamide neuropeptide 
                 QRF-amide 
               
               
                   
               
               
                 NP05241 
                 SEEPPISLDLTFHLLREVLEMARAEQLAQQAHSNRKLMEII 
                 41 
                 Sauvagine/corticotropin- 
                 Corticoliberin 
               
               
                   
                   
                   
                 releasing 
                   
               
               
                   
                   
                   
                 factor/urotensin I 
                   
               
               
                   
               
               
                 NP05242 
                 DNPSLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV 
                 40 
                 Sauvagine/corticotropin- 
                 Urocortin 
               
               
                   
                   
                   
                 releasing 
                   
               
               
                   
                   
                   
                 factor/urotensin I 
                   
               
               
                   
               
               
                 NP05243 
                 IVLSLDVPIGLLQILLEQARARAAREQATTNARILARVGHC 
                 41 
                 Sauvagine/corticotropin- 
                 Urocortin-2 
               
               
                   
                   
                   
                 releasing 
                   
               
               
                   
                   
                   
                 factor/urotensin I 
                   
               
               
                   
               
               
                 NP05244 
                 FTLSLDVPTNIMNLLFNIAKAKNLRAQAAANAHLMAQI 
                 38 
                 Sauvagine/corticotropin- 
                 Urocortin-3 
               
               
                   
                   
                   
                 releasing 
                   
               
               
                   
                   
                   
                 factor/urotensin I 
                   
               
               
                   
               
               
                 NP05299 
                 MDPNAAYVNMSNHHRGLASANVDFAFSLYKHLVALSPKKNIFISPVSISMALAMLS 
                 383 
                 Serpin 
                 Corticosteroid-binding 
               
               
                   
                 LGTCGHTRAQLLQGLGFNLTERSETEIHQGFQHLHQLFAKSDTSLEMTMGNALFLD 
                   
                   
                 globulin 
               
               
                   
                 GSLELLESFSADIKHYYESEVLAMNFQDWATASRQINSYVKNKTQGKIVDLFSGLD 
                   
                   
                   
               
               
                   
                 SPAILVLVNYIFFKGTWTQPFDLASTREENFYVDETTVVKVPMMLQSSTISYLHDSE 
                   
                   
                   
               
               
                   
                 LPCQLVQMNYVGNGTVFFILPDKGKMNTVIAALSRDTINRWSAGLTSSQVDLYIPK 
                   
                   
                   
               
               
                   
                 VTISGVYDLGDVLEEMGIADLFTNQANFSRITQDAQLKSSKVVHKAVLQLNEEGV 
                   
                   
                   
               
               
                   
                 DTAGSTGVTLNLTSKPIILRFNQPFIIMIFDHFTWSSLFLARVMNPV 
                   
                   
                   
               
               
                   
               
               
                 NP05300 
                 QPLLAHGDKSLQGPQPPRHQLSEPAPAYHRITPTITNFALRLYKELAADAPGNIFFSP 
                 403 
                 Serpin 
                 Serpin A11 
               
               
                   
                 VSISTTLALLSLGAQANTSALILEGLGFNLTETPEADIHQGFRSLLHTLALPSPKLELK 
                   
                   
                   
               
               
                   
                 VGNSLFLDKRLKPRQHYLDSIKELYGAFAFSANFTDSVTTGRQINDYLRRQTYGQV 
                   
                   
                   
               
               
                   
                 VDCLPEFSQDTFMVLANYIFFKAKWKHPFSRYQTQKQESFFVDERTSLQVPMMHQ 
                   
                   
                   
               
               
                   
                 KEMHRFLYDQDLACTVLQIEYRGNALALLVLPDPGKMKQVEAALQPQTLRKWGQ 
                   
                   
                   
               
               
                   
                 LLLPSLLDLHLPRFSISGTYNLEDILPQIGLTNILNLEADFSGVTGQLNKTISKVSHKA 
                   
                   
                   
               
               
                   
                 MVDMSEKGTEAGAASGLLSQPPSLNTMSDPHAHFNRPFLLLLWEVTTQSLLFLGK 
                   
                   
                   
               
               
                   
                 VVNPVAG 
                   
                   
                   
               
               
                   
               
               
                 NP05301 
                 LKPSFSPRNYKALSEVQGWKQRMAAKELARQNMDLGFKLLKKLAFYNPGRNIFLS 
                 394 
                 Serpin 
                 Serpin A12 
               
               
                   
                 PLSISTAFSMLCLGAQDSTLDEIKQGFNFRKMPEKDLHEGFHYIIHELTQKTQDLKL 
                   
                   
                   
               
               
                   
                 SIGNTLFIDQRLQPQRKFLEDAKNFYSAETILTNFQNLEMAQKQINDFISQKTHGKIN 
                   
                   
                   
               
               
                   
                 NLIENIDPGTVMLLANYIFFRARWKHEFDPNVTKEEDFFLEKNSSVKVPMMFRSGI 
                   
                   
                   
               
               
                   
                 YQVGYDDKLSCTILEIPYQKNITAIFILPDEGKLKHLEKGLQVDTFSRWKTLLSRRV 
                   
                   
                   
               
               
                   
                 VDVSVPRLHMTGTFDLKKTLSYIGVSKIFEEHGDLTKIAPHRSLKVGEAVHKAELK 
                   
                   
                   
               
               
                   
                 MDERGTEGAAGTGAQTLPMETPLVVKIDKPYLLLIYSEKIPSVLFLGKIVNPIGK 
                   
                   
                   
               
               
                   
               
               
                 NP05302 
                 SRCSAQKNTEFAVDLYQEVSLSHKDNIIFSPLGITLVLEMVQLGAKGKAQQQIRQTL 
                 387 
                 Serpin 
                 Serpin I2 
               
               
                   
                 KQQETSAGEEFFVLKSFFSAISEKKQEFTFNLANALYLQEGFTVKEQYLHGNKEFFQ 
                   
                   
                   
               
               
                   
                 SAIKLVDFQDAKACAEMISTWVERKTDGKIKDMFSGEEFGPLTRLVLVNAIYFKGD 
                   
                   
                   
               
               
                   
                 WKQKFRKEDTQLINFTKKNGSTVKIPMMKALLRTKYGYFSESSLNYQVLELSYKG 
                   
                   
                   
               
               
                   
                 DEFSLIIILPAEGMDIEEVEKLITAQQILKWLSEMQEEEVEISLPRFKVEQKVDFKDV 
                   
                   
                   
               
               
                   
                 LYSLNITEIFSGGCDLSGITDSSEVYVSQVTQKVFFEINEDGSEAATSTGIHIPVIMSL 
                   
                   
                   
               
               
                   
                 AQSQFIANHPFLFIMKHNPTESILFMGRVTNPDTQEIKGRDLDSL 
                   
                   
                   
               
               
                   
               
               
                 NP05326 
                 DRVY 
                 4 
                 Serpin 
                 Angiotensin 1-4 
               
               
                   
               
               
                 NP05327 
                 DRVYI 
                 5 
                 Serpin 
                 Angiotensin 1-5 
               
               
                   
               
               
                 NP05328 
                 DRVYIHP 
                 7 
                 Serpin 
                 Angiotensin 1-7 
               
               
                   
               
               
                 NP05329 
                 DRVYIHPFH 
                 9 
                 Serpin 
                 Angiotensin 1-9 
               
               
                   
               
               
                 NP05330 
                 DRVYIHPFHL 
                 10 
                 Serpin 
                 Angiotensin-1 
               
               
                   
               
               
                 NP05331 
                 DRVYIHPF 
                 8 
                 Serpin 
                 Angiotensin-2 
               
               
                   
               
               
                 NP05332 
                 RVYIHPF 
                 7 
                 Serpin 
                 Angiotensin-3 
               
               
                   
               
               
                 NP05333 
                 VYIHPF 
                 6 
                 Serpin 
                 Angiotensin-4 
               
               
                   
               
               
                 NP05334 
                 DRVYIHPFHLVIHNESTCEQLAKANAGKPKDPTFIPAPIQAKTSPVDEKALQDQLVL 
                 452 
                 Serpin 
                 Angiotensinogen 
               
               
                   
                 VAAKLDTEDKLRAAMVGMLANFLGFRIYGMHSELWGVVHGATVLSPTAVFGTLA 
                   
                   
                   
               
               
                   
                 SLYLGALDHTADRLQAILGVPWKDKNCTSRLDAHKVLSALQAVQGLLVAQGRAD 
                   
                   
                   
               
               
                   
                 SQAQLLLSTVVGVFTAPGLHLKQPFVQGLALYTPVVLPRSLDFTELDVAAEKIDRF 
                   
                   
                   
               
               
                   
                 MQAVTGWKTGCSLMGASVDSTLAFNTYVHFQGKMKGFSLLAEPQEFWVDNSTSV 
                   
                   
                   
               
               
                   
                 SVPMLSGMGTFQHWSDIQDNFSVTQVPFTESACLLLIQPHYASDLDKVEGLTFQQN 
                   
                   
                   
               
               
                   
                 SLNWMKKLSPRTIHLTMPQLVLQGSYDLQDLLAQAELPAILHTELNLQKLSNDRIR 
                   
                   
                   
               
               
                   
                 VGEVLNSIFFELEADEREPTESTQQLNKPEVLEVTLNRPFLFAVYDQSATALHFLGR 
                   
                   
                   
               
               
                   
                 VANPLSTA 
                   
                   
                   
               
               
                   
               
               
                 NP05404 
                 DRMPCRNFFWKTFSSCK 
                 17 
                 Somastostatin 
                 Cortistatin-17 
               
               
                   
               
               
                 NP05405 
                 QEGAPPQQSARRDRMPCRNFFWKTFSSCK 
                 29 
                 Somastostatin 
                 Cortistatin-29 (Potential) 
               
               
                   
               
               
                 NP05406 
                 AGCKNFFWKTFTSC 
                 14 
                 Somastostatin 
                 Somatostatin-14 
               
               
                   
               
               
                 NP05407 
                 SANSNPAMAPRERKAGCKNFFWKTFTSC 
                 28 
                 Somastostatin 
                 Somatostatin-28 
               
               
                   
               
               
                 NP05514 
                 LPICPGGAARCQVTLRDLFDRAVVLSHYIHNLSSEMFSEFDKRYTHGRGFITKAINS 
                 199 
                 Somatotropin/prolactin 
                 Prolactin 
               
               
                   
                 CHTSSLATPEDKEQAQQMNQKDFLSLIVSILRSWNEPLYHLVTEVRGMQEAPEAIL 
                   
                   
                   
               
               
                   
                 SKAVEIEEQTKRLLEGMELIVSQVHPETKENEIYPVWSGLPSLQMADEESRLSAYY 
                   
                   
                   
               
               
                   
                 NLLHCLRRDSHKIDNYLKLLKCRIIHNNNC 
                   
                   
                   
               
               
                   
               
               
                 NP05529 
                 RPKPQFFGLM 
                 10 
                 Tachykinin 
                 Substance P 
               
               
                   
               
               
                 NP05682 
                 ALNSVAYERSAMQNYE 
                 16 
                 Tachykinin 
                 C-terminal-flanking peptide 
               
               
                   
               
               
                 NP05683 
                 HKTDSFVGLM 
                 10 
                 Tachykinin 
                 Neurokinin A 
               
               
                   
               
               
                 NP05684 
                 DADSSIEKQVALLKALYGHGQISHKRHKTDSFVGLM 
                 36 
                 Tachykinin 
                 Neuropeptide K 
               
               
                   
               
               
                 NP05685 
                 RPKPQQFFGLM 
                 11 
                 Tachykinin 
                 Substance P 
               
               
                   
               
               
                 NP05686 
                 DMHDFFVGLM 
                 10 
                 Tachykinin 
                 Neurokinin-B 
               
               
                   
               
               
                 NP05799 
                 QPEAAQQEAVTAAEHPGLDDFLRQVERLLFLRENIQRLQGDQGEHSASQIFQSDWL 
                 218 
                 TRH 
                 Pro-thyrotropin-releasing 
               
               
                   
                 SKRQHPGKREEEEEEGVEEEEEEEGGAVGPHKRQHPGRREDEASWSVDVTQHKRQ 
                   
                   
                 hormone 
               
               
                   
                 HPGRRSPWLAYAVPKRQHPGRRLADPKAQRSWEEEEEEEEREEDLMPEKRQHPGK 
                   
                   
                   
               
               
                   
                 RALGGPCGPQGAYGQAGLLLGLLDDLSRSQGAEEKRQHPGRRAAWVREPLEE 
                   
                   
                   
               
               
                   
               
               
                 NP05800 
                 QHP 
                 3 
                 TRH 
                 Thyrotropin-releasing 
               
               
                   
                   
                   
                   
                 hormone 
               
               
                   
               
               
                 NP05810 
                 ETPDCFWKYCV 
                 11 
                 Urotensin-2 
                 Urotensin-2 
               
               
                   
               
               
                 NP05811 
                 ACFWKYCV 
                 8 
                 Urotensin-2 
                 Urotensin-2B 
               
               
                   
               
               
                 NP05890 
                 AAPDLDVRKCLPCGPGGKGRCFGPNICCAEELGCFVGTAEALRCQEENYLPSPCQS 
                 94 
                 Vasopressin/oxytocin 
                 Neurophysin 1 
               
               
                   
                 GQKACGSGGRCAVLGLCCSPDGCHADPACDAEATFSQR 
                   
                   
                   
               
               
                   
               
               
                 NP05891 
                 CYIQNCPLG 
                 9 
                 Vasopressin/oxytocin 
                 Oxytocin 
               
               
                   
               
               
                 NP05892 
                 CYFQNCPRG 
                 9 
                 Vasopressin/oxytocin 
                 Arg-vasopressin 
               
               
                   
               
               
                 NP05893 
                 ASDRSNATQLDGPAGALLLRLVQLAGAPEPFEPAQPDAY 
                 39 
                 Vasopressin/oxytocin 
                 Copeptin 
               
               
                   
               
               
                 NP05894 
                 AMSDLELRQCLPCGPGGKGRCFGPSICCADELGCFVGTAEALRCQEENYLPSPCQS 
                 93 
                 Vasopressin/oxytocin 
                 Neurophysin 2 
               
               
                   
                 GQKACGSGGRCAAFGVCCNDESCVTEPECREGFHRRA 
                   
                   
                   
               
               
                   
               
               
                 NP05912 
                 TLQPPSALRRRHYHHALPPSRHYP 
                 24 
                 VGF 
                 Antimicrobial peptide 
               
               
                   
                   
                   
                   
                 VGF[554-577] 
               
               
                   
               
               
                 NP05913 
                 RPESALLGGSEAGERLLQQGLAQVEA 
                 26 
                 VGF 
                 Neuroendocrine regulatory 
               
               
                   
                   
                   
                 peptide-1 
                   
               
               
                   
               
               
                 NP05914 
                 QAEATRQAAAQEERLADLASDLLLQYLLQGGARQRGLG 
                 38 
                 VGF 
                 Neuroendocrine regulatory 
               
               
                   
                   
                   
                 peptide-2 
                   
               
               
                   
               
               
                 NP05915 
                 APPGRPEAQPPPLSSEHKEPVAGDAVPGPKDGSAPEVRGARNSEPQDEGELFQGVD 
                 593 
                 VGF 
                 Neurosecretory protein VGF 
               
               
                   
                 PRALAAVLLQALDRPASPPAPSGSQQGPEEEAAEALLTETVRSQTHSLPAPESPEPA 
                   
                   
                   
               
               
                   
                 APPRPQTPENGPEASDPSEELEALASLLQELRDFSPSSAKRQQETAAAETETRTHTLT 
                   
                   
                   
               
               
                   
                 RVNLESPGPERVWRASWGEFQARVPERAPLPPPAPSQFQARMPDSGPLPETHKFGE 
                   
                   
                   
               
               
                   
                 GVSSPKTHLGEALAPLSKAYQGVAAPFPKARRPESALLGGSEAGERLLQQGLAQVE 
                   
                   
                   
               
               
                   
                 AGRRQAEATRQAAAQEERLADLASDLLLQYLLQGGARQRGLGGRGLQEAAEERE 
                   
                   
                   
               
               
                   
                 SAREEEEAEQERRGGEERVGEEDEEAAEAEAEAEEAERARQNALLFAEEEDGEAG 
                   
                   
                   
               
               
                   
                 AEDKRSQEETPGHRRKEAEGTEEGGEEEDDEEMDPQTIDSLIELSTKLHLPADDVVS 
                   
                   
                   
               
               
                   
                 IIEEVEEKRKRKKNAPPEPVPPPRAAPAPTHVRSPQPPPPAPAPARDELPDWNEVLPP 
                   
                   
                   
               
               
                   
                 WDREEDEVYPPGPYHPFPNYIRPRTLQPPSALRRRHYHHALPPSRHYPGREAQARR 
                   
                   
                   
               
               
                   
                 AQEEAEAEERRLQEQEELENYIEHVLLRRP 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
               
               
             
               
                 TABLE 5 
               
               
                   
               
               
                   
                 Peptide 
                   
                   
                 Analogue suquence (potential glycan highlighted 
               
               
                 Peptide hormone name 
                 analogue name 
                 Trade name 
                 Producer 
                 in bold/underscore) (SEQ ID NO) 
               
               
                   
               
             
            
               
                 Amylin 
                 NN9838/AM833 
                 NA 
                 Novo Nordisk 
                 ? 
               
               
                   
               
               
                 Amylin 
                 Pramlintide 
                 Symlin 
                 Bristol-Myers 
                 KCNTA   T   CA   T   QRLANFLVHSSNNFGPILPP   T   NVGSNTY- 
               
               
                   
                   
                   
                 Squibb 
                 NH2 (SEQ ID NO: 280) 
               
               
                   
               
               
                 ANP 32 
                 Urodilatin 
                 Ularitide 
                 ? 
                 TAPRSLRRSSCFGGRMDRIGAQSGLGCN   S   FRY (SEQ ID 
               
               
                   
                   
                   
                   
                 NO: 281) 
               
               
                   
               
               
                 ANP 28 
                 Carperitide 
                 HANP 
                 Daiichi Sankyo 
                 SLRRSSCFGGRMDRIGAQSGLGCN   S   FRY (SEQ ID NO: 
               
               
                   
                   
                   
                   
                 282) 
               
               
                   
               
               
                 ANP 40 
                 mutant ANP 
                 ? 
                 ? 
                 SLRRSSCFGGRMDRIGAQSGLGCN   S   FRYRITAREDKQ 
               
               
                   
                   
                   
                   
                 GWA (SEQ ID NO: 283) 
               
               
                   
               
               
                 BNP 32 
                 Nesiritide 
                 Natrecor 
                 Scios, Inc. 
                 SPKMVQGSGCFGRKMDRISSS   S   GLGCKVLRRH (SEQ 
               
               
                   
                   
                   
                   
                 ID NO: 284) 
               
               
                   
               
               
                 Bradykinin 
                 Icatibant 
                 Firazyr 
                 Shire 
                 RRPXGX   S   XXR (SEQ ID NO: 285) 
               
               
                   
               
               
                 Calcitonin 
                 Salmon Calcitonin 
                 Fortical/ 
                 Several 
                 CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP (SEQ ID 
               
               
                   
                   
                 Miacalcin... 
                   
                 NO: 286) 
               
               
                   
               
               
                 DNP/CNP 
                 cdNP/cenderitide 
                 ? 
                 ? 
                 GLSKGCFGLKLDRIGSM   S   GLGCPSLRDPRPNAPSTSA 
               
               
                 (snake DNP CNP combination) 
                   
                   
                   
                 (SEQ ID NO: 287) 
               
               
                   
               
               
                 GIP/GLP-1 
                 NN9277 GG dual 
                 NA 
                 Novo Nordisk 
                 ? 
               
               
                   
                 agonist 
                   
                   
                   
               
               
                   
               
               
                 GIP/GLP-1/Glucagon 
                 NN9423 Triagonist  
                 NA 
                 Novo Nordisk 
                 ? 
               
               
                   
                 1706 
                   
                   
                   
               
               
                   
               
               
                 GLP-1 
                 Exenatide 
                 BYETTA/ 
                 Bristol-Myers 
                 HGEGTF   T   SDLSKQMEEEAVRLFIEWLKNGGPSSGAPPP 
               
               
                   
                   
                 BYDUREON 
                 Squibb 
                 S (SEQ ID NO: 288) 
               
               
                   
               
               
                 GLP-1 
                 Lixisenatide 
                 Lyxumia/Adlyxin 
                 Sanofi 
                 HGEGTF   T   SDLSKQMEEEAVRLFIEWLKNGGPSSGAPPS 
               
               
                   
                   
                   
                   
                 KKKKKK (SEQ ID NO: 289) 
               
               
                   
               
               
                 GLP-1 GLP-1(7-37) linked to Albumin) 
                 Albiglutide 
                 Tanzeum 
                 GlaxoSmithKline 
                 ? 
               
               
                   
               
               
                 GLP-1 GLP-1(7-37) linked to an Fc 
                 Dulaglutide 
                 Trulicity 
                 Eli Lilly 
                 ? 
               
               
                 fragment of human IgG4 
                   
                   
                   
                   
               
               
                   
               
               
                 GLP-1 
                 LIRAGLUTIDE 
                 Victoza/Saxenda 
                 Novo Nordisk 
                 HAEGTF   T   SDVSSYLEGQAAK-E-EFIAWLVRGRG (SEQ 
               
               
                   
                   
                   
                   
                 ID NO: 290) 
               
               
                   
               
               
                 GLP-1 (37 aa acylated peptide) 
                 Semaglutide 
                 NA 
                 Novo Nordisk 
                 HAEGTF   T   SDVSSYLEGQAAKEEFIIAWLVKGRG (SEQ 
               
               
                   
                   
                   
                   
                 ID NO: 291) 
               
               
                   
               
               
                 GLP-2 
                 Teduglutide 
                 GATTEX 
                 NPS 
                 HGDGSF   S   DEMNTILDNLAARDFINWLIQTKITD (SEQ 
               
               
                   
                   
                   
                 Pharmaceuticals 
                 ID NO: 292) 
               
               
                   
               
               
                 Glucagon 
                 NN9030/G530S 
                 NA 
                 Novo Nordisk 
                 ? 
               
               
                   
               
               
                 Glucagon (produced in  Saccharomyces ) 
                 Glucagon 
                 GlucaGen 
                 Novo Nordisk 
                 HSQGTF   T   SDYSKYLDSRRAQDFVQWLMNT (SEQ ID 
               
               
                   
                   
                   
                   
                 NO: 293) 
               
               
                   
               
               
                 Glucagon (produced in  Escherichia coli ) 
                 Glucagon 
                 Glucagon 
                 Eli Lilly 
                 HSQGTF   T   SDYSKYLDSRRAQDFVQWLMNT (SEQ ID 
               
               
                   
                   
                   
                   
                 NO: 293; same as previous line) 
               
               
                   
               
               
                 PTHR 
                 Abaloparatide/ 
                 Tymlos 
                 Radiuspharm 
                 AV   S   EHQLLHDKGKSIQDLRRRELLEKLLXKLHTA 
               
               
                   
                 BA058 
                   
                   
                 (SEQ ID NO: 294) 
               
               
                   
               
               
                 PYY 
                 NN9747/NN9748 
                 NA 
                 Novo Nordisk 
                   
               
               
                   
               
               
                 Secretin 
                 Secretin 
                 Secremax/ 
                 Repligen Corp 
                 HSDGTF   T   SELSRLRDSARLQRLLQGLV (SEQ ID NO: 
               
               
                   
                   
                 Secreflow 
                   
                 295) 
               
               
                   
               
               
                 Somatoliberin 
                 Sermorelin 
                 Sermorelin  
                 Emd serono inc 
                 YADAIF   T   NSYRKVLGQLSARKLLQDIMSRQ (SEQ ID 
               
               
                   
                   
                 acetate 
                   
                 NO: 296) 
               
               
                   
               
               
                 Somatoliberin 
                 Tesamorelin 
                 Egrifta 
                 Thera- 
                 YADAIF   T   NSYRKVLGQLSARKLLQDIMSRQQGESNQE 
               
               
                   
                   
                   
                 technologies 
                 RGARARL (SEQ ID NO: 297) 
               
               
                   
               
            
           
         
       
     
                     TABLE 6                  *(Bold; identified or conserved in human, Italic; identified in non-human and not conserved; the SEQ ID Nos. are found in the tables infra)                                                                     *Site position                                   (Bold; identified                                   or conserved in                                   human, Italic;                               Peptide   identified in non-   No.       Entry_   Peptide       Peptide   Peptide   Hormone   human and not   of       Human   Start   Peptide_Sequence   end   Name   Family   conserved)   sites                                                     P05408   200       S   VPHFSDEDKDPE   212   C-terminal   7B2   S200   1                       peptide (By                                   similarity)                           P05408   27   Y   S   PR   T   PDRV   S   EADIQRLLHGVMEQLGIARPRVEYPAHQA   212   Neuroendocrine   7B2   S28, T31, S36,   4               MNLVGPQSIEGGAHEGLQHLGPFGNIPNIVAELTGDNIPK       protein 7B2       T134 S200                   DFSEDQGYPDPPNPCPVGKTADDGCLEN   T   PDTAEFSREFQ                                   LHQHLFDPEHDYPGLGKWNKKLLYEKMKGGERRKRRSV                                   NPYLQGQRLDNVVAKK   S   VPHFSDEDKDPE                                   P05408   27   Y   S   PR   T   PDRV   S   EADIQRLLHGVMEQLGIARPRVEYPAHQA   176   N-terminal   7B2   S28, T31, S36,   3               MNLVGPQSIEGGAHEGLQHLGPFGNIPNIVAELTGDNIPK       peptide (By       T134                   DFSEDQGYPDPPNPCPVGKTADDGCLEN   T   PDTAEFSREFQ       similarity)                           LHQHLFDPEHDYPGLGKWNKKLLYEKMKGGE                                   Q8N6N7   1   MALQADFDRAAEDVRKLKARPDDGELKELYGLYKQAIV   88   Acyl-CoA-   ACBP                       GDINIACPGMLDLKGKAKWEAWNLKKGLSTEDATSAYIS       binding domain-                           KAKELIEKYGI       containing                                   protein 7                           P07108   2   SQAEFEKAAEEVRHLKTKPSDEEMLFIYGHYKQA   T   VGDI   87   Acyl-CoA-   ACBP   T36 or T42   1               N   T   ERPGMLDFTGKAKWDAWNELKGTSKEDAMKAYINK       binding protein       (ambiguous)                   VEELKKKYGI                                   P35318   95   YRQSMNNFQGLRSEGCREGTCTVQKLAHQIYQFTDKDKD   146   Adrenomedullin   Adrenomedullin                       NVAPRSKISPQGY                                   Q7Z4H4   101   TQAQLLRVGCVLGTCQVQNLSHRLWQLMGPAGRQDSAP   147   Adrenomedullin-   Adrenomedullin                       VDPSSPHSY       2 (By similarity)                           Q7Z4H4   108   VGCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPH   147   Intermedin-short   Adrenomedullin                       SY       (Potential)                           P35318   22   ARLDVASEFRKKWNKWALSR   41   Proadrenomedull   Adrenomedullin                               in N-20 terminal                                   peptide                           Q9ULZ1   65   QRPRLSHKGPMPF   77   Apelin-13 (By   Apelin                               similarity)                           Q9ULZ1   50   NGPGPWQGGRRKFRRQRPRLSHKGPMPF   77   Apelin-28 (By   Apelin                               similarity)                           Q9ULZ1   47   GSRNGPGPWQGGRRKFRRQRPRLSHKGPMPF   77   Apelin-31 (By   Apelin                               similarity)                           Q9ULZ1   42   LVQPRGSRNGPGPWQGGRRKFRRQRPRLSHKGPMPF   77   Apelin-36 (By   Apelin                               similarity)                           P07492   24   VPL   P   AGGG   T   VLTKMYPRGNHWAVGHLM   50   Gastrin-releasing   Bombesin/neurom   P27, T32   2                       peptide   edin-B/ranatensin                       P08949   47   GNLWA   T   GHFM   56   Neuromedin-B   Bombesin/neurom   T52   0                           edin-B/ranatensin                       P08949   25   APLSWDLPEPRSRASKIRVHSRGNLWA   T   GHFM   56   Neuromedin-B-   Bombesin/neurom   T52   0                       32   edin-B/ranatensin                       P07492   41   GNHWAVGHLM   50   Neuromedin-C   Bombesin/neurom                                   edin-B/ranatensin                       P01042   381   RPPGFSPFR   389   Bradykinin   Bradykinin                       P01042   380   KRPPGFSPFR   389   Lysyl-bradykinin   Bradykinin                       P01042   376   ISLMKRPPGFSPFR   389   T-kinin   Bradykinin                       P01258   85   CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP   116   Calcitonin   Calcitonin                       P06881   83   ACDTATCV   T   HRLAGLLSRSGGVVKNNFVPTNVGSKAF   119   Calcitonin gene-   Calcitonin   T91   1                       related peptide 1                           P10092   82   ACNTATCV   T   HRLAGLLSRSGGMVKSNFVPTNVGSKAF   118   Calcitonin gene-   Calcitonin   T90   1                       related peptide 2                           P10997   34   KCNTA   T   CA   T   QRLANFLVHSSNNFGAILSS   T   NVGSNTY   70   Islet amyloid   Calcitonin   T38, T42, T63   3                       polypeptide                           P01258   121   DMSSDLERDHRPHV   S   MPQNAN   141   Katacalcin   Calcitonin   S135   0               Q16568   28   QEDAELQPRALDIYSAVDDASHEKELIEALQEVLKKLKS   66   CART(1-39)   CART                       Q16568   69   VPIYEKKYGQVPMCDAGEQCAVRKGARIGKLCDCPRGTS   116   CART(42-89)   CART                       CNSFLLKCL                                   Q16568   28   QEDAELQPRALDIYSAVDDASHEKELIEALQEVLKKLKSK   116   Cocaine- and   CART                       RVPIYEKKYGQVPMCDAGEQCAVRKGARIGKLCDCPRGT       amphetamine-                           SCNSFLLKCL       regulated                           P23435   58   GSAKVAFSAIRSTNH   72   [des-Ser1]   Cerebellins                               cerebellin                           P23435   57   SGSAKVAFSAIRSTNH   72   Cerebellin   Cerebellins                       P23435   22   QNEIEPIVLEGKCLVVCDSNPTSDPTGTALGISVRSGSAKV   193   Cerebellin-1   Cerebellins                       AFSAIRSTNHEPSEMSNRTMIIYEDQVLVNIGNNEDSERST                                   FIAPRKGIYSENFHVVKVYNRQTIQVSLMLNGWPVISAFA                                   GDQDVTREAASNGVLIQMEKGDRAYLKLERGNLMGGW                                   KYSTFSGFLVFPL                                   Q8IUK8   52   QNDIEPIVLEGKCLVVCDSSPSADGAVTSSLGISVRSGSAK   224   Cerebellin-2   Cerebellins                       VAFSATRSTNHEPSEMSNRTMTIYEDQVLVNIGNHFDLAS                                   SIFVAPRKGIYSFSFHVVKVYNRQTIQVSLMQNGYPVISAF                                   AGDQDVTREAASNGVLLLMEREDKVHLKLERGNLMGG                                   WKYSTFSGFLVFPL                                   Q6UW01   33   QEGSEPVLLEGECLVVCEPGRAAAGGPGGAALGEAPPGR   205   Cerebellin-3   Cerebellins                       VAFAAVRSHHHEPAGETGNGTSGAIYEDQVLVNEGGGED                                   RASGSFVAPVRGVYSFRFHVVKVYNRQTVQVSLMLNTW                                   PVISAFANDPDVTREAATSSVLLPLDPGDRVSLRLRRGNL                                   LGGWKYSSFSGFLIFPL                                   Q9NTU7   28   QNDIEPIVLEGKCLVVCDSNPATDSKGSSSSPLGISVRAAN   201   Cerebellin-4   Cerebellins                       SKVAFSAVRSTNHEPSEMSNKTRIIYEDQILVNVGNEFTLE                                   SVEVAPRKGIYSFSFHVIKVYQSQTIQVNLMLNGKPVISAF                                   AGDKDVTREAATNGVLLYLDKEDKVYLKLEKGNLVGG                                   WQYSTFSGFLVFPL                                   P10645   380   AYGFRGPGPQL   390   AL-11   Chromogranin/                                   secretogranin                       P05060   617   SAEFPDFYDSEEP   S   VTHQEAENEKDRADQTVLTEDEKKEL   673   CCB peptide   Chromogranin/   S631   1               ENLAAMDLELQKIAEKF           secretogranin                       P10645   19   LPVNSPMNKGDIEVMKCIVEVISDTL   S   KP   S   PMPV   S   QECFE   457   Chromogranin-A   Chromogranin/   S45, S48, S54,   39               TLRGDERILSILRHQNLLKELQDLALQGAKERAHQQKKH   S               secretogranin   S98, E122, S126,                   GFEDELSEVLENQSSQAELKEAV   E   EPS   S   KDVMEKREDSKE               A145, T146,                   AEKSGE   A   T   DGARPQ   AL   PEPMQE   S   KAEGNNQ   A   PGEEEEEEE               A153, L154,                   EAT   N   T   H   P   P   A   S   LP   S   QKYPGPQ   A   EGDSEG   L   S   QGL   V   DREKGL   S                   S161, A169,                   AEPGWQAKREEEEEEEEEAEAGEEAVPEEEGP   T   VV   LNP   HP               N182, T183,                       S   LG   Y   KEIRKGESRSEALAVDGAGK   P   GA   E   EAQD   P   EGKGEQ               P185, A187,                   EHSQQKEEEEE   M   AV   V   PQGLFRGGKSGELEQEEERLSKEW               S188, S191,                   EDSKRWSKMDQLAKEL   T   AEKRLEGQEEEEDNRDSSMKL               E200, L206,                   SFR   A   RAYGFRGPGPQLRRGWRPS   S   REDSLEAGLPLQVR   G   Y               S207, V211,                   PEEKKEEEGSANRRPEDQELESLSAIEAELEKVAHQLQAL               S218, T251                   RRG               L254, N255,                                   P256, S259,                                   Y262, P283,                                   E286, P291,                                   S300, M309,                                   V312, T353,                                   A378, S398,                                   G413                   P10645   134   EDSKEAEKSGE   A   T   DGARPQ   AL   PEPMQE   S   KAEGNNQ   A   PGE   225   EA-92   Chromogranin/   A145, T146,   17               EEEEEEEAT   N   T   HPP   A   S   LP   S   QKYPGPQA   E   GDSEG   L   S   QGL   V   D           secretogranin   A153, L154,                   REKGL   S   AEPGWQA               S161, A169,                                   N182, T183,                                   P185, A187,                                   S188, S191,                                   E200, L206,                                   S207, V211,                                   S218                   P10645   420   EEEGSANRRPEDQELE   S   L   S   AIEAELEKVAHQLQALRR   456   ER-37   Chromogranin/   S436 or   1                           secretogranin   S438(Ambiguous)                   P10645   228   EEEEEEEEEAEAGEEAVPEEEGP   T   VV   LNP   HP   S   L   260   ES-43   Chromogranin/   T251, L254,   5                           secretogranin   N255, P256,                                   S259                   P05060   440   FLGEGH   H   RVQE   N   QMDKARRHPQGAWKELDRNYLN   Y   GE   513   GAWK peptide   Chromogranin/   H446, N451,   5               EGAPGKWQQQGDLQDTKENREEARFQDKQYSSHH   T   A   E           secretogranin   Y474, T511,                                   A512                   P10645   413       G   YPEEKKEEEGSANRRPEDQELESLSAIEAELEKVAHQLQ   456   GR-44   Chromogranin/   G413   1               ALRR           secretogranin                       P10645   393   GWRPS   S   REDSLEAGLPLQV   411   GV-19   Chromogranin/   5398   1                           secretogranin                       P10645   358   LEGQEEEEDNRDSSMKLSF   376   LF-19   Chromogranin/                                   secretogranin                       P10645   272   SEALAVDGAGK   P   GAL   E   AQD   P   EGKGEQEH   S   QQKEEEEE   M       319   Pancreastatin   Chromogranin/   P283, E286,   6               AV   V   PQGLFRG           secretogranin   P291, S300,                                   M309, V312                   P05060   21   MPVDNRNHNEGMV   T   RCIIEVLSNAL   S   K   S   SAP   P   ITPECRQV   677   Secretogranin-1   Chromogranin/   T34, S46, S48,   40               LKTSRKDVKDKETFENEN   T   KFEVRLLRDPADA   S   E   A   HESS   S               secretogranin   S49, P52, T79,                   RGE   A   GAPG   E   EDIQGP   T   KADILKWAEGGGHSRERADEPQ               S93, A95, S100,                   W   S   LYP   S   DSQV   S   EEVKTRHSEKSQREDEEEEEGENYQKGE               A104, E109,                   RGEDSSEEKHLEEPGE   T   Q   N   AFLNERKQA   S   AIKKEELVARS               T116, S140,                   ETHAAGHSQEKTHSREKSSQESGEETGSQENHPQESKGQP               S144, S149,                   RSQEESEEGEEDATSEVDKRRTRPRHHHGRSRPDR   SS   QGG               T194, N196   ,                    S   LPSEEKGH   P   QEESEESNV   S   M   A   S   LGEKR   D   HHS   T   HYRASEE               S206, S293,                   EPEYGEEIKG   Y   PG   VQAPEDLEWERYRGRGSEEYRAPRPQS               S294, S298,                   EESWDEEDKRNYPSLELD   KM   AHGYGEESEEERGLEPGKG               P307, S317,                   RHHRGRGGEPRAYFMSDTREEKRFLGEGH   H   RVQENQMD               M318, S320,                   KARRHPQGAWKELDRNYLN   Y   GEEGAPGKWQQQGDLQD               D326, T330,                   TKENREEARFQDKQYSSHH   T   A   EKRKRLGELFNPYYDPLQ               Y348, P349,                   WKSSHFERRDNMNDNFLEGEEENEL   T   LNEKNFFPEYNYD               G350, K396,                   WVVEKKPF   S   EDVNWGYEKR   N   LARVPKLDLKRQYDRVAQ               M397, H446,                   LDQLLHYRKKSAEFPDFYDSEEPV   S   THQEAENEKDRADQ               Y474, T511,                   TVLTEDEKKELENLAAMDLELQKIAEKFSQRG               A512, T556                                   S577, N588,                                   S631                   P13521   31   QRNQLLQKEPDLRLENVQKFP   S   PEMIRALEYIENLRQQAH   617   Secretogranin-2   Chromogranin/   S52, S75, A136,   16               KEESSPDYNPYQGVSVPLQQKENGDESHLPERDSLSEED           secretogranin   Y190, T191,                   WMRIILEALRQAENEPQSAPKENKPY   A   LNSEKNFPMDMS               S194, T197,                   DDYETQQWPERKLKHMQFPPMYEENSRDNPFKRTNEIVE               S259, T261,                   EQ   YT   PQ   S   LA   T   LESVFQELGKLTGPNNQKRERMDEEQKLY               S378, T450,                   TDDEDDIYKANNIAYEDVVGGEDWNPVEEKIE   S   Q   T   QEEV               N489, G529,                   RDSKENIEKNEQINDEMKRSGQLGIQEEDLRKESKDQLSD               S556, S566,                   DVSKVIAYLKRLVNAAGSGRLQNGQNGERATRLFEKPLD               P573                   SQSIYQLIEISRNLQIPPEDLIEMLKTGEKPNG   S   VEPERELD                                   LPVDLDDISEADLDHPDLFQNRMLSKSGYPKTPGRAGILA                                   LPDGLSVEDILNLLGMESAANQK   T   SYFPNPYNQEKVLPRL                                   PYGAGRSRSNQLPKAAWIPHVE   N   RQMAYENLNDKDQEL                                   GEYLARMLVKYPEIINSNQVKRVP   G   QGSSEDDLQEEEQIE                                   QAIKEHLNQGS   S   QETDKLAPV   S   KRFPVG   P   PKNDDTPNRQ                                   YVVDEDLLMKVLEYLNQEKAEKGREHIAKRAMENM                                   Q8WXD2   20   FPKPGGSQDKSLHNRELSAERPLNEQIAEAEEDKIKKTYP   P       468   Secretogranin-3   Chromogranin/   P60, T82, S122,   15               ENKPGQSNYSFVDNLNLLKAI   T   EKEKIEKERQSIRSSPLDN           secretogranin   T123, T144,                   KLNVEDVDSTKNRKLIDDYD   ST   KSGLDHKFQDDPDGLHQ               A157, D211,                   LDG   T   PLTAEDIVHKIAARIYEENDRAVFDKIVSKLLNLGLI               P212, T216,                   FESQAHTLEDEVAEVLQKLISKEANNYEE   DP   NKP   TS   W   T   E               S217, T219,                   NQAGKIPEKV   T   PMAA   I   QDGL   A   KGENDETVSNTLTLTNGL               T231, I236,                   ERRTKTYSEDNFLELQYFPNFYALLKSIDSEKEAKEKETLI               A241, S359                   TIMKTLIDFVKMMVKYGTISPEEGVSYLENLDEMIALQTK                                   NKLEKNATDNISKLFPAP   S   EKSHEETDSTKEEAAKMEKEY                                   GSLKDSTKDDNSNPGGKTDEPKGKTEAYLEAIRKNIEWL                                   KKHDKKGNKEDYDLSKMRDFINKQADAYVEKGILDKEE                                   AEAIKRIYSSL                                   P13521   182   TNEIVEEQ   YT   PQ   S   LA   T   LESVFQELGKLTGPNNQ   214   Secretoneurin   Chromogranin/   Y190, T191,   4                           secretogranin   S194, T197                   P10645   322   SGELEQEEERLSKEWEDS   339   SS-18   Chromogranin/                                   secretogranin                       P10645   19   LPVNSPMNKGDIEVMKCIVEVISDTL   S   KP   S   PMPV   S   QECFE   94   Vasostatin-1   Chromogranin/   S45, S48, S54   3               TLRGDERILSILRHQNLLKELQDLALQGAKERAHQQ           secretogranin                       P10645   19   LPVNSPMNKGDIEVMKCIVEVISDTL   S   KP   S   PMPV   S   QECFE   131   Vasostatin-2   Chromogranin/   S45, S48, S54,   6               TLRGDERILSILRHQNLLKELQDLALQGAKERAHQQKKH   S               secretogranin   S98, E122, S126                   GFEDELSEVLENQSSQAELKEAV   E   EPS   S   KDVME                                   P10645   342   WSKMDQLA   349   WA-8   Chromogranin/                                   secretogranin                       P10645   342   WSKMDQLAKEL   T   AE   355   WE-14   Chromogranin/   T353   1                           secretogranin                       P01042   19   QESQSEEIDCNDKDLFKAVDAALKKYNSQNQSNNQFVLY   644   Kininogen-1   Cystatin   T137, T151,   15               RITEATKTVGSDTFYSFKYEIKEGDCPVQSGKTWQDCEYK               T261, T273,                   DAAKAATGECTATVGKRSSTKFSVATQTCQITPAEGPVV               E399, T400,                       T   AQYDCLGCVHPI   S   TQSPDLEPILRHGIQYFNNNTQHSSLF               T401, S403,                   MLNEVKRAQRQVVAGLNFRITYSIVQTNCSKENFLFLTPD               T407, S408,                   CKSLWNGDTGECTDNAYIDIQLRIASFSQNCDIYPGKDEV               T546, S604,                   QPP   T   KICVGCPRDIP   T   NSPELEETLTHTITKLNAENNATFYF               T610, S611,                   KIDNVKKARVQVVAGKKYFIDFVARETTCSKESNEELTES               T628                   CETKKLGQSLDCNAEVYVVPWEKKIYPTVNCQPLGMISL                                   MKRPPGESPERSSRIGEIKE   E   TT   V   S   PPH   TS   MAPAQDEERDS                                   GKEQGHTRRHDWGHEKQRKHNLGHGHKHERDQGHGHQ                                   RGHGLGHGHEQQHGLGHGHKFKLDDDLEHQGGHVLDH                                   GHKHKHGHGHGKHKNKGKKNGKHNGWKTEHLASSSED                                   STTPSAQTQEKTEGP   T   PIPSLAKPGVTVTFSDFQDSDLIAT                                   MMPPISPAPIQSDDDWIPDIQIDPNGLSFNPI   S   DFPDT   TS   PK                                   CPGRPWKSVSEINP   T   TQMKESYYFDLTDGLS                                   P01042   19   QESQSEEIDCNDKDLFKAVDAALKKYNSQNQSNNQFVLY   380   Kininogen-1   Cystatin   T137,   4               RITEATKTVGSDTFYSFKYEIKEGDCPVQSGKTWQDCEYK       heavy chain       T151, T261,                   DAAKAATGECTATVGKRSSTKFSVATQTCQITPAEGPVV               T273                       T   AQYDCLGCVHPIS   T   QSPDLEPILRHGIQYFNNNTQHSSLF                                   MLNEVKRAQRQVVAGLNFRITYSIVQTNCSKENFLFLTPD                                   CKSLWNGDTGECTDNAYIDIQLRIASFSQNCDIYPGKDEV                                   QPP   T   KICVGCPRDIP   T   NSPELEETLTHTITKLNAENNATFYF                                   KIDNVKKARVQVVAGKKYFIDFVARETTCSKESNEELTES                                   CETKKLGQSLDCNAEVYVVPWEKKIYPTVNCQPLGMISL                                   MK                                   P01042   390   SSRIGEIKE   E   TT   V   S   PPH   TS   MAPAQDEERDSGKEQGHTRRH   644   Kininogen-1   Cystatin   E399, T400,   11               DWGHEKQRKHNLGHGHKHERDQGHGHQRGHGLGHGHE       light chain       T401, S403,                   QQHGLGHGHKFKLDDDLEHQGGHVLDHGHKHKHGHGH               T407, S408,                   GKHKNKGKKNGKHNGWKTEHLASSSEDSTTPSAQTQEK               T546, S604,                   FEGP   T   PIPSLAKPGVTVTFSDFQDSDLIATMMPPISPAPIQS               T610, S611,                   DDDWIPDIQIDPNGLSFNPI   S   DFPDT   TS   PKCPGRPWKSVSEI               T628                   NP   T   TQMKESYYFDLTDGLS                                   P01042   431   WGHE   434   Low molecular   Cystatin                               weight growth-                                   promoting factor                           P05305   53   CSCSSLMDKECVYFCHLDIIWVNTPEHVVPYGLGSPRS   90   Big endothelin-1   Endothelin/                                   sarafotoxin                       P05305   53   CSCSSLMDKECVYFCHLDIIW   73   Endothelin-1   Endothelin/                                   sarafotoxin                       P20800   49   CSCSSWLDKECVYFCHLDIIW   69   Endothelin-2   Endothelin/                                   sarafotoxin                       P14138   97   CTCFTYKDKECVYYCHLDIIW   117   Endothelin-3   Endothelin/                                   sarafotoxin                       O15130   93   AGEGLNSQFWSLAAPQRF   110   Neuropeptide AF   FMRFamide                                   related peptide                       O15130   69   FLFQPQRF   76   Neuropeptide FF   FMRFamide                                   related peptide                       Q9HCQ7   56   SLNFEELKDWGPKNVIKMSTPAVNKMPHSFANLPLRF   92   Neuropeptide   FMRFamide                               NPSF (Potential)   related peptide                       Q9HCQ7   124   VPNLPQRF   131   Neuropeptide   FMRFamide                               NPVF   related peptide                       Q9HCQ7   81   MPHSFANLPLRF   92   Neuropeptide   FMRFamide                               RFRP-1   related peptide                       Q9HCQ7   101   SAGATANLPLRS   112   Neuropeptide   FMRFamide                               RFRP-2   related peptide                               (Potential)                           O15130   66   SQAFLFQPQRF   76   Neuropeptide SF   FMRFamide                               related peptide                           P81277   34   TPDINPAWYASRGIRPVGRF   53   Prolactin-   FMRFamide                               releasing peptide   related peptide                               PrRP20                           P81277   23   SRTHRHSMEIRTPDINPAWYASRGIRPVGRF   53   Prolactin-   FMRFamide                               releasing peptide   related peptide                               PrRP31                           P22466   33   GWTLNSAGYLLGPHAVGNHRSF   S   DKNGLTS   62   Galanin   Galanin   S55   0               P22466   65   ELRPEDDMKPGSFDRSIPENNIMRTHEFLSELHLKEAGALD   123   Galanin   Galanin   A113   1               RLLDLP A AASSEDIERS       message-                                   associated                                   peptide                           Q9UBC7   25   APAHRGRGGWTLNSAGYLLGPVLHLPQMGDQDGKRETA   84   Galanin-like   Galanin                       LEILDLWKAIDGLPYSHPPQPS       peptide                           P01350   59   QLGPQGPPHLVADPSKKQGPWLEEEEEAYGWMDF   92   Big gastrin   Gastrin/                                   cholecystokinin                       P06307   21   QPVPPADPAGSGLQRAEEAPRRQLRVSQR   T   DGESRAHLG   115   Cholecystokinin   Gastrin/   A28, T50, N85   3               ALLARYIQQARKAPSGRMSIVKNLQ N LDPSHRISDRDYM           cholecystokinin                       GWMDFGRRSAEEYEYPS                                   P06307   92   ISDRDYMGWMDF   103   Cholecystokinin-   Gastrin/                               12   cholecystokinin                       P06307   86   LDPSHRISDRDYMGWMDF   103   Cholecystokinin-   Gastrin/                               18 (By   cholecystokinin                               similarity)                           P06307   79   IVKNLQ N LDPSHRISDRDYMGWMDF   103   Cholecystokinin-   Gastrin/   N85   1                       25 (By   cholecystokinin                               similarity)                           P06307   71   KAPSGRMSIVKNLQ N LDPSHRISDRDYMGWMDF   103   Cholecystokinin-   Gastrin/   N85   1                       33   cholecystokinin                       P06307   65   YIQQARKAPSGRMSIVKNLQ N LDPSHRISDRDYMGWMDF   103   Cholecystokinin-   Gastrin/   N85   1                       39   cholecystokinin                       P06307   99   GWMDF   103   Cholecystokinin-   Gastrin/                               5 (By similarity)   cholecystokinin                       P06307   46   VSQR   T   DGESRAHLGALLARYIQQARKAPSGRMSIVKNLQ   103   Cholecystokinin-   Gastrin/   T50, N85   2                 N LDPSHRISDRDYMGWMDF       58   cholecystokinin                       P06307   46   VSQR   T   DGESRAHLGALLARYIQQARKAPSGRMSIVKNLQ   94   Cholecystokinin-   Gastrin/   T50, N85   2                 N LDPSHRISD       58   cholecystokinin                               desnonopeptide                                   (By similarity)                           P06307   97   YMGWMDF   103   Cholecystokinin-   Gastrin/                               7 (By similarity)   cholecystokinin                       P06307   96   DYMGWMDF   103   Cholecystokinin-   Gastrin/                               8   cholecystokinin                       P01350   76   QGPWLEEEEEAYGWMDF   92   Gastrin   Gastrin/                                   cholecystokinin                       P01350   79   WLEEEEEAYGWMDF   92   Gastrin-14   Gastrin/                                   cholecystokinin                       P01350   41   DLELPWLEQQGPASHHRRQLGPQGPPHLVADPSKKQGPW   92   Gastrin-52   Gastrin/                       LEEEEEAYGWMDF           cholecystokinin                       P01350   87   YGWMDF   92   Gastrin-6   Gastrin/                                   cholecystokinin                       P01350   22   SWKPRSQQPDAP   LG   TGANRDLELPWLEQQGPASHHRRQL   92   Gastrin-71   Gastrin/   L33 or G34   1               GPQGPPHLVADPSKKQGPWLEEEEEAYGWMDF           cholecystokinin   (Ambiguous)                   P09681   52   YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKH   93   Gastric inhibitory   Glucagon                       NITQ       polypeptide                           P01275   21   RSLQDTEEKSR   S   FSASQADPLSDPDQMNEDKRHSQGTF   T   S   89   Glicentin (By   Glucagon   S32, T59   2               DYSKYLDSRRAQDFVQWLMNTKRNRNNIA       similarity)                           P01275   21   RSLQDTEEKSR   S   FSASQADPLSDPDQMNED   50   Glicentin-related   Glucagon   S32   1                       polypeptide (By                                   similarity)                           P01275   53   HSQGTF   T   SDYSKYLDSRRAQDFVQWLMNT   81   Glucagon   Glucagon   T59   1               P01275   92   HDEFERHAEG   T   F   TS   DVSSYLEGQAAKEFIAWLVKGRG   128   Glucagon-like   Glucagon   T102 or T104 or   1                       peptide 1       S105                                   (Ambiguous)                   P01275   98   HAEG   T   F   TS   DVSSYLEGQAAKEFIAWLVKGR   128   Glucagon-like   Glucagon   T102 or T104 or   1                       peptide 1(7-36)       S105                                   (Ambiguous)                   P01275   98   HAEG   T   F   TS   DVSSYLEGQAAKEFIAWLVKGRG   127   Glucagon-like   Glucagon   T102 or T104 or   1                       peptide 1(7-37)       S105                                   (Ambiguous)                   P01275   146   HADGSFSDEMNTILDNLAARDFINVVLIQTKITD   178   Glucagon-like   Glucagon                               peptide 2 (By                                   similarity)                           P01282   81   HADGVF   TS   DFSKLLGQLSAKKYLESLM   107   Intestinal peptide   Glucagon   T87, S88   2                       PHM-27                           P01282   81   HADGVF   TS   DFSKLLGQLSAKKYLESLMGKRVSSNISEDPV   122   Intestinal peptide   Glucagon   T87, S88   2               PV       PHV-42                           P01275   53   HSQGTF   T   SDYSKYLDSRRAQDFVQWLMNTKRNRNNIA   89   Oxyntomodulin   Glucagon   T59   1                       (By similarity)                           P18509   82   DVAHGILNEAYRKVLDQLSAGKHLQSLVARGVGGSLGG   129   PACAP-related   Glucagon                       GAGDDAEPLS       peptide                           P18509   132   HSDGIFTDSYSRYRKQMAVKKYLAAVL   158   Pituitary   Glucagon                               adenylate                                   cyclase-                                   activating                                   polypeptide 27                           P18509   132   HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK   169   Pituitary   Glucagon                               adenylate                                   cyclase-                                   activating                                   polypeptide 38                           P09683   28   HSDGTF   TS   EL   S   RLREGARLQRLLQGLV   54   Secretin   Glucagon   T34, S35, S38   3               P01286   32   YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERG   75   Somatoliberin   Glucagon                       ARARL                                   P01282   125   HSDAVF   T   DNYTRLRKQMAVKKYLNSILN   152   Vasoactive   Glucagon   T131   1                       intestinal peptide                           P01148   37   DAENLIDSFQEIVKEVGQLAETQRFEC   T   THQPRSPLRDLK   92   GnRH-associated   GnRH   T64   1               GALESLIEEETGQKKI       peptide 1                           O43555   37   ALS SAQDPQNALRPPGRALDTAAGSPVQTAHGLPSDALA   120   GnRH-associated   GnRH                       PLDDSMPWEGRTTAQWSLHRKRHLARTLLTAAREPRPAP       peptide 2                           PSSNKV                                   P01148   24   QHWSYGLRPG   33   Gonadoliberin-1   GnRH                       O43555   24   QHWSHGWYPG   33   Gonadoliberin-2   GnRH                       P01148   24   QHWSYGLRPGGKRDAENLIDSFQEIVKEVGQLAETQRFE   92   Progonadoliberin-   GnRH   T64   1               C   T   THQPRSPLRDLKGALESLIEEETGQKKI       1                           O43555   24   QHWSHGWYPGGKRALSSAQDPQNALRPPGRALDTAAGS   120   Progonadoliberin-   GnRH                       PVQTAHGLPSDALAPLDDSMPWEGRTTAQWSLHRKRHL       2                           ARTLLTAAREPRPAPPSSNKV                                   P01308   90   GIVEQCCTSICSLYQLENYCN   110   Insulin A chain   Insulin                       P01308   25   FVNQHLCGSHLVEALYLVCGERGFFY   T   PKT   54   Insulin B chain   Insulin   T51   1                               (Ambiguous)                   P05019   49   GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAP   118   Insulin-like   Insulin                       QTGIVDECCFRSCDLRRLEMYCAPLKPAKSA       growth factor I                           P01344   25   AYRPSETLCGGELVDTLQFVCGDRGFYFSRPASRVSRRSR   91   Insulin-like   Insulin   S74, T86   0               GIVEECCFRSCDLALLETYCATPAKSE       growth factor II                           P01344   26   YRPSETLCGGELVDTLQFVCGDRGFYFSRPASRVSRRSRG   91   Insulin-like   Insulin   S74, T86   0               IVEECCFR   S   CDLALLETYCATPAKSE       growth factor II                                   Ala-25 Del                           P01344   93   DV   ST   PP   T   VLPDNFPRYPVGKFFQYDTVVKQSTQRL   126   Preptin   Insulin   S95, T96, T99   3               P04090   162   QLYSALANKCCHVGCTKRSLARFC   185   Relaxin A chain   Insulin                       P04808   163   PYVALFEKCCLIGCTKRSLAKYC   185   Relaxin A chain   Insulin                               (By similarity)                           P04090   25   DSWMEEVIKLCGRELVRAQIAICGMSTWS   53   Relaxin B chain   Insulin                       P04808   23   VAAKWKDDVIKLCGRELVRAQIAICGMSTWS   53   Relaxin B chain   Insulin                               (By similarity)                           Q8WXF3   119   DVLAGLSSSCCKWGCSKSEISSLC   142   Relaxin-3 A   Insulin                               chain (By                                   similarity)                           Q8WXF3   26   RAAPYGVRLCGREFIRAVIFTCGGSRW   52   Relaxin-3 B   Insulin                               chain (By                                   similarity)                           Q15726   112   YNWNSFGLRF   121   Kisspeptin-10   KISS1                       Q15726   109   LPNYNVVNSFGLRF   121   Kisspeptin-13   KISS1                       Q15726   108   DLPNYNWNSFGLRF   121   Kisspeptin-14   KISS1                       Q15726   20   EPLEKVASVGNSRPTGQQLESLGLLAPGEQSLPCTERKPA   138   Metastasis-   KISS1   A88   1               ATARLSRRGTSLSPPPESSGSPQQPGLS   A   PHSRQIPAPQGA       suppressor KiSS-                           VLVQREKDLPNYNWNSFGLRFGKREAAPGNHGRSAGRG       1                           Q15726   68   GTSLSPPPESSGSPQQPGLS   A   PHSRQIPAPQGAVLVQREKD   121   Metastin   KISS1   A88   1               LPNYNVVNSFGLRF                                   P41159   22   VPIQKVQDDTKTLIKTIVTRINDISHTQSVSSKQKVTGLDFI   167   Leptin   Leptin                       PGLHPILTLSKMDQTLAVYQQILTSMPSRNVIQISNDLENL                                   RDLLHVLAFSKSCHLPWASGLETLDSLGGVLEASGYSFEV                                   VALSRLQGSLQDMLWQLDLSPGC                                   P20382   147   DFDMLRCMLGRVYRPCWQV   165   Melanin-   Melanin-                               concentrating   concentrating                               hormone   hormone                       P20382   131   EIGDEENSAKFPI   143   Neuropeptide-   Melanin-                               glutamic acid-   concentrating                               isoleucine   hormone                       P20382   110   GSVAFPAENGVQN   T   E   ST   QE   128   Neuropeptide-   Melanin-   T123, T125,   3                       glycine-glutamic   concentrating   T126                           acid(Potential)   hormone                       P20382   22   ILLSASKSIRNLDDDMVFNTFRLGKGFQKEDTAEK   S   VIAP   S       165   Pro-MCH   Melanin-   S57, S62, N93,   6               LEQYKNDESSFMNEEENKVSKNTGSKHNFL   N   HGLPLNLAI           concentrating   T123, T125                   KPYLALKGSVAFPAENGVQN   T   ES   T   QEKREIGDEENSAKFP           hormone   T126                   IGRRDFDMLRCMLGRVYRPCWQV                                   Q9UBU3   24   GSSFLSPEHQRVQQRKESKKPPAKLQP   50   Ghrelins-27   Motilin                       Q9UBU3   24   GSSFLSPEHQRVQQRKESKKPPAKLQPR   51   Ghrelins-28   Motilin                       P12872   26   FVPIFTYGELQRMQEKERNKGQ   47   Motilin   Motilin                       P12872   50   SLSVWQRSGEEGPVDPAEPIREEENEMIKLTAPLEIGMRM   115   Motilin-   Motilin                       NSRQLEKYPATLEGLLSEMLPQHAAK       associated                                   peptide                           Q9UBU3   76   FNAPFDVGIKLSGVQYQQHSQAL   98   Obestatin   Motilin                       P12872   26   FVPIFTYGELQRMQEKERNKGQKKSLSVWQRSGEEGPVD   115   Promotilin   Motilin                       PAEPIREEENEMIKLTAPLEIGMRMNSRQLEKYPATLEGLL                                   SEMLPQHAAK                                   Q15848   19   ETT   T   QGPGVLLPLPKGACTGWMAGIPGHPGHNGAPGRDG   244   Adiponectin   NA   T22   1               RDGTPGEKGEKGDPGLIGPKGDIGETGVPGAEGPRGFPGI                                   QGRKGEPGEGAYVYRSAFSVGLETYVTIPNMPIRFTKIFY                                   NQQNHYDGSTGKFHCNIPGLYYFAYHITVYMKDVKVSLF                                   KKDKAMLFTYDQYQENNVDQASGSVLLHLEVGDQVWL                                   QVYGEGERNGLYADNDNDSTFTGFLLYHDTN                                   O00253   21   AQMGLAPMEGIRRPDQALLPELPGLGLRAPLKKT   T   AEQA   131   Agouti-related   NA   T55   1               EEDLLQEAQALAEVLDLQDREPRSSRRCVRLHESCLGQQ       protein                           VPCCDPCATCYCRFFNAFCYCRKLGTAMNPCSRT                                   Q9BZL1   1   MIEVVCNDRLGKKVRVKCNTDDTIGDLKKLIAAQTGTRW   73   Ubiquitin-like   NA                       NKIVLKKWYTIFKDHVSLGDYEIHDGMNLELYYQ       protein 5                           P43490   1   MNPAAEAEFNILLATDSYKVTHYKQYPPNTSKVYSYFEC   491   Nicotinamide   NAPRTase                       REKKFENSKLRKVKYEETVEYGLQVILNKYLKGKVVTKE       phosphoribosyltr                           KIQEAKDVYKEHFQDDVFNEKGWNYILEKYDGHLPIEIK       ansferase                           AVPEGFVIPRGNVLFTVENTDPECYWLTNVVIETILVQSWY                                   PITVATNSREQKKILAKYLLETSGNLDGLEYKLHDFGYRG                                   VSSQETAGIGASAHLVNFKGTDTVAGLALIKKYYGTKDP                                   VPGYSVPAAEHSTITAWGKDHEKDAFEHIVTQFSSVPVSV                                   VSDSYDIYNACEKIWGEDLRHLIVSRSTQAPLIIRPDSGNP                                   LDTVLKVLEILGKKFPVTENSKGYKLLPPYLRVIQGDGVD                                   INTLQEIVEGMKQKMVVSIENIAFGSGGGLLQKLTRDLLNC                                   SFKCSYVVTNGLGINVFKDPVADPNKRSKKGRLSLHRTPA                                   GNFVTLEEGKGDLEEYGQDLLHTVFKNGKVTKSYSFDEI                                   RKNAQLNIELEAAHH                                   P01160   124   SLRRSSCFGGRMDRIGAQ   S   GLGCN   S   FRY   151   Atrial natriuretic   Natriuretic peptide   S142, S148   2                       factor                           P16860   103   SPKMVQGSGCFGRKMDRISSSSGLGCKV   130   BNP(1-28)   Natriuretic peptide                       P16860   103   SPKMVQGSGCFGRKMDRISSSSGLGCKVL   131   BNP(1-29)   Natriuretic peptide                       P16860   103   SPKMVQGSGCFGRKMDRISSSSGLGCKVLR   132   BNP(1-30)   Natriuretic peptide                       P16860   104   PKMVQGSGCFGRKMDRISSSSGLGCKVLRR   133   BNP(2-31)   Natriuretic peptide                       P16860   105   KMVQGSGCFGRKMDRISSSSGLGCKVL   131   BNP(3-29)   Natriuretic peptide                       P16860   105   KMVQGSGCFGRKMDRISSSSGLGCKVLR   132   BNP(3-30)   Natriuretic peptide                       P16860   105   KMVQGSGCFGRKMDRISSSSGLGCKVLRRH   134   BNP(3-32)   Natriuretic peptide                       P16860   106   MVQGSGCFGRKMDRISSSSGLGCK   129   BNP(4-27)   Natriuretic peptide                       P16860   106   MVQGSGCFGRKMDRISSSSGLGCKVL   131   BNP(4-29)   Natriuretic peptide                       P16860   106   MVQGSGCFGRKMDRISSSSGLGCKVLR   132   BNP(4-30)   Natriuretic peptide                       P16860   106   MVQGSGCFGRKMDRISSSSGLGCKVLRR   133   BNP(4-31)   Natriuretic peptide                       P16860   106   MVQGSGCFGRKMDRISSSSGLGCKVLRRH   134   BNP(4-32)   Natriuretic peptide                       P16860   107   VQGSGCFGRKMDRISSSSGLGCKVL   131   BNP(5-29)   Natriuretic peptide                       P16860   107   VQGSGCFGRKMDRISSSSGLGCKVLRR   133   BNP(5-31)   Natriuretic peptide                       P16860   107   VQGSGCFGRKMDRISSSSGLGCKVLRRH   134   BNP(5-32)   Natriuretic peptide                       P16860   103   SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH   134   Brain natriuretic   Natriuretic peptide                               peptide 32                           P01160   26   NPM   Y   N   A   V   S   NADLMDFKNLLDHLEEKMPLED   55   Cardiodilatin-   Natriuretic peptide   Y29, A31, S33   1                       related peptide       (Ambiguous)                   P23582   105   GLSKGCFGLKLDRIGSMSGLGC   126   CNP-22   Natriuretic peptide                       P23582   98   YKGANKKGLSKGCFGLKLDRIGSMSGLGC   126   CNP-29   Natriuretic peptide                       P23582   74   DLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGCF   126   CNP-53   Natriuretic peptide                       GLKLDRIGSMSGLGC                                   P16860   27   HPLGSPGSASDLETSGLQEQRNHLQGKLSELQVEQTSLEP   134   Natriuretic   Natriuretic peptide   T74, E85   2               LQESPRP   T   GVWKSREVAT   E   GIRGHRKMVLYTLRAPRSPK       peptides B                           MVQGSGCFGRKMDRISSSSGLGCKVLRRH                                   P58417   22   ANLTNGGKSELLKSGSSKSTLKHIW1ESSKDLSISRLLSQT   271   Neurexophilin-1   Neurexophilin                       FRGKENDTDLDLRYDTPEPYSEQDLWDWLRNSTDLQEPR                                   PRAKRRPIVKTGKFKKMFGWGDFHSNIKTVKLNLLITGKI                                   VDHGNGTFSVYFRHNSTGQGNVSVSLVPPTKIVEFDLAQ                                   QTVIDAKDSKSFNCRIEYEKVDKATKNTLCNYDPSKTCY                                   QEQTQSHVSWLCSKPFKVICIYISFYSTDYKLVQKVCPDY                                   NYHSDTPYFPSG                                   O95156   23   KEVVHA   T   EGLDWEDKDAPGTLVGNVVHSRIISPLRLFVK   264   Neurexophilin-2   Neurexophilin   T29   1               QSPVPKPGPMAYADSMENFWDWLANIFEIQEPLARTKRR                                   PIVKTGKFKKMFGWGDFHSNIKTVKLNLLITGKIVDHGNG                                   TFSVYFRHNSTGLGNVSVSLVPPSKVVEFEVSPQSTLETKE                                   SKSFNCRIEYEKTDRAKKTALCNFDPSKICYQEQTQSHVS                                   WLCSKPFKVICIYIAFYSVDYKLVQKVCPDYNYHSETPYL                                   SSG                                   O95157   23   QDDGPPGSEDPERDDHEGQPRPRVPRKRGHISPKSRPMAN   252   Neurexophilin-3   Neurexophilin                       STLLGLLAPPGEAWGILGQPPNRPNHSPPPSAKVKKIFGW                                   GDFYSNIKTVALNLLVTGKIVDHGNGTFSVHFQHNATGQ                                   GNISISLVPPSKAVEFHQEQQIFIEAKASKIFNCRMEWEKV                                   ERGRRTSLCTHDPAKICSRDHAQSSATVVSCSQPFKVVCVY                                   IAFYSTDYRLVQKVCPDYNYHSDTPYYPSG                                   O95158   24   QIPESGRPQYLGLRPAAAGAGAPGQQLPEPRSSDGLGVGR   308   Neurexophilin-4   Neurexophilin                       AWSWAWPTNHTGALARAGAAGALPAQRTKRKPSIKAAR                                   AKKIFGWGDFYFRVHTLKFSLLVTGKIVDHVNGTFSVYFR                                   HNSSSLGNLSVSIVPPSKRVEFGGVWLPGPVPHPLQSTLAL                                   EGVLPGLGPPLGMAAAAAGPGLGGSLGGALAGPLGGAL                                   GVPGAKESRAFNCHVEYEKTNRARKHRPCLYDPSQVCFT                                   EHTQSQAAWLCAKPFKVICIFVSFLSFDYKLVQKVCPDYN                                   FQSEHPYFG                                   Q5H8A3   109   ILQRGSGTAAVDFTKKDHTATWGRPFFLFRPRN   141   Neuromedin-S   Neuromedins                       P48645   142   FRVDEEFQSPFASQSRGYFLFRPRN   166   Neuromedin-U-   Neuromedins                               25                           Q8NG41   25   WYKPAAGHSSYSVGRAAGLLSGLR   48   Neuropeptide B-   Neuromedins                               23                           Q8NG41   25   WYKPAAGHSSYSVGRAAGLLSGLRRSPYA   53   Neuropeptide B-   Neuromedins                               29                           P0C0P6   70   SFRNGVGTGMKKTSFQRAKS   89   Neuropeptide S   Neuromedins                       Q8N729   33   WYKHVASPRYHTVGRAAGLLMGL   55   Neuropeptide W-   Neuromedins                               23                           Q8N729   33   WYKHVASPRYHTVGRAAGLLMGLRRSPYLW   62   Neuropeptide W-   Neuromedins                               30                           P30990   24   SDSEEEMKALEADFLTNMHTSKISKAHVPSWKMTLLNVC   148   Large   Neurotensin                       SLVNNLNSPAEETGEVHEEELVARRKLPTALDGFSLEAML       neuromedin N                           TIYQLHKICHSRAFQHWELIQEDILDTGNDKNGKEEVIKR                                   KIPYIL                                   P30990   144   IPYIL   148   Neuromedin N   Neurotensin                       P30990   151   QLYENKPRRPYIL   163   Neurotensin   Neurotensin                       P30990   166   DSYYY   170   Tail peptide   Neurotensin                               (Potential)                           P01303   68       SS   PETLISDLLMRES   T   ENVPR   T   RLEDPAMW   97   C-flanking   NPY   S68, S69, T83   3                       peptide of NPY       T88, A95                   P01303   29   YP   S   KPDNPGEDAPAEDMARYYSALRH   Y   INLI   T   RQRY   64   Neuropeptide Y   NPY   S31,   2                               (Ambiguous                                   Y55 or T60                   P01298   30   APLEPVYPGDNATPEQMAQYAADLRRYINML   T   RPRY   65   Pancreatic   NPY   T61   1                       hormone                           P01298   69   HKEDTLAFSEWGSPHAAVPR   88   Pancreatic   NPY                               icosapeptide                           P10082   29   YPIKPEAPREDASPEELNRYYASLRHYLNLV   T   RQRY   64   Peptide YY   NPY   T60   1               P10082   31   IKPEAPREDASPEELNRYYASLRHYLNLV   T   RQRY   64   Peptide YY(3-   NPY   T60   1                       36)                           P80303   25   VPIDIDK   T   KVQN   I   HPVE   S   AKIEPPD   T   GL   YY   DEYLKQVIDVL   106   Nesfatin-1   Nucleobindin   T32, I37, S42,   8               E   T   DKHFREKLQKADIEEIKSGRLSKELDLV   S   HHVRTKLDE               T50, Y53, Y54,                   L               T67, S96                   Q02818   27   VPLERGA   P   NKEE   T   PA   T   E   S   PD   T   GL   Y   YHRYLQEVIDVLETDG   461   Nucleobindin-1   Nucleobindin   P34, T39, T42,   22               HFREKLQAANAEDIKSGKLSRELDFV   S   HHVRTKLDELKR               S44, T47, Y50,                   QEVSRLRMLLKAKMDAEQDPNVQVDHLNLLKQFEHLDP               S93, T148,                   QNQH   T   FEARDLELLIQTA   T   RDLAQYDAAHHEEFKRYEML               T162, S224,                   KEHERRRYLESLGEEQRKEAERKLEEQQRRHREHPKVNV               S320, S321,                   PG   S   QAQLKEVWEELDGLDPNRFNPKTFFILHDINSDGVLD               T335, H339,                   EQELEALFTKELEKVYDPKNEEDDMREMEEERLRMREHV               S369, T372,                   MKNVDTNQDRLVTLEEFLA   ST   QRKEFGDTGEGWE   T   VEM               S378, Q407,                       H   PAYFEEELRRFEEELAAREAELNAKAQRL   S   QE   T   EALGR   S                   A414, T426,                   QGRLEAQKRELQQAVLHMEQRKQQQQQQ   Q   GHKAPA   A   H               L452                   PEGQLKFHPD   T   DDVPVPAPAGDQKEVDTSEKKLLER   L   PE               x459(deleterious                   VEVPQHL               mutation)                   P80303   25   VPIDIDK   T   KVQN   I   HPVE   S   AKIEPPD   T   GL   YY   DEYLKQVIDVL   420   Nucleobindin-2   Nucleobindin   T32,   16               E   T   DKHFREKLQKADIEEIKSGRLSKELDLV   S   HHVRTKLDE               I37,                   LKRQEVGRLRMLIKAKLDSLQDIGMDHQALLKQFDHLNH               S42, T50, Y53,                   LNPDKFE   S   TDLDMLIKAA   T   SDLEHYDK   T   RHEEFKKYEMM               Y54, T67, S96,                   KEHERREYLKTLNEEKRKEEESKFEEMKKKHENHPKVNH               S152, T163,                   PGSKDQLKEVWEETDGLDPNDFDPKTFFKLHDVNSDGFL               T172, A355,                   DEQELEALFTKELEKVYDPKNEEDDMVEMEEERLRMRE               Y389, P406,                   HVMSEVDTNKDRLVTLEEFLKATEKKEFLEPDSWETLDQ               S408, L414                   QQFFTEEELKEYENII   A   LQENELKKKADELQKQKEELQRQ                                   HDQLEAQKLE   Y   HQVIQQMEQKKLQQGI   P   P   S   GPAGE   L   KFE                                   PHI                                   P01213   175   YGGFLRKYPK   184   Alpha-   Opioid                               neoendorphin                           P01213   175   YGGFLRKYP   183   Beta-   Opioid                               neoendorphin                           P01213   207   YGGFLRRIRPKLKWDNQKRYGGFLRRQFKVVT   238   Big dynorphin   Opioid                       P01213   207   YGGFLRRIRPKLK   219   Dynorphin A(1-   Opioid                               13) (By                                   similarity)                           P01213   207   YGGFLRRIRPKLKWDNQ   223   Dynorphin A(1-   Opioid                               17)                           P01213   207   YGGFLRRI   214   Dynorphin A(1-   Opioid                               8) (By similarity)                           P01213   175   YGGFL   179   Leu-enkephalin   Opioid                       P01213   226   YGGFLRRQFKVVTRSQEDPNAYSGELFDA   254   Leumorphin   Opioid                       P01210   100   YGGFM   104   Met-enkephalin   Opioid                       P01210   186   YGGFMRGL   193   Met-enkephalin-   Opioid                               Arg-Gly-Leu                           P01210   261   YGGFMRF   267   Met-enkephalin-   Opioid                               Arg-Phe                           Q13519   98   MPRVRSLFQEQEE   P   EPGMEEAGEMEQKQLQ   127   Neuropeptide 1   Opioid   P111   1                       (Probable)                           Q13519   149   FSEFMRQYLVLSMQSSQ   165   Neuropeptide 2   Opioid                               (Probable)                           Q13519   130   FGGFTGARKSARKLANQ   146   Nociceptin   Opioid                       P01210   143   DAEEDDSLANSSDLLKELLETGDNRERSHHQDGSDNEEE   183   PENK(143-183)   Opioid                       VS       (By similarity)                           P01210   237   FAEALPSDEEGESYSKEVPEME   258   PENK(237-258)   Opioid                               (By similarity)                           P01213   226   YGGFLRRQFKVVT   238   Rimorphin   Opioid                       P01210   114   MDELYPMEPEEEANGSEILA   133   rimorphin   Opioid                       P01210   25   ECSQDCATCSYRLVRPADINFLACVMECEGKLPSLKIWET   97   Synenkephalin   Opioid                       CKELLQLSKPELPQDGTSTLRENSKPEESHLLA                                   O43612   34   QPLPDCCRQKTCSCRLYELLHGAGNHAAGILTL   66   Orexin-A   Orexin                       O43612   70   RSGPPGLQGRLQRLLQASGNHAAGILTM   97   Orexin-B   Orexin                       P12272   143   TRSAWLDSGVTGSGLEGDHLSDTSTTSLELDSR   175   Osteostatin   Parathyroid                                   hormone                       P12272   37   AVSEHQLLHDKGKSIQDLRRREFLHHLIAEIHTAEIRA   T   SE   177   Parathyroid   Parathyroid   T75   1               VSPNSKPSPNTKNHPVRFGSDDEGRYLTQETNKVETYKE       hormone-related   hormone                       QPLKTPGKKKKGKPGKRKEQEKKKRRTRSAWLDSGVTG       protein                           SGLEGDHLSDTSTTSLELDSRRH                                   P12272   37   AVSEHQLLHDKGKSIQDLRRREFLHHLIAEIHTAEI   72   PTHrP[1-36]   Parathyroid                                   hormone                       P12272   74   A   T   SEVSPNSKPSPNTKNHPVRFGSDDEGRYLTQETNKVET   130   PTHrP[38-94[   Parathyroid   T75   1               YKEQPLKTPGKKKKGKP           hormone                       Q96A98   62   SLALADDAAFRERARLLAALERRHWLNSYMHKLLVLDA   100   Tuberoinfundibular   Parathyroid                       P       peptide of   hormone                               39residues                           P01189   237   YGGFMTSEK   S   Q   T   PLV   T   LEKNAIIKNAYKKGE   267   Beta-endorphin   POMC   S246, T248,   3                               T252                   P01189   138   SYSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEF   176   Corticotropin   POMC                       P01189   156   PVKVYPNGAEDESAEAFPLEF   176   Corticotropin-   POMC                               like intermediary                                   peptide                           P01189   179   ELTGQRLREGDGPDGPADDGAGAQADLEHSLLVAAEKK   267   Lipotropin beta   POMC   S246, T248,   3               DEGPYRMEHFRWGSPPKDKRYGGFMTSEK   S   Q   T   PLV   T   LFK               T252                   NAIIKNAYKKGE                                   P01189   179   ELTGQRLREGDGPDGPADDGAGAQADLEHSLLVAAEKK   234   Lipotropin   POMC                       DEGPYRMEHFRWGSPPKD       gamma                           P01189   138   SYSMEHFRWGKPV   150   Melanotropin   POMC                               alpha                           P01189   217   DEGPYRMEHFRWGSPPKD   234   Melanotropin   POMC                               beta                           P01189   77   YVMGHFRWDRF   87   Melanotropin   POMC                               gamma                           P01189   27   WCLESSQCQDLTTESNLLECIRACKPDLSAETPMFPGNGD   102   NPP   POMC   T71   1               EQPL   T   ENPRKYVMGHFRWDRFGRRNSSSSGSSGAGQ                                   P01189   105   EDVSAGEDCGPLPEGGPEPRSDGAKPGPRE   134   Potential peptide   POMC                       Q9UHG2   245   LE T     PA   PQVPARRLLPP   260   Big LEN (By   ProSAAS   T247, P248,   2                       similarity)       A249                   Q9UHG2   221   AADHDVGSELPPEGVLGALLRVKRLE T     PA   PQVPARRLLPP   260   Big PEN-LEN   ProSAAS   T247, P248,   2                       (By similarity)       A249                   Q9UHG2   34   ARPVKEPR   G   LSAA   S   PPLAE   T   GA   PRRF   59   Big SAAS (By   ProSAAS   G42, S47, T53,   5                       similarity)       G54, A55                   Q9UHG2   34   ARPVKEP   40   KEP (By   ProSAAS                               similarity)                           Q9UHG2   245   LET   PA   PQVPA   254   Little LEN (By   ProSAAS   T247, P248,   2                       similarity)       A249                   Q9UHG2   42       G   LSAA   S   PPLAE   T   GA   PRRF   59   Little SAAS (By   ProSAAS   G42, S47, T53,   5                       similarity)       G54, A55                   Q9UHG2   221   AADHDVGSELPPEGVLGALLRV   242   PEN (By   ProSAAS                               similarity)                           Q9UHG2   34   ARPVKEPR   G   LSAA   S   PPLAE   T   GA   PRRFRRSVPRGEAAGAVQ   260   ProSAAS   ProSAAS   G42, S47, T53,   13               ELARALAHLLEAERQERARAEAQEAEDQQARVLAQLLR               G54, A55, A115,                   VWG   A   PR   N   S   DPALGLDDDPDAPAAQLARALLRARLDPAAL               N118, S119,                   AAQLVPAPVPAAALRPRPPVYDDGP   A   GPDAEEAGDETPD               A176, S206,                   VDPELLRYLLGRILAG   S   A   DSEGVAAPRRLRRAADHDVGSE               A207, T247,                   LPPEGVLGALLRVKRLE T     PA   PQVPARRLLPP               P248, A249                   Q9HD89   19   KTLCSMEEAINERIQEVAGSLIFRAISSIGLECQSVTSRGDL   108   Resistin   Resistin/FIZZ                       ATCPRGFAVTGCTCGSACGSWDVRAETTCHCQCAGMDW                                   TGARCCRVQP                                   Q9BQ08   24   QCSLDSVMDKKIKDVLNSLEYSPSPISKKLSCASVKSQGR   111   Resistin-like beta   Resistin/FIZZ                       PSSCPAGMAVTGCACGYGCGSWDVQLETTCHCQCSVVD                                   WTTARCCHLT                                   P83859   91   QDEGSEATGFLPAAGEKTSGPLGNLAEELNGYSRKKGGF   133   QRF-amide   RFamide                       SFRF           neuropeptide                       P06850   154   SEEPPISLDLTFHLLREVLEMARAEQLAQQAHSNRKLMEII   194   Corticoliberin   Sauvagine/                                   corticotropin-                                   releasing                                   factor/urotensin I                       P55089   83   DNPSLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV   122   Urocortin   Sauvagine/                                   corticotropin-                                   releasing                                   factor/urotensin I                       Q96RP3   72   IVLSLDVPIGLLQILLEQARARAAREQATTNARILARVGHC   112   Urocortin-2   Sauvagine/                                   corticotropin-                               releasing                                       factor/urotensin I                       Q969E3   120   FTLSLDVPTNIMNLLFNIAKAKNLRAQAAANAHLMAQI   157   Urocortin-3   Sauvagine/                                   corticotropin-                                   releasing                                   factor/urotensin I                       P01019   34   DRVY   37   Angiotensin 1-4   Serpin                       P01019   34   DRVYI   38   Angiotensin 1-5   Serpin                       P01019   34   DRVYIHP   40   Angiotensin 1-7   Serpin                       P01019   34   DRVYIHPFH   42   Angiotensin 1-9   Serpin                       P01019   34   DRVYIHPFHL   43   Angiotensin-1   Serpin                       P01019   34   DRVYIHPF   41   Angiotensin-2   Serpin                       P01019   35   RVYIHPF   41   Angiotensin-3   Serpin                       P01019   36   VYIHPF   41   Angiotensin-4   Serpin                       P01019   34   DRVYIHPFHLVIHNESTCEQLAKANAGKPKDPTFIPAPIQA   485   Angiotensinogen   Serpin   T440 or S442 or   1               KTSPVDEKALQDQLVLVAAKLDFEDKLRAAMVGMLANF               T443 or T455                   LGFRIYGMHSELWGVVHGATVLSPTAVFGTLASLYLGAL               (Ambiguous)                   DHTADRLQAILGVPWKDKNCTSRLDAHKVLSALQAVQG                                   LLVAQGRADSQAQLLLSTVVGVFTAPGLHLKQPFVQGLA                                   LYTPVVLPRSLDFTELDVAAEKIDRFMQAVTGWKTGCSL                                   MGASVDSTLAFNTYVHFQGKMKGFSLLAEPQEFWVDNS                                   TSVSVPMLSGMGTFQHWSDIQDNFSVTQVPFTESACLLLI                                   QPHYASDLDKVEGLTFQQNSLNVVMKKLSPRTIHLTMPQL                                   VLQGSYDLQDLLAQAELPAILHFELNLQKLSNDRIRVGEV                                   LNSIFFELEADEREP   T   ES   T   QQLNKPEVLEV   T   LNRPFLFAVY                                   DQSATALHFLGRVANPLSTA                                   P08185   23   MDPNAAYVNMSNHHRGLASANVDFAFSLYKHLVALSPK   405   Corticosteroid-   Serpin                       KNIFISPVSISMALAMLSLGTCGHTRAQLLQGLGFNLTERS       binding globulin                           ETEIHQGFQHLHQLFAKSDTSLEMTMGNALFLDGSLELLE                                   SFSADIKHYYESEVLAMNFQDWATASRQINSYVKNKTQG                                   KIVDLFSGLDSPAILVLVNYIFFKGTWTQPFDLASTREENF                                   YVDETTVVKVPMMLQSSTISYLHDSELPCQLVQMNYVGN                                   GTVFFILPDKGKMNTVIAALSRDTINRWSAGLTSSQVDLY                                   IPKVTISGVYDLGDVLEEMGIADLFTNQANFSRITQDAQL                                   KSSKVVHKAVLQLNEEGVDTAGSTGVTLNLTSKPIILRFN                                   QPFIIMIFDHFTWSSLFLARVMNPV                                   Q86U17   20   QPLLAHGDKSLQGPQPPRHQLSEPAPAYHRITPTITNFALR   422   Serpin A11   Serpin                       LYKELAADAPGNIFFSPVSISTTLALLSLGAQANTSALILEG                                   LGFNLTETPEADIHQGFRSLLHTLALPSPKLELKVGNSLFL                                   DKRLKPRQHYLDSIKELYGAFAFSANFTDSVTTGRQINDY                                   LRRQTYGQVVDCLPEFSQDTFMVLANYIFFKAKWKHPFS                                   RYQTQKQESFFVDERTSLQVPMMHQKEMHRFLYDQDLA                                   CTVLQIEYRGNALALLVLPDPGKMKQVEAALQPQTLRK                                   WGQLLLPSLLDLHLPRFSISGTYNLEDILPQIGLTNILNLEA                                   DFSGVTGQLNKTISKVSHKAMVDMSEKGFLAGAASGLLS                                   QPPSLNTMSDPHAHFNRPFLLLLWEVTTQSLLFLGKVVNP                                   VAG                                   Q8IW75   21   LKPSFSPRNYKALSEVQGWKQRMAAKELARQNMDLGFK   414   Serpin A12   Serpin                       LLKKLAFYNPGRNIFLSPLSISTAFSMLCLGAQDSTLDEIK                                   QGFNFRKMPEKDLHEGFHYIIHELTQKTQDLKLSIGNTLFI                                   DQRLQPQRKFLEDAKNFYSAETILTNFQNLEMAQKQINDF                                   ISQKTHGKINNLIENIDPGTVMLLANYIFFRARWKHEFDPN                                   VTKEEDFFLEKNSSVKVPMMFRSGIYQVGYDDKLSCTILE                                   IPYQKNITAIFILPDEGKLKHLEKGLQVDTFSRWKTLLSRR                                   VVDVSVPRLHMTGTFDLKKTLSYIGVSKIFLEHGDLTKIA                                   PHRSLKVGEAVHKAELKMDERGFEGAAGTGAQTLPMET                                   PLVVKIDKPYLLLIYSEKIPSVLFLGKIVNPIGK                                   O75830   19   SRCSAQKNTEFAVDLYQEVSLSHKDNIIFSPLGITLVLEMV   405   Serpin 12   Serpin                       QLGAKGKAQQQIRQTLKQQETSAGEEFFVLKSFFSAISEK                                   KQEFTFNLANALYLQEGFTVKEQYLHGNKEFFQSAIKLV                                   DEQDAKACAEMISTWVERKTDGKIKDMFSGEEFGPLTRL                                   VLVNAIYFKGDWKQKFRKEDTQLINFTKKNGSTVKIPMM                                   KALLRTKYGYFSESSLNYQVLELSYKGDEFSLIIILPAEGM                                   DIEEVEKLITAQQILKWLSEMQEEEVEISLPREKVEQKVDF                                   KDVLYSLNITEIFSGGCDLSGITDSSEVYVSQVTQKVFFEIN                                   EDGSEAATSTGIHIPVIMSLAQSQFIANHPFLFIMKHNPTES                                   ILFMGRVTNPDTQEIKGRDLDSL                                   O00230   89   DRMPCRNFFVVICITSSCK   105   Cortistatin-17   Somastostatin                       O00230   77   QEGAPPQQSARRDRMPCRNFFWKTFSSCK   105   Cortistatin-29   Somastostatin                               (Potential)                           P61278   103   AGCKNFFWKTFTSC   116   Somatostatin-14   Somastostatin                       P61278   89       S   AN   S   NPAMAPRERKAGCKNFFWKTFTSC   116   Somatostatin-28   Somastostatin   S89 or S92   1                               (Ambiguous)                   P01236   29   LPICPGGAARCQVTLRDLFDRAVVLSHYIHNLSSEMFSEF   227   Prolactin   Somatotropin/                       DKRYTHGRGFITKAINSCHTSSLATPEDKEQAQQMNQKD           prolactin                       FLSLIVSILRSWNEPLYHLVTEVRGMQEAPEAILSKAVEIE                                   EQTKRLLEGMELIVSQVHPETKENEIYPVWSGLPSLQMAD                                   EESRLSAYYNLLHCLRRDSHKIDNYLKLLKCRIIHNNNC                                   P20366   111   ALNSVAYERSAMQNYE   125   C-terminal-   Tachykinin   A111, S114   2                       flanking peptide                           P20366   98   HKTDSFVGLM   107   Neurokinin A   Tachykinin                       Q9UHF0   81   DMHDFFVGLM   90   Neurokinin-B   Tachykinin                       P20366   72   DADSSIEKQVALLKALYGHGQISHKRHKTDSFVGLM   107   Neuropeptide K   Tachykinin                       P20366   58   RPKPQQFFGLM   68   Substance P   Tachykinin                       P20396   25   QPEAAQQEAVTAAEHPGLDDFLRQVERLLFLRENIQRLQ   242   Pro-thyrotropin-   TRH   174   1               GDQGEHSASQIFQSDWLSKRQHPGKREEEEEEGVEEEEEE       releasing                           EGGAVGPHKRQHPGRREDEASWSVDVTQHKRQHPGRRS       hormone                           PWLAYAVPKRQHPGRRLADPKAQRSWEEEEEEEEREEDL                                   MPEKRQHPGKRALGGPCGPQGAYGQAGLLLGLLDDLSRS                                   QGAEEKRQHPGRRAAWVREPLEE                                   P20396   84   QHP   86   Thyrotropin-   TRH                               releasing                                   hormone                           O95399   114   ETPDCFWKYCV   124   Urotensin-2   Urotensin-2                       Q76510   112   ACFVVKYCV   119   Urotensin-2B   Urotensin-2                       P01185   20   CYFQNCPRG   28   Arg-vasopressin   Vasopressin/                                   oxytocin                       P01185   126   ASDRSNATQLDGPAGALLLRLVQLAG   A   PEPFEPAQPDAY   164   Copeptin   Vasopressin/   A152   1                           oxytocin                       P01178   32   AAPDLDVRKCLPCGPGGKGRCFGPNICCAEELGCFVGTA   125   Neurophysin 1   Vasopressin/                       EALRCQEENYLPSPCQSGQKACGSGGRCAVLGLCCSPDG           oxytocin                       CHADPACDAEATFSQR                                   P01185   32   AMSDLELRQCLPCGPGGKGRCFGPSICCADELGCFVGTAE   124   Neurophysin 2   Vasopressin/                       ALRCQEENYLPSPCQSGQKACGSGGRCAAFGVCCNDESC           oxytocin                       VTEPECREGFHRRA                                   P01178   20   CYIQNCPLG   28   Oxytocin   Vasopressin/                                   oxytocin                       O15240   554   TLQPPSALRRRHYHHALPPSRHYP   577   Antimicrobial   VGF                               peptide                                   VGF[554-577]                           O15240   281   RPESALLGGSEAGERLLQQGLAQVEA   306   Neuroendocrine   VGF                               regulatory                                   peptide-1                           O15240   310   QAEATRQAAAQEERLADLASDLLLQYLLQGGARQRGLG   347   Neuroendocrine   VGF                               regulatory                                   peptide-2                           O15240   25   AP   P   GRPEAQPPPL   S   SEHKEPVAGDAVPGPKDGSAPEVRGA   615   Neurosecretory   VGF   P25, S36, P226,   5               RNSEPQDEGELFQGVDPRALAAVLLQALDRPASPPAPSGS       protein VGF       S229, T501                   QQGPEEEAAEALLTETVRSQTHSLPAPESPEPAAPPRPQTP                                   ENGPEASDPSEELEALASLLQELRDFSPSSAKRQQETAAA                                   ETETRTHTLTRVNLESPGPERVWRASWGEFQARVPERAP                                   LPP   P   APSQFQARMPDSGPLPETHKFGEGVSSPKTHLGEAL                                   APLSKAYQGVAAPFPKARRPESALLGGSEAGERLLQQGL                                   AQVEAGRRQAEATRQAAAQEERLADLASDLLLQYLLQG                                   GARQRGLGGRGLQEAAEERESAREEEEAEQERRGGEERV                                   GEEDEEAAEAEAEAEEAERARQNALLFAEEEDGEAGAED                                   KRSQEETPGHRRKEAEGTEEGGEEEDDEEMDPQTIDSLIE                                   LSTKLHLPADDVVSIIEEVEEKRKRKKNAPPEPVPPPRAAP                                   AP   T   HVRSPQPPPPAPAPARDELPDWNEVLPPWDREEDEV                                   YPPGPYHPFPNYIRPRTLQPPSALRRRHYHHALPPSRHYPG                                   REAQARRAQEEAEAEERRLQEQEELENYIEHVLLRRP                    
Specific embodiments of the invention are disclosed below with indication of the respective SEQ ID NO.
 
     
       
         
           
               
               
               
               
               
               
               
               
               
             
               
                 TABLE 6A 
               
               
                   
               
               
                   
                   
                   
                   
                   
                   
                   
                 *Site position (Bold; identified 
                   
               
               
                 SEQ 
                   
                   
                   
                   
                   
                 Peptide 
                 or conserved in human, Italic: 
                 No. 
               
               
                 ID 
                 Entry_ 
                 Peptide 
                   
                 Peptide 
                 Peptide 
                 Hormone 
                 identified in non-human and not 
                 of 
               
               
                 NO 
                 Human 
                 Start 
                 Peptide_Sequence 
                 end 
                 Name 
                 Family 
                 conserved 
                 sites 
               
               
                   
               
             
            
               
                 147 
                 P01160 
                 1 
                 SLRRSSCFGGRMDRIGAQ   S   GLGCN   S   FRY 
                 28 
                 Atrial 
                 Natriuretic  
                 
                   
                     S19N, S25 
                   
                 
                 2 
               
               
                   
                   
                   
                   
                   
                 natriuretic 
                 peptide 
                   
                   
               
               
                   
                   
                   
                   
                   
                 factor 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
               
               
               
               
               
               
             
               
                 TABLE 6B 
               
               
                   
               
               
                   
                   
                   
                   
                   
                   
                   
                 *Site position (Bold; identified 
                   
               
               
                 SEQ 
                   
                   
                   
                   
                   
                 Peptide 
                 or conserved in human, Italic: 
                 No. 
               
               
                 ID 
                 Entry_ 
                 Peptide 
                   
                 Peptide 
                 Peptide 
                 Hormone 
                 identified in non-human and not 
                 of 
               
               
                 NO 
                 Human 
                 Start 
                 Peptide_Sequence 
                 end 
                 Name 
                 Family 
                 conserved 
                 sites 
               
               
                   
               
             
            
               
                  72 
                 P22466 
                 1 
                 GW   T   LNSAGYLLGPHAVGNHRSF   S   DKNGLTS 
                 30 
                 Galanin 
                 Galanin 
                 
                   
                     T3, S23 
                   
                 
                 2 
               
               
                   
               
               
                  95 
                 P01275 
                 1 
                 HSQGTF   T   SDYSKYLDSRRAQDFVQWLMNT 
                 29 
                 Glucagon 
                 Glucagon 
                 
                   
                     T7 
                   
                 
                 1 
               
               
                   
               
               
                  97 
                 P01275 
                 1 
                 HAEG   T   F   T   SDVSSYLEGQAAKEFIAWLVKGR 
                 31 
                 Glucago-like 
                 Glucagon 
                 
                   
                     T5 or T7 or S8 (Ambiguous) 
                   
                 
                 1 
               
               
                   
                   
                   
                   
                   
                 peptide 1 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 (7-36) 
                   
                   
                   
               
               
                   
               
               
                 106 
                 P09683 
                 1 
                 HSDGTF   TS   EL   S   RLREGARLQRLLQGLV 
                 27 
                 Secretin 
                 Glucagon 
                 
                   
                     T7, S8, S11 
                   
                 
                 3 
               
               
                   
               
               
                 108 
                 P01282 
                 1 
                 HSDAVF   T   DNYTRLRKQMAVKKYLNSILN 
                 28 
                 Vasoactive 
                 Glucagon 
                 
                   
                     T7 
                   
                 
                 1 
               
               
                   
                   
                   
                   
                   
                 intestinal 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 peptide 
                   
                   
                   
               
               
                   
               
               
                 147 
                 P01160 
                 1 
                 SLRRSSCFGGRMDRIGAQ   S   GLGCN   S   FRY 
                 28 
                 Atrial 
                 Natriuretic 
                 
                   
                     S19, S25 
                   
                 
                 2 
               
               
                   
                   
                   
                   
                   
                 natriuretic 
                 peptide 
                   
                   
               
               
                   
                   
                   
                   
                   
                 factor 
                   
                   
                   
               
               
                   
               
               
                 185 
                 P01303 
                 1 
                 YPSKPDNPGEDAPAEDMARYYSALRHYINLI   T   RQRY 
                 36 
                 Neuropeptide Y 
                 NPY 
                 
                   
                     S3, T32 
                   
                 
                 2 
               
               
                   
               
               
                 188 
                 P10082 
                 1 
                 YPIKPAPREDASPEELNRYYASLRHYLNLV   T   RQRY 
                 36 
                 Peptide YY 
                 NPY 
                 
                   
                     T32 
                   
                 
                 1 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
               
               
               
               
               
               
             
               
                 TABLE 6C 
               
               
                   
               
               
                 SEQ 
                   
                   
                   
                   
                   
                 Peptide 
                   
                 No. 
               
               
                 ID 
                 Entry_ 
                 Peptide 
                   
                 Peptide 
                 Peptide 
                 Hormone 
                 *Site position (identified 
                 of 
               
               
                 NO 
                 Human 
                 Start 
                 Peptide_Sequence 
                 end 
                 Name 
                 Family 
                 or conserved in humans) 
                 sites 
               
               
                   
               
             
            
               
                  92 
                 P09681 
                 1 
                 YAEGTFI   S   DYSIAMDKIHQQDFVNWLLAQKGKKNDW 
                 42 
                 Gastric  
                 Glucagon 
                 S8 
                 1 
               
               
                   
                   
                   
                 KHNITQ 
                   
                 inhibitory  
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 polypeptide 
                   
                   
                   
               
               
                   
               
               
                  95 
                 P01275 
                 1 
                 HSQGTF   T   SDYSKYLDSRRAQDFVQWLMNT 
                 29 
                 Glucagon 
                 Glucagon 
                 T7 
                 1 
               
               
                   
               
               
                  97 
                 P01275 
                 1 
                 HAEG   T   F   T   SDVSSYLEGQAAKEFIAWLVKGR 
                 31 
                 Glucago-like 
                 Glucagon 
                 T5 or T7 or S8 (Ambiguous) 
                 1 
               
               
                   
                   
                   
                   
                   
                 peptide 1 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 (7-36) 
                   
                   
                   
               
               
                   
               
               
                  99 
                 P01275 
                 1 
                 HADGSF   S   DEMNTILDNLAARDFINWLIQTKITD 
                 33 
                 Glucagon-like 
                 Glucagon 
                 S7 
                 1 
               
               
                   
                   
                   
                   
                   
                 peptide 2 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 (By similarity) 
                   
                   
                   
               
               
                   
               
               
                 100 
                 P01282 
                 1 
                 HADGVF   TS   DFSKLLGQLSAKKYLESLM 
                 27 
                 Intestinal 
                 Glucagon 
                 T7, S8 
                 2 
               
               
                   
                   
                   
                   
                   
                 peptide 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 PHM-27 
                   
                   
                   
               
               
                   
               
               
                 106 
                 P09683 
                 1 
                 HSDGTF   TS   EL   S   RLREGARLQRLLQGLV 
                 27 
                 Secretin 
                 Glucagon 
                 T7, S8, S11 
                 3 
               
               
                   
               
               
                 107 
                 P01286 
                 1 
                 YADAIF   T   NSYRKVLGQLSARKLLQDIMSRQQGESNQ 
                 44 
                 Somatoliberin 
                 Blucagon 
                 T7 
                 1 
               
               
                   
                   
                   
                 ERGARARL 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 108 
                 P01282 
                 1 
                 HSDAVF   T   DNYTRLRKQMAVKKYLNSILN 
                 28 
                 Vasoactive 
                 Glucagon 
                 T7 
                 1 
               
               
                   
                   
                   
                   
                   
                 intestinal 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 peptide 
                   
                   
                   
               
               
                   
               
               
                  21 
                 P01258 
                 1 
                 CGNLS   T   CMLG   T   Y   T   QDFNKFH   T   FPQ   T   AIGVGAP 
                 32 
                 Calcitonin 
                 Calcitonin 
                 T6, T11. T13, T21, T25 
                 5 
               
               
                   
               
               
                  22 
                 P06881 
                 1 
                 ACDTATCV   T   HRLAGLL   S   RSGGVVKNNFVPTNVGSK 
                 37 
                 Calcitonin 
                 Calcitonin 
                 T9, S17 
                 2 
               
               
                   
                   
                   
                 AF 
                   
                 gene- 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 related 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 peptide 1 
                   
                   
                   
               
               
                   
               
               
                  23 
                 P10092 
                 1 
                 ACNTATCV   T   HRLAGLL   S   RSGGMVK   S   NFVP   T   NVG   S   K 
                 37 
                 Calcitonin 
                 Calcitonin 
                 T9, S17, S25, T30, S34 
                 5 
               
               
                   
                   
                   
                 AG 
                   
                 gene- 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 related 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 peptide 2 
                   
                   
                   
               
               
                   
               
               
                  24 
                 P10997 
                 1 
                 KCNTA   T   CA   T   QRLANFLVHSSNNFGAILSSTNVGSN 
                 37 
                 Islet amyloid 
                 Calcitonin 
                 T6, T9 
                 3 
               
               
                   
                   
                   
                 TY 
                   
                 polypeptide 
                   
                   
                   
               
               
                   
               
               
                   6 
                 P35318 
                 1 
                 YRQSMNNFQGLRSFGCRFGTC   T   VQKLAHQI   Y   QF   T   D 
                 52 
                 Adrenomedullin 
                 Adrenomedullin 
                 T22, Y31, T34 
                 3 
               
               
                   
                   
                   
                 KDKDNVAPRSKISPQGY 
                   
                   
                   
                   
                   
               
               
                   
               
               
                   7 
                 Q7Z4H4 
                 1 
                 TQAQLLRVGCVLG   T   CQVQNLSHRLWQLMGPAGRQDS 
                 47 
                 Adrenomedullin- 
                 Adrenomedullin 
                 T14 
                 1 
               
               
                   
                   
                   
                 APVDPSSPHSY 
                   
                 2 (By 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 116 
                 P01308 
                 1 
                 FVNQHLCGSHLVEALYLVCGERGFFY   T   PKT 
                 30 
                 Insulin B 
                 Insulin 
                 T27 (Ambiguous) 
                 1 
               
               
                   
                   
                   
                   
                   
                 chain 
                   
                   
                   
               
               
                   
               
               
                 117 
                 P05019 
                 1 
                 GPETLCGAELVDALQFVCGDRGFYFNKP   T   GYGSSSS 
                 70 
                 Inslulin-like 
                 Insulin 
                 T29 
                 1 
               
               
                   
                   
                   
                 RAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA 
                   
                 growth factor I 
                   
                   
                   
               
               
                   
               
               
                 118 
                 P01344 
                 1 
                 AYRPSETLCGGELVDTLQFVCGDRGFYF   S   RPASRVS 
                 67 
                 Inslulin-like 
                 Insulin 
                 S29, S50, T62 
                 2 
               
               
                   
                   
                   
                 RRSRGIVEECCFR S CDLALLETYCA T PAKSE 
                   
                 growth factor 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 II 
                   
                   
                   
               
               
                   
               
               
                  72 
                 P22466 
                 1 
                 GW   T   LNSAGYLLGPHAVGNHRSF   S   DKNGLTS 
                 30 
                 Galanin 
                 Galanin 
                 T3, S23 
                 2 
               
               
                   
               
               
                  74 
                 Q9UBC7 
                 1 
                 APAHRGRGGW T LNSAGYLLGPVLHLPQMGDQDGKRE 
                 60 
                 Galanin-like 
                 Galanin 
                 T11 
                 1 
               
               
                   
                   
                   
                 TALEILDLWKAIDGLPYSHPPQPS 
                   
                 peptide 
                   
                   
                   
               
               
                   
               
               
                 185 
                 P01303 
                 1 
                 YP   S   KPDNPGEDAPAEDMARYYSALRHYINLI   T   RQRY 
                 36 
                 Neuropeptide Y 
                 NPY 
                 S3, T32 
                 2 
               
               
                   
               
               
                 186 
                 P01298 
                 1 
                 APLEPVYPGDNATPEQMAQYAADLRRYINML   T   RPRY 
                 36 
                 Pancreatic 
                 NPY 
                 T32 
                 1 
               
               
                   
                   
                   
                   
                   
                 hormone 
                   
                   
                   
               
               
                   
               
               
                 188 
                 P10082 
                 1 
                 YPIKPAPREDASPEELNRYYASLRHYLNLV   T   RQRY 
                 36 
                 Peptide YY 
                 NPY 
                 T32 
                 1 
               
               
                   
               
               
                 147 
                 P01160 
                 1 
                 SLRRSSCFGGRMDRIGAQ   S   GLGCN   S   FRY 
                 28 
                 Atrial 
                 Natriuretic 
                 S19, S25 
                 2 
               
               
                   
                   
                   
                   
                   
                 natriuretic 
                 peptide 
                   
                   
               
               
                   
                   
                   
                   
                   
                 factor 
                   
                   
                   
               
               
                   
               
               
                 163 
                 P16860 
                 1 
                 SPKMVQGSGCFGRKMDRISSS S GLGCKVLRRH 
                 32 
                 Brain 
                 Natriuretic 
                 S22 
                 1 
               
               
                   
                   
                   
                   
                   
                 natriuretic 
                 peptide 
                   
                   
               
               
                   
               
               
                 167 
                 P23582 
                 1 
                 DLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKG 
                 53 
                 CNP-53 
                 Natriuretic 
                 S47 
                 1 
               
               
                   
                   
                   
                 CFGLKLDRIG S MSGLGC 
                   
                   
                 peptide 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
               
               
               
               
               
               
             
               
                 TABLE 6D 
               
               
                   
               
               
                   
                   
                   
                   
                   
                   
                   
                 *Site position (Bold: 
                   
               
               
                   
                   
                   
                   
                   
                   
                   
                 identified or conserved 
                   
               
               
                 SEQ 
                   
                 Pep- 
                   
                 Pep- 
                   
                 Peptide 
                 in human, Italic; 
                 No. 
               
               
                 ID 
                 Entry_ 
                 tide 
                   
                 tide 
                 Peptide 
                 Hormone 
                 identified in non-human  
                 of 
               
               
                 NO. 
                 Human 
                 Start 
                 Peptide_Sequence 
                 end 
                 Name 
                 Family 
                 and not conserved) 
                 sites 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
            
               
                 1 
                 P05408 
                 1 
                     S   VPHFSDEDKDPE 
                  13 
                 C-terminal 
                 7B2 
                 S1 
                 1 
               
               
                   
                   
                   
                   
                   
                 peptide (By 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 2 
                 P05408 
                 1 
                 Y   S   PR   T   PDRV   S   EADIQRLLHGVMEQLGIARPRVEYPAHQ 
                 186 
                 Neuroendocrine 
                 7B2 
                 S2, T5, S10, T108, S174 
                 5 
               
               
                   
                   
                   
                 AMNLVGPQSIEGGAHEGLQHLGPFGNIPNIVAELTGDN 
                   
                 protein 7B2 
                   
                   
                   
               
               
                   
                   
                   
                 IPKDFSEDQGYPDPPNPCPVGKTADDGCLEN   T   PDTAEF 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 SREFQLHQHLFDPEHDYPGLGKWNKKLLYEKMKGGE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 RRKRRSVNPYLQGQRLDNVVAKK   S   VPHFSDEDKDPE 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 3 
                 P05408 
                 1 
                 Y   S   PR   T   PDRV   S   EADIQRLLHGVMEQLGIARPRVEYPAHQ 
                 150 
                 N-terminal 
                 7B2 
                 S2, T5, S10, T108 
                 4 
               
               
                   
                   
                   
                 AMNLVGPQSIEGGAHEGLQHLGPFGNIPNIVAELTGDN 
                   
                 peptide (By 
                   
                   
                   
               
               
                   
                   
                   
                 IPKDFSEDQGYPDPPNPCPVGKTADDGCLEN   T   PDTAEF 
                   
                 similarity) 
                   
                   
                   
               
               
                   
                   
                   
                 SREFQLHQHLFDPEHDYPGLGKWNKKLLYEKMKGGE 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 5 
                 P07108 
                 1 
                 SQAEFEKAAEEVRHLKTKPSDEEMLFIYGHYKQA   T   VG 
                  86 
                 Acyl-CoA- 
                 ACBP 
                 T35 or T41 (ambiguous) 
                 1 
               
               
                   
                   
                   
                 DIN   T   ERPGMLDFTGKAKWDAWNELKGTSKEDAMKA 
                   
                 binding protein 
                   
                   
                   
               
               
                   
                   
                   
                 YINKVEELKKKYGI 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 6 
                 P35318 
                 1 
                 YRQSMNNFQGLRSFGCRFGTC   T   VQKLAHQI   Y   QF   T   DKD 
                  52 
                 Adrenomedullin 
                 Adrenomedullin 
                 T22, Y31, T34 
                 3 
               
               
                   
                   
                   
                 KDNVAPRSKISPQGY 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 7 
                 Q7Z4H4 
                 1 
                 TQAQLLRVGCVLG   T   CQVQNLSHRLWQLMGPAGRQDS 
                  47 
                 Adrenomedullin-2 
                 Adrenomedullin 
                 T14 
                 1 
               
               
                   
                   
                   
                 APVDPSSPHSY 
                   
                 (By similarity) 
                   
                   
                   
               
               
                   
               
               
                 14 
                 P07492 
                 1 
                 VPL   P   AGGG   T   VLTKMYPRGNHWAVGHLM 
                  27 
                 Gastrin-releasing 
                 Bombesin/neuromedin- 
                 P4, T9 
                 2 
               
               
                   
                   
                   
                   
                   
                 peptide 
                 B/ranatensin 
                   
                   
               
               
                   
               
               
                 15 
                 P08949 
                 1 
                 GNLWA   T   GHFM 
                  10 
                 Neuromedin-B 
                 Bombesin/neuromedin- 
                 T6 
                 1 
               
               
                   
                   
                   
                   
                   
                   
                 B/ranatensin 
                   
                   
               
               
                   
               
               
                 16 
                 P08949 
                 1 
                 APLSWDLPEPRSRASKIRVHSRGNLWA   T   GHFM 
                  32 
                 Neuromedin-B-32 
                 Bombesin/neuromedin- 
                 T28 
                 1 
               
               
                   
                   
                   
                   
                   
                   
                 B/ranatensin 
                   
                   
               
               
                   
               
               
                 21 
                 P01258 
                 1 
                 CGNLS   T   CMLG   T   Y   T   QDFNKFH   T   FPQTAIGVGAP 
                  32 
                 Calcitonin 
                 Calcitonin 
                 T6, T11, T13, T21, T25 
                 5 
               
               
                   
               
               
                 22 
                 P06881 
                 1 
                 ACDTATCV   T   HRLAGLL   S   RSGGVVKNNFVPTNVGSKAF 
                  37 
                 Calcitonin gene- 
                 Calcitonin 
                 T9, S17 
                 2 
               
               
                   
                   
                   
                   
                   
                 related peptide 1 
                   
                   
                   
               
               
                   
               
               
                 23 
                 P10092 
                 1 
                 ACNTATCV   T   HRLAGLL   S   RSGGMVK   S   NFVP   T   NVG   S   KAF 
                  37 
                 Calcitonin gene- 
                 Calcitonin 
                 T9, S17, S25, T30, S34 
                 5 
               
               
                   
                   
                   
                   
                   
                 related peptide 2 
                   
                   
                   
               
               
                   
               
               
                 24 
                 P10997 
                 1 
                 KCNTA   T   CA   T   QRLANFLVHSSNNFGAILSS   T   NVGSNTY 
                  37 
                 Islet amyloid 
                 Calcitonin 
                 T5, T9, T30 
                 3 
               
               
                   
                   
                   
                   
                   
                 polypeptide 
                   
                   
                   
               
               
                   
               
               
                 25 
                 P01258 
                 1 
                 DMSSDLERDHRPHV   S   MPQNAN 
                  21 
                 Katacalcin 
                 Calcitonin 
                 S15 
                 1 
               
               
                   
               
               
                 36 
                 P05060 
                 1 
                 SAEFPDFYDSEEPV   S   THQEAENEKDRADQTVLTEDEKK 
                  57 
                 CCB peptide 
                 Chromogranin/ 
                 S15 
                 1 
               
               
                   
                   
                   
                 ELENLAAMDLELQKIAEKF 
                   
                   
                 secretogranin 
                   
                   
               
               
                   
               
               
                 37 
                 P10645 
                 1 
                 LPVNSPMNKGDTEVMKCIVEVISDTL   S   KP   S   PMPV   S   QEC 
                 439 
                 Chromogranin-A 
                 Chromogranin/ 
                 S27, S30, S36, S80, E104, S108, 
                 39 
               
               
                   
                   
                   
                 FETLRGDERILSILRHQNLLKELQDLALQGAKERAHQQ 
                   
                   
                 secretogranin 
                 A127, T128, A135, L136, S143 
                   
               
               
                   
                   
                   
                 KKH   S   GFEDELSEVLENQSSQAELKEAV   E   EPS   S   KDVME 
                   
                   
                   
                 A151, N164, T165 P167, A169, 
                   
               
               
                   
                   
                   
                 KREDSKEAEKSGE   A   T   DGARPQ   AL   PEPMQESKAEGNNQ 
                   
                   
                   
                 S170, S173, E182, L188 S189, 
                   
               
               
                   
                   
                   
                     A   PGEEEEEEEEAT   N   T   H   P   P   A   S   LP   S   QKYPGPQA   E   GDSEG   L   S     
                   
                   
                   
                 V193, S200, T233, L236, N237, 
                   
               
               
                   
                   
                   
                 QGL   V   DREKGL   S   AEPGWQAKREEEEEEEEEAEAGEEAV 
                   
                   
                   
                 P238, S241, Y244, P265, E268, 
                   
               
               
                   
                   
                   
                 PEEEGP   T   VV   LNP   HP   S   LG   Y   KEIRKGESRSEALAVDGAGK 
                   
                   
                   
                 P273, S282, M291, V294, T335, 
                   
               
               
                   
                   
                   
                     P   GA   E   EAQD   P   EGKGEQEH   S   QQKEEEEE   M   AV   V   PQGLFRG 
                   
                   
                   
                 A360, S380, G395 
                   
               
               
                   
                   
                   
                 GKSGELEQEEERLSKEWEDSKRWSKMDQLAKEL   T   AE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KRLEGQEEEEDNRDSSMKLSFR   A   RAYGFRGPGPQLRR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GWRPS   S   REDSLEAGLPLQVR   G   YPEEKKEEEGSANRRPE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DQELESLSAIEAELEKVAHQLQALRRG 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 38 
                 P10645 
                 1 
                 EDSKEAEKSGE   A   T   DGARPQ   AL   PEPMQE   S   KAEGNNQ   A   P 
                  92 
                 EA-92 
                 Chromogranin/ 
                 A12, T13, A20, L21, S28, A36, 
                 17 
               
               
                   
                   
                   
                 GEEEEEEEEAT   N   T   H   P   PA   S   LP   S   QKYPGPQA   E   GDSEG   L   S   Q 
                   
                   
                 secretogranin 
                 N49, T50, P52, A54, S55, S58, 
                   
               
               
                   
                   
                   
                 GL   V   DREKGL   S   AEPGWQA 
                   
                   
                   
                 E67, L73, S74, V78, S85 
                   
               
               
                   
               
               
                 39 
                 P10645 
                 1 
                 EEEGSANRRPEDQELE   S   L   S   AIEAELEKVAHQLQALRR 
                  37 
                 ER-37 
                 Chromogranin/ 
                 S17 or S19 (Ambiguous) 
                 1 
               
               
                   
                   
                   
                   
                   
                   
                 secretogranin 
                   
                   
               
               
                   
               
               
                 40 
                 P10645 
                 1 
                 EEEEEEEEEAEAGEEAVPEEEGP   T   VV   LNP   HP   S   L 
                  33 
                 ES-43 
                 Chromogranin/ 
                 T24, L27, N28, P29, S32 
                 5 
               
               
                   
                   
                   
                   
                   
                   
                 secretogranin 
                   
                   
               
               
                   
               
               
                 41 
                 P05060 
                 1 
                 FLGEGH   H   RVQE   N   QMDKARRHPQGAWKELDRNYLN   Y     
                  74 
                 GAWK peptide 
                 Chromogranin/ 
                 H7, N12, Y35, T72, A73 
                 5 
               
               
                   
                   
                   
                 GEEGAPGKWQQQGDLQDTKENREEARFQDKQYSSHH 
                   
                   
                 secretogranin 
                   
                   
               
               
                   
                   
                   
                     T   A   E 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 42 
                 P10645 
                 1 
                     G   YPEEKKEEEGSANRRPEDQELESLSAIEAELEKVAHQ 
                  44 
                 GR-44 
                 Chromogranin/ 
                 G1 
                 1 
               
               
                   
                   
                   
                 LQALRR 
                   
                   
                 secretogranin 
                   
                   
               
               
                   
               
               
                 43 
                 P10645 
                 1 
                 GWRPS   S   REDSLEAGLPLQV 
                  19 
                 GV-19 
                 Chromogranin/ 
                 S6 
                 1 
               
               
                   
                   
                   
                   
                   
                   
                 secretogranin 
                   
                   
               
               
                   
               
               
                 45 
                 P10645 
                 1 
                 SEALAVDGAGK   P   GA   E   EAQD   P   EGKGEQEH   S   QQKEEEEE 
                  48 
                 Pancreastatin 
                 Chromogranin/ 
                 P12, E15, P20, S29, M38, V41 
                 6 
               
               
                   
                   
                   
                     M   AV   V   PQGLFRG 
                   
                   
                 secretogranin 
                   
                   
               
               
                   
               
               
                 46 
                 P05060 
                 1 
                 MPVDNRNHNEGMV   T   RCIIEVLSNAL   S   K   S   SAP   P   ITPECR 
                 657 
                 Secretogranin-1 
                 Chromogranin/ 
                 T14, S26, S28, S29, P32, T59, 
                 40 
               
               
                   
                   
                   
                 QVLKTSRKDVKDKETTENEN   T   KFEVRLLRDPADA   S   E   A     
                   
                   
                 secretogranin 
                 S73, A75, S80, A84, E89, T96, 
                   
               
               
                   
                   
                   
                 HESS   S   RGE   A   GAPG   E   EDIQGP   T   KADTEKWAEGGGHSRE 
                   
                   
                   
                 S120, S124, S129, T174, N176, 
                   
               
               
                   
                   
                   
                 RADEPQW   S   LYP   S   DSQV   S   EEVKTRHSEKSQREDEEEEEG 
                   
                   
                   
                 S186, S273, S274, S278, P287, 
                   
               
               
                   
                   
                   
                 ENYQKGERGEDSSEEKHLEEPGE   T   Q   N   AFLNERKQA   S   AI 
                   
                   
                   
                 S22L, M298, S300, D306, T310, 
                   
               
               
                   
                   
                   
                 KKEELVARSETHAAGHSQEKTHSREKSSQESGEETGSQ 
                   
                   
                   
                 Y328, P329, G330, K376, M377, 
                   
               
               
                   
                   
                   
                 ENHPQESKGQPRSQEESEEGEEDATSEVDKRRTRPRHH 
                   
                   
                   
                 H426, Y454, T491, A492, T536, 
                   
               
               
                   
                   
                   
                 HGRSRPDR   SS   QGG   S   LPSEEKGH   P   QEESEESNV   S   M   A   S   LG 
                   
                   
                   
                 S557, N568, S611 
                   
               
               
                   
                   
                   
                 EKR   D   HHS   T   HYRASEEEPEYGEEIKG   Y   PG   VQAPEDLEW 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 ERYRGRGSEEYRAPRPQSEESWDEEDKRNYPSLELD   K     
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                     M   AHGYGEESEEERGLEPGKGRHHRGRGGEPRAYFMS 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DTREEKRFLGEGH   H   RVQENQMDKARRHPQGAWKELD 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 RNYLN   Y   GEEGAPGKWQQQGDLQDTKENREEARFQDK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 QYSSHH   T   A   EKRKRLGELFNPYYDPLQWKSSHFERRDN 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 MNDNFLEGEEENEL   T   LNEKNFFPEYNYDWWEKKPF   S   E 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DVNWGYEKR   N   LARVPKLDLKRQYDRVAQLDQLLHY 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 RKKSAEFPDFYDSEEPV   S   THQEAENEKDRADQTVLTE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DEKKELENLAAMDLELQKIAEKFSQRG 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 47 
                 P13521 
                 1 
                 QRNQLLQKEPDLRLENVQKFP   S   PEMIRALEYIENLRQQ 
                 587 
                 Secretogranin-2 
                 Chromogranin/ 
                 S22, S45, A106, Y160, T161, 
                 16 
               
               
                   
                   
                   
                 AHKEES   S   PDYNPYQGVSVPLQQKENGDESHLPERDSLS 
                   
                   
                 secretogranin 
                 S164, T167, S229, T231, S348, 
                   
               
               
                   
                   
                   
                 EEDWMRIILEALRQAENEPQSAPKENKPY   A   LNSEKNFP 
                   
                   
                   
                 T420, N459, G499, S526, S536, 
                   
               
               
                   
                   
                   
                 MDMSDDYETQQWPERKLKHMQFPPMYEENSRDNPFK 
                   
                   
                   
                 P543 
                   
               
               
                   
                   
                   
                 RTNEIVEEQ   YT   PQ   S   LA   T   LESVFQELGKLTGPNNQKRER 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 MDEEQKLYTDDEDDIYKANNIAYEDVVGGEDWNPVE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 EKIE   S   Q   T   QEEVRDSKENIEKNEQINDEMKRSGQLGIQEE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DLRKESKDQLSDDVSKVIAYLKRLVNAAGSGRLQNGQ 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 NGERATRLFEKPLDSQSIYQLIEISRNLQIPPEDLIEMLK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 TGEKPNG   S   VEPERELDLPVDLDDISEADLDHPDLFQNR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 MLSKSGYPKTPGRAGTEALPDGLSVEDILNLLGMESA 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 ANQK   T   SYFPNPYNQEKVLPRLPYGAGRSRSNQLPKAA 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 WIPHVE   N   RQMAYENLNDKDQELGEYLARMLVKYPEII 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 NSNQVKRVP   G   QGSSEDDLQEEEQIEQAIKEHLNQGS   S   Q 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 ETDKLAPV   S   KRFPVG   P   PKNDDTPNRQYWDEDLLMKV 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LEYLNQEKAEKGREHIAKRAMENM 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 48 
                 Q8WXD2 
                 1 
                 FPKPGGSQDKSLHNRELSAERPLNEQIAEAEEDKIKKT 
                 449 
                 Secretogranin-3 
                 Chromogranin/ 
                 P41, T63, S103, T104, T125, 
                 15 
               
               
                   
                   
                   
                 YP   P   ENKPGQSNYSFVDNLNLLKAI   T   EKEKIEKERQSIRS 
                   
                   
                 secretogranin 
                 A138, D192, P193, T197, S198, 
                   
               
               
                   
                   
                   
                 SPLDNKLNVEDVDSTKNRKLIDDYD   ST   KSGLDHKFQD 
                   
                   
                   
                 T200, T212, I217, A222, S340 
                   
               
               
                   
                   
                   
                 DPDGLHQLDG   T   PLTAEDIVHKIA   A   RIYEENDRAVFDKI 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 VSKLLNLGLITESQAHTLEDEVAEVLQKLISKEANNYE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 E   DP   NKP   TS   W   T   ENQAGKIPEKV   T   PMAA   I   QDGL   A   KGEND 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 ETVSNTLTLTNGLERRTKTYSEDNFEELQYFPNFYALL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KSIDSEKEAKEKETLITIMKTLIDFVKMMVKYGTISPEE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GVSYLENLDEMIALQTKNKLEKNATDNISKLFPAP   S   EK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 SHEETDSTKEEAAKMEKEYGSLKDSTKDDNSNPGGKT 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DEPKGKTEAYLEAIRKNIEWLKKHDKKGNKEDYDLSK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 MRDFINKQADAYVEKGILDKEEAEAIKRIYSSL 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 49 
                 P13521 
                 1 
                 TNEIVEEQ   YT   PQ   S   LA   T   LESVFQELGKLTGPNNQ 
                  33 
                 Secretoneurin 
                 Chromogranin/ 
                 Y9, T10, S13, T16, 
                 4 
               
               
                   
                   
                   
                   
                   
                   
                 secretogranin 
                   
                   
               
               
                   
               
               
                 51 
                 P10645 
                 1 
                 LPVNSPMNKGDTEVMKCIVEVISDTL   S   KP   S   PMPV   S   QEC 
                  76 
                 Vasostatin-1 
                 Chromogranin/ 
                 S27, S30, S36 
                 3 
               
               
                   
                   
                   
                 FETLRGDERILSILRHQNLLKELQDLALQGAKERAHQQ 
                   
                   
                 secretogranin 
                   
                   
               
               
                   
               
               
                 52 
                 P10645 
                 1 
                 LPVNSPMNKGDTEVMKCIVEVISDTL   S   KP   S   PMPV   S   QEC 
                 113 
                 Vasostatin-2 
                 Chromogranin/ 
                 S27, S30, S36, S80, E104, 
                 6 
               
               
                   
                   
                   
                 FETLRGDERILSILRHQNLLKELQDLALQGAKERAHQQ 
                   
                   
                 secretogranin 
                 S108 
                   
               
               
                   
                   
                   
                 KKH   S   GFEDELSEVLENQSSQAELKEAV   E   EPS   S   KDVME 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 54 
                 P10645 
                 1 
                 WSKMDQLAKEL   T   AE 
                  14 
                 WE-14 
                 Chromogranin/ 
                 T12 
                 1 
               
               
                   
                   
                   
                   
                   
                   
                 secretogranin 
                   
                   
               
               
                   
               
               
                 55 
                 P01042 
                 1 
                 QESQSEEIDCNDKDLFKAVDAALKKYNSQNQSNNQFV 
                 626 
                 Kininogen-1 
                 Cystatin 
                 T119, T133, T243, T255, E381, 
                 15 
               
               
                   
                   
                   
                 LYRITEATKTVGSDTFYSFKYEIKEGDCPVQSGKTWQD 
                   
                   
                   
                 T382, T383, S385, T389, S390, 
                   
               
               
                   
                   
                   
                 CEYKDAAKAATGECTATVGKRSSTKFSVATQTCQITP 
                   
                   
                   
                 T528, S586, T592, S593, T610 
                   
               
               
                   
                   
                   
                 AEGPVV   T   AQYDCLGCVHPI   S   TQSPDLEPILRHGIQYFN 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 NNTQHSSLFMLNEVKRAQRQVVAGLNFRITYSIVQTN 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 CSKENFLFLTPDCKSLWNGDTGECTDNAYIDIQLRIASF 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 SQNCDIYPGKDFVQPP   T   KICVGCPRDIP   T   NSPELEETLT 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 HTITKLNAENNATFYFKIDNVKKARVQVVAGKKYFID 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 FVARETTCSKESNEELTESCETKKLGQSLDCNAEVYVV 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 PWEKKIYPTVNCQPLGMISLMKRPPGFSPFRSSRIGEIK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 E   E   TT   V   S   PPH   TS   MAPAQDEERDSGKEQGHTRRHDWGH 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 EKQRKHNLGHGHKHERDQGHGHQRGHGLGHGHEQQ 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 HGLGHGHKFKLDDDLEHQGGHVLDHGHKHKHGHGH 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GKHKNKGKKNGKHNGWKTEHLASSSEDSTTPSAQTQ 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 EKTEGP   T   PIPSLAKPGVTVTFSDFQDSDLIATMMPPISP 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 APIQSDDDWIPDIQIDPNGLSFNPISDFPDT   TS   PKCPGRP 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 WKSVSEINP   T   TQMKESYYFDLTDGLS 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 56 
                 P01042 
                 1 
                 QESQSEEIDCNDKDLFKAVDAALKKYNSQNQSNNQFV 
                 362 
                 Kininogen-1 
                 Cystatin 
                 T119, T133, T243, T255 
                 4 
               
               
                   
                   
                   
                 LYRITEATKTVGSDTFYSFKYEIKEGDCPVQSGKTWQD 
                   
                 heavy chain 
                   
                   
                   
               
               
                   
                   
                   
                 CEYKDAAKAATGECTATVGKRSSTKFSVATQTCQITP 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 AEGPVV   T   AQYDCLGCVHPIS   T   QSPDLEPILRHGIQYFN 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 NNTQHSSLFMLNEVKRAQRQVVAGLNFRITYSIVQTN 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 CSKENFLFLTPDCKSLWNGDTGECTDNAYIDIQLRIASF 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 SQNCDIYPGKDFVQPP   T   KICVGCPRDIP   T   NSPELEETLT 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 HTITKLNAENNATFYFKIDNVKKARVQVVAGKKYFID 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 FVARETTCSKESNEELTESCETKKLGQSLDCNAEVYVV 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 PWEKKIYPTVNCQPLGMISLMK 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 57 
                 P01042 
                 1 
                 SSRIGEIKE   E   TT   VSPPH   TS   MAPAQDEERDSGKEQGHTR 
                 255 
                 Kininogen-1 light 
                 Cystatin 
                 E10, T11, T12, S14, T18, S19, 
                 11 
               
               
                   
                   
                   
                 RHDWGHEKQRKHNLGHGHKHERDQGHGHQRGHGLG 
                   
                 chain 
                   
                 T157, S215, T221, S222, T239 
                   
               
               
                   
                   
                   
                 HGHEQQHGLGHGHKFKLDDDLEHQGGHVLDHGHKH 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KHGHGHGKHKNKGKKNGKHNGWKTEHLASSSEDSTT 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 PSAQTQEKTEGP   T   PIPSLAKPGVTVTFSDFQDSDLIATM 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 MPPISPAPIQSDDDWIPDIQIDPNGLSFNPI   S   DFPDT   T     
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                     S   PKCPGRPWKSVSEINP   T   TQMKESYYFDLTDGLS 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 72 
                 P22466 
                 1 
                 GW   T   LNSAGYLLGPHAVGNHRSF   S   DKNGLTS 
                  30 
                 Galanin 
                 Galanin 
                 T3, S23 
                 2 
               
               
                   
               
               
                 73 
                 P22466 
                 1 
                 ELRPEDDMKPGSFDRSIPENNIMRTIIEFLSFLHLKEA 
                  59 
                 Galanin message- 
                 Galanin 
                 A49 
                 1 
               
               
                   
                   
                   
                 GALDRLLDLP   A   AASSEDIERS 
                   
                 associated peptide 
                   
                   
                   
               
               
                   
               
               
                 74 
                 Q9UBC7 
                 1 
                 APAHRGRGGWTLNSAGYLLGPVLHLPQMGDQDGKRE 
                  60 
                 Galanin-like 
                 Galanin 
                 T11 
                 1 
               
               
                   
                   
                   
                 TALEILDLWKAIDGLPYSHPPQPS 
                   
                 peptide 
                   
                   
                   
               
               
                   
               
               
                 76 
                 P06307 
                 1 
                 QPVPPADP   A   GSGLQRAEEAPRRQLRVSQR   T   DGESRAH 
                  95 
                 Cholecystokinin 
                 Gastrin/ 
                 A8, T30, N65 
                 3 
               
               
                   
                   
                   
                 LGALLARYIQQARKAPSGRMSIVKNLQ   N   LDPSHRISDR 
                   
                   
                 cholecystokinin 
                   
                   
               
               
                   
                   
                   
                 DYMGWMDFGRRSAEEYEYPS 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 79 
                 P06307 
                 1 
                 IVKNLQ   N   LDPSHRISDRDYMGWMDF 
                  25 
                 Cholecystokinin- 
                 Gastrin/ 
                 N7 
                 1 
               
               
                   
                   
                   
                   
                   
                 25 (By 
                 cholecystokinin 
                   
                   
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 80 
                 P06307 
                 1 
                 KAPSGRMSIVKNLQ   N   LDPSHRISDRDYMGWMDF 
                  33 
                 Cholecystokinin- 
                 Gastrin/ 
                 N15 
                 1 
               
               
                   
                   
                   
                   
                   
                 33 
                 cholecystokinin 
                   
                   
               
               
                   
               
               
                 81 
                 P06307 
                 1 
                 YIQQARKAPSGRMSIVKNLQ   N   LDPSHRISDRDYMGWM 
                  39 
                 Cholecystokinin- 
                 Gastrin/ 
                 N21 
                 1 
               
               
                   
                   
                   
                 DF 
                   
                 39 
                 cholecystokinin 
                   
                   
               
               
                   
               
               
                 83 
                 P06307 
                 1 
                 VSQR   T   DGESRAHLGALLARYIQQARKAPSGRMSIVKN 
                  58 
                 Cholecystokinin- 
                 Gastrin/ 
                 T5, N40 
                 2 
               
               
                   
                   
                   
                 LQ   N   LDPSHRISDRDYMGWMDF 
                   
                 58 
                 cholecystokinin 
                   
                   
               
               
                   
               
               
                 84 
                 P06307 
                 1 
                 VSQR   T   DGESRAHLGALLARYIQQARKAPSGRMSIVKN 
                  49 
                 Cholecystokinin- 
                 Gastrin/ 
                 T5, N40 
                 2 
               
               
                   
                   
                   
                 LQ   N   LDPSHRISD 
                   
                 58 
                 cholecystokinin 
                   
                   
               
               
                   
                   
                   
                   
                   
                 desnonopeptide 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 (By similarity) 
                   
                   
                   
               
               
                   
               
               
                 91 
                 P01350 
                 1 
                 SWKPRSQQPDAP   LG   TGANRDLELPWLEQQGPASHHRR 
                  71 
                 Gastrin-71 
                 Gastrin/ 
                 L12 or G13 (Ambiguous) 
                 1 
               
               
                   
                   
                   
                 QLGPQGPPHLVADPSKKQGPWLEEEEEAYGWMDF 
                   
                   
                 cholecystokinin 
                   
                   
               
               
                   
               
               
                 92 
                 P09681 
                 1 
                 YAEGTFI   S   DYSIAMDKIHQQDFVNWLLAQKGKKNDW 
                  42 
                 Gastric 
                 Glucagon 
                 S8 
                 1 
               
               
                   
                   
                   
                 KHNITQ 
                   
                 inhibitory 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 polypeptide 
                   
                   
                   
               
               
                   
               
               
                 93 
                 P01275 
                 1 
                 RSLQDTEEKSR   S   FSASQADPLSDPDQMNEDKRHSQGTF 
                  69 
                 Glicentin (By 
                 Glucagon 
                 S12, T39 
                 2 
               
               
                   
                   
                   
                     T   SDYSKYLDSRRAQDFVQWLMNTKRNRNNIA 
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 94 
                 P01275 
                 1 
                 RSLQDTEEKSR   S   FSASQADPLSDPDQMNED 
                  30 
                 Glicentin-related 
                 Glucagon 
                 S12 
                 1 
               
               
                   
                   
                   
                   
                   
                 polypeptide (By 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 95 
                 P01275 
                 1 
                 HSQGTF   T   SDYSKYLDSRRAQDFVQWLMNT 
                  29 
                 Glucagon 
                 Glucagon 
                 T7 
                 1 
               
               
                   
               
               
                 96 
                 P01275 
                 1 
                 HDEFERHAEG   T   F   TS   DVSSYLEGQAAKEFIAWLVKGRG 
                  37 
                 Glucagon-like 
                 Glucagon 
                 T11 or T13 or S14 (Ambiguous) 
                 1 
               
               
                   
                   
                   
                   
                   
                 peptide 1 
                   
                   
                   
               
               
                   
               
               
                 97 
                 P01275 
                 1 
                 HAEG   T   F   TS   DVSSYLEGQAAKEFIAWLVKGR 
                  31 
                 Glucagon-like 
                 Glucagon 
                 T5 or T7 or S8 (Ambiguous) 
                 1 
               
               
                   
                   
                   
                   
                   
                 peptide 1(7-36) 
                   
                   
                   
               
               
                   
               
               
                 98 
                 P01275 
                 1 
                 HAEG   T   F   TS   DVSSYLEGQAAKEFIAWLVKGRG 
                  30 
                 Glucagon-like 
                 Glucagon 
                 T5 or T7 or S8 (Ambiguous) 
                 1 
               
               
                   
                   
                   
                   
                   
                 peptide 1(7-37) 
                   
                   
                   
               
               
                   
               
               
                 99 
                 P01275 
                 1 
                 HADGSF   S   DEMNTILDNLAARDFINWLIQTKITD 
                  33 
                 Glucagon-like 
                 Glucagon 
                 S7 
                 1 
               
               
                   
                   
                   
                   
                   
                 peptide 2 (By 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 100 
                 P01282 
                 1 
                 HADGVF   TS   DFSKLLGQLSAKKYLESLM 
                  27 
                 Intestinal 
                 Glucagon 
                 T7, S8 
                 2 
               
               
                   
                   
                   
                   
                   
                 peptide PHM-27 
                   
                   
                   
               
               
                   
               
               
                 101 
                 P01282 
                 1 
                 HADGVF   TS   DFSKLLGQLSAKKYLESLMGKRVSSNISED 
                  42 
                 Intestinal 
                 Glucagon 
                 T7, S8 
                 2 
               
               
                   
                   
                   
                 PVPV 
                   
                 peptide PHV-42 
                   
                   
                   
               
               
                   
               
               
                 102 
                 P01275 
                 1 
                 HSQGTF   T   SDYSKYLDSRRAQDFVQWLMNTKRNRNNI 
                 3 7 
                 Oxyntomodulin 
                 Glucagon 
                 T7 
                 1 
               
               
                   
                   
                   
                 A 
                   
                 (By similarity) 
                   
                   
                   
               
               
                   
               
               
                 106 
                 P09683 
                 1 
                 HSDGTF   TS   EL   S   RLREGARLQRLLQGLV 
                  27 
                 Secretin 
                 Glucagon 
                 T7, S8, S11 
                 3 
               
               
                   
               
               
                 107 
                 P01286 
                 1 
                 YADAIF   T   NSYRKVLGQLSARKLLQDIMSRQQGESNQE 
                  44 
                 Somatoliberin 
                 Glucagon 
                 T7 
                 1 
               
               
                   
                   
                   
                 RGARARL 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 108 
                 P01282 
                 1 
                 HSDAVF   T   DNYTRLRKQMAVKKYLNSILN 
                  28 
                 Vasoactive 
                 Glucagon 
                 T7 
                 1 
               
               
                   
                   
                   
                   
                   
                 intestinal peptide 
                   
                   
                   
               
               
                   
               
               
                 109 
                 P01148 
                 1 
                 DAENLIDSFQEIVKEVGQLAETQRFEC   T   THQPRSPLRDL 
                  56 
                 GnRH-associated 
                 GnRH 
                 T28 
                 1 
               
               
                   
                   
                   
                 KGALESLIEEETGQKKI 
                   
                 peptide 1 
                   
                   
                   
               
               
                   
               
               
                 113 
                 P01148 
                 1 
                 QHWSYGLRPGGKRDAENLIDSFQEIVKEVGQLAETQR 
                  69 
                 Progonadoliberin- 
                 GnRH 
                 T41 
                 1 
               
               
                   
                   
                   
                 FEC   T   THQPRSPLRDLKGALESLIEEETGQKKI 
                   
                 1 
                   
                   
                   
               
               
                   
               
               
                 116 
                 P01308 
                 1 
                 FVNQHLCGSHLVEALYLVCGERGFFY   T   PKT 
                  30 
                 Insulin B chain 
                 Insulin 
                 T27 (Ambiguous) 
                 1 
               
               
                   
               
               
                 117 
                 P05019 
                 1 
                 GPETLCGAELVDALQFVCGDRGFYFNKP   T   GYGSSSRR 
                  70 
                 Insulin-like 
                 Insulin 
                 T29 
                 1 
               
               
                   
                   
                   
                 APQTGIVDECCFR S CDLRRLEMYCA T PLKPAKSA 
                   
                 growth factor I 
                   
                   
                   
               
               
                   
               
               
                 118 
                 P01344 
                 1 
                 AYRPSETLCGGELVDTLQFVCGDRGFYFSRPASRVSRR 
                  67 
                 Insulin-like 
                 Insulin 
                 S50, T62 
                 2 
               
               
                   
                   
                   
                 SRGIVEECCFR   S   CDLALLETYCA T PAKSE 
                   
                 growth factor II 
                   
                   
                   
               
               
                   
               
               
                 119 
                 P01344 
                 1 
                 YRPSETLCGGELVDTLQFVCGDRGFYFSRPASRVSRRS 
                  66 
                 Insulin-like 
                 Insulin 
                 S49, T61 
                 2 
               
               
                   
                   
                   
                 RGIVEECCFRSCDLALLETYCATPAKSE 
                   
                 growth factor II 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 Ala-25 Del 
                   
                   
                   
               
               
                   
               
               
                 120 
                 P01344 
                 1 
                 DV   ST   PP   T   VLPDNFPRYPVGKFFQYDTWKQSTQRL 
                  34 
                 Preptin 
                 Insulin 
                 S3, T4, T7 
                 3 
               
               
                   
               
               
                 130 
                 Q15726 
                 1 
                 EPLEKVASVGNSRPTGQQLESLGLLAPGEQSLPCTERK 
                 119 
                 Metastasis- 
                 KISS1 
                 A69 
                 1 
               
               
                   
                   
                   
                 PAATARLSRRGTSLSPPPESSGSPQQPGLS   A   PHSRQIPA 
                   
                 suppressor KiSS-1 
                   
                   
                   
               
               
                   
                   
                   
                 PQGAVLVQREKDLPNYNWNSFGLRFGKREAAPGNHGR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 SAGRG 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 131 
                 Q15726 
                 1 
                 GTSLSPPPESSGSPQQPGLS   A   PHSRQIPAPQGAVLVQRE 
                  54 
                 Metastin 
                 KISS1 
                 A21 
                 1 
               
               
                   
                   
                   
                 KDLPNYNWNSFGLRF 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 135 
                 P20382 
                 1 
                 GSVAFPAENGVQN   T   E   ST   QE 
                  19 
                 Neuropeptide- 
                 Melanin- 
                 T14, T16, T17 
                 3 
               
               
                   
                   
                   
                   
                   
                 glycine-glutamic 
                 concentrating 
                   
                   
               
               
                   
                   
                   
                   
                   
                 acid (Potential) 
                 hormone 
                   
                   
               
               
                   
               
               
                 136 
                 P20382 
                 1 
                 ILLSASKSIRNLDDDMVFNTFRLGKGFQKEDTAEK   S   VI 
                 144 
                 Pro-MCH 
                 Melanin- 
                 S36, S41, N72, T102, T104, 
                 6 
               
               
                   
                   
                   
                 AP   S   LEQYKNDESSFMNEEENKVSKNTGSKHNFL   N   HGL 
                   
                   
                 concentrating 
                 T105 
                   
               
               
                   
                   
                   
                 PLNLAIKPYLALKGSVAFPAENGVQN   T   ES   T   QEKREIGD 
                   
                   
                 hormone 
                   
                   
               
               
                   
                   
                   
                 EENSAKFPIGRRDFDMLRCMLGRVYRPCWQV 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 143 
                 Q15848 
                 1 
                 ETT   T   QGPGVLLPLPKGACTGWMAGIPGHPGHNGAPGR 
                 226 
                 Adiponectin 
                 NA 
                 T4 
                 1 
               
               
                   
                   
                   
                 DGRDGTPGEKGEKGDPGLIGPKGDIGETGVPGAEGPR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GFPGIQGRKGEPGEGAYVYRSAFSVGLETYVTIPNMPI 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 RFTKIFYNQQNHYDGSTGKFHCNIPGLYYFAYHITVYM 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KDVKVSLFKKDKAMLFTYDQYQENNVDQASGSVLLH 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LEVGDQVWLQVYGEGERNGLYADNDNDSTFTGFLLY 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 HDTN 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 144 
                 O00253 
                 1 
                 AQMGLAPMEGIRRPDQALLPELPGLGLRAPLKKT   T   AE 
                 111 
                 Agouti-related 
                 NA 
                 T35 
                 1 
               
               
                   
                   
                   
                 QAEEDLLQEAQALAEVLDLQDREPRSSRRCVRLHESC 
                   
                 protein 
                   
                   
                   
               
               
                   
                   
                   
                 LGQQVPCCDPCATCYCRFFNAFCYCRKLGTAMNPCSR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 T 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 147 
                 P01160 
                 1 
                 SLRRSSCFGGRMDRIGAQ   S   GLGCN   S   FRY 
                  28 
                 Atrial 
                 Natriuretic peptide 
                 S19, S25 
                 2 
               
               
                   
                   
                   
                   
                   
                 natriuretic 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 factor 
                   
                   
                   
               
               
                   
               
               
                 163 
                 P16860 
                 1 
                 SPKMVQGSGCFGRKMDRISSS S GLGCKVLRRH 
                  32 
                 Brain natriuretic 
                 Natriuretic peptide 
                 S22 
                 1 
               
               
                   
                   
                   
                   
                   
                 peptide 32 
                   
                   
                   
               
               
                   
               
               
                 164 
                 P01160 
                 1 
                 NPM   Y   N   A   V   S   NADLMDFKNLLDHLEEKMPLED 
                  30 
                 Cardiodilatin- 
                 Natriuretic peptide 
                 Y4, A6, S8 (Ambiguous) 
                 1 
               
               
                   
                   
                   
                   
                   
                 related peptide 
                   
                   
                   
               
               
                   
               
               
                 167 
                 P23582 
                 1 
                 DLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKG 
                  53 
                 CNP-53 
                 Natriuretic peptide 
                 S47 
                 1 
               
               
                   
                   
                   
                 CFGLKLDRIGSM S GLGC 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 168 
                 P16860 
                 1 
                 HPLGSPGSASDLETSGLQEQRNHLQGKLSELQVEQTSL 
                 108 
                 Natriuretic 
                 Natriuretic peptide 
                 T48, E59 
                 2 
               
               
                   
                   
                   
                 EPLQESPRP   T   GVWKSREVAT   E   GIRGHRKMVLYTLRAP 
                   
                 peptides B 
                   
                   
                   
               
               
                   
                   
                   
                 RSPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 170 
                 O95156 
                 1 
                 KEVVHA   T   EGLDWEDKDAPGTLVGNVVHSRIISPLRLF 
                 242 
                 Neurexophilin-2 
                 Neurexophilin 
                 T7 
                 1 
               
               
                   
                   
                   
                 VKQSPVPKPGPMAYADSMENFWDWLANITEIQEPLAR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 TKRRPIVKTGKFKKMFGWGDFHSNIKTVKLNLLITGKI 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 VDHGNGTFSVYFRHNSTGLGNVSVSLVPPSKVVEFEVS 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 PQSTLETKESKSFNCRIEYEKTDRAKKTALCNFDPSKIC 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 YQEQTQSHVSWLCSKPFKVICIYIAFYSVDYKLVQKVC 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 PDYNYHSETPYLSSG 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 184 
                 P01303 
                 1 
                     SS   PETLISDLLMRES   T   ENVPR   T   RLEDPAMW 
                  30 
                 C-flanking 
                 NPY 
                 S1, S2, T16, T21, A28 
                 3 
               
               
                   
                   
                   
                   
                   
                 peptide of NPY 
                   
                   
                   
               
               
                   
               
               
                 185 
                 P01303 
                 1 
                 YP   S   KPDNPGEDAPAEDMARYYSALRH   Y   INLI   T   RQRY 
                  36 
                 Neuropeptide Y 
                 NPY 
                 S3, T32 
                 2 
               
               
                   
               
               
                 186 
                 P01298 
                 1 
                 APLEPVYPGDNATPEQMAQYAADLRRYINML   T   RPRY 
                  36 
                 Pancreatic 
                 NPY 
                 T32 
                 1 
               
               
                   
                   
                   
                   
                   
                 hormone 
                   
                   
                   
               
               
                   
               
               
                 188 
                 P10082 
                 1 
                 YPIKPEAPREDASPEELNRYYASLRHYLNLV   T   RQRY 
                  36 
                 Peptide YY 
                 NPY 
                 T32 
                 1 
               
               
                   
               
               
                 189 
                 P10082 
                 1 
                 IKPEAPREDASPEELNRYYASLRHYLNLV   T   RQRY 
                  34 
                 Peptide YY(3-36) 
                 NPY 
                 T30 
                 1 
               
               
                   
               
               
                 190 
                 P80303 
                 1 
                 VPIDIDK   T   KVQN   I   HPVE   S   AKIEPPD   T   GL   YY   DEYLKQVID 
                  82 
                 Nesfatin-1 
                 Nucleobindin 
                 T8, I13, S18, T26, Y29, Y30, 
                 8 
               
               
                   
                   
                   
                 VLE   T   DKHFREKLQKADIEEIKSGRLSKELDLV   S   HHVRT 
                   
                   
                   
                 T43, S72 
                   
               
               
                   
                   
                   
                 KLDEL 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 191 
                 Q02818 
                 1 
                 VPLERGA   P   NKEE   T   PA   T   E   S   PD   T   GL   Y   YHRYLQEVIDVLET 
                 435 
                 Nucleobindin-1 
                 Nucleobindin 
                 P8, T13, T16, S18, T21, Y24, 
                 22 
               
               
                   
                   
                   
                 DGHFREKLQAANAEDIKSGKLSRELDFV   S   HHVRTKLD 
                   
                   
                   
                 S67, T122, T136, S198, S294, 
                   
               
               
                   
                   
                   
                 ELKRQEVSRLRMLLKAKMDAEQDPNVQVDHLNLLKQ 
                   
                   
                   
                 S295, T309, H313, S343, T346, 
                   
               
               
                   
                   
                   
                 FEHLDPQNQH   T   FEARDLELLIQTA   T   RDLAQYDAAHHE 
                   
                   
                   
                 S352, Q381, A388, T400, L1126, 
                   
               
               
                   
                   
                   
                 EFKRYEMLKEHERRRYLESLGEEQRKEAERKLEEQQR 
                   
                   
                   
                 x433 (deleterious mutation) 
                   
               
               
                   
                   
                   
                 RHREHPKVNVPG   S   QAQLKEVWEELDGLDPNRFNPKTF 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 FILHDINSDGVLDEQELEALFTKELEKVYDPKNEEDDM 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 REMEEERLRMREHVMKNVDTNQDRLVTLEEFLA   ST   Q 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 RKEFGDTGEGWE   T   VEM   H   PAYTEEELRRFEEELAAREA 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 ELNAKAQRL   S   QE   T   EALGR   S   QGRLEAQKRELQQAVLH 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 MEQRKQQQQQQ   Q   GHKAPA   A   HPEGQLKFHPD   T   DDVPV 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 PAPAGDQKEVDTSEKKLLER   L   PEVEVPQHL 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 192 
                 P80303 
                 1 
                 VPIDIDK   T   KVQN   I   HPVE   S   AKIEPPD   T   GL   Y   YDEYLKQVID 
                 396 
                 Nucleobindin-2 
                 Nucleobindin 
                 T8, I13, S18, T26, Y29, Y30, 
                 16 
               
               
                   
                   
                   
                 VLE   T   DKHFREKLQKADIEEIKSGRLSKELDLV   S   HHVRT 
                   
                   
                   
                 T43, S72, S128, T139, T148, 
                   
               
               
                   
                   
                   
                 KLDELKRQEVGRLRMLIKAKLDSLQDIGMDHQALLKQ 
                   
                   
                   
                 A331, Y365, P382, S384, L390 
                   
               
               
                   
                   
                   
                 FDHLNHLNPDKFE   S   TDLDMLIKAA   T   SDLEHYDK   T   RHE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 EFKKYEMMKEHERREYLKTLNEEKRKEEESKFEEMKK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KHENHPKVNHPGSKDQLKEVWEETDGLDPNDFDPKTF 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 FKLHDVNSDGFLDEQELEALFTKELEKVYDPKNEEDD 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 MVEMEEERLRMREHVMSEVDTNKDRLVTLEEFLKAT 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 EKKEFLEPDSWETLDQQQFFTEEELKEYENII   A   LQENEL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KKKADELQKQKEELQRQHDQLEAQKLE   Y   HQVIQQME 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 QKKLQQGI   P   P   S   GPAGE   L   KFEPHI 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 204 
                 Q13519 
                 1 
                 MPRVRSLFQEQEE   P   EPGMEEAGEMEQKQLQ 
                  30 
                 Neuropeptide 1 
                 Opioid 
                 P14 
                 1 
               
               
                   
                   
                   
                   
                   
                 (Probable) 
                   
                   
                   
               
               
                   
               
               
                 215 
                 P12272 
                 1 
                 AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTAEIRA   T     
                 141 
                 Parathyroid 
                 Parathyroid hormone 
                 T39 
                 1 
               
               
                   
                   
                   
                 SEVSPNSKPSPNTKNHPVRFGSDDEGRYLTQETNKVET 
                   
                   
                 hormone-related 
                   
                   
               
               
                   
                   
                   
                 YKEQPLKTPGKKKKGKPGKRKEQEKKKRRTRSAWLD 
                   
                   
                 protein 
                   
                   
               
               
                   
                   
                   
                 SGVTGSGLEGDHLSDTSTTSLELDSRRH 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 217 
                 P12272 
                 1 
                 A   T   SEVSPNSKPSPNTKNHPVRFGSDDEGRYLTQETNKV 
                  57 
                 PTHrP[38-94] 
                 Parathyroid hormone 
                 T2 
                 1 
               
               
                   
                   
                   
                 ETYKEQPLKTPGKKKKGKP 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 219 
                 P01189 
                 1 
                 YGGFMTSEK   S   Q   T   PLV   T   LFKNAIIKNAYKKGE 
                  31 
                 Beta-endorphin 
                 POMC 
                 S10, T12, T16 
                 3 
               
               
                   
               
               
                 222 
                 P01189 
                 1 
                 ELTGQRLREGDGPDGPADDGAGAQADLEHSLLVAAE 
                  89 
                 Lipotropin beta 
                 POMC 
                 S68, T70, T74 
                 3 
               
               
                   
                   
                   
                 KKDEGPYRMEHFRWGSPPKDKRYGGFMTSEK   S   Q   T   PL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 V   T   LFKNAIIKNAYKKGE 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 227 
                 P01189 
                 1 
                 WCLESSQCQDLTTESNLLECIRACKPDLSAETPMFPGN 
                  76 
                 NPP 
                 POMC 
                 T45 
                 1 
               
               
                   
                   
                   
                 GDEQPL   T   ENPRKYVMGHFRWDRFGRRNSSSSGSSGAG 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 Q 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 229 
                 Q9UHG2 
                 1 
                 LE T     PA   PQVPARRLLPP 
                  16 
                 Big LEN (By 
                 ProSAAS 
                 T3, P4, A5 
                 2 
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 230 
                 Q9UHG2 
                 1 
                 AADHDVGSELPPEGVLGALLRVKRLE T     PA   PQVPARRL 
                  40 
                 Big PEN-LEN 
                 ProSAAS 
                 T27, P28, A29 
                 2 
               
               
                   
                   
                   
                 LPP 
                   
                 (By similarity) 
                   
                   
                   
               
               
                   
               
               
                 231 
                 Q9UHG2 
                 1 
                 ARPVKEPR   G   LSAA   S   PPLAE   T   GA   PRRF 
                  26 
                 Big SAAS (By 
                 ProSAAS 
                 G9, S14, T20, G21, A22 
                 5 
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 233 
                 Q9UHG2 
                 1 
                 LET   PA   PQVPA 
                  10 
                 Little LEN (By 
                 ProSAAS 
                 T3, P4, A5 
                 2 
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 234 
                 Q9UHG2 
                 1 
                     G   LSAA   S   PPLAE   T   GA   PRRF 
                  18 
                 Little SAAS (By 
                 ProSAAS 
                 G1, S6, T12, G13, A14 
                 5 
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 236 
                 Q9UHG2 
                 1 
                 ARPVKEPR   G   LSAA   S   PPLAE   T   GA   PRRFRRSVPRGEAAGA 
                 227 
                 ProSAAS 
                 ProSAAS 
                 13 
                   
               
               
                   
                   
                   
                 VQELARALAHLLEAERQERARAEAQEAEDQQARVLA 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 QLLRVWG   A   PR   N   S   DPALGLDDDPDAPAAQLARALLRAR 
                   
                   
                   
                 G9, S14, T20, G21, A22, A82, 
                   
               
               
                   
                   
                   
                 LDPAALAAQLVPAPVPAAALRPRPPVYDDGP   A   GPDAE 
                   
                   
                   
                 N85, S86, A143, S173, A174, 
                   
               
               
                   
                   
                   
                 EAGDETPDVDPELLRYLLGRILAG   S   A   DSEGVAAPRRLR 
                   
                   
                   
                 T214, P215, A216 
                   
               
               
                   
                   
                   
                 RAADHDVGSELPPEGVLGALLRVKRLE T     PA   PQVPARR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LLPP 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 252 
                 P01019 
                 1 
                 DRVYIHPFHLVIHNESTCEQLAKANAGKPKDPTFIPAPI 
                 452 
                 Angiotensinogen 
                 Serpin 
                 T407 or S409 or T410 or T422 
                 1 
               
               
                   
                   
                   
                 QAKTSPVDEKALQDQLVLVAAKLDTEDKLRAAMVG 
                   
                   
                   
                 (Ambiguous) 
                   
               
               
                   
                   
                   
                 MLANFLGFRIYGMHSELWGVVHGATVLSPTAVFGTLA 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 SLYLGALDHTADRLQAILGVPWKDKNCTSRLDAHKVL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 SALQAVQGLLVAQGRADSQAQLLLSTVVGVFTAPGLH 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LKQPFVQGLALYTPVVLPRSLDFTELDVAAEKIDRFMQ 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 AVTGWKTGCSLMGASVDSTLAFNTYVHFQGKMKGFS 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LLAEPQEFWVDNSTSVSVPMLSGMGTFQHWSDIQDNF 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 SVTQVPFTESACLLLIQPHYASDLDKVEGLTFQQNSLN 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 WMKKLSPRTIHLTMPQLVLQGSYDLQDLLAQAELPAI 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LHTELNLQKLSNDRIRVGEVLNSIFFELEADEREP   T   ES   T     
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 QQLNKPEVLEV   T   LNRPFLFAVYDQSATALHFLGRVAN 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 PLSTA 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 260 
                 P61278 
                 1 
                     S   AN   S   NPAMAPRERKAGCKNFFWKTFTSC 
                  28 
                 Somatostatin-28 
                 Somastostatin 
                 S1 or S4 (Ambiguous) 
                 1 
               
               
                   
               
               
                 262 
                 P20366 
                 1 
                     A   LN   S   VAYERSAMQNYE 
                  15 
                 C-terminal- 
                 Tachykinin 
                 A1, S4 
                 2 
               
               
                   
                   
                   
                   
                   
                 flanking peptide 
                   
                   
                   
               
               
                   
               
               
                 267 
                 P20396 
                 1 
                 QPEAAQQEAVTAAEHPGLDDFLRQVERLLFLRENIQRL 
                 218 
                 Pro-thyrotropin- 
                 TRH 
                 I50 
                 1 
               
               
                   
                   
                   
                 QGDQGEHSASQ   I   FQSDWLSKRQHPGKREEEEEEGVEE 
                   
                 releasing hormone 
                   
                   
                   
               
               
                   
                   
                   
                 EEEEEGGAVGPHKRQHPGRREDEASWSVDVTQHKRQ 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 HPGRRSPWLAYAVPKRQHPGRRLADPKAQRSWEEEEE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 EEEREEDLMPEKRQHPGKRALGGPCGPQGAYGQAGLL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LGLLDDLSRSQGAEEKRQHPGRRAAWVREPLEE 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 272 
                 P01185 
                 1 
                 ASDRSNATQLDGPAGALLLRLVQLAG   A   PEPFEPAQPDA 
                  39 
                 Copeptin 
                 Vasopressin/oxytocin 
                 A27 
                 1 
               
               
                   
                   
                   
                 Y 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 279 
                 O15240 
                 1 
                 AP   P   GRPEAQPPPL   S   SEHKEPVAGDAVPGPKDGSAPEVR 
                 591 
                 Neurosecretory 
                 VGF 
                 P1, S12, P202, S205, 
                 5 
               
               
                   
                   
                   
                 GARNSEPQDEGELFQGVDPRALAAVLLQALDRPASPP 
                   
                 protein VGF 
                 T477 
                   
                   
               
               
                   
                   
                   
                 APSGSQQGPEEEAAEALLTETVRSQTHSLPAPESPEPAA 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 PPRPQTPENGPEASDPSEELEALASLLQELRDFSPSSAK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 RQQETAAAETETRTHTLTRVNLESPGPERVWRASWGE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 FQARVPERAPLPP   P   APSQFQARMPDSGPLPETHKFGEG 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 VSSPKTHLGEALAPLSKAYQGVAAPFPKARRPESALLG 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GSEAGERLLQQGLAQVEAGRRQAEATRQAAAQEERL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 ADLASDLLLQYLLQGGARQRGLGGRGLQEAAEERESA 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 REEEEAEQERRGGEERVGEEDEEAAEAEAEAEEAERA 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 RQNALLFAEEEDGEAGAEDKRSQEETPGHRRKEAEGT 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 EEGGEEEDDEEMDPQTIDSLIELSTKLHLPADDVVSIIEE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 VEEKRKRKKNAPPEPVPPPRAAPAP   T   HVRSPQPPPPAP 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 APARDELPDWNEVLPPWDREEDEVYPPGPYHPFPNYIR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 PRTLQPPSALRRRHYHHALPPSRHYPGREAQARRAQEE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 AEAEERRLQEQEELENYIEHVLLRRP 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
               
               
               
               
               
               
             
               
                 TABLE 6E 
               
               
                   
               
               
                   
                   
                   
                   
                   
                   
                   
                 *Site position (Bold: 
                   
               
               
                   
                   
                   
                   
                   
                   
                   
                 identified or conserved 
                   
               
               
                 SEQ 
                   
                 Pep- 
                   
                 Pep- 
                   
                 Peptide 
                 in human, Italic; 
                 No. 
               
               
                 ID 
                 Entry_ 
                 tide 
                   
                 tide 
                 Peptide 
                 Hormone 
                 identified in non-human  
                 of 
               
               
                 NO: 
                 Human 
                 Start 
                 Peptide_Sequence 
                 end 
                 Name 
                 Family 
                 and not conserved) 
                 sites 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
            
               
                 1 
                 P05408 
                 1 
                     S   VPHFSDEDKDPE 
                 13 
                 C-terminal 
                 7B2 
                 S1 
                 1 
               
               
                   
                   
                   
                   
                   
                 peptide (By 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 2 
                 P05408 
                 1 
                 Y   S   PR   T   PDRV   S   EADIQRLLHGVMEQLGIARPRVEYPA 
                 186 
                 Neuroendocrine 
                 7B2 
                 S2, T5, S10, T108, S174 
                 5 
               
               
                   
                   
                   
                 HQAMNLVGPQSIEGGAHEGLQHLGPFGNIPNIVAEL 
                   
                 protein 7B2 
                   
                   
                   
               
               
                   
                   
                   
                 TGDNIPKDFSEDQGYPDPPNPCPVGKTADDGCLEN   T     
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 PDTAEFSREFQLHQHLFDPEHDYPGLGKWNKKLLY 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 EKMKGGERRKRRSVNPYLQGQRLDNVVAKK   S   VPH 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 FSDEDKDPE 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 3 
                 P05408 
                 1 
                 Y   S   PR   T   PDRV   S   EADIQRLLHGVMEQLGIARPRVEYPA 
                 150 
                 N-terminal 
                 7B2 
                 S2, T5, S10, T108 
                 4 
               
               
                   
                   
                   
                 HQAMNLVGPQSIEGGAHEGLQHLGPFGNIPNIVAEL 
                   
                 peptide (By 
                   
                   
                   
               
               
                   
                   
                   
                 TGDNIPKDFSEDQGYPDPPNPCPVGKTADDGCLEN   T     
                   
                 similarity) 
                   
                   
                   
               
               
                   
                   
                   
                 PDTAEFSREFQLHQHLFDPEHDYPGLGKWNKKLLY 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 EKMKGGE 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 4 
                 Q8N6N7 
                 1 
                 MALQADFDRAAEDVRKLKARPDDGELKELYGLYK 
                 88 
                 Acyl-CoA- 
                 ACBP 
                   
                   
               
               
                   
                   
                   
                 QAIVGDINIACPGMLDLKGKAKWEAWNLKKGLSTE 
                   
                 binding domain- 
                   
                   
                   
               
               
                   
                   
                   
                 DATSAYISKAKELIEKYGI 
                   
                 containing 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 protein 7 
                   
                   
                   
               
               
                   
               
               
                 5 
                 P07108 
                 1 
                 SQAEFEKAAEEVRHLKTKPSDEEMLFIYGHYKQA   T     
                 86 
                 Acyl-CoA- 
                 ACBP 
                 T35 or T41 (ambiguous) 
                 1 
               
               
                   
                   
                   
                 VGDIN   T   ERPGMLDFTGKAKWDAWNELKGTSKEDA 
                   
                 binding protein 
                   
                   
                   
               
               
                   
                   
                   
                 MKAYINKVEELKKKYGI 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 6 
                 P35318 
                 1 
                 YRQSMNNFQGLRSFGCRFGTC   T   VQKLAHQI   Y   QF   T   D 
                 52 
                 Adrenomedullin 
                 Adrenomedullin 
                 T22, Y31, T34 
                 3 
               
               
                   
                   
                   
                 KDKDNVAPRSKISPQGY 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 7 
                 Q7Z4H4 
                 1 
                 TQAQLLRVGCVLGTCQVQNLSHRLWQLMGPAGRQ 
                 47 
                 Adrenomedullin- 
                 Adrenomedullin 
                   
                   
               
               
                   
                   
                   
                 DSAPVDPSSPHSY 
                   
                 2 (By similarity) 
                   
                   
                   
               
               
                   
               
               
                 8 
                 Q7Z4H4 
                 1 
                 VGCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVDP 
                 40 
                 Intermedin-short 
                 Adrenomedullin 
                   
                   
               
               
                   
                   
                   
                 SSPHSY 
                   
                 (Potential) 
                   
                   
                   
               
               
                   
               
               
                 9 
                 P35318 
                 1 
                 ARLDVASEFRKKWNKWALSR 
                 20 
                 Proadreno- 
                 Adrenomedullin 
                   
                   
               
               
                   
                   
                   
                   
                   
                 medullin N-20 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 terminal peptide 
                   
                   
                   
               
               
                   
               
               
                 10 
                 Q9ULZ1 
                 1 
                 QRPRLSHKGPMPF 
                 13 
                 Apelin-13 (By 
                 Apelin 
                   
                   
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 11 
                 Q9ULZ1 
                 1 
                 NGPGPWQGGRRKFRRQRPRLSHKGPMPF 
                 28 
                 Apelin-28 (By 
                 Apelin 
                   
                   
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 12 
                 Q9ULZ1 
                 1 
                 GSRNGPGPWQGGRRKFRRQRPRLSHKGPMPF 
                 31 
                 Apelin-31 (By 
                 Apelin 
                   
                   
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 13 
                 Q9ULZ1 
                 1 
                 LVQPRGSRNGPGPWQGGRRKFRRQRPRLSHKGPMP 
                 36 
                 Apelin-36 (By 
                 Apelin 
                   
                   
               
               
                   
                   
                   
                 F 
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 14 
                 P07492 
                 1 
                 VPL   P   AGGG   T   VLTKMYPRGNHWAVGHLM 
                 27 
                 Gastrin-releasing 
                 Bombesin/ 
                 P4, T9 
                 2 
               
               
                   
                   
                   
                   
                   
                 peptide 
                 neuromedin- 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 B/ranatensin 
                   
                   
               
               
                   
               
               
                 15 
                 P08949 
                 1 
                 GNLWA   T   GHFM 
                 10 
                 Neuromedin-B 
                 Bombesin/ 
                 T6 
                 1 
               
               
                   
                   
                   
                   
                   
                   
                 neuromedin- 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 B/ranatensin 
                   
                   
               
               
                   
               
               
                 16 
                 P08949 
                 1 
                 APLSWDLPEPRSRASKIRVHSRGNLWA   T   GHFM 
                 32 
                 Neuromedin-B- 
                 Bombesin/ 
                 T28 
                 1 
               
               
                   
                   
                   
                   
                   
                 32 
                 neuromedin- 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 B/ranatensin 
                   
                   
               
               
                   
               
               
                 17 
                 P07492 
                 1 
                 GNHWAVGHLM 
                 10 
                 Neuromedin-C 
                 Bombesin/ 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 neuromedin- 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 B/ranatensin 
                   
                   
               
               
                   
               
               
                 18 
                 P01042 
                 1 
                 RPPGFSPFR 
                 9 
                 Bradykinin 
                 Bradykinin 
                   
                   
               
               
                   
               
               
                 19 
                 P01042 
                 1 
                 KRPPGFSPFR 
                 10 
                 Lysyl-bradykinin 
                 Bradykinin 
                   
                   
               
               
                   
               
               
                 20 
                 P01042 
                 1 
                 ISLMKRPPGFSPFR 
                 14 
                 T-kinin 
                 Bradykinin 
                   
                   
               
               
                   
               
               
                 21 
                 P01258 
                 1 
                 CGNLS   T   CMLG   T   Y   T   QDFNKFH   T   FPQTAIGVGAP 
                 32 
                 Calcitonin 
                 Calcitonin 
                 T6, T11, T13, T21, T25 
                 5 
               
               
                   
               
               
                 22 
                 P06881 
                 1 
                 ACDTATCV   T   HRLAGLL   S   RSGGVVKNNFVPTNVGSK 
                 37 
                 Calcitonin gene- 
                 Calcitonin 
                 T9, S17 
                 2 
               
               
                   
                   
                   
                 AF 
                   
                 related peptide 1 
                   
                   
                   
               
               
                   
               
               
                 23 
                 P10092 
                 1 
                 ACNTATCV   T   HRLAGLL   S   RSGGMVK   S   NFVP   T   NVG   S   K 
                 37 
                 Calcitonin gene- 
                 Calcitonin 
                 T9, S17, S25, T30, S34 
                 5 
               
               
                   
                   
                   
                 AF 
                   
                 related peptide 2 
                   
                   
                   
               
               
                   
               
               
                 24 
                 P10997 
                 1 
                 KCNTA   T   CA   T   QRLANFLVHSSNNFGAILSS   T   NVGSNT 
                 37 
                 Islet amyloid 
                 Calcitonin 
                 T5, T9, T30 
                 3 
               
               
                   
                   
                   
                 Y 
                   
                 polypeptide 
                   
                   
                   
               
               
                   
               
               
                 25 
                 P01258 
                 1 
                 DMSSDLERDHRPHV   S   MPQNAN 
                 21 
                 Katacalcin 
                 Calcitonin 
                 S15 
                 1 
               
               
                   
               
               
                 26 
                 Q16568 
                 1 
                 QEDAELQPRALDIYSAVDDASHEKELIEALQEVLKK 
                 39 
                 CART(1-39) 
                 CART 
                   
                   
               
               
                   
                   
                   
                 LKS 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 27 
                 Q16568 
                 1 
                 VPIYEKKYGQVPMCDAGEQCAVRKGARIGKLCDCP 
                 48 
                 CART(42-89) 
                 CART 
                   
                   
               
               
                   
                   
                   
                 RGTSCNSFLLKCL 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 28 
                 Q16568 
                 1 
                 QEDAELQPRALDIYSAVDDASHEKELIEALQEVLKK 
                 89 
                 Cocaine- and 
                 CART 
                   
                   
               
               
                   
                   
                   
                 LKSKRVPIYEKKYGQVPMCDAGEQCAVRKGARIGK 
                   
                 amphetamine- 
                   
                   
                   
               
               
                   
                   
                   
                 LCDCPRGTSCNSFLLKCL 
                   
                 regulated 
                   
                   
                   
               
               
                   
               
               
                 29 
                 P23435 
                 1 
                 GSAKVAFSAIRSTNH 
                 15 
                 [des-Ser1]- 
                 Cerebellins 
                   
                   
               
               
                   
                   
                   
                   
                   
                 cerebellin 
                   
                   
                   
               
               
                   
               
               
                 30 
                 P23435 
                 1 
                 SGSAKVAFSAIRSTNH 
                 16 
                 Cerebellin 
                 Cerebellins 
                   
                   
               
               
                   
               
               
                 31 
                 P23435 
                 1 
                 QNETEPIVLEGKCLVVCDSNPTSDPTGTALGISVRSG 
                 172 
                 Cerebellin-1 
                 Cerebellins 
                   
                   
               
               
                   
                   
                   
                 SAKVAFSAIRSTNHEPSEMSNRTMIIYFDQVLVNIGN 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 NFDSERSTFIAPRKGIYSFNFHVVKVYNRQTIQVSLM 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LNGWPVISAFAGDQDVTREAASNGVLIQMEKGDRA 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 YLKLERGNLMGGWKYSTFSGFLVFPL 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 32 
                 Q8IUK8 
                 1 
                 QNDTEPIVLEGKCLVVCDSSPSADGAVTSSLGISVRS 
                 173 
                 Cerebellin-2 
                 Cerebellins 
                   
                   
               
               
                   
                   
                   
                 GSAKVAFSATRSTNHEPSEMSNRTMTIYFDQVLVNI 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GNHFDLASSIFVAPRKGIYSFSFHVVKVYNRQTIQVS 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LMQNGYPVISAFAGDQDVTREAASNGVLLLMERED 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KVHLKLERGNLMGGWKYSTFSGFLVFPL 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 33 
                 Q6UW01 
                 1 
                 QEGSEPVLLEGECLVVCEPGRAAAGGPGGAALGEA 
                 173 
                 Cerebellin-3 
                 Cerebellins 
                   
                   
               
               
                   
                   
                   
                 PPGRVAFAAVRSHHHEPAGETGNGTSGAIYFDQVL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 VNEGGGFDRASGSFVAPVRGVYSFRFHVVKVYNRQ 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 TVQVSLMLNTWPVISAFANDPDVTREAATSSVLLPL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DPGDRVSLRLRRGNLLGGWKYSSFSGFLIFPL 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 34 
                 Q9NTU7 
                 1 
                 QNDTEPIVLEGKCLVVCDSNPATDSKGSSSSPLGISV 
                 174 
                 Cerebellin-4 
                 Cerebellins 
                   
                   
               
               
                   
                   
                   
                 RAANSKVAFSAVRSTNHEPSEMSNKTRIIYFDQILVN 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 VGNFFTLESVFVAPRKGIYSFSFHVIKVYQSQTIQVN 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LMLNGKPVISAFAGDKDVTREAATNGVLLYLDKED 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KVYLKLEKGNLVGGWQYSTFSGFLVFPL 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 35 
                 P10645 
                 1 
                 AYGFRGPGPQL 
                 11 
                 AL-11 
                 Chromogranin/ 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 secretogranin 
                   
                   
               
               
                   
               
               
                 36 
                 P05060 
                 1 
                 SAEFPDFYDSEEPV   S   THQEAENEKDRADQTVLTEDE 
                 57 
                 CCB peptide 
                 Chromogranin/ 
                 S15 
                 1 
               
               
                   
                   
                   
                 KKELENLAAMDLELQKIAEKF 
                   
                   
                 secretogranin 
                   
                   
               
               
                   
               
               
                 37 
                 P10645 
                 1 
                 LPVNSPMNKGDTEVMKCIVEVISDTL   S   KP   S   PMPV   S   Q 
                 439 
                 Chromogranin-A 
                 Chromogranin/ 
                 S27, S30, S36, S80, E104, 
                 39 
               
               
                   
                   
                   
                 ECFETLRGDERILSILRHQNLLKELQDLALQGAKER 
                   
                   
                 secretogranin 
                 S108, A127, T128, A135, L136, 
                   
               
               
                   
                   
                   
                 AHQQKKH   S   GFEDELSEVLENQSSQAELKEAV   E   EPS   S     
                   
                   
                   
                 S143, A151, N164, T165, P167, 
                   
               
               
                   
                   
                   
                 KDVMEKREDSKEAEKSGE   A   T   DGARPQ   AL   PEPMQE   S     
                   
                   
                   
                 A169, S170, S173, E182, L188, 
                   
               
               
                   
                   
                   
                 KAEGNNQ   A   PGEEEEEEEEAT   N   T   H   P   P   A   S   LP   S   QKYPGP 
                   
                   
                   
                 S189, V193, S200, T233, L236, 
                   
               
               
                   
                   
                   
                 QA   E   GDSEG   L   S   QGLVDREKGL   S   AEPGWQAKREEEEE 
                   
                   
                   
                 N237, P238, S241, Y244, P265, 
                   
               
               
                   
                   
                   
                 EEEEAEAGEEAVPEEEGP   T   VV   LNP   HP   S   LG   Y   KEIRKG 
                   
                   
                   
                 E268, P273, S282, M291, V294, 
                   
               
               
                   
                   
                   
                 ESRSEALAVDGAGK   P   GA   E   EAQD   P   EGKGEQEH   S   QQK 
                   
                   
                   
                 T335, A360, S380, G395 
                   
               
               
                   
                   
                   
                 EEEEE   M   AV   V   PQGLFRGGKSGELEQEEERLSKEWEDS 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KRWSKMDQLAKEL   T   AEKRLEGQEEEEDNRDSSMK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LSFR   A   RAYGFRGPGPQLRRGWRPS   S   REDSLEAGLPL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 QVR   G   YPEEKKEEEGSANRRPEDQELESLSAIEAELE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KVAHQLQALRRG 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 38 
                 P10645 
                 1 
                 EDSKEAEKSGE   A   T   DGARPQ   AL   PEPMQE   S   KAEGNNQ 
                 92 
                 EA-92 
                 Chromogranin/ 
                 A12, T13, A20, L21, S28, A36, 
                 17 
               
               
                   
                   
                   
                     A   PGEEEEEEEEAT   N   T   H   P   P   A   S   LP   S   QKYPGPQA   E   GDSEG 
                   
                   
                 secretogranin 
                 N49, T50, P52, A54, S55, S58, 
                   
               
               
                   
                   
                   
                     L   S   QGL   V   DREKGL   S   AEPGWQA 
                   
                   
                   
                 E67, L73, S74, V78, S85 
                   
               
               
                   
               
               
                 39 
                 P10645 
                 1 
                 EEEGSANRRPEDQELE   S   L   S   AIEAELEKVAHQLQALR 
                 37 
                 ER-37 
                 Chromogranin/ 
                 S17 or S19 (Ambiguous) 
                 1 
               
               
                   
                   
                   
                 R 
                   
                   
                 secretogranin 
                   
                   
               
               
                   
               
               
                 40 
                 P10645 
                 1 
                 EEEEEEEEEAEAGEEAVPEEEGP   T   VV   L   NP   HP   S   L 
                 33 
                 ES-43 
                 Chromogranin/ 
                 T24, L27, N28, P29, S32 
                 5 
               
               
                   
                   
                   
                   
                   
                   
                 secretogranin 
                   
                   
               
               
                   
               
               
                 41 
                 P05060 
                 1 
                 FLGEGH   H   RVQE   N   QMDKARRHPQGAWKELDRNYLN 
                 74 
                 GAWK peptide 
                 Chromogranin/ 
                 H7, N12, Y35, T72, A73 
                 5 
               
               
                   
                   
                   
                     Y   GEEGAPGKWQQQGDLQDTKENREEARFQDKQYS 
                   
                   
                 secretogranin 
                   
                   
               
               
                   
                   
                   
                 SHH   T   A   E 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 42 
                 P10645 
                 1 
                     G   YPEEKKEEEGSANRRPEDQELESLSAIEAELEKVA 
                 44 
                 GR-44 
                 Chromogranin/ 
                 G1 
                 1 
               
               
                   
                   
                   
                 HQLQALRR 
                   
                   
                 secretogranin 
                   
                   
               
               
                   
               
               
                 43 
                 P10645 
                 1 
                 GWRPS   S   REDSLEAGLPLQV 
                 19 
                 GV-19 
                 Chromogranin/ 
                 S6 
                 1 
               
               
                   
                   
                   
                   
                   
                   
                 secretogranin 
                   
                   
               
               
                   
               
               
                 44 
                 P10645 
                 1 
                 LEGQEEEEDNRDSSMKLSF 
                 19 
                 LF-19 
                 Chromogranin/ 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 secretogranin 
                   
                   
               
               
                   
               
               
                 45 
                 P10645 
                 1 
                 SEALAVDGAGK   P   GA   E   EAQD   P   EGKGEQEH   S   QQKEEE 
                 48 
                 Pancreastatin 
                 Chromogranin/ 
                 P12, E15, P20, S29, M38, V41 
                 6 
               
               
                   
                   
                   
                 EE   M   AV   V   PQGLFRG 
                   
                   
                 secretogranin 
                   
                   
               
               
                   
               
               
                 46 
                 P05060 
                 1 
                 MPVDNRNHNEGMV   T   RCIIEVLSNAL   S   K   S   SAP   P   ITPEC 
                 657 
                 Secretogranin-1 
                 Chromogranin/ 
                 T14, S26, S28, S29, P32, T59, 
                 40 
               
               
                   
                   
                   
                 RQVLKTSRKDVKDKETFENEN   T   KFEVRLLRDPADA 
                   
                   
                 secretogranin 
                 S73, A75, S80, A84, E89, T96, 
                   
               
               
                   
                   
                   
                     S   E   A   HESS   S   RGE   A   GAPG   E   EDIQGP   T   KADTEKWAEGGG 
                   
                   
                   
                 S120, S124, S129, T174, N176, 
                   
               
               
                   
                   
                   
                 HSRERADEPQW   S   LYP   S   DSQV   S   EEVKTRHSEKSQRED 
                   
                   
                   
                 S186, S273, S274, S278, P287, 
                   
               
               
                   
                   
                   
                 EEEEEGENYQKGERGEDSSEEKHLEEPGE   T   Q   N   AFLN 
                   
                   
                   
                 S297, M298, S300, D306, T310, 
                   
               
               
                   
                   
                   
                 ERKQA   S   AIKKEELVARSETHAAGHSQEKTHSREKSS 
                   
                   
                   
                 Y328, P329, G330, K376, 
                   
               
               
                   
                   
                   
                 QESGEETGSQENHPQESKGQPRSQEESEEGEEDATS 
                   
                   
                   
                 M377, H426, Y454, T491, 
                   
               
               
                   
                   
                   
                 EVDKRRTRPRHHHGRSRPDR   SS   QGG   S   LPSEEKGH   P   Q 
                   
                   
                   
                 A492, T536, S557, N568, S611 
                   
               
               
                   
                   
                   
                 EESEESNV   S   M   A   S   LGEKR   D   HHS   T   HYRASEEEPEYGEE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 IKG   Y   PG   VQAPEDLEWERYRGRGSEEYRAPRPQSEES 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 WDEEDKRNYPSLELD   KM   AHGYGEESEEERGLEPGK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GRHHRGRGGEPRAYFMSDTREEKRFLGEGH   H   RVQE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 NQMDKARRHPQGAWKELDRNYLN   Y   GEEGAPGKW 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 QQQGDLQDTKENREEARFQDKQYSSHH   T   A   EKRKRL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GELFNPYYDPLQWKSSHFERRDNMNDNFLEGEEEN 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 EL   T   LNEKNFFPEYNYDWWEKKPF   S   EDVNWGYEKR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                     N   LARVPKLDLKRQYDRVAQLDQLLHYRKKSAEFPD 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 FYDSEEPV   S   THQEAENEKDRADQTVLTEDEKKELE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 NLAAMDLELQKIAEKFSQRG 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 47 
                 P13521 
                 1 
                 QRNQLLQKEPDLRLENVQKFP   S   PEMIRALEYIENLR 
                 587 
                 Secretogranin-2 
                 Chromogranin/ 
                 S22, S45, A106, Y160, T161, 
                 16 
               
               
                   
                   
                   
                 QQAHKEES   S   PDYNPYQGVSVPLQQKENGDESHLPE 
                   
                   
                 secretogranin 
                 S164, T167, S229, T231, S348, 
                   
               
               
                   
                   
                   
                 RDSLSEEDWMRIILEALRQAENEPQSAPKENKPY   A   L 
                   
                   
                   
                 T420, N459, G499, S526, S536, 
                   
               
               
                   
                   
                   
                 NSEKNFPMDMSDDYETQQWPERKLKHMQFPPMYE 
                   
                   
                   
                 P543 
                   
               
               
                   
                   
                   
                 ENSRDNPFKRTNEIVEEQ   YT   PQ   S   LA   T   LESVFQELGK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LTGPNNQKRERMDEEQKLYTDDEDDIYKANNIAYE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DVVGGEDWNPVEEKIE   S   Q   T   QEEVRDSKENIEKNEQI 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 NDEMKRSGQLGIQEEDLRKESKDQLSDDVSKVIAY 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LKRLVNAAGSGRLQNGQNGERATRLFEKPLDSQSIY 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 QLIEISRNLQIPPEDLIEMLKTGEKPNG   S   VEPERELDL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 PVDLDDISEADLDHPDLFQNRMLSKSGYPKTPGRAG 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 TEALPDGLSVEDILNLLGMESAANQK   T   SYFPNPYNQ 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 EKVLPRLPYGAGRSRSNQLPKAAWIPHVE   N   RQMAY 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 ENLNDKDQELGEYLARMLVKYPEIINSNQVKRVP   G     
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 QGSSEDDLQEEEQIEQAIKEHLNQGS   S   QETDKLAPV 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                     S   KRFPVG   P   PKNDDTPNRQYWDEDLLMKVLEYLNQ 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 EKAEKGREHIAKRAMENM 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 48 
                 Q8WXD2 
                 1 
                 FPKPGGSQDKSLHNRELSAERPLNEQIAEAEEDKIKK 
                 449 
                 Secretogranin-3 
                 Chromogranin/ 
                 P41, T63, S103, T104, T125, 
                 15 
               
               
                   
                   
                   
                 TYP   P   ENKPGQSNYSFVDNLNLLKAI   T   EKEKIEKERQ 
                   
                   
                 secretogranin 
                 A138, D192, P193, T197, S198, 
                   
               
               
                   
                   
                   
                 SIRSSPLDNKLNVEDVDSTKNRKLIDDYD   ST   KSGLD 
                   
                   
                   
                 T200, T212, T217, A222, S340 
                   
               
               
                   
                   
                   
                 HKFQDDPDGLHQLDG   T   PLTAEDIVHKIA   A   RIYEEND 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 RAVFDKIVSKLLNLGLITESQAHTLEDEVAEVLQKLI 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 SKEANNYEE   DP   NKP   TS   W   T   ENQAGKIPEKV   T   PMAA   I     
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 QDGL   A   KGENDETVSNTLTLTNGLERRTKTYSEDNFE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 ELQYFPNFYALLKSIDSEKEAKEKETLITIMKTLIDFV 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KMMVKYGTISPEEGVSYLENLDEMIALQTKNKLEK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 NATDNISKLFPAP   S   EKSHEETDSTKEEAAKMEKEYG 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 SLKDSTKDDNSNPGGKTDEPKGKTEAYLEAIRKNIE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 WLKKHDKKGNKEDYDLSKMRDFINKQADAYVEK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GILDKEEAEAIKRIYSSL 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 49 
                 P13521 
                 1 
                 TNEIVEEQ   YT   PQ   S   LA   T   LESVFQELGKLTGPNNQ 
                 33 
                 Secretoneurin 
                 Chromogranin/ 
                 Y9, T10, S13, T16, 
                 4 
               
               
                   
                   
                   
                   
                   
                   
                 secretogranin 
                   
                   
               
               
                   
               
               
                 50 
                 P10645 
                 1 
                 SGELEQEEERLSKEWEDS 
                 18 
                 SS-18 
                 Chromogranin/ 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 secretogranin 
                   
                   
               
               
                   
               
               
                 51 
                 P10645 
                 1 
                 LPVNSPMNKGDTEVMKCIVEVISDTL   S   KP   S   PMPV   S   Q 
                 76 
                 Vasostatin-1 
                 Chromogranin/ 
                 S27, S30, S36 
                 3 
               
               
                   
                   
                   
                 ECFETLRGDERILSILRHQNLLKELQDLALQGAKER 
                   
                   
                 secretogranin 
                   
                   
               
               
                   
                   
                   
                 AHQQ 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 52 
                 P10645 
                 1 
                 LPVNSPMNKGDTEVMKCIVEVISDTL   S   KP   S   PMPV   S   Q 
                 113 
                 Vasostatin-2 
                 Chromogranin/ 
                 S27, S30, S36, S80, E104, 
                 6 
               
               
                   
                   
                   
                 ECFETLRGDERILSILRHQNLLKELQDLALQGAKER 
                   
                   
                 secretogranin 
                 S108 
                   
               
               
                   
                   
                   
                 AHQQKKH   S   GFEDELSEVLENQSSQAELKEAV   E   EPS   S     
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KDVME 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 53 
                 P10645 
                 1 
                 WSKMDQLA 
                 8 
                 WA-8 
                 Chromogranin/ 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 secretogranin 
                   
                   
               
               
                   
               
               
                 54 
                 P10645 
                 1 
                 WSKMDQLAKEL   T   AE 
                 14 
                 WE-14 
                 Chromogranin/ 
                 T12 
                 1 
               
               
                   
                   
                   
                   
                   
                   
                 secretogranin 
                   
                   
               
               
                   
               
               
                 55 
                 P01042 
                 1 
                 QESQSEEIDCNDKDLFKAVDAALKKYNSQNQSNNQ 
                 626 
                 Kininogen-1 
                 Cystatin 
                 T119, T133, T243, T255, E381, 
                 15 
               
               
                   
                   
                   
                 FVLYRIFLATKTVGSDTFYSFKYEIKEGDCPVQSGKT 
                   
                   
                   
                 T382, T383, S385, T389, S390, 
                   
               
               
                   
                   
                   
                 WQDCEYKDAAKAATGECTATVGKRSSTKFSVATQ 
                   
                   
                   
                 T528, S586, T592, S593, T610 
                   
               
               
                   
                   
                   
                 TCQITPAEGPVV   T   AQYDCLGCVHPI   S   TQSPDLEPILR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 HGIQYENNNTQHSSLEMLNEVKRAQRQVVAGLNFR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 ITYSIVQTNCSKENFLFLTPDCKSLWNGDTGECTDN 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 AYIDIQLRIASFSQNCDIYPGKDEVQPP   T   KICVGCPR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DIP   T   NSPELEETLTHTITKLNAENNATFYFKIDNVKK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 ARVQVVAGKKYFIDFVARETTCSKESNEELTESCET 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KKLGQSLDCNAEVYVVPWEKKIYPTVNCQPLGMIS 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LMKRPPGESPERSSRIGEIKE   E   TT   VSPPH   TS   MAPAQD 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 EERDSGKEQGHTRRHDWGHEKQRKHNLGHGHKHE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 RDQGHGHQRGHGLGHGHEQQHGLGHGHKFKLDD 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DLEHQGGHVLDHGHKHKHGHGHGKHKNKGKKNG 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KHNGWKFEHLASSSEDSTTPSAQTQEKFEGP   T   PIPSL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 AKPGVTVTFSDFQDSDLIATMMPPISPAPIQSDDDWI 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 PDIQIDPNGLSENPI   S   DEPDT   TS   PKCPGRPWKSVSEIN 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 P   T   TQMKESYYFDLTDGLS 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 56 
                 P01042 
                 1 
                 QESQSEEIDCNDKDLFKAVDAALKKYNSQNQSNNQ 
                 362 
                 Kininogen-1 
                 Cystatin 
                 T119, T133, T243, T255 
                 4 
               
               
                   
                   
                   
                 FVLYRIFLATKTVGSDTFYSFKYEIKEGDCPVQSGKT 
                   
                 heavy chain 
                   
                   
                   
               
               
                   
                   
                   
                 WQDCEYKDAAKAATGECTATVGKRSSTKFSVATQ 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 TCQITPAEGPVV   T   AQYDCLGCVHPIS   T   QSPDLEPILR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 HGIQYENNNTQHSSLEMLNEVKRAQRQVVAGLNFR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 ITYSIVQTNCSKENFLFLTPDCKSLWNGDTGECTDN 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 AYIDIQLRIASFSQNCDIYPGKDEVQPP   T   KICVGCPR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DIP   T   NSPELEETLTHTITKLNAENNATFYFKIDNVKK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 ARVQVVAGKKYFIDFVARETTCSKESNEELTESCET 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KKLGQSLDCNAEVYVVPWEKKIYPTVNCQPLGMIS 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LMK 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 57 
                 P01042 
                 1 
                 SSRIGEIKE   E   TT   VSPPH   TS   MAPAQDEERDSGKEQGH 
                 255 
                 Kininogen-1 
                 Cystatin 
                 E10, T11, T12, S14, T18, S19, 
                 11 
               
               
                   
                   
                   
                 TRRHDWGHEKQRKHNLGHGHKHERDQGHGHQRG 
                   
                 light chain 
                   
                 T157, S215, T221, S222, T239 
                   
               
               
                   
                   
                   
                 HGLGHGHEQQHGLGHGHKFKLDDDLEHQGGHVLD 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 HGHKHKHGHGHGKHKNKGKKNGKHNGWKFEHL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 ASSSEDSTTPSAQTQEKFEGP   T   PIPSLAKPGVTVITS 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DFQDSDLIATMMPPISPAPIQSDDDWIPDIQIDPNGLS 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 FNPI   S   DEPDT   TS   PKCPGRPWKSVSEINP   T   TQMKESYY 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 FDLTDGLS 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 58 
                 P01042 
                 1 
                 WGHE 
                 4 
                 Low molecular 
                 Cystatin 
                   
                   
               
               
                   
                   
                   
                   
                   
                 weight growth- 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 promoting factor 
                   
                   
                   
               
               
                   
               
               
                 59 
                 P05305 
                 1 
                 CSCSSLMDKECVYFCHLDIIWVNTPEHVVPYGLGSP 
                 38 
                 Big endothelin-1 
                 Endothelin/ 
                   
                   
               
               
                   
                   
                   
                 RS 
                   
                   
                 sarafotoxin 
                   
                   
               
               
                   
               
               
                 60 
                 P05305 
                 1 
                 CSCSSLMDKECVYFCHLDIIW 
                 21 
                 Endothelin-1 
                 Endothelin/ 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 sarafotoxin 
                   
                   
               
               
                   
               
               
                 61 
                 P20800 
                 1 
                 CSCSSWLDKECVYFCHLDIIVV 
                 21 
                 Endothelin-2 
                 Endothelin/ 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 sarafotoxin 
                   
                   
               
               
                   
               
               
                 62 
                 P14138 
                 1 
                 CTCFTYKDKECVYYCHLDIIW 
                 21 
                 Endothelin-3 
                 Endothelin/ 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 sarafotoxin 
                   
                   
               
               
                   
               
               
                 63 
                 O15130 
                 1 
                 AGEGLNSQFVVSLAAPQRF 
                 18 
                 Neuropeptide AF 
                 FMRFamide related 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 peptide 
                   
                   
               
               
                   
               
               
                 64 
                 O15130 
                 1 
                 FLFQPQRF 
                 8 
                 Neuropeptide FF 
                 FMRFamide related 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 peptide 
                   
                   
               
               
                   
               
               
                 65 
                 Q9HCQ7 
                 1 
                 SLNFEELKDWGPKNVIKMSTPAVNKMPHSFANLPL 
                 37 
                 Neuropeptide 
                 FMRFamide related 
                   
                   
               
               
                   
                   
                   
                 RF 
                   
                 NPSF (Potential) 
                 peptide 
                   
                   
               
               
                   
               
               
                 66 
                 Q9HCQ7 
                 1 
                 VPNLPQRF 
                 8 
                 Neuropeptide 
                 FMRFamide related 
                   
                   
               
               
                   
                   
                   
                   
                   
                 NPVF 
                 peptide 
                   
                   
               
               
                   
               
               
                 67 
                 Q9HCQ7 
                 1 
                 MPHSFANLPLRF 
                 12 
                 Neuropeptide 
                 FMRFamide related 
                   
                   
               
               
                   
                   
                   
                   
                   
                 RFRP-1 
                 peptide 
                   
                   
               
               
                   
               
               
                 68 
                 Q9HCQ7 
                 1 
                 SAGATANLPLRS 
                 12 
                 Neuropeptide 
                 FMRFamide related 
                   
                   
               
               
                   
                   
                   
                   
                   
                 RFRP-2 
                 peptide 
                   
                   
               
               
                   
                   
                   
                   
                   
                 (Potential) 
                   
                   
                   
               
               
                   
               
               
                 69 
                 O15130 
                 1 
                 SQAFLFQPQRF 
                 11 
                 Neuropeptide SF 
                 FMRFamide related 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 peptide 
                   
                   
               
               
                   
               
               
                 70 
                 P81277 
                 1 
                 TPDINPAWYASRGIRPVGRF 
                 20 
                 Prolactin- 
                 FMRFamide related 
                   
                   
               
               
                   
                   
                   
                   
                   
                 releasing peptide 
                 peptide 
                   
                   
               
               
                   
                   
                   
                   
                   
                 PrRP20 
                   
                   
                   
               
               
                   
               
               
                 71 
                 P81277 
                 1 
                 SRTHRHSMEIRTPDINPAWYASRGIRPVGRF 
                 31 
                 Prolactin- 
                 FMRFamide related 
                   
                   
               
               
                   
                   
                   
                   
                   
                 releasing peptide 
                 peptide 
                   
                   
               
               
                   
                   
                   
                   
                   
                 PrRP31 
                   
                   
                   
               
               
                   
               
               
                 72 
                 P22466 
                 1 
                 GW   T   LNSAGYLLGPHAVGNHRSF   S   DKNGLTS 
                 30 
                 Galanin 
                 Galanin 
                 T3, S23 
                 2 
               
               
                   
               
               
                 73 
                 P22466 
                 1 
                 ELRPEDDMKPGSFDRSIPENNIMRTIIEFLSFLHLKEA 
                 59 
                 Galanin 
                 Galanin 
                 A49 
                 1 
               
               
                   
                   
                   
                 GALDRLLDLP   A   AASSEDIERS 
                   
                 message- 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 associated 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 peptide 
                   
                   
                   
               
               
                   
               
               
                 74 
                 Q9UBC7 
                 1 
                 APAHRGRGGWTLNSAGYLLGPVLHLPQMGDQDGK 
                 60 
                 Galanin-like 
                 Galanin 
                   
                   
               
               
                   
                   
                   
                 RETALEILDLWKAIDGLPYSHPPQPS 
                   
                 peptide 
                   
                   
                   
               
               
                   
               
               
                 75 
                 P01350 
                 1 
                 QLGPQGPPHLVADPSKKQGPWLEEEEEAYGWMDF 
                 34 
                 Big gastrin 
                 Gastrin/ 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 cholecystokinin 
                   
                   
               
               
                   
               
               
                 76 
                 P06307 
                 1 
                 QPVPPADP   A   GSGLQRAEEAPRRQLRVSQR   T   DGESRA 
                 95 
                 Cholecystokinin 
                 Gastrin/ 
                 A8, T30, N65 
                 3 
               
               
                   
                   
                   
                 HLGALLARYIQQARKAPSGRMSIVKNLQ   N   LDPSHRI 
                   
                   
                 cholecystokinin 
                   
                   
               
               
                   
                   
                   
                 SDRDYMGWMDFGRRSAEEYEYPS 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 77 
                 P06307 
                 1 
                 ISDRDYMGWMDF 
                 12 
                 Cholecystokinin- 
                 Gastrin/ 
                   
                   
               
               
                   
                   
                   
                   
                   
                 12 
                 cholecystokinin 
                   
                   
               
               
                   
               
               
                 78 
                 P06307 
                 1 
                 LDPSHRISDRDYMGWMDF 
                 18 
                 Cholecystokinin- 
                 Gastrin/ 
                   
                   
               
               
                   
                   
                   
                   
                   
                 18 (By 
                 cholecystokinin 
                   
                   
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 79 
                 P06307 
                 1 
                 IVKNLQ   N   LDPSHRISDRDYMGWMDF 
                 25 
                 Cholecystokinin- 
                 Gastrin/ 
                 N7 
                 1 
               
               
                   
                   
                   
                   
                   
                 25 (By 
                 cholecystokinin 
                   
                   
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 80 
                 P06307 
                 1 
                 KAPSGRMSIVKNLQ   N   LDPSHRISDRDYMGWMDF 
                 33 
                 Cholecystokinin- 
                 Gastrin/ 
                 N15 
                 1 
               
               
                   
                   
                   
                   
                   
                 33 
                 cholecystokinin 
                   
                   
               
               
                   
               
               
                 81 
                 P06307 
                 1 
                 YIQQARKAPSGRMSIVKNLQ   N   LDPSHRISDRDYMG 
                 39 
                 Cholecystokinin- 
                 Gastrin/ 
                 N21 
                 1 
               
               
                   
                   
                   
                 WMDF 
                   
                 39 
                 cholecystokinin 
                   
                   
               
               
                   
               
               
                 82 
                 P06307 
                 1 
                 GWMDF 
                 5 
                 Cholecystokinin- 
                 Gastrin/ 
                   
                   
               
               
                   
                   
                   
                   
                   
                 5 (By similarity) 
                 cholecystokinin 
                   
                   
               
               
                   
               
               
                 83 
                 P06307 
                 1 
                 VSQR   T   DGESRAHLGALLARYIQQARKAPSGRMSIV 
                 58 
                 Cholecystokinin- 
                 Gastrin/ 
                 T5, N40 
                 2 
               
               
                   
                   
                   
                 KNLQ   N   LDPSHRISDRDYMGWMDF 
                   
                 58 
                 cholecystokinin 
                   
                   
               
               
                   
               
               
                 84 
                 P06307 
                 1 
                 VSQR   T   DGESRAHLGALLARYIQQARKAPSGRMSIV 
                 49 
                 Cholecystokinin- 
                 Gastrin/ 
                 T5, N40 
                 2 
               
               
                   
                   
                   
                 KNLQ   N   LDPSHRISD 
                   
                 58 
                 cholecystokinin 
                   
                   
               
               
                   
                   
                   
                   
                   
                 desnonopeptide 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 (By similarity) 
                   
                   
                   
               
               
                   
               
               
                 85 
                 P06307 
                 1 
                 YMGWMDF 
                 7 
                 Cholecystokinin- 
                 Gastrin/ 
                   
                   
               
               
                   
                   
                   
                   
                   
                 7 (By similarity) 
                 cholecystokinin 
                   
                   
               
               
                   
               
               
                 86 
                 P06307 
                 1 
                 DYMGWMDF 
                 8 
                 Cholecystokinin- 
                 Gastrin/ 
                   
                   
               
               
                   
                   
                   
                   
                   
                 8 
                 cholecystokinin 
                   
                   
               
               
                   
               
               
                 87 
                 P01350 
                 1 
                 QGPWLEEEEEAYGWMDF 
                 17 
                 Gastrin 
                 Gastrin/ 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 cholecystokinin 
                   
                   
               
               
                   
               
               
                 88 
                 P01350 
                 1 
                 WLEEEEEAYGWMDF 
                 14 
                 Gastrin-14 
                 Gastrin/ 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 cholecystokinin 
                   
                   
               
               
                   
               
               
                 89 
                 P01350 
                 1 
                 DLELPWLEQQGPASHHRRQLGPQGPPHLVADPSKK 
                 52 
                 Gastrin-52 
                 Gastrin/ 
                   
                   
               
               
                   
                   
                   
                 QGPWLEEEEEAYGWMDF 
                   
                   
                 cholecystokinin 
                   
                   
               
               
                   
               
               
                 90 
                 P01350 
                 1 
                 YGWMDF 
                 6 
                 Gastrin-6 
                 Gastrin/ 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 cholecystokinin 
                   
                   
               
               
                   
               
               
                 91 
                 P01350 
                 1 
                 SWKPRSQQPDAP   LG   TGANRDLELPWLEQQGPASHH 
                 71 
                 Gastrin-71 
                 Gastrin/ 
                 L12 or G13 (Ambiguous) 
                 1 
               
               
                   
                   
                   
                 RRQLGPQGPPHLVADPSKKQGPWLEEEEEAYGWM 
                   
                   
                 cholecystokinin 
                   
                   
               
               
                   
                   
                   
                 DF 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 92 
                 P09681 
                 1 
                 YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKND 
                 42 
                 Gastric inhibitory 
                 Glucagon 
                   
                   
               
               
                   
                   
                   
                 WKHNITQ 
                   
                 polypeptide 
                   
                   
                   
               
               
                   
               
               
                 93 
                 P01275 
                 1 
                 RSLQDTEEKSR   S   FSASQADPLSDPDQMNEDKRHSQG 
                 69 
                 Glicentin (By 
                 Glucagon 
                 S12, T39 
                 2 
               
               
                   
                   
                   
                 TF   T   SDYSKYLDSRRAQDFVQWLMNTKRNRNNIA 
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 94 
                 P01275 
                 1 
                 RSLQDTEEKSR   S   FSASQADPLSDPDQMNED 
                 30 
                 Glicentin-related 
                 Glucagon 
                 S12 
                 1 
               
               
                   
                   
                   
                   
                   
                 polypeptide (By 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 95 
                 P01275 
                 1 
                 HSQGTF   T   SDYSKYLDSRRAQDFVQWLMNT 
                 29 
                 Glucagon 
                 Glucagon 
                 T7 
                 1 
               
               
                   
               
               
                 96 
                 P01275 
                 1 
                 HDEFERHAEG   T   F   TS   DVSSYLEGQAAKEFIAWLVKG 
                 37 
                 Glucagon-like 
                 Glucagon 
                 T11 or T13 or S14 
                 1 
               
               
                   
                   
                   
                 RG 
                   
                 peptide 1 
                   
                 (Ambiguous) 
                   
               
               
                   
               
               
                 97 
                 P01275 
                 1 
                 HAEG   T   F   TS   DVSSYLEGQAAKEFIAWLVKGR 
                 31 
                 Glucagon-like 
                 Glucagon 
                 T5 or T7 or S8 (Ambiguous) 
                 1 
               
               
                   
                   
                   
                   
                   
                 peptide 1(7-36) 
                   
                   
                   
               
               
                   
               
               
                 98 
                 P01275 
                 1 
                 HAEG   T   F   TS   DVSSYLEGQAAKEFIAWLVKGRG 
                 30 
                 Glucagon-like 
                 Glucagon 
                 T5 or T7 or S8 (Ambiguous) 
                 1 
               
               
                   
                   
                   
                   
                   
                 peptide 1(7-37) 
                   
                   
                   
               
               
                   
               
               
                 99 
                 P01275 
                 1 
                 HADGSFSDEMNTILDNLAARDFINWLIQTKITD 
                 33 
                 Glucagon-like 
                 Glucagon 
                   
                   
               
               
                   
                   
                   
                   
                   
                 peptide 2 (By 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 100 
                 P01282 
                 1 
                 HADGVF   TS   DFSKLLGQLSAKKYLESLM 
                 27 
                 Intestinal peptide 
                 Glucagon 
                 T7, S8 
                 2 
               
               
                   
                   
                   
                   
                   
                 PHM-27 
                   
                   
                   
               
               
                   
               
               
                 101 
                 P01282 
                 1 
                 HADGVF   TS   DFSKLLGQLSAKKYLESLMGKRVSSNIS 
                 42 
                 Intestinal peptide 
                 Glucagon 
                 T7, S8 
                 2 
               
               
                   
                   
                   
                 EDPVPV 
                   
                 PHV-42 
                   
                   
                   
               
               
                   
               
               
                 102 
                 P01275 
                 1 
                 HSQGTF   T   SDYSKYLDSRRAQDFVQWLMNTKRNRN 
                 37 
                 Oxyntomodulin 
                 Glucagon 
                 T7 
                 1 
               
               
                   
                   
                   
                 NIA 
                   
                 (By similarity) 
                   
                   
                   
               
               
                   
               
               
                 103 
                 P18509 
                 1 
                 DVAHGILNEAYRKVLDQLSAGKHLQSLVARGVGGS 
                 48 
                 PACAP-related 
                 Glucagon 
                   
                   
               
               
                   
                   
                   
                 LGGGAGDDAEPLS 
                   
                 peptide 
                   
                   
                   
               
               
                   
               
               
                 104 
                 P18509 
                 1 
                 HSDGIFTDSYSRYRKQMAVKKYLAAVL 
                 27 
                 Pituitary 
                 Glucagon 
                   
                   
               
               
                   
                   
                   
                   
                   
                 adenylate 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 cyclase- 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 activating 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 polypeptide 27 
                   
                   
                   
               
               
                   
               
               
                 105 
                 P18509 
                 1 
                 HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQR 
                 38 
                 Pituitary 
                 Glucagon 
                   
                   
               
               
                   
                   
                   
                 VKNK 
                   
                 adenylate 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 cyclase- 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 activating 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 polypeptide 38 
                   
                   
                   
               
               
                   
               
               
                 106 
                 P09683 
                 1 
                 HSDGTF   TS   EL   S   RLREGARLQRLLQGLV 
                 27 
                 Secretin 
                 Glucagon 
                 T7, S8, S11 
                 3 
               
               
                   
               
               
                 107 
                 P01286 
                 1 
                 YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESN 
                 44 
                 Somatoliberin 
                 Glucagon 
                   
                   
               
               
                   
                   
                   
                 QERGARARL 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 108 
                 P01282 
                 1 
                 HSDAVF   T   DNYTRLRKQMAVKKYLNSILN 
                 28 
                 Vasoactive 
                 Glucagon 
                 T7 
                 1 
               
               
                   
                   
                   
                   
                   
                 intestinal 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 peptide 
                   
                   
                   
               
               
                   
               
               
                 109 
                 P01148 
                 1 
                 DAENLIDSFQEIVKEVGQLAETQRFEC   T   THQPRSPLR 
                 56 
                 GnRH-associated 
                 GnRH 
                 T28 
                 1 
               
               
                   
                   
                   
                 DLKGALESLIEEETGQKKI 
                   
                 peptide 1 
                   
                   
                   
               
               
                   
               
               
                 110 
                 O43555 
                 1 
                 ALSSAQDPQNALRPPGRALDTAAGSPVQTAHGLPS 
                 84 
                 GnRH-associated 
                 GnRH 
                   
                   
               
               
                   
                   
                   
                 DALAPLDDSMPWEGRTTAQWSLHRKRHLARTLLT 
                   
                 peptide 2 
                   
                   
                   
               
               
                   
                   
                   
                 AAREPRPAPPSSNKV 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 111 
                 P01148 
                 1 
                 QHWSYGLRPG 
                 10 
                 Gonadoliberin-1 
                 GnRH 
                   
                   
               
               
                   
               
               
                 112 
                 O43555 
                 1 
                 QHWSHGWYPG 
                 10 
                 Gonadoliberin-2 
                 GnRH 
                   
                   
               
               
                   
               
               
                 113 
                 P01148 
                 1 
                 QHWSYGLRPGGKRDAENLIDSFQEIVKEVGQLAET 
                 69 
                 Progonadoliberin- 
                 GnRH 
                 T41 
                 1 
               
               
                   
                   
                   
                 QRFEC   T   THQPRSPLRDLKGALESLIEEETGQKKI 
                   
                 1 
                   
                   
                   
               
               
                   
               
               
                 114 
                 O43555 
                 1 
                 QHWSHGWYPGGKRALSSAQDPQNALRPPGRALDT 
                 97 
                 Progonadoliberin- 
                 GnRH 
                   
                   
               
               
                   
                   
                   
                 AAGSPVQTAHGLPSDALAPLDDSMPWEGRTTAQW 
                   
                 2 
                   
                   
                   
               
               
                   
                   
                   
                 SLHRKRHLARTLLTAAREPRPAPPSSNKV 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 115 
                 P01308 
                 1 
                 GIVEQCCTSICSLYQLENYCN 
                 21 
                 Insulin A chain 
                 Insulin 
                   
                   
               
               
                   
               
               
                 116 
                 P01308 
                 1 
                 FVNQHLCGSHLVEALYLVCGERGFFY   T   PKT 
                 30 
                 Insulin B chain 
                 Insulin 
                 T27 (Ambiguous) 
                 1 
               
               
                   
               
               
                 117 
                 P05019 
                 1 
                 GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSR 
                 70 
                 Insulin-like 
                 Insulin 
                   
                   
               
               
                   
                   
                   
                 RAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA 
                   
                 growth factor I 
                   
                   
                   
               
               
                   
               
               
                 118 
                 P01344 
                 1 
                 AYRPSETLCGGELVDTLQFVCGDRGFYFSRPASRVS 
                 67 
                 Insulin-like 
                 Insulin 
                 S50, T62 
                 2 
               
               
                   
                   
                   
                 RRSRGIVEECCFR S CDLALLETYCA T PAKSE 
                   
                 growth factor II 
                   
                   
                   
               
               
                   
               
               
                 119 
                 P01344 
                 1 
                 YRPSETLCGGELVDTLQFVCGDRGFYFSRPASRVSR 
                 66 
                 Insulin-like 
                 Insulin 
                 S49, T61 
                 2 
               
               
                   
                   
                   
                 RSRGIVEECCFR   S   CDLALLETYCA T PAKSE 
                   
                 growth factor II 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 Ala-25 Del 
                   
                   
                   
               
               
                   
               
               
                 120 
                 P01344 
                 1 
                 DV   ST   PP   T   VLPDNFPRYPVGKFFQYDTWKQSTQRL 
                 34 
                 Preptin 
                 Insulin 
                 S3, T4, T7 
                 3 
               
               
                   
               
               
                 121 
                 P04090 
                 1 
                 QLYSALANKCCHVGCTKRSLARFC 
                 24 
                 Relaxin A chain 
                 Insulin 
                   
                   
               
               
                   
               
               
                 122 
                 P04808 
                 1 
                 PYVALFEKCCLIGCTKRSLAKYC 
                 23 
                 Relaxin A chain 
                 Insulin 
                   
                   
               
               
                   
                   
                   
                   
                   
                 (By similarity) 
                   
                   
                   
               
               
                   
               
               
                 123 
                 P04090 
                 1 
                 DSWMEEVIKLCGRELVRAQIAICGMSTWS 
                 29 
                 Relaxin B chain 
                 Insulin 
                   
                   
               
               
                   
               
               
                 124 
                 P04808 
                 1 
                 VAAKWKDDVIKLCGRELVRAQIAICGMSTWS 
                 31 
                 Relaxin B chain 
                 Insulin 
                   
                   
               
               
                   
                   
                   
                   
                   
                 (By similarity) 
                   
                   
                   
               
               
                   
               
               
                 125 
                 Q8WXF3 
                 1 
                 DVLAGLSSSCCKWGCSKSEISSLC 
                 24 
                 Relaxin-3 A 
                 Insulin 
                   
                   
               
               
                   
                   
                   
                   
                   
                 chain (By 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 126 
                 Q8WXF3 
                 1 
                 RAAPYGVRLCGREFIRAVIFTCGGSRW 
                 27 
                 Relaxin-3 B 
                 Insulin 
                   
                   
               
               
                   
                   
                   
                   
                   
                 chain (By 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 127 
                 Q15726 
                 1 
                 YNWNSFGLRF 
                 10 
                 Kisspeptin-10 
                 KISS1 
                   
                   
               
               
                   
               
               
                 128 
                 Q15726 
                 1 
                 LPNYNWNSFGLRF 
                 13 
                 Kisspeptin-13 
                 KISS1 
                   
                   
               
               
                   
               
               
                 129 
                 Q15726 
                 1 
                 DLPNYNWNSFGLRF 
                 14 
                 Kisspeptin-14 
                 KISS1 
                   
                   
               
               
                   
               
               
                 130 
                 Q15726 
                 1 
                 EPLEKVASVGNSRPTGQQLESLGLLAPGEQSLPCIL 
                 119 
                 Metastasis- 
                 KISS1 
                 A69 
                 1 
               
               
                   
                   
                   
                 RKPAATARLSRRGTSLSPPPESSGSPQQPGLS   A   PHSR 
                   
                 suppressor KiSS- 
                   
                   
                   
               
               
                   
                   
                   
                 QIPAPQGAVLVQREKDLPNYNVVNSFGLRFGKREAA 
                   
                 1 
                   
                   
                   
               
               
                   
                   
                   
                 PGNHGRSAGRG 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 131 
                 Q15726 
                 1 
                 GTSLSPPPESSGSPQQPGLS   A   PHSRQIPAPQGAVLVQ 
                 54 
                 Metastin 
                 KISS1 
                 A21 
                 1 
               
               
                   
                   
                   
                 REKDLPNYNWNSFGLRF 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 132 
                 P41159 
                 1 
                 VPIQKVQDDTKTLIKTIVTRINDISHTQSVSSKQKVT 
                 146 
                 Leptin 
                 Leptin 
                   
                   
               
               
                   
                   
                   
                 GLDFIPGLHPILTLSKMDQTLAVYQQILTSMPSRNVI 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 QISNDLENLRDLLHVLAFSKSCHLPWASGLETLDSL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GGVLEASGYSTEVVALSRLQGSLQDMLWQLDLSPG 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 C 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 133 
                 P20382 
                 1 
                 DFDMLRCMLGRVYRPCWQV 
                 19 
                 Melanin- 
                 Melanin- 
                   
                   
               
               
                   
                   
                   
                   
                   
                 concentrating 
                 concentrating 
                   
                   
               
               
                   
                   
                   
                   
                   
                 hormone 
                 hormone 
                   
                   
               
               
                   
               
               
                 134 
                 P20382 
                 1 
                 EIGDEENSAKFPI 
                 13 
                 Neuropeptide- 
                 Melanin- 
                   
                   
               
               
                   
                   
                   
                   
                   
                 glutamic acid- 
                 concentrating 
                   
                   
               
               
                   
                   
                   
                   
                   
                 isoleucine 
                 hormone 
                   
                   
               
               
                   
               
               
                 135 
                 P20382 
                 1 
                 GSVAFPAENGVQN   T   ES   T   QE 
                 19 
                 Neuropeptide- 
                 Melanin- 
                 T14, T16, T17 
                 3 
               
               
                   
                   
                   
                   
                   
                 glycine-glutamic 
                 concentrating 
                   
                   
               
               
                   
                   
                   
                   
                   
                 acid (Potential) 
                 hormone 
                   
                   
               
               
                   
               
               
                 136 
                 P20382 
                 1 
                 ILLSASKSIRNLDDDMVFNTFRLGKGFQKEDTAEK   S     
                 144 
                 Pro-MCH 
                 Melanin- 
                 S36, S41, N72, T102, T104, 
                 6 
               
               
                   
                   
                   
                 VIAP   S   LEQYKNDESSFMNEEENKVSKNTGSKHNFL   N     
                   
                   
                 concentrating 
                 T105 
                   
               
               
                   
                   
                   
                 HGLPLNLAIKPYLALKGSVAFPAENGVQN   T   ES   T   QEK 
                   
                   
                 hormone 
                   
                   
               
               
                   
                   
                   
                 REIGDEENSAKFPIGRRDFDMLRCMLGRVYRPCWQ 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 V 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 137 
                 Q9UBU3 
                 1 
                 GSSFLSPEHQRVQQRKESKKPPAKLQP 
                 27 
                 Ghrelins-27 
                 Motilin 
                   
                   
               
               
                   
               
               
                 138 
                 Q9UBU3 
                 1 
                 GSSFLSPEHQRVQQRKESKKPPAKLQPR 
                 28 
                 Ghrelins-28 
                 Motilin 
                   
                   
               
               
                   
               
               
                 139 
                 P12872 
                 1 
                 FVPIFTYGELQRMQEKERNKGQ 
                 22 
                 Motilin 
                 Motilin 
                   
                   
               
               
                   
               
               
                 140 
                 P12872 
                 1 
                 SLSVWQRSGEEGPVDPAEPIREEENEMIKLTAPLEIG 
                 66 
                 Motilin- 
                 Motilin 
                   
                   
               
               
                   
                   
                   
                 MRMNSRQLEKYPATLEGLLSEMLPQHAAK 
                   
                 associated 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 peptide 
                   
                   
                   
               
               
                   
               
               
                 141 
                 Q9UBU3 
                 1 
                 FNAPFDVGIKLSGVQYQQHSQAL 
                 23 
                 Obestatin 
                 Motilin 
                   
                   
               
               
                   
               
               
                 142 
                 P12872 
                 1 
                 FVPIFTYGELQRMQEKERNKGQKKSLSVWQRSGEE 
                 90 
                 Promotilin 
                 Motilin 
                   
                   
               
               
                   
                   
                   
                 GPVDPAEPIREEENEMIKLTAPLEIGMRMNSRQLEK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 YPATLEGLLSEMLPQHAAK 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 143 
                 Q15848 
                 1 
                 ETT   T   QGPGVLLPLPKGACTGWMAGIPGHPGHNGAP 
                 226 
                 Adiponectin 
                 NA 
                 T4 
                 1 
               
               
                   
                   
                   
                 GRDGRDGTPGEKGEKGDPGLIGPKGDIGETGVPGAE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GPRGFPGIQGRKGEPGEGAYVYRSAFSVGLETYVTI 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 PNMPIRETKIFYNQQNHYDGSTGKEHCNIPGLYYFA 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 YHITVYMKDVKVSLFKKDKAMLFTYDQYQENNVD 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 QASGSVLLHLEVGDQVWLQVYGEGERNGLYADND 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 NDSTFTGFLLYHDTN 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 144 
                 O00253 
                 1 
                 AQMGLAPMEGIRRPDQALLPELPGLGLRAPLKKT   T     
                 111 
                 Agouti-related 
                 NA 
                 T35 
                 1 
               
               
                   
                   
                   
                 AEQAEEDLLQEAQALAEVLDLQDREPRSSRRCVRL 
                   
                 protein 
                   
                   
                   
               
               
                   
                   
                   
                 HESCLGQQVPCCDPCATCYCRFFNAFCYCRKLGTA 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 MNPCSRT 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 145 
                 Q9BZL1 
                 1 
                 MIEVVCNDRLGKKVRVKCNTDDTIGDLKKLIAAQT 
                 73 
                 Ubiquitin-like 
                 NA 
                   
                   
               
               
                   
                   
                   
                 GTRWNKIVLKKWYTIFKDHVSLGDYEIHDGMNLEL 
                   
                 protein 5 
                   
                   
                   
               
               
                   
                   
                   
                 YYQ 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 146 
                 P43490 
                 1 
                 MNPAAEAEFNILLATDSYKVTHYKQYPPNTSKVYS 
                 491 
                 Nicotinamide 
                 NAPRTase 
                   
                   
               
               
                   
                   
                   
                 YFECREKKTENSKLRKVKYEETVEYGLQYILNKYL 
                   
                 phosphoribosyltr 
                   
                   
                   
               
               
                   
                   
                   
                 KGKVVTKEKIQEAKDVYKEHFQDDVFNEKGWNYI 
                   
                 ansferase 
                   
                   
                   
               
               
                   
                   
                   
                 LEKYDGHLPIEIKAVPEGFVIPRGNVLFTVENTDPEC 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 YWLTNWIETILVQSWYPITVATNSREQKKILAKYLL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 ETSGNLDGLEYKLHDFGYRGVSSQETAGIGASAHL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 VNFKGTDTVAGLALIKKYYGTKDPVPGYSVPAAEH 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 STITAWGKDHEKDAFEHIVTQFSSVPVSVVSDSYDI 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 YNACEKIWGEDLRHLIVSRSTQAPLIIRPDSGNPLDT 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 VLKVLEILGKKFPVTENSKGYKLLPPYLRVIQGDGV 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DINTLQEIVEGMKQKMVVSIENIAFGSGGGLLQKLTR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DLLNCSEKCSYVVTNGLGINVEKDPVADPNKRSKK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GRLSLHRTPAGNFVTLEEGKGDLEEYGQDLLHTVF 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KNGKVTKSYSFDEIRKNAQLNIELEAAHH 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 147 
                 P01160 
                 1 
                 SLRRSSCFGGRMDRIGAQ   S   GLGCN   S   FRY 
                 28 
                 Atrial natriuretic 
                 Natriuretic peptide 
                 S19, S25 
                 2 
               
               
                   
                   
                   
                   
                   
                 factor 
                   
                   
                   
               
               
                   
               
               
                 148 
                 P16860 
                 1 
                 SPKMVQGSGCFGRKMDRISSSSGLGCKV 
                 28 
                 BNP(1-28) 
                 Natriuretic peptide 
                   
                   
               
               
                   
               
               
                 149 
                 P16860 
                 1 
                 SPKMVQGSGCFGRKMDRISSSSGLGCKVL 
                 29 
                 BNP(1-29) 
                 Natriuretic peptide 
                   
                   
               
               
                   
               
               
                 150 
                 P16860 
                 1 
                 SPKMVQGSGCFGRKMDRISSSSGLGCKVLR 
                 30 
                 BNP(1-30) 
                 Natriuretic peptide 
                   
                   
               
               
                   
               
               
                 151 
                 P16860 
                 1 
                 PKMVQGSGCFGRKMDRISSSSGLGCKVLRR 
                 30 
                 BNP(2-31) 
                 Natriuretic peptide 
                   
                   
               
               
                   
               
               
                 152 
                 P16860 
                 1 
                 KMVQGSGCFGRKMDRISSSSGLGCKVL 
                 27 
                 BNP(3-29) 
                 Natriuretic peptide 
                   
                   
               
               
                   
               
               
                 153 
                 P16860 
                 1 
                 KMVQGSGCFGRKMDRISSSSGLGCKVLR 
                 28 
                 BNP(3-30) 
                 Natriuretic peptide 
                   
                   
               
               
                   
               
               
                 154 
                 P16860 
                 1 
                 KMVQGSGCFGRKMDRISSSSGLGCKVLRRH 
                 30 
                 BNP(3-32) 
                 Natriuretic peptide 
                   
                   
               
               
                   
               
               
                 155 
                 P16860 
                 1 
                 MVQGSGCFGRKMDRISSSSGLGCK 
                 24 
                 BNP(4-27) 
                 Natriuretic peptide 
                   
                   
               
               
                   
               
               
                 156 
                 P16860 
                 1 
                 MVQGSGCFGRKMDRISSSSGLGCKVL 
                 26 
                 BNP(4-29) 
                 Natriuretic peptide 
                   
                   
               
               
                   
               
               
                 157 
                 P16860 
                 1 
                 MVQGSGCFGRKMDRISSSSGLGCKVLR 
                 27 
                 BNP(4-30) 
                 Natriuretic peptide 
                   
                   
               
               
                   
               
               
                 158 
                 P16860 
                 1 
                 MVQGSGCFGRKMDRISSSSGLGCKVLRR 
                 28 
                 BNP(4-31) 
                 Natriuretic peptide 
                   
                   
               
               
                   
               
               
                 159 
                 P16860 
                 1 
                 MVQGSGCFGRKMDRISSSSGLGCKVLRRH 
                 29 
                 BNP(4-32) 
                 Natriuretic peptide 
                   
                   
               
               
                   
               
               
                 160 
                 P16860 
                 1 
                 VQGSGCFGRKMDRISSSSGLGCKVL 
                 25 
                 BNP(5-29) 
                 Natriuretic peptide 
                   
                   
               
               
                   
               
               
                 161 
                 P16860 
                 1 
                 VQGSGCFGRKMDRISSSSGLGCKVLRR 
                 27 
                 BNP(5-31) 
                 Natriuretic peptide 
                   
                   
               
               
                   
               
               
                 162 
                 P16860 
                 1 
                 VQGSGCFGRKMDRISSSSGLGCKVLRRH 
                 28 
                 BNP(5-32) 
                 Natriuretic peptide 
                   
                   
               
               
                   
               
               
                 163 
                 P16860 
                 1 
                 SPKIVIVQGSGCFGRKMDRISSSSGLGCKVLRRH 
                 32 
                 Brain natriuretic 
                 Natriuretic peptide 
                   
                   
               
               
                   
                   
                   
                   
                   
                 peptide 32 
                   
                   
                   
               
               
                   
               
               
                 164 
                 P01160 
                 1 
                 NPM   Y   N   A   V   S   NADLMDFKNLLDHLEEKMPLED 
                 30 
                 Cardiodilatin- 
                 Natriuretic peptide 
                 Y4, A6, S8 (Ambiguous) 
                 1 
               
               
                   
                   
                   
                   
                   
                 related peptide 
                   
                   
                   
               
               
                   
               
               
                 165 
                 P23582 
                 1 
                 GLSKGCFGLKLDRIGSMSGLGC 
                 22 
                 CNP-22 
                 Natriuretic peptide 
                   
                   
               
               
                   
               
               
                 166 
                 P23582 
                 1 
                 YKGANKKGLSKGCFGLKLDRIGSMSGLGC 
                 29 
                 CNP-29 
                 Natriuretic peptide 
                   
                   
               
               
                   
               
               
                 167 
                 P23582 
                 1 
                 DLRVDTKSRAAWARLLQEHPNARKYKGANKKGLS 
                 53 
                 CNP-53 
                 Natriuretic peptide 
                   
                   
               
               
                   
                   
                   
                 KGCFGLKLDRIGSMSGLGC 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 168 
                 P16860 
                 1 
                 HPLGSPGSASDLETSGLQEQRNHLQGKLSELQVEQT 
                 108 
                 Natriuretic 
                 Natriuretic peptide 
                 T48, E59 
                 2 
               
               
                   
                   
                   
                 SLEPLQESPRP   T   GVWKSREVAT   E   GIRGHRKMVLYTL 
                   
                 peptides B 
                   
                   
                   
               
               
                   
                   
                   
                 RAPRSPKMVQGSGCFGRKMDRISSSSGLGCKVLRR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 H 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 169 
                 P58417 
                 1 
                 ANLTNGGKSELLKSGSSKSTLKHIWTESSKDLSISRL 
                 250 
                 Neurexophilin-1 
                 Neurexophilin 
                   
                   
               
               
                   
                   
                   
                 LSQTFRGKENDTDLDLRYDTPEPYSEQDLWDWLRN 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 STDLQEPRPRAKRRPIVKTGKFKMFGWGDFHSNIK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 TVKLNLLITGKIVDHGNGTFSVYFRHNSTGQGNVSV 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 SLVPPTKIVEFDLAQQTVIDAKDSKSFNCRIEYEKVD 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KATKNTLCNYDPSKTCYQEQTQSHVSWLCSKPFKV 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 ICIYISFYSTDYKLVQKVCPDYNYHSDTPYFPSG 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 170 
                 O95156 
                 1 
                 KEVVHA   T   EGLDWEDKDAPGTLVGNVVHSRIISPLR 
                 242 
                 Neurexophilin-2 
                 Neurexophilin 
                 T7 
                 1 
               
               
                   
                   
                   
                 LFVKQSPVPKPGPMAYADSMENFWDWLANITEIQE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 PLARTKRRPIVKTGKFKKMFGWGDFHSNIKTVKLN 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LLITGKIVDHGNGTFSVYFRHNSTGLGNVSVSLVPPS 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KVVEFEVSPQSTLETKESKSFNCRIEYEKTDRAKKT 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 ALCNFDPSKICYQEQTQSHVSWLCSKPFKVICIYIAF 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 YSVDYKLVQKVCPDYNYHSETPYLSSG 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 171 
                 O95157 
                 1 
                 QDDGPPGSEDPERDDHEGQPRPRVPRKRGHISPKSR 
                 230 
                 Neurexophilin-3 
                 Neurexophilin 
                   
                   
               
               
                   
                   
                   
                 PMANSTLLGLLAPPGEAWGILGQPPNRPNHSPPPSA 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KVKKIFGWGDFYSNIKTVALNLLVTGKIVDHGNGT 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 FSVHFQHNATGQGNISISLVPPSKAVEFHQEQQIFIEA 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KASKIFNCRMEWEKVERGRRTSLCTHDPAKICSRDH 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 AQSSATWSCSQPFKVVCVYIAFYSTDYRLVQKVCP 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DYNYHSDTPYYPSG 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 172 
                 O95158 
                 1 
                 QIPESGRPQYLGLRPAAAGAGAPGQQLPEPRSSDGL 
                 285 
                 Neurexophilin-4 
                 Neurexophilin 
                   
                   
               
               
                   
                   
                   
                 GVGRAWSWAWPTNHTGALARAGAAGALPAQRTK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 RKPSIKAARAKKIFGWGDFYFRVHTLKFSLLVTGKI 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 VDHVNGTFSVYFRHNSSSLGNLSVSIVPPSKRVEFG 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GVWLPGPVPHPLQSTLALEGVLPGLGPPLGMAAAA 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 AGPGLGGSLGGALAGPLGGALGVPGAKESRAFNCH 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 VEYEKTNRARKHRPCLYDPSQVCFTEHTQSQAAWL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 CAKPFKVICIFVSFLSFDYKLVQKVCPDYNFQSEHPY 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 FG 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 173 
                 Q5H8A3 
                 1 
                 ILQRGSGTAAVDFTKKDHTATWGRPFFLFRPRN 
                 33 
                 Neuromedin-S 
                 Neuromedins 
                   
                   
               
               
                   
               
               
                 174 
                 P48645 
                 1 
                 FRVDEEFQSPFASQSRGYFLFRPRN 
                 25 
                 Neuromedin-U- 
                 Neuromedins 
                   
                   
               
               
                   
                   
                   
                   
                   
                 25 
                   
                   
                   
               
               
                   
               
               
                 175 
                 Q8NG41 
                 1 
                 WYKPAAGHSSYSVGRAAGLLSGLR 
                 24 
                 Neuropeptide B- 
                 Neuromedins 
                   
                   
               
               
                   
                   
                   
                   
                   
                 23 
                   
                   
                   
               
               
                   
               
               
                 176 
                 Q8NG41 
                 1 
                 WYKPAAGHSSYSVGRAAGLLSGLRRSPYA 
                 29 
                 Neuropeptide B- 
                 Neuromedins 
                   
                   
               
               
                   
                   
                   
                   
                   
                 29 
                   
                   
                   
               
               
                   
               
               
                 177 
                 POC0P6 
                 1 
                 SFRNGVGTGMKKTSFQRAKS 
                 20 
                 Neuropeptide S 
                 Neuromedins 
                   
                   
               
               
                   
               
               
                 178 
                 Q8N729 
                 1 
                 WYKHVASPRYHTVGRAAGLLMGL 
                 23 
                 Neuropeptide W- 
                 Neuromedins 
                   
                   
               
               
                   
                   
                   
                   
                   
                 23 
                   
                   
                   
               
               
                   
               
               
                 179 
                 Q8N729 
                 1 
                 WYKHVASPRYHTVGRAAGLLMGLRRSPYLW 
                 30 
                 Neuropeptide W- 
                 Neuromedins 
                   
                   
               
               
                   
                   
                   
                   
                   
                 30 
                   
                   
                   
               
               
                   
               
               
                 180 
                 P30990 
                 1 
                 SDSEEEMKALEADFLTNMHTSKISKAHVPSWKMTL 
                 125 
                 Large 
                 Neurotensin 
                   
                   
               
               
                   
                   
                   
                 LNVCSLVNNLNSPAEETGEVHEEELVARRKLPTALD 
                   
                 neuromedin N 
                   
                   
                   
               
               
                   
                   
                   
                 GFSLEAMLTIYQLHKICHSRAFQHWELIQEDILDTGN 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DKNGKEEVIKRKIPYIL 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 181 
                 P30990 
                 1 
                 IPYIL 
                 5 
                 Neuromedin N 
                 Neurotensin 
                   
                   
               
               
                   
               
               
                 182 
                 P30990 
                 1 
                 QLYENKPRRPYIL 
                 13 
                 Neurotensin 
                 Neurotensin 
                   
                   
               
               
                   
               
               
                 183 
                 P30990 
                 1 
                 DSYYY 
                 5 
                 Tail peptide 
                 Neurotensin 
                   
                   
               
               
                   
                   
                   
                   
                   
                 (Potential) 
                   
                   
                   
               
               
                   
               
               
                 184 
                 P01303 
                 1 
                     SS   PETLISDLLMRES   T   ENVPR   T   RLEDP   A   MW 
                 30 
                 C-flanking 
                 NPY 
                 S1, S2, T16, T21, A28 
                 3 
               
               
                   
                   
                   
                   
                   
                 peptide of NPY 
                   
                   
                   
               
               
                   
               
               
                 185 
                 P01303 
                 1 
                 YP   S   KPDNPGEDAPAEDMARYYSALRH   Y   INLI   T   RQRY 
                 36 
                 Neuropeptide Y 
                 NPY 
                 S3, T32 
                 2 
               
               
                   
               
               
                 186 
                 P01298 
                 1 
                 APLEPVYPGDNATPEQMAQYAADLRRYINML   T   RPR 
                 36 
                 Pancreatic 
                 NPY 
                 T32 
                 1 
               
               
                   
                   
                   
                 Y 
                   
                 hormone 
                   
                   
                   
               
               
                   
               
               
                 187 
                 P01298 
                 1 
                 HKEDTLAFSEWGSPHAAVPR 
                 20 
                 Pancreatic 
                 NPY 
                   
                   
               
               
                   
                   
                   
                   
                   
                 icosapeptide 
                   
                   
                   
               
               
                   
               
               
                 188 
                 P10082 
                 1 
                 YPIKPEAPREDASPEELNRYYASLRHYLNLV   T   RQRY 
                 36 
                 Peptide YY 
                 NPY 
                 T32 
                 1 
               
               
                   
               
               
                 189 
                 P10082 
                 1 
                 IKPEAPREDASPEELNRYYASLRHYLNLV   T   RQRY 
                 34 
                 Peptide YY (3- 
                 NPY 
                 T30 
                 1 
               
               
                   
                   
                   
                   
                   
                 36) 
                   
                   
                   
               
               
                   
               
               
                 190 
                 P80303 
                 1 
                 VPIDIDK   T   KVQN   I   HPVE   S   AKIEPPD   T   GL   YY   DEYLKQV 
                 82 
                 Nesfatin-1 
                 Nucleobindin 
                 T8, I13, S18, T26, Y29, Y30, 
                 8 
               
               
                   
                   
                   
                 IDVLE   T   DKHFREKLQKADIEEIKSGRLSKELDLV   S   HH 
                   
                   
                   
                 T43, S72 
                   
               
               
                   
                   
                   
                 VRTKLDEL 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 191 
                 Q02818 
                 1 
                 VPLERGA   P   NKEE   T   PA   T   ESPD   T   GL   Y   YHRYLQEVIDVL 
                 435 
                 Nucleobindin-1 
                 Nucleobindin 
                 P8, T13, T16, S18, T21, Y24, 
                 22 
               
               
                   
                   
                   
                 ETDGHFREKLQAANAEDIKSGKLSRELDFV   S   HHVRT 
                   
                   
                   
                 S67, T122, T136, S198, S294, 
                   
               
               
                   
                   
                   
                 KLDELKRQEVSRLRMLLKAKMDAEQDPNVQVDHL 
                   
                   
                   
                 S295, T309, H313, S343, T346, 
                   
               
               
                   
                   
                   
                 NLLKQFEHLDPQNQH   T   FEARDLELLIQTA   T   RDLAQY 
                   
                   
                   
                 S352, Q381, A388, T400, L426, 
                   
               
               
                   
                   
                   
                 DAAHHEEFKRYEMLKEHERRRYLESLGEEQRKEAE 
                   
                   
                   
                 x433(deleterious mutation) 
                   
               
               
                   
                   
                   
                 RKLEEQQRRHREHPKVNVPG   S   QAQLKEVWEELDGL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DPNRFNPKTFFILHDINSDGVLDEQELEALFTKELEK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 VYDPKNEEDDMREMEEERLRMREHVMKNVDTNQ 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DRLVTLEEFLA   ST   QRKEFGDTGEGWE   T   VEM   H   PAYT 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 EEELRRFEEELAAREAELNAKAQRL   S   QE   T   EALGR   S   Q 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GRLEAQKRELQQAVLHMEQRKQQQQQQ   Q   GHKAP 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 A   A   HPEGQLKFHPD   T   DDVPVPAPAGDQKEVDTSEKK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LLER   L   PEVEVPQHL 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 192 
                 P80303 
                 1 
                 VPIDIDK   T   KVQN   I   HPVE   S   AKIEPPD   T   GL   YY   DEYLKQV 
                 396 
                 Nucleobindin-2 
                 Nucleobindin 
                 T8, I13, S18, T26, Y29, Y30, 
                 16 
               
               
                   
                   
                   
                 IDVLE   T   DKHFREKLQKADIEEIKSGRLSKELDLV   S   HH 
                   
                   
                   
                 T43, S72, S128, T139, T148, 
                   
               
               
                   
                   
                   
                 VRTKLDELKRQEVGRLRMLIKAKLDSLQDIGMDHQ 
                   
                   
                   
                 A331, Y365, P382, S384, L390 
                   
               
               
                   
                   
                   
                 ALLKQFDHLNHLNPDKEE   S   TDLDMLIKAA   T   SDLEH 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 YDK   T   RHEEFKKYEMMKEHERREYLKTLNEEKRKE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 EESKILEMKKKHENHPKVNHPGSKDQLKEVWEET 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DGLDPNDFDPKTFFKLHDVNSDGFLDEQELEALFTK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 ELEKVYDPKNEEDDMVEMEEERLRMREHVMSEVD 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 TNKDRLVTLEEFLKATEKKEFLEPDSWETLDQQQFF 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 TEEELKEYENH   A   LQENELKKKADELQKQKEELQRQ 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 HDQLEAQKLE   Y   HQVIQQMEQKKLQQGI   P   P   S   GPAGE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                     L   KFEPHI 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 193 
                 P01213 
                 1 
                 YGGFLRKYPK 
                 10 
                 Alpha- 
                 Opioid 
                   
                   
               
               
                   
                   
                   
                   
                   
                 neoendorphin 
                   
                   
                   
               
               
                   
               
               
                 194 
                 P01213 
                 1 
                 YGGFLRKYP 
                 9 
                 Beta- 
                 Opioid 
                   
                   
               
               
                   
                   
                   
                   
                   
                 neoendorphin 
                   
                   
                   
               
               
                   
               
               
                 195 
                 P01213 
                 1 
                 YGGFLRRIRPKLKWDNQKRYGGFLRRQFKVVT 
                 32 
                 Big dynorphin 
                 Opioid 
                   
                   
               
               
                   
               
               
                 196 
                 P01213 
                 1 
                 YGGFLRRIRPKLK 
                 13 
                 Dynorphin A(1- 
                 Opioid 
                   
                   
               
               
                   
                   
                   
                   
                   
                 13) (By 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 197 
                 P01213 
                 1 
                 YGGFLRRIRPKLKWDNQ 
                 17 
                 Dynorphin A(1- 
                 Opioid 
                   
                   
               
               
                   
                   
                   
                   
                   
                 17) 
                   
                   
                   
               
               
                   
               
               
                 198 
                 P01213 
                 1 
                 YGGFLRRI 
                 8 
                 Dynorphin A(1- 
                 Opioid 
                   
                   
               
               
                   
                   
                   
                   
                   
                 8) (By similarity) 
                   
                   
                   
               
               
                   
               
               
                 199 
                 P01213 
                 1 
                 YGGFL 
                 5 
                 Leu-enkephalin 
                 Opioid 
                   
                   
               
               
                   
               
               
                 200 
                 P01213 
                 1 
                 YGGFLRRQFKVVTRSQEDPNAYSGELFDA 
                 29 
                 Leumorphin 
                 Opioid 
                   
                   
               
               
                   
               
               
                 201 
                 P01210 
                 1 
                 YGGFM 
                 5 
                 Met-enkephalin 
                 Opioid 
                   
                   
               
               
                   
               
               
                 202 
                 P01210 
                 1 
                 YGGFMRGL 
                 8 
                 Met-enkephalin- 
                 Opioid 
                   
                   
               
               
                   
                   
                   
                   
                   
                 Arg-Gly-Leu 
                   
                   
                   
               
               
                   
               
               
                 203 
                 P01210 
                 1 
                 YGGFMRF 
                 7 
                 Met-enkephalin- 
                 Opioid 
                   
                   
               
               
                   
                   
                   
                   
                   
                 Arg-Phe 
                   
                   
                   
               
               
                   
               
               
                 204 
                 Q13519 
                 1 
                 MPRVRSLFQEQEE   P   EPGMEEAGEMEQKQLQ 
                 30 
                 Neuropeptide 1 
                 Opioid 
                 P14 
                 1 
               
               
                   
                   
                   
                   
                   
                 (Probable) 
                   
                   
                   
               
               
                   
               
               
                 205 
                 Q13519 
                 1 
                 FSEFMRQYLVLSMQSSQ 
                 17 
                 Neuropeptide 2 
                 Opioid 
                   
                   
               
               
                   
                   
                   
                   
                   
                 (Probable) 
                   
                   
                   
               
               
                   
               
               
                 206 
                 Q13519 
                 1 
                 FGGFTGARKSARKLANQ 
                 17 
                 Nociceptin 
                 Opioid 
                   
                   
               
               
                   
               
               
                 207 
                 P01210 
                 1 
                 DAEEDDSLANSSDLLKELLETGDNRERSHHQDGSD 
                 41 
                 PENK(143-183) 
                 Opioid 
                   
                   
               
               
                   
                   
                   
                 NEEEVS 
                   
                 (By similarity) 
                   
                   
                   
               
               
                   
               
               
                 208 
                 P01210 
                 1 
                 FAEALPSDEEGESYSKEVPEME 
                 22 
                 PENK(237-258) 
                 Opioid 
                   
                   
               
               
                   
                   
                   
                   
                   
                 (By similarity) 
                   
                   
                   
               
               
                   
               
               
                 209 
                 P01213 
                 1 
                 YGGFLRRQFKVVT 
                 13 
                 Rimorphin 
                 Opioid 
                   
                   
               
               
                   
               
               
                 210 
                 P01210 
                 1 
                 MDELYPMEPEEEANGSEILA 
                 20 
                 rimorphin 
                 Opioid 
                   
                   
               
               
                   
               
               
                 211 
                 P01210 
                 1 
                 ECSQDCATCSYRLVRPADINFLACVMECEGKLPSLK 
                 73 
                 Synenkephalin 
                 Opioid 
                   
                   
               
               
                   
                   
                   
                 IWETCKELLQLSKPELPQDGTSTLRENSKPEESHLLA 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 212 
                 O43612 
                 1 
                 QPLPDCCRQKTCSCRLYELLHGAGNHAAGILTL 
                 33 
                 Orexin-A 
                 Orexin 
                   
                   
               
               
                   
               
               
                 213 
                 O43612 
                 1 
                 RSGPPGLQGRLQRLLQASGNHAAGILTM 
                 28 
                 Orexin-B 
                 Orexin 
                   
                   
               
               
                   
               
               
                 214 
                 P12272 
                 1 
                 TRSAWLDSGVTGSGLEGDHLSDTSTTSLELDSR 
                 33 
                 Osteostatin 
                 Parathyroid hormone 
                   
                   
               
               
                   
               
               
                 215 
                 P12272 
                 1 
                 AVSEHQLLHDKGKSIQDLRRREFLHHLIAEIHTAEIR 
                 141 
                 Parathyroid 
                 Parathyroid hormone 
                 T39 
                 1 
               
               
                   
                   
                   
                 A   T   SEVSPNSKPSPNTKNHPVREGSDDEGRYLTQETN 
                   
                 hormone-related 
                   
                   
                   
               
               
                   
                   
                   
                 KVETYKEQPLKTPGKKKKGKPGKRKEQEKKKRRTR 
                   
                 protein 
                   
                   
                   
               
               
                   
                   
                   
                 SAWLDSGVTGSGLEGDHLSDTSTTSLELDSRRH 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 216 
                 P12272 
                 1 
                 AVSEHQLLHDKGKSIQDLRRREFLHHLIAEIHTAEI 
                 36 
                 PTHrP[1-36] 
                 Parathyroid hormone 
                   
                   
               
               
                   
               
               
                 217 
                 P12272 
                 1 
                 A   T   SEVSPNSKPSPNTKNHPVRFGSDDEGRYLTQETN 
                 57 
                 PTHrP[38-94] 
                 Parathyroid hormone 
                 T2 
                 1 
               
               
                   
                   
                   
                 KVETYKEQPLKTPGKKKKGKP 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 218 
                 Q96A98 
                 1 
                 SLALADDAAFRERARLLAALERRHWLNSYMHKLL 
                 39 
                 Tuberoinfundibular 
                 Parathyroid hormone 
                   
                   
               
               
                   
                   
                   
                 VLDAP 
                   
                 peptide of 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 39residues 
                   
                   
                   
               
               
                   
               
               
                 219 
                 P01189 
                 1 
                 YGGFMTSEK   S   Q   T   PLV   T   LEKNAIIKNAYKKGE 
                 31 
                 Beta-endorphin 
                 POMC 
                 S10, T12, T16 
                 3 
               
               
                   
               
               
                 220 
                 P01189 
                 1 
                 SYSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEA 
                 39 
                 Corticotropin 
                 POMC 
                   
                   
               
               
                   
                   
                   
                 FPLEF 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 221 
                 P01189 
                 1 
                 PVKVYPNGAEDESAEAFPLEF 
                 21 
                 Corticotropin- 
                 POMC 
                   
                   
               
               
                   
                   
                   
                   
                   
                 like intermediary 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 peptide 
                   
                   
                   
               
               
                   
               
               
                 222 
                 P01189 
                 1 
                 ELTGQRLREGDGPDGPADDGAGAQADLEHSLLVAA 
                 89 
                 Lipotropin beta 
                 POMC 
                 S68, T70, T74 
                 3 
               
               
                   
                   
                   
                 EKKDEGPYRMEHFRWGSPPKDKRYGGFMTSEK   S   Q 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                     T   PLV   T   LFKNAIIKNAYKKGE 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 223 
                 P01189 
                 1 
                 ELTGQRLREGDGPDGPADDGAGAQADLEHSLLVAA 
                 56 
                 Lipotropin 
                 POMC 
                   
                   
               
               
                   
                   
                   
                 EKKDEGPYRMEHFRWGSPPKD 
                   
                 gamma 
                   
                   
                   
               
               
                   
               
               
                 224 
                 P01189 
                 1 
                 SYSMEHFRWGKPV 
                 13 
                 Melanotropin 
                 POMC 
                   
                   
               
               
                   
                   
                   
                   
                   
                 alpha 
                   
                   
                   
               
               
                   
               
               
                 225 
                 P01189 
                 1 
                 DEGPYRMEHFRWGSPPKD 
                 18 
                 Melanotropin 
                 POMC 
                   
                   
               
               
                   
                   
                   
                   
                   
                 beta 
                   
                   
                   
               
               
                   
               
               
                 226 
                 P01189 
                 1 
                 YVMGHFRWDRF 
                 11 
                 Melanotropin 
                 POMC 
                   
                   
               
               
                   
                   
                   
                   
                   
                 gamma 
                   
                   
                   
               
               
                   
               
               
                 227 
                 P01189 
                 1 
                 WCLESSQCQDLTTESNLLECIRACKPDLSAETPMFP 
                 76 
                 NPP 
                 POMC 
                 T45 
                 1 
               
               
                   
                   
                   
                 GNGDEQPL   T   ENPRKYVMGHFRWDRFGRRNSSSSGS 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 SGAGQ 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 228 
                 P01189 
                 1 
                 EDVSAGEDCGPLPEGGPEPRSDGAKPGPRE 
                 30 
                 Potential peptide 
                 POMC 
                   
                   
               
               
                   
               
               
                 229 
                 Q9UHG2 
                 1 
                 LE T     PA   PQVPARRLLPP 
                 16 
                 Big LEN (By 
                 ProSAAS 
                 T3, P4, A5 
                 2 
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 230 
                 Q9UHG2 
                 1 
                 AADHDVGSELPPEGVLGALLRVKRLE T     PA   PQVPAR 
                 40 
                 Big PEN-LEN 
                 ProSAAS 
                 T27, P28, A29 
                 2 
               
               
                   
                   
                   
                 RLLPP 
                   
                 (By similarity) 
                   
                   
                   
               
               
                   
               
               
                 231 
                 Q9UHG2 
                 1 
                 ARPVKEPR   G   LSAA   S   PPLAE   T   GA   PRRF 
                 26 
                 Big SAAS (By 
                 ProSAAS 
                 G9, S14, T20, G21, A22 
                 5 
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 232 
                 Q9UHG2 
                 1 
                 ARPVKEP 
                 7 
                 KEP (By 
                 ProSAAS 
                   
                   
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 233 
                 Q9UHG2 
                 1 
                 LET   PA   PQVPA 
                 10 
                 Little LEN (By 
                 ProSAAS 
                 T3, P4, A5 
                 2 
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 234 
                 Q9UHG2 
                 1 
                     G   LSAA   S   PPLAE   T   GA   PRRF 
                 18 
                 Little SAAS (By 
                 ProSAAS 
                 G1, S6, T12, G13, A14 
                 5 
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 235 
                 Q9UHG2 
                 1 
                 AADHDVGSELPPEGVLGALLRV 
                 22 
                 PEN (By 
                 ProSAAS 
                   
                   
               
               
                   
                   
                   
                   
                   
                 similarity) 
                   
                   
                   
               
               
                   
               
               
                 236 
                 Q9UHG2 
                 1 
                 ARPVKEPR   G   LSAA   S   PPLAE   T   GA   PRRFRRSVPRGEAA 
                 227 
                 ProSAAS 
                 ProSAAS 
                 G9, S14, T20, G21, A22, A82, 
                 13 
               
               
                   
                   
                   
                 GAVQELARALAHLLEAERQERARAEAQEAEDQQA 
                   
                   
                   
                 N85, S86, A143, S173, A174, 
                   
               
               
                   
                   
                   
                 RVLAQLLRVWG   A   PR   N   S   DPALGLDDDPDAPAAQLAR 
                   
                   
                   
                 T214, P215, A216 
                   
               
               
                   
                   
                   
                 ALLRARLDPAALAAQLVPAPVPAAALRPRPPVYDD 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GP   A   GPDAEEAGDETPDVDPELLRYLLGRILAG   S   A   DS 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 EGVAAPRRLRRAADHDVGSELPPEGVLGALLRVKR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LE T     PA   PQVPARRLLPP 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 237 
                 Q9HD89 
                 1 
                 KTLCSMEEAINERIQEVAGSLIFRAISSIGLECQSVTS 
                 90 
                 Resistin 
                 Resistin/FIZZ 
                   
                   
               
               
                   
                   
                   
                 RGDLATCPRGFAVTGCTCGSACGSWDVRAETTCHC 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 QCAGMDWTGARCCRVQP 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 238 
                 Q9BQ08 
                 1 
                 QCSLDSVMDKKIKDVLNSLEYSPSPISKKLSCASVKS 
                 88 
                 Resistin-like beta 
                 Resistin/FIZZ 
                   
                   
               
               
                   
                   
                   
                 QGRPSSCPAGMAVTGCACGYGCGSWDVQLETTCH 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 CQCSVVDWTTARCCHLT 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 239 
                 P83859 
                 1 
                 QDEGSEATGFLPAAGEKTSGPLGNLAEELNGYSRK 
                 43 
                 QRF-amide 
                 RFamide neuropeptide 
                   
                   
               
               
                   
                   
                   
                 KGGFSFRF 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 240 
                 P06850 
                 1 
                 SEEPPISLDLTFHLLREVLEMARAEQLAQQAHSNRK 
                 41 
                 Corticoliberin 
                 Sauvagine/ 
                   
                   
               
               
                   
                   
                   
                 LMEII 
                   
                   
                 corticotropin- 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 releasing 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 factor/urotensin I 
                   
                   
               
               
                   
               
               
                 241 
                 P55089 
                 1 
                 DNPSLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFD 
                 40 
                 Urocortin 
                 Sauvagine/ 
                   
                   
               
               
                   
                   
                   
                 SV 
                   
                   
                 corticotropin- 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 releasing 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 factor/urotensin I 
                   
                   
               
               
                   
               
               
                 242 
                 Q96RP3 
                 1 
                 IVLSLDVPIGLLQILLEQARARAAREQATTNARILAR 
                 41 
                 Urocortin-2 
                 Sauvagine/ 
                   
                   
               
               
                   
                   
                   
                 VGHC 
                   
                   
                 corticotropin- 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 releasing 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 factor/urotensin I 
                   
                   
               
               
                   
               
               
                 243 
                 Q969E3 
                 1 
                 FTLSLDVPTNIMNLLFNIAKAKNLRAQAAANAHLM 
                 38 
                 Urocortin-3 
                 Sauvagine/ 
                   
                   
               
               
                   
                   
                   
                 AQI 
                   
                   
                 corticotropin- 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 releasing 
                   
                   
               
               
                   
                   
                   
                   
                   
                   
                 factor/urotensin I 
                   
                   
               
               
                   
               
               
                 244 
                 P01019 
                 1 
                 DRVY 
                 4 
                 Angiotensin 1-4 
                 Serpin 
                   
                   
               
               
                   
               
               
                 245 
                 P01019 
                 1 
                 DRVYI 
                 5 
                 Angiotensin 1-5 
                 Serpin 
                   
                   
               
               
                   
               
               
                 246 
                 P01019 
                 1 
                 DRVYIHP 
                 7 
                 Angiotensin 1-7 
                 Serpin 
                   
                   
               
               
                   
               
               
                 247 
                 P01019 
                 1 
                 DRVYIHPFH 
                 9 
                 Angiotensin 1-9 
                 Serpin 
                   
                   
               
               
                   
               
               
                 248 
                 P01019 
                 1 
                 DRVYIHPFHL 
                 10 
                 Angiotensin-1 
                 Serpin 
                   
                   
               
               
                   
               
               
                 249 
                 P01019 
                 1 
                 DRVYIHPF 
                 8 
                 Angiotensin-2 
                 Serpin 
                   
                   
               
               
                   
               
               
                 250 
                 P01019 
                 1 
                 RVYIHPF 
                 7 
                 Angiotensin-3 
                 Serpin 
                   
                   
               
               
                   
               
               
                 251 
                 P01019 
                 1 
                 VYIHPF 
                 6 
                 Angiotensin-4 
                 Serpin 
                   
                   
               
               
                   
               
               
                 252 
                 P01019 
                 1 
                 DRVYIHPFHLVIHNESTCEQLAKANAGKPKDPTFIPA 
                 452 
                 Angiotensinogen 
                 Serpin 
                 T407 or S409 or T410 or T422 
                 1 
               
               
                   
                   
                   
                 PIQAKTSPVDEKALQDQLVLVAAKLDFEDKLRAAM 
                   
                   
                   
                 (Ambiguous) 
                   
               
               
                   
                   
                   
                 VGMLANFLGFRIYGMHSELWGVVHGATVLSPTAVF 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GTLASLYLGALDHTADRLQAILGVPWKDKNCTSRL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DAHKVLSALQAVQGLLVAQGRADSQAQLLLSTVV 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GVFTAPGLHLKQPFVQGLALYTPVVLPRSLDFTELD 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 VAAEKIDRFMQAVTGWKTGCSLMGASVDSTLAFN 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 TYVHFQGKMKGFSLLAEPQEFWVDNSTSVSVPMLS 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GMGTFQHWSDIQDNFSVTQVPFTESACLLLIQPHYA 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 SDLDKVEGLTFQQNSLNWMKKLSPRTIHLTMPQLV 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LQGSYDLQDLLAQAELPAILHFELNLQKLSNDRIRV 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GEVLNSIFFELEADEREP   T   E   ST   QQLNKPEVLEV   T   LNR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 PFLFAVYDQSATALHFLGRVANPLSTA 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 253 
                 P08185 
                 1 
                 MDPNAAYVNMSNHHRGLASANVDFAFSLYKHLVA 
                 383 
                 Corticosteroid- 
                 Serpin 
                   
                   
               
               
                   
                   
                   
                 LSPKKNIFISPVSISMALAMLSLGTCGHTRAQLLQGL 
                   
                 binding globulin 
                   
                   
                   
               
               
                   
                   
                   
                 GFNLTERSETEIHQGFQHLHQLFAKSDTSLEMTMGN 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 ALFLDGSLELLESFSADIKHYYESEVLAMNFQDWAT 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 ASRQINSYVKNKTQGKIVDLFSGLDSPAILVLVNYIF 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 FKGTWTQPFDLASTREENFYVDETTVVKVPMMLQS 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 STISYLHDSELPCQLVQMNYVGNGTVFFILPDKGKM 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 NTVIAALSRDTINRWSAGLTSSQVDLYIPKVTISGVY 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DLGDVLEEMGIADLFTNQANFSRITQDAQLKSSKVV 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 HKAVLQLNEEGVDTAGSTGVTLNLTSKPIILRFNQPF 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 IIMIFDHFTWSSLFLARVMNPV 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 254 
                 Q86U17 
                 1 
                 QPLLAHGDKSLQGPQPPRHQLSEPAPAYHRITPTITN 
                 403 
                 Serpin A11 
                 Serpin 
                   
                   
               
               
                   
                   
                   
                 FALRLYKELAADAPGNIFFSPVSISTTLALLSLGAQA 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 NTSALILEGLGFNLTETPEADIHQGFRSLLHTLALPSP 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KLELKVGNSLFLDKRLKPRQHYLDSIKELYGAFAFS 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 ANFTDSVTTGRQINDYLRRQTYGQVVDCLPEFSQDT 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 FMVLANYIFFKAKWKHPFSRYQTQKQESFFVDERTS 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LQVPMMHQKEMHRFLYDQDLACTVLQIEYRGNAL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 ALLVLPDPGKMKQVEAALQPQTLRKWGQLLLPSLL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DLHLPRFSISGTYNLEDILPQIGLTNILNLEADFSGVT 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GQLNKTISKVSHKAMVDMSEKGTEAGAASGLLSQP 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 PSLNTMSDPHAHFNRPFLLLLWEVTTQSLLFLGKVV 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 NPVAG 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 255 
                 Q8IW75 
                 1 
                 LKPSFSPRNYKALSEVQGWKQRMAAKELARQNMD 
                 394 
                 Serpin A12 
                 Serpin 
                   
                   
               
               
                   
                   
                   
                 LGFKLLKKLAFYNPGRNIFLSPLSISTAFSMLCLGAQ 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DSTLDEIKQGFNFRKMPEKDLHEGFHYIIHELTQKT 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 QDLKLSIGNTLFIDQRLQPQRKFLEDAKNFYSAETIL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 TNFQNLEMAQKQINDFISQKTHGKINNLIENIDPGTV 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 MLLANYIFFRARWKHEFDPNVTKEEDFFLEKNSSVK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 VPMMFRSGIYQVGYDDKLSCTILEIPYQKNITAIFILP 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DEGKLKHLEKGLQVDTFSRWKTLLSRRVVDVSVPR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LHMTGTFDLKKTLSYIGVSKIFEEHGDLTKIAPHRSL 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KVGEAVHKAELKMDERGTEGAAGTGAQTLPMETP 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LVVKIDKPYLLLIYSEKIPSVLFLGKIVNPIGK 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 256 
                 O75830 
                 1 
                 SRCSAQKNTEFAVDLYQEVSLSHKDNIIFSPLGITLV 
                 387 
                 Serpin 12 
                 Serpin 
                   
                   
               
               
                   
                   
                   
                 LEMVQLGAKGKAQQQIRQTLKQQETSAGEEFFVLK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 SFFSAISEKKQEFTFNLANALYLQEGFTVKEQYLHG 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 NKEFFQSAIKLVDFQDAKACAEMISTWVERKTDGKI 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 KDMFSGEEFGPLTRLVLVNAIYFKGDWKQKFRKED 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 TQLINFTKKNGSTVKIPMMKALLRTKYGYFSESSLN 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 YQVLELSYKGDEFSLIIILPAEGMDIEEVEKLITAQQI 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LKWLSEMQEEEVEISLPREKVEQKVDEKDVLYSLNI 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 TEIFSGGCDLSGITDSSEVYVSQVTQKVFFEINEDGS 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 EAATSTGIHIPVIMSLAQSQFIANHPFLFIMKHNPTES 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 ILFMGRVTNPDTQEIKGRDLDSL 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 257 
                 O00230 
                 1 
                 DRMPCRNFFWKTFSSCK 
                 17 
                 Cortistatin-17 
                 Somastostatin 
                   
                   
               
               
                   
               
               
                 258 
                 O00230 
                 1 
                 QEGAPPQQSARRDRMPCRNFFWKITSSCK 
                 29 
                 Cortistatin-29 
                 Somastostatin 
                   
                   
               
               
                   
                   
                   
                   
                   
                 (Potential) 
                   
                   
                   
               
               
                   
               
               
                 259 
                 P61278 
                 1 
                 AGCKNFFWKTFTSC 
                 14 
                 Somatostatin-14 
                 Somastostatin 
                   
                   
               
               
                   
               
               
                 260 
                 P61278 
                 1 
                     S   AN   S   NPAMAPRERKAGCKNFFWKTFTSC 
                 28 
                 Somatostatin-28 
                 Somastostatin 
                 S1 or S4 (Ambiguous) 
                 1 
               
               
                   
               
               
                 261 
                 P01236 
                 1 
                 LPICPGGAARCQVTLRDLFDRAVVLSHYIHNLSSEM 
                 199 
                 Prolactin 
                 Somatotropin/ 
                   
                   
               
               
                   
                   
                   
                 FSEFDKRYTHGRGFITKAINSCHTSSLATPEDKEQAQ 
                   
                   
                 prolactin 
                   
                   
               
               
                   
                   
                   
                 QMNQKDFLSLIVSILRSWNEPLYHLVTEVRGMQEAP 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 EAILSKAVEIEEQTKRLLEGMELIVSQVHPETKENEI 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 YPVWSGLPSLQMADEESRLSAYYNLLHCLRRDSHK 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 IDNYLKLLKCRIIHNNNC 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 262 
                 P20366 
                 1 
                     A   LN   S   VAYERSAMQNYE 
                 15 
                 C-terminal- 
                 Tachykinin 
                 A1, S4 
                 2 
               
               
                   
                   
                   
                   
                   
                 flanking peptide 
                   
                   
                   
               
               
                   
               
               
                 263 
                 P20366 
                 1 
                 HKTDSFVGLM 
                 10 
                 Neurokinin A 
                 Tachykinin 
                   
                   
               
               
                   
               
               
                 264 
                 Q9UHF0 
                 1 
                 DMHDFFVGLM 
                 10 
                 Neurokinin-B 
                 Tachykinin 
                   
                   
               
               
                   
               
               
                 265 
                 P20366 
                 1 
                 DADSSIEKQVALLKALYGHGQISHKRHKTDSFVGL 
                 36 
                 Neuropeptide K 
                 Tachykinin 
                   
                   
               
               
                   
                   
                   
                 M 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 266 
                 P20366 
                 1 
                 RPKPQQFFGLM 
                 11 
                 Substance P 
                 Tachykinin 
                   
                   
               
               
                   
               
               
                 267 
                 P20396 
                 1 
                 QPEAAQQEAVTAAEHPGLDDFLRQVERLLFLRENIQ 
                 218 
                 Pro-thyrotropin- 
                 TRH 
                 I50 
                 1 
               
               
                   
                   
                   
                 RLQGDQGEHSASQ   I   FQSDWLSKRQHPGKREEEEEEG 
                   
                   
                 releasing 
                   
                   
               
               
                   
                   
                   
                 VEEEEEEEGGAVGPHKRQHPGRREDEASWSVDVTQ 
                   
                   
                 hormone 
                   
                   
               
               
                   
                   
                   
                 HKRQHPGRRSPWLAYAVPKRQHPGRRLADPKAQR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 SWEEEEEEEEREEDLMPEKRQHPGKRALGGPCGPQ 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GAYGQAGLLLGLLDDLSRSQGAEEKRQHPGRRAA 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 WVREPLEE 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 268 
                 P20396 
                 1 
                 QHP 
                 3 
                 Thyrotropin- 
                 TRH 
                   
                   
               
               
                   
                   
                   
                   
                   
                 releasing 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 hormone 
                   
                   
                   
               
               
                   
               
               
                 269 
                 O95399 
                 1 
                 ETPDCFWKYCV 
                 11 
                 Urotensin-2 
                 Urotensin-2 
                   
                   
               
               
                   
               
               
                 270 
                 Q76510 
                 1 
                 ACFWKYCV 
                 8 
                 Urotensin-2B 
                 Urotensin-2 
                   
                   
               
               
                   
               
               
                 271 
                 P01185 
                 1 
                 CYFQNCPRG 
                 9 
                 Arg-vasopressin 
                 Vasopressin/oxytocin 
                   
                   
               
               
                   
               
               
                 272 
                 P01185 
                 1 
                 ASDRSNATQLDGPAGALLLRLVQLAG   A   PEPFLPAQP 
                 39 
                 Copeptin 
                 Vasopressin/oxytocin 
                 A27 
                 1 
               
               
                   
                   
                   
                 DAY 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 273 
                 P01178 
                 1 
                 AAPDLDVRKCLPCGPGGKGRCFGPNICCAEELGCFV 
                 94 
                 Neurophysin 1 
                 Vasopressin/oxytocin 
                   
                   
               
               
                   
                   
                   
                 GTAEALRCQEENYLPSPCQSGQKACGSGGRCAVLG 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LCCSPDGCHADPACDAEATFSQR 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 274 
                 P01185 
                 1 
                 AMSDLELRQCLPCGPGGKGRCFGPSICCADELGCFV 
                 93 
                 Neurophysin 2 
                 Vasopressin/oxytocin 
                   
                   
               
               
                   
                   
                   
                 GTAEALRCQEENYLPSPCQSGQKACGSGGRCAAFG 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 VCCNDESCVTEPECREGFFIRRA 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 275 
                 P01178 
                 1 
                 CYIQNCPLG 
                 9 
                 Oxytocin 
                 Vasopressin/oxytocin 
                   
                   
               
               
                   
               
               
                 276 
                 O15240 
                 1 
                 TLQPPSALRRRHYHHALPPSRHYP 
                 24 
                 Antimicrobial 
                 VGF 
                   
                   
               
               
                   
                   
                   
                   
                   
                 peptide 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 VGF[554-577] 
                   
                   
                   
               
               
                   
               
               
                 277 
                 O15240 
                 1 
                 RPESALLGGSEAGERLLQQGLAQVEA 
                 26 
                 Neuroendocrine 
                 VGF 
                   
                   
               
               
                   
                   
                   
                   
                   
                 regulatory 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 peptide-1 
                   
                   
                   
               
               
                   
               
               
                 278 
                 O15240 
                 1 
                 QAEATRQAAAQEERLADLASDLLLQYLLQGGARQR 
                 38 
                 Neuroendocrine 
                 VGF 
                   
                   
               
               
                   
                   
                   
                 GLG 
                   
                 regulatory 
                   
                   
                   
               
               
                   
                   
                   
                   
                   
                 peptide-2 
                   
                   
                   
               
               
                   
               
               
                 279 
                 O15240 
                 1 
                 AP   P   GRPEAQPPPL   S   SEHKEPVAGDAVPGPKDGSAPE 
                 591 
                 Neurosecretory 
                 VGF 
                 P1, S12, P202, S205, 
                 5 
               
               
                   
                   
                   
                 VRGARNSEPQDEGELFQGVDPRALAAVLLQALDRP 
                   
                 protein VGF 
                   
                 T477 
                   
               
               
                   
                   
                   
                 ASPPAPSGSQQGPEEEAAEALLTETVRSQTHSLPAPE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 SPEPAAPPRPQTPENGPEASDPSEELEALASLLQELR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 DFSPSSAKRQQETAAAETETRTHTLTRVNLESPGPE 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 RVWRASWGEFQARVPERAPLPP   P   APSQFQARMPDS 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GPLPETHKFGEGVSSPKTHLGEALAPLSKAYQGVAA 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 PFPKARRPESALLGGSEAGERLLQQGLAQVEAGRR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 QAEATRQAAAQEERLADLASDLLLQYLLQGGARQR 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 GLGGRGLQEAAEERESAREEEEAEQERRGGEERVG 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 EEDEEAAEAEAEAEEAERARQNALLFAEEEDGEAG 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 AEDKRSQEETPGHRRKEAEGTEEGGEEEDDEEMDP 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 QTIDSLIELSTKLHLPADDVVSIIEEVEEKRKRKKNA 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 PPEPVPPPRAAPAP   T   HVRSPQPPPPAPAPARDELPDW 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 NEVLPPWDREEDEVYPPGPYHPFPNYIRPRTLQPPSA 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 LRRRHYHHALPPSRHYPGREAQARRAQEEAEAEER 
                   
                   
                   
                   
                   
               
               
                   
                   
                   
                 RLQEQEELENYIEHVLLRRP 
               
               
                   
               
            
           
         
       
     
     EMBODIMENTS 
     1. An isolated peptide hormone, such as recombinant, such as a neuropeptide comprising one or more O-linked glycan at a predetermined specific site, such as in the receptor-binding region. 
     2. The peptide hormone according to embodiment 1, wherein the one or more O-glycan structures include a glycan structure selected from a core1, core2, core3, or core4 structure with sialic acid capping, such as a structure as illustrated in  FIG. 1 . 
     3. The peptide hormone according to embodiments 1 or 2, wherein the one or more O-glycan structures include a Tn (GalNAc) structure. 
     4. The peptide hormone according to any one of embodiments 1-3, wherein the one or more O-glycan structures include Tn (GalNAc) structure with one sialic acid capping (alpha2-6). 
     5. The peptide hormone according to any one of embodiments 1-4, wherein the one or more O-glycan structures include the core1 structures with one sialic acid capping (alpha2-6). 
     6. The peptide hormone according to any one of embodiments 1-5, wherein the one or more O-glycan structures include the core1 structures with one sialic acid capping (alpha 2-3) 
     7. The peptide hormone according to any one of embodiments 1-6, wherein the one or more O-glycan structures include the core1 structures with two sialic acids capping (alpha 2-3 and alpha 2-6). 
     8. The peptide hormone according to any one of embodiments 1-7, which peptide hormone has improved, such as increased stability and/or circulatory half-life and/or other pharmacokinetic properties, such as improved stability in in vitro assays, plasma and/or bodyfluids. 
     9. The peptide hormone according to any one of embodiments 1-8, which peptide hormone has lower bioactivity in receptor signalling, such as decreased receptor stimulation in in vitro cell assays and/or in man. 
     10. The peptide hormone according to any one of embodiments 1-9, which peptide hormone exhibits improved receptor stimulation in in vitro cell assays and/or in man. 
     11. The peptide hormone according to any one of embodiments 1-10, which peptide hormone exhibits altered blood-brain barrier uptake in animals or in man, such as increased blood-brain barrier uptake in animals or in man, or decreased blood-brain barrier uptake in animals or in human. 
     12. The peptide hormone according to any one of embodiments 1-11, which peptide hormone exhibits receptor sub-type selectivity switch. 
     13. The peptide hormone according to any one of embodiments 1-12, which peptide hormone is specific to one or more tissue in human, such as specific to tissue of the nervous system. 
     14. The peptide hormone according to any one of embodiments 1-13, which peptide hormone is selected from any one of tables 4, 5, or 6, such as selected from the list consisting of a peptide of the Neuropeptide Y family, such as NPY, PPY and PYY; a peptide of the Glucagon/Secretin family, such as GIP, Glucagon, GLP-1, GLP-2, PACAP, Secretin, PHM-27/PHV-42, Somatoliberin, and VIP; a peptide of the Natriuretic peptide family, such as ANP, BNP and CNP, a peptide of the calcitonin family, such as calcitonin, and amylin. 
     15. The peptide hormone according to any one of embodiments 1-14, which peptide hormone is not found in nature. 
     16. The peptide hormone according to any one of embodiments 1-15, which peptide hormone is a truncated version or a variant as compared to the corresponding wild-type peptide hormone found in nature. 
     17. The peptide hormone according to any one of embodiments 1-16, which peptide hormone is selected from any one of table 6 comprising one or more O-linked glycan at a site as indicated in table 6, such as at a bold underlined position and/or an italic underlined position. 
     18. The peptide hormone according to any one of embodiments 1-17, which peptide hormone is selected from any one of table 6 comprising at least, not more than, or the exact number of O-linked glycan sites as indicated in table 6. 
     19. The peptide hormone according to any one of embodiments 1-16, which peptide hormone is selected from any one of table 5. 
     20. A host cell comprising two or more glycosyltransferase genes that have been inactivated such that 
     (a) Homogenous Tn (GalNAc) glycosylation is obtained by inactivation and/or downregulation of one or more genes selected from COSMC and C1GALT1;
 
(b) Homogenous T (Gal/GalNAc) glycosylation is obtained by inactivation and/or downregulation of one or more genes selected from GCNT1, GCNT3, GCNT4, B3GNT6; and
 
(c) Homogenous ST or STn glycosylation is obtained by inactivation and/or downregulation of one or more genes selected from ST6GALNAC1-6, ST3GAL1, GCNT3, GCNT4, B3GNT6.
 
     21. The host cell according to embodiment 20, further comprising a gene encoding an exogenous peptide hormone, such as a peptide hormone as defined in any one of embodiments 14-19. 
     22. A method for producing an isolated peptide hormone comprising one or more O-linked glycan at a predetermined specific site, such as in the receptor-binding region, the method comprising;
         a) inactivation and/or downregulation of one or more glycosyltransferases, and/or knock in of one or more glycosyltransferases, or any combination hereof in a host cell, and   b) expression of said peptide hormone in said host cell.       

     23. The method according to embodiment 22, wherein one or more genes selected from COSMC, C1GALT1, GCNT1, GCNT3, GCNT4, B3GNT6, ST6GALNAC1-6, ST3GAL1 has been inactivated and/or downregulated. 
     24. The method according to embodiments 22 or 23, wherein said peptide hormone produced is as defined in any one of embodiments 1-19. 
     25. The method according to any one of embodiments 22-24, wherein said host cell is as defined in any of embodiments 20-21. 
     26. A method for the production of recombinant glycosylated peptide hormones that do not have specific types of glycosylation, the method comprising the step of inactivating two or more glycogenes to block and/or truncate one or more glycosylation pathways. 
     27. A method for the production of an isolated peptide hormone, such as a neuropeptide comprising one or more O-linked glycan at a predetermined specific site, such as in the receptor-binding region, said method comprising
         a) providing a non-O-glycosylated peptide hormone; and   b) treating said non-O-glycosylated synthetic peptide hormone with one or more recombinant purified glycosyl transferase, such as a GalNAc-transferase, such as GalNAc-T1, T2, T3, T4, T5, T6, T7, T10, T11, T12, T13, T14, and/or T16, and/or a Galactosyl-transferases (C1GalT1) and/or a sialyl-transferases, such as ST6GalNAc1 and/or ST3Gall under conditions to add one or more specific O-linked glycan to said peptide hormone.       

     28. The method according to embodiment 27, wherein said non-O-glycosylated peptide hormone is provided as a chemically produced peptide hormone produced using solid phase peptide synthesis Fmoc SPPS. 
     29. The method according to embodiment 27, wherein said non-O-glycosylated peptide hormone is provided as a recombinantly produced peptide hormone, such as produced in a production cell line. 
     30. The method according to any one of embodiments 27-29, wherein said peptide hormone produced is as defined in any one of embodiments 1-19. 
     31. A method for the production of an isolated peptide hormone, such as a neuropeptide comprising one or more O-linked glycan at a predetermined specific site, such as in the receptor-binding region, said method comprising the building of said peptide hormone using solid phase peptide synthesis Fmoc SPPS including the use of glycosylated amino acids building blocks at said predetermined specific site(s). 
     32. The method according to embodiment 31, wherein the peptide hormone produced is as defined in any one of embodiments 1-19. 
     ADDITIONAL EMBODIMENTS 
     a. An isolated peptide hormone, such as recombinant, such as a neuropeptide comprising one or more O-linked glycan at a predetermined specific site, such as in the receptor-binding region. 
     b. The peptide hormone according to embodiment a), wherein the one or more O-glycan structures include a glycan structure selected from a core1, core2, core3, or core4 structure with sialic acid capping, such as a structure as illustrated in  FIG. 1 . 
     c. The peptide hormone according to embodiments a) or b), wherein the one or more O-glycan structures include a Tn (GalNAc) structure. 
     d. The peptide hormone according to any one of embodiments a) to c), wherein the one or more O-glycan structures include Tn (GalNAc) structure with one sialic acid capping (alpha2-6). 
     e. The peptide hormone according to any one of embodiments a)-d), wherein the one or more O-glycan structures include the core1 structures with one sialic acid capping (alpha2-6). 
     f. The peptide hormone according to any one of embodiments a)-e), wherein the one or more O-glycan structures include the core1 structures with one sialic acid capping (alpha 2-3) 
     g. The peptide hormone according to any one of embodiments a)-f), wherein the one or more O-glycan structures include the core1 structures with two sialic acids capping (alpha 2-3 and alpha 2-6). 
     h. The peptide hormone according to any one of embodiments a)-g), which peptide hormone has improved, such as increased stability and/or circulatory half-life and/or other pharmacokinetic properties, such as improved stability in in vitro assays, plasma and/or bodyfluids. 
     i. The peptide hormone according to any one of embodiments a)-h), which peptide hormone has lower bioactivity in receptor signalling, such as decreased receptor stimulation in in vitro cell assays and/or in man. 
     j. The peptide hormone according to any one of embodiments a)-i), which peptide hormone exhibits improved receptor stimulation in in vitro cell assays and/or in man. 
     k. The peptide hormone according to any one of embodiments a)-j), which peptide hormone exhibits altered blood-brain barrier uptake in animals or in man, such as increased blood-brain barrier uptake in animals or in man, or decreased blood-brain barrier uptake in animals or in human. 
     l. The peptide hormone according to any one of embodiments a)-k), which peptide hormone exhibits receptor sub-type selectivity switch. 
     m. The peptide hormone according to any one of embodiments a)-l), which peptide hormone is selected from any one of tables 4, 5, or 6, such as selected from the list consisting of a peptide of the Neuropeptide Y family, such as NPY, PPY and PYY; a peptide of the Glucagon/Secretin family, such as GIP, Glucagon, GLP-1, GLP-2, PACAP, Secretin, PHM-27/PHV-42, Somatoliberin, and VIP; a peptide of the Natriuretic peptide family, such as ANP, BNP and CNP, a peptide of the calcitonin family, such as calcitonin, and amylin. 
     n. The peptide hormone according to any one of embodiments a)-m), which peptide hormone is not found in nature, such as a truncated version or a variant as compared to the corresponding wild-type peptide hormone found in nature. 
     o. The peptide hormone according to any one of embodiments a)-n), which peptide hormone is selected from any one of table 6 comprising one or more O-linked glycan at a site as indicated in table 6, such as at a bold underlined position and/or an italic underlined position. 
     LIST OF REFERENCES 
     
         
         1 Seidah, N. G. What lies ahead for the proprotein convertases?  Ann N Y Acad Sci  1220, 149-161, doi: 10.1111/j. 1749-6632.2010.05883.x (2011). 
         2 Milgram, S. L., Mains, R. E. &amp; Eipper, B. A. COOH-terminal signals mediate the trafficking of a peptide processing enzyme in endocrine cells.  J Cell Biol  121, 23-36 (1993). 
         3 Bundgaard, J. R., Vuust, J. &amp; Rehfeld, J. F. Tyrosine O-sulfation promotes proteolytic processing of progastrin.  The EMBO journal  14, 3073-3079 (1995). 
         4 Drazic, A., Myklebust, L. M., Ree, R. &amp; Arnesen, T. The world of protein acetylation.  Biochim Biophys Acta  1864, 1372-1401, doi:10.1016/j.bbapap.2016.06.007 (2016). 
         5 Secher, A. et at. Analytic framework for peptidomics applied to large-scale neuropeptide identification.  Nature communications  7, 11436, doi:10.1038/ncomms11436 (2016). 
         6 Mentlein, R. Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides.  Regulatory peptides  85, 9-24 (1999). 
         7 Potter, L. R. Natriuretic peptide metabolism, clearance and degradation.  Febs J  278, 1808-1817, doi:10.1111/j.1742-4658.2011.08082.x (2011). 
         8 Deacon, C. F., Nauck, M. A., Meier, J., Hucking, K. &amp; Holst, J. J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.  J Clin Endocrinol Metab  85, 3575-3581, doi: 10.1210/jcem.85.10.6855 (2000). 
         9 Halim, A., Ruetschi, U., Larson, G. &amp; Nilsson, J. LC-MS/MS characterization of O-glycosylation sites and glycan structures of human cerebrospinal fluid glycoproteins.  Journal of proteome research  12, 573-584, doi:10.1021/pr300963 h (2013). 
         10 Halim, A., Nilsson, J., Ruetschi, U., Hesse, C. &amp; Larson, G. Human urinary glycoproteomics; attachment site specific analysis of N- and O-linked glycosylations by CID and ECD.  Molecular  &amp; cellular proteomics: MCP 11, Mill 013649, doi: 10.1074/mcp.M 111.013649 (2012). 
         11 Khetarpal, S. A. et at Loss of Function of GALNT2 Lowers High-Density Lipoproteins in Humans, Nonhuman Primates, and Rodents.  Cell Metab  24, 234-245, doi: 10.1016/j.cmet.2016.07.012 (2016). 
         12 King, S. L. et at Characterizing the O-glycosylation landscape of human plasma, platelets, and endothelial cells.  Blood Advances  1, 429-442, doi: 10.1182/bloodadvances. 2016002121 (2017). 
         13 Yu, Q. et at Targeted Mass Spectrometry Approach Enabled Discovery of O-Glycosylated Insulin and Related Signaling Peptides in Mouse and Human Pancreatic Islets.  Anal Chem, doi: 10.1021/acs.analchem.7b01926 (2017). 
         14 Cao, F. et at Detection of Biosynthetic Precursors, Discovery of Glycosylated Forms, and Homeostasis of Calcitonin in Human Cancer Cells.  Anal Chem  89, 6992-6999, doi: 10.1021/acs.analchem.7b00457 (2017). 
         15 Bennett, E. P. et at Control of mucin-type O-glycosylation: A classification of the polypeptide GalNAc-transferase gene family.  Glycobiology  22, 736-756, doi:Doi 10.1093/Glycob/Cwr182 (2012). 
         16 Topaz, O. et at Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis.  Nat Genet  36, 579-581, doi:10.1038/ng1358 (2004). 
         17 Kato, K. et at Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation.  J Biol Chem  281, 18370-18377, doi:M602469200 [pii]10.1074/jbe.M602469200 (2006). 
         18 Schjoldager, K. T. et at Probing isoform-specific functions of polypeptide GalNAc-transferases using zinc finger nuclease glycoengineered SimpleCells.  Proc Natl Acad Sci U SA  109, 9893-9898, doi: 10.1073/pnas. 1203563109 (2012). 
         19 Chretien, M. &amp; Mbikay, M. 60 YEARS OF POMC: From the prohormone theory to pro-opiomelanocortin and to proprotein convertases (PCSK1 to PCSK9).  J Mol Endocrinol  56, T49-62, doi: 10.1530/JME-15-0261 (2016). 
         20 Walsh, G. &amp; Jefferis, R. Post-translational modifications in the context of therapeutic proteins.  Nature biotechnology  24, 1241-1252, doi:10.1038/nbt1252 (2006). 
         21 Tenno, M. et al. Initiation of protein O glycosylation by the polypeptide GalNAcT-1 in vascular biology and humoral immunity. Mol Cell Biol 27, 8783-8796, doi:10.1128/MCB.01204-07 (2007). 
         22 Tian, E. &amp; Ten Hagen, K. G. A UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase is required for epithelial tube formation. J Biol Chem 282, 606-614, doi: 10.1074/jbe.M606268200 (2007). 
         23 Freire-de-Lima, L. et al. Involvement of O-glycosylation defining oncofetal fibronectin in epithelial-mesenchymal transition process.  Proc Natl Acad Sci USA  108, 17690-17695, doi: 10.1073/pnas. 1115191108 (2011). 
         24 Schjoldager, K. T. &amp; Clausen, H. Site-specific protein O-glycosylation modulates proprotein processing—deciphering specific functions of the large polypeptide GalNAc-transferase gene family.  Biochim Biophys Acta  1820, 2079-2094, doi:10.1016/j.bbagen.2012.09.014 (2012). 
         25 Tagliabracci, V. S. et al. Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis.  Proc Natl Acad Sci USA  111, 5520-5525, doi: 10.1073/pnas. 1402218111 (2014). 
         26 Goth, C. K. et at. A systematic study of modulation of ADAM-mediated ectodomain shedding by site-specific O-glycosylation.  Proc Natl Acad Sci USA  112, 14623-14628, doi: 10.1073/pnas. 1511175112 (2015). 
         27 Norden, R. et al. O-linked glycosylation of the mucin domain of the herpes simplex virus type 1-specific glycoprotein gC-1 is temporally regulated in a seed-and-spread manner.  The Journal of biological chemistry  290, 5078-5091, doi:10.1074/jbc.M114.616409 (2015). 
         28 Schjoldager, K. T. et al. Deconstruction of O-glycosylation—GalNAc-T isoforms direct distinct subsets of the O-glycoproteome.  EMBO Rep  16, 1713-1722, doi: 10.15252/embr.201540796 (2015). 
         29 Tian, E. et al. Galnt1 is required for normal heart valve development and cardiac function.  PLoS One  10, e0115861, doi:10.1371/journal.pone.0115861 (2015). 
         30 Akasaka-Manya, K. et al. Excess APP O-glycosylation by GalNAc-T6 decreases Abeta production.  Journal of biochemistry  161, 99-111, doi: 10.1093/jb/mvw056 (2017). 
         31 Lin, J. et al. GALNT6 Stabilizes GRP78 Protein by O-glycosylation and Enhances its Activity to Suppress Apoptosis Under Stress Condition.  Neoplasia  ( New York, N.Y.  19, 43-53, doi: 10.1016/j.neo.2016.11.007 (2017). 
         32 Goth, C. K. et al. Site-specific O-glycosylation by Polypeptide GalNAc-transferase T2 Co-regulates Beta1-adrenergic Receptor N-terminal Cleavage. J Biol Chem, doi: 10.1074/j be. Ml 16.730614 (2017). 
         33 Schjoldager, K. T. B. G. et al. A Systematic Study of Site-specific GalNAc-type O-Glycosylation Modulating Proprotein Convertase Processing.  Journal of Biological Chemistry  286, 40122-40132, doi:10.1074/jbc.M111.287912 (2011). 
         34 Schjoldager, K. T. B. G. et al. O-Glycosylation Modulates Proprotein Convertase Activation of Angiopoietin-like Protein 3 POSSIBLE ROLE OF POLYPEPTIDE GalNAc-TRANSFERASE-2 IN REGULATION OF CONCENTRATIONS OF PLASMA LIPIDS.  Journal of Biological Chemistry  285, 36293-36303, doi:10.1074/jbc.M110.156950 (2010). 
         35 Pedersen, N. B. et al. Low density lipoprotein receptor class a repeats are o-glycosylated in linker regions.  J Biol Chem  289, 17312-17324, doi:10.1074/jbc.M113.545053 (2014). 
         36 Wang, S. et al. Site-specific O-glycosylation of members of the low-density lipoprotein receptor superfamily enhances ligand interactions.  J Biol Chem, doi:  10.1074/j be. Ml 17.817981 (2018). 
         37 Pedragosa-Badia, X., Stichel, J. &amp; Beck-Sickinger, A. G. Neuropeptide Y receptors: how to get subtype selectivity.  Front Endocrinol  ( Lausanne ) 4, 5, doi: 10.3389/fendo.2013.00005 (2013). 
         38 Tan, T. et al. The effect of a subcutaneous infusion of GLP-1, OXM and PYY on Energy intake and Expenditure in Obese volunteers.  J Clin Endocrinol Metab, doi: 10.1210/jc.2017-00469 (2017). 
         39 van Deursen, V. M. et al. Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF).  Circulation  130, 958-965, doi:10.1161/CIRCULATIONAHA.113.003046 (2014). 
         40 Boerrigter, G. &amp; Burnett, J. C., Jr. Natriuretic peptides renal protective after all?  J Am Coll  Cardiol 58, 904-906, doi:10.1016/j.jacc.2010.12.053 (2011). 
         41 Hata, N. et al. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study.  Circ J  72, 1787-1793 (2008). 
         42 Fosgerau, K. &amp; Hoffmann, T. Peptide therapeutics: current status and future directions.  Drug Discov Today  20, 122-128, doi:10.1016/j.drudis.2014.10.003 (2015). 
         43 Yi, J., Warunek, D. &amp; Craft, D. Degradation and Stabilization of Peptide Hormones in Human Blood Specimens.  PLoS One  10, e0134427, doi: 10.1371/journal.pone.0134427 (2015). 
         44 Chapter, M. C. et at. Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.  Pharmacol Ther  125, 39-54, doi:10.1016/j.pharmthera.2009.07.006 (2010). 
         45 DeFrees, S. et al. GlycoPEGylation of recombinant therapeutic proteins produced in  Escherichia coli. Glycoblology  16, 833-843, doi:10.1093/glycob/cwl004 (2006). 
         46 Meurer, J. A., Colca, J. R., Burton, P. S. &amp; Elhammer, A. P. Properties of native and in vitro glycosylated forms of the glucagon-like peptide-1 receptor antagonist exendin(9-39).  Metabolism: clinical and experimental  48, 716-724 (1999). 
         47 Egleton, R. D. et al. Improved blood-brain barrier penetration and enhanced analgesia of an opioid peptide by glycosylation.  J Pharmacol Exp Ther  299, 967-972 (2001). 
         48 Kihlberg, J. et al. Glycosylated peptide hormones: pharmacological properties and conformational studies of analogues of [1-desamino,8-D-arginine]vasopressin.  J Med Chem  38, 161-169 (1995). 
         49 Ueda, T. et al. Chemoenzymatic synthesis of glycosylated glucagon-like peptide 1: effect of glycosylation on proteolytic resistance and in vivo blood glucose-lowering activity.  Journal of the American Chemical Society  131, 6237-6245, doi:10.1021/ja900261 g (2009). 
         50 Pedersen, S. L., Steentoft, C., Vrang, N. &amp; Jensen, K. J. Glyco-scan: varying glycosylation in the sequence of the peptide hormone PYY3-36 and its effect on receptor selectivity.  Chembiochem  11, 366-374, doi:10.1002/cbic.200900661 (2010). 
         51 Sato, M. et al. Glycoinsulins: dendritic sialyloligosaccharide-displaying insulins showing a prolonged blood-sugar-lowering activity.  Journal of the American Chemical Society  126, 14013-14022, doi: 10.1021/ja046426l (2004). 
         52 Dangoor, D. et al. Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability.  J Pept Sci  14, 321-328, doi: 10.1002/psc.932 (2008). 
         53 Semenov, A. G. et al. Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site.  Clin Chem  55, 489-498, doi: 10.1373/clinchem.2008.113373 (2009). 
         54 Duguay, S. J. et al. Post-translational processing of the insulin-like growth factor-2 precursor. Analysis of O-glycosylation and endoproteolysis.  The Journal of biological chemistry  273, 18443-18451 (1998). 
         55 Birch, N. P., Estivariz, F. E., Bennett, H. P. &amp; Loh, Y. P. Differential glycosylation of N-POMC1-77 regulates the production of gamma 3-MSH by purified pro-opiomelanocortin converting enzyme. A possible mechanism for tissue-specific processing.  FEBS Lett  290, 191-194 (1991). 
         56 Patzelt, C. &amp; Weber, B. Early O-glycosidic glycosylation of proglucagon in pancreatic islets: an unusual type of prohormonal modification.  The EMBO journal  5, 2103-2108 (1986). 
         57 Luckenbill, K. N. et al. Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage.  Clin Chem  54, 619-621, doi: 10.1373/clinchem.2007.097998 (2008). 
         58 Stovold, R. et al. Biomarkers for small cell lung cancer: neuroendocrine, epithelial and circulating tumour cells.  Lung Cancer  76, 263-268, doi:10.1016/j.lungcan.2011.11.015 (2012). 
         59 Wang, J. et al. Identification of kininogen-1 as a serum biomarker for the early detection of advanced colorectal adenoma and colorectal cancer.  PLoS One  8, e70519, doi:10.1371/journal.pone.0070519 (2013). 
         60 Goetze, J. P., Alehagen, U., Flyvbjerg, A. &amp; Rehfeld, J. F. Chromogranin A as a biomarker in cardiovascular disease.  Biomark Med  8, 133-140, doi:10.2217/bmm.13.102 (2014). 
         61 Nielsen, S. J., Iversen, P., Rehfeld, J. F., Jensen, H. L. &amp; Goetze, J. P. C-type natriuretic peptide in prostate cancer.  APMIS  117, 60-67, doi: 10.1111/j. 1600-0463.2008.00016.x 60 (2009). 
         62 Ju, T., Aryal, R. P., Stowell, C. J. &amp; Cummings, R. D. Regulation of protein O-glycosylation by the endoplasmic reticulum-localized molecular chaperone Cosmc.  J Cell Biol  182, 531-542, doi:10.1083/jcb.200711151 (2008). 
         63 Steentoft, C. et al. Mining the O-glycoproteome using zinc-finger nuclease-glycoengineered SimpleCell lines.  Nat Methods  8, 977-982, doi:10.1038/nmeth.1731 (2011). 
         64 Steentoft, C. et al. Precision genome editing: A small revolution for glycobiology. Glycobiology 24, 663-680, doi: 10.1093/glycob/cwu046 (2014). 
         65 Yamane-Ohnuki, N. et at Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity.  Biotechnol Bioeng  87, 614-622, doi: 10.1002/bit. 20151 (2004). 
         66 Malphettes, L. et at Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies.  Biotechnol Bioeng  106, 774-783, doi: 10.1002/bit.22751 (2010). 
         67 Ronda, C. et at Accelerating genome editing in CHO cells using CRISPR Cas9 and CRISPy, a web-based target finding tool.  Biotechnol Bioeng  111, 1604-1616, doi: 10.1002/bit.25233 (2014). 
         68 El Mai, N., Donadio-Andrei, S., Iss, C., Calabro, V. &amp; Ronin, C. Engineering a human-like glycosylation to produce therapeutic glycoproteins based on 6-linked sialylation in CHO cells.  Methods in molecular biology  988, 19-29, doi:10.1007/978-1-62703-327-5_2 (2013). 
         69 Sewell, R. et at The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer.  The Journal of biological chemistry  281, 3586-3594, doi: 10.1074/jbc.M511826200 (2006). 
         70 Torang, S. et at In vivo and in vitro degradation of peptide YY3-36 to inactive peptide YY3-34 in humans.  Am J Physiol Regul Integr Comp Physiol  310, R866-874, doi: 10.1152/ajpregu.00394.2015 (2016). 
         71 Steentoft, C. et at Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology.  The EMBO journal  32, 1478-1488, doi:10.1038/emboj.2013.79 (2013). 
         72 Levery, S. B. et at Advances in mass spectrometry driven O-glycoproteomics.  Biochim Biophys Acta , doi:10.1016/j.bbagen.2014.09.026 (2014). 
         73 Schietinger, A. et at A mutant chaperone converts a wild-type protein into a tumor-specific antigen.  Science  314, 304-308, doi:10.1126/science.1129200 (2006). 
         74 Yabu, M., Korekane, H. &amp; Miyamoto, Y. Precise structural analysis of O-linked oligosaccharides in human serum.  Glycobiology  24, 542-553, doi:10.1093/glycob/cwu022 (2014). 
         75 Locke, A. E. et at Genetic studies of body mass index yield new insights for obesity biology.  Nature  518, 197-206, doi:10.1038/nature14177 (2015). 
         76 Zougman, A. et at Integrated analysis of the cerebrospinal fluid peptidome and proteome.  Journal of proteome research  7, 386-399, doi:10.1021/pr070501k (2008). 
         77 Lottspeich, F., Kellermann, J., Henschen, A., Foertsch, B. &amp; Muller-Esterl, W. The amino acid sequence of the light chain of human high-molecular-mass kininogen.  European journal of biochemistry/FEBS  152, 307-314 (1985). 
         78 Makimattila, S., Fineman, M. S. &amp; Yki-Jarvinen, H. Deficiency of total and nonglycosylated amylin in plasma characterizes subjects with impaired glucose tolerance and type 2 diabetes.  J Clin Endocrinol Metab  85, 2822-2827, doi: 10.1210/jcem.85.8.6721 (2000). 
         79 Schellenberger, U. et at The precursor to B-type natriuretic peptide is an O-linked glycoprotein.  Arch Biochem Biophys  451, 160-166, doi:10.1016/j.abb.2006.03.028 (2006). 
         80 Pal, K., Melcher, K. &amp; Xu, H. E. Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors.  Acta Pharmacol Sin  33, 300-311, 55 doi:10.1038/aps.2011.170 (2012). 
         81 Naot, D. &amp; Cornish, J. The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism.  Bone  43, 813-818, doi: 10.1016/j.bone.2008.07.003 (2008). 
         82 Muff, R., Born, W. &amp; Fischer, J. A. Calcitonin, calcitonin gene-related peptide, adrenomedullin and amylin: homologous peptides, separate receptors and overlapping biological actions.  European journal of endocrinology/European Federation of Endocrine Societies  133, 17-20 (1995). 
         83 Tagashira, M., Iijima, H. &amp; Toma, K. An NMR study of O-glycosylation induced structural changes in the alpha-helix of calcitonin.  Glycoconj J  19, 43-52 (2002). 
         84 Fisone, G. et al. N-terminal galanin-(1-16) fragment is an agonist at the hippocampal galanin receptor.  Proc Natl Acad Sci USA  86, 9588-9591 (1989). 
         85 Cabrele, C. &amp; Beck-Sickinger, A. G. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family.  J Pept Sci  6, 97-122, doi: 10.1002/(SICI)1099-1387(200003)6:3&lt;97::AID-PSC236&gt;3.0.CO;2-E (2000). 
         86 Nicole, P. et al. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide.  J Biol Chem  275, 24003-24012, doi: 10.1074/jbc.M002325200 (2000). 
         87 Cerda-Reverter, J. M. &amp; Larhammar, D. Neuropeptide Y family of peptides: structure, anatomical expression, function, and molecular evolution.  Biochem Cell Biol  78, 371-392 (2000). 
         88 Scarborough, R. M. et al. D-amino acid-substituted atrial natriuretic peptide analogs reveal novel receptor recognition requirements.  J Biol Chem  263, 16818-16822 (1988). 
         89 Campbell, D. J. Long-term neprilysin inhibition—implications for ARNIs.  Nat Rev Cardiol  14, 171-186, doi:10.1038/nrcardio.2016.200 (2017). 
         90 Lambeir, A. M., Durinx, C., Scharpe, S. &amp; De Meester, I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.  Crit Rev Clin Lab Sci  40, 209-294, doi:10.1080/713609354 (2003). 
         91 Nauck, M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.  Diabetes Obes Metab  18, 203-216, doi: 10.1111/dom. 12591 (2016). 
         92 Deacon, C. F. et al. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.  Diabetologia  41, 271-278, doi: 10.1007/s001250050903 (1998). 
         93 Plamboeck, A., Holst, J. J., Carr, R. D. &amp; Deacon, C. F. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig.  Diabetologia  48, 1882-1890, doi:10.1007/s00125-005-1847-7 (2005). 
         94 Hupe-Sodmann, K. et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides.  Regulatory peptides  58, 149-156 (1995). 
         95 Torang, S., Veedfald, S., Rosenkilde, M. M., Hartmann, B. &amp; Holst, J. J. The anorexic hormone Peptide YY3-36 is rapidly metabolized to inactive Peptide YY3-34 in vivo.  Physiol Rep  3, doi: 10.14814/phy2.12455 (2015).